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General Summary
This thesis is in two parts. In the first three chapters the pathogenesis of 
osteoarthritis is discussed with particular reference to the mediators and enzymes 
involved. Current knowledge of medical treatment with analgesics, non-steroidal 
anti-inflammatory drugs (NSAIDs) and disease modifying drugs is presented. Chapters 
4 and 5 detail experimental work on the NSAID carprofen and the steroid-NSAID 
combination PLT® Tablets.
Canine osteoarthritis usually occurs secondary to primary joint incongruity or 
instabilty but it may occur as a primary entity in older animals. Over the last two decades 
some of the ultrastructural pathogenic mechanisms of osteoarthritis have become clearer. 
Whatever the initiating cause of articular cartilage degeneration, there appear to be 
common mediator and enzyme pathways which induce biochemical and gross changes in 
articular cartilage and synovium. The chondrocyte reacts to alterations in pressure and 
forces within articular cartilage. The synovium liberates a number of mediators which 
affect chondrocyte metabolism. Free proteoglycan fragments in the synovial fluid induce 
synovial production of the cytokine interleukin-1. An increasingly important role is being 
ascribed to interleukins, and a number of other cytokines, growth factors and 
chondrocyte stress proteins may also be involved. There is evidence of humoral immune 
response to 'hidden' autoantigen in articular cartilage which is liberated as the cartilage is 
damaged.
The degradation of the matrix appears to be due to enzymatic destruction of 
proteoglycan by neutral metalloproteinases which are produced in increased quantities by 
chondrocytes in osteoarthritic cartilage. A reduction in specific tissue inhibitors of 
metalloproteinases (TIMP) may make available increased amounts of free active 
metalloproteinases. Proteoglycan loss exposes the collagen network to enzymatic damage 
and also reduces the elasticity and resilience of articular cartilage such that mechanical 
damage of collagen is possible. Loss of matrix may reduce the barrier to mediators in the 
synovial fluid. The net result is cartilage fibrillation and erosion.
The treatment of osteoarthritis involves the avoidance or elimination of factors 
which promote joint damage such as joint instability, obesity, or inappropriate exercise. 
Analgesics are used to control the symptoms of pain and stiffness. The opiates are not 
recommended for long term use because of their central depressent effects. NSAIDs, 
which have analgesic and anti-inflammatory activity, have demonstrated better efficacy in 
osteoarthritis than pure analgesics such as paracetamol.
The activity of NSAIDs is primarily due to the inhibition of the synthesis of 
prostanoids, some of which are beleived to mediate or modulate synovial inflammation 
and pain. The inhibition of prostaglandin synthesis by NSAIDs can be potentially 
damaging since it is responsible for toxic effects, particularly in gastrointestinal and renal 
tissue. The NSAIDs have different pharmacokinetics in different species and dose rates 
cannot be extrapolated between species. A number of drugs have been used in the dog. 
Some of the drugs used in man are much more toxic in dogs and should not be used. The 
drugs presently available are discussed in Chapter 3.
The NSAIDs only offer symptomatic treatment and do not inhibit disease 
progression. Some NSAIDs promote degenerative changes in osteoarthritic cartilage in 
vitro and in vivo. More recently, interest has been shown in 'disease modifying drugs'. 
Although higher doses of corticosteroids cause osteoarthritic changes in joints, low doses 
have demonstrated inhibitory effects on articular cartilage degradation. 
Glycosaminoglycan polysulphated esters, hyaluronate and glucosamine have 
demonstrated chondroprotective properties in vitro and in vivo. These drugs and agents 
which affect cytokines or mimic growth factors may be important in the therapy of canine 
osteoarthritis in the future. However, NSAIDs are the most widely used drugs in the 
medical therapy of osteoarthritis to date and will probably remain important therapeutic 
agents.
One of the newer NSAIDs, carprofen, a propionic acid derivative has been 
demonstrated to be better tolerated in the dog than many other NSAIDs. Daily oral 
administration of carprofen at over 5 times the recommended daily dose for over 12 
months has been well tolerated by experimental dogs. Pharmacokinetics were studied in 
beagles after a single oral dose at a rate of 4 mg/kg bodyweight. A fourteen day tolerance 
study at 9 mg/kg bodyweight/day was performed to assess the clinical, haematological 
and biochemical effects of carprofen at a supratherapeutic dose. A clinical trial on the 
efficacy of carprofen in the therapy of osteoarthritis in dogs was carried out with the 
cooperation of practicing veterinarians. Although a blinded cross-over trial with 
radiological corroboration of the clinical diagnosis would have been the prefered 
experimental method, it was not considered practical since no funds were available for the 
remuneration of participating veterinarians. Instead, it was only possible to perform an 
unblinded trial using two groups of limited comparability, and using phenylbutazone 
treated dogs as positive controls. The experimental evidence suggested that carprofen was 
at least as efficacious as phenylbutazone in the therapy of osteoarthritis and may be a 
useful drug in the chronic therapy of osteoarthritis at 2-4 mg/kg/day as a single dose or 
divided into two doses.
PLT ® Tablets are a development of Predno-Leucotropin ® Tablets which 
have been used in the therapy of musculoskeletal disorders for 22 years. PLT Tablets 
contain the NSAID cinchophen and a low dose of the steroid prednisolone but, unlike 
Predno-Leucotropin Tablets, they do not contain hexamine. The combination may have 
synergistic activity since the two drugs have anti-inflammatory activity at different levels 
of the arachidonic acid conversion pathway. The prednisolone dose rate is similar to that 
demonstrated to have chondroprotective properties in early experimental osteoarthritis. A 
clinical trial on the efficacy of PLT Tablets was carried out since there are no reports in 
the veterinary literature on the efficacy of cinchophen, or of cinchophen and prednisolone 
in combination. Trial design resembled that for the carprofen clinical efficacy trial and had 
the same drawbacks. PLT Tablets appeared to be at least as efficacious as phenylbutazone 
in the therapy of osteoarthritis in the dog and were efficacious at dose rates below the 
manufacturers recommendations.
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Chapter 1
An Overview of the Aetiology and Pathogenesis
of Osteoarthritis
1An Overview of The Aetiology 
and Pathogenesis of Osteoarthritis
L I  Introduction
Canine osteoarthritis has been recognised for many years. Osteoarthritis is 
also a very common disease in man. Osteoarthritic changes are present in 35% of knees 
of people aged 30, and are almost universal in people over 70 (Roberts and Burch,
1966). In man, clinical osteoarthritis is two or three times as prevalent as rheumatoid 
arthritis (DiPascale, 1986). Osteoarthritis affects all mammals except sloths and bats; this 
includes aquatic, non-weightbearing mammals such as whales, dolphins and porpoises.
L I  Nomenclature
At least fifty-four different names have been used for the pathological process 
which is called osteoarthritis in this thesis (Tamopolsky, 1950). The term "degenerative 
joint disease " implies that the process is catabolic, but much of the pathophysiological 
process in osteoarthritis is anabolic, synthetic, and reparative. In the UK and Europe the 
pathological process is often called osteoarthrosis. This term is often used to describe 
subclinical or preclinical osteoarthritic changes, or changes not associated with 
inflammation. Many authors are not happy with the term osteoarthritis since it implies an 
inflammatory component whereas inflammation is not detectable in all osteoarthritic 
joints. However, osteoarthritis is the terminology widely used and accepted in human and 
veterinary literature and is therefore the term used in this thesis.
LA Aetiology of Osteoarthritis
Although osteoarthritis is very common, many aspects of the aetiology and 
pathogenesis are poorly understood. Osteoarthritis is now widely considered to be not a 
single entity but a pattern of reactions to injury of the articular and periarticular tissues 
(eg.Amoczky and Marshall, 1981; Berry and Paulus, 1983; McCarty, 1989). It would 
perhaps be better to regard the subclinical (but radiographic and anatomical) changes 
which are common in so many older people, and in many older animals (Tirgari and 
Vaughan, 1975), as normal processes of repair, remodelling and adjustment in response 
to joint insult (Bland, 1986). Where clinical signs develop then the term osteoarthritis can 
be applied and regarded as a failure of normal subclinical joint repair and readjustment.
1
Historically, osteoarthritis has been divided into primary and secondary types. 
Primary osteoarthritis could also be termed idiopathic since the factor or factors which 
have caused a clinical problem are unclear. Secondary osteoarthritis develops as a 
response to an identifiable causative factor such as acute or chronic trauma, articular 
fractures, infection, aseptic necrosis and so on. In man, secondary osteoarthritis is being 
increasingly recognised with a concurrent reduction in cases that are designated as 
primary osteoarthritis (Stulberg and others, 1975; Berry and Paulus, 1983; Hough and 
Sokoloff, 1989). Primary canine osteoarthritis has been documented. In one study, 20% 
of dogs at necropsy, selected at random, had osteoarthritic changes in one or more joints. 
In 61% there was no identifiable predisposing cause (Tirgari and Vaughan, 1975). Some 
investigators have stated that primary osteoarthritis of the shoulder is common in dogs 
(Ljunggren and Olsson, 1975; Tirgari and Vaughan, 1975). Primary osteoarthritis of the 
elbow also occurs but is less common (Ljunggren and Olsson, 1975). However, many 
cases of primary osteoarthritis may be secondary to a cause which has become obscured 
by the osteoarthritic process.
Secondary osteoarthritis is apparently much more common in the dog 
(Clayton-Jones, 1985). Joints most often affected in canine osteoarthritis are 
weightbearing synovial joints: the hip, the elbow, the stifle and the shoulder. In contrast 
to human osteoarthritis, interphalangeal joints are rarely affected in the dog. Primary 
causes are often identifiable in the young dog such as hip dysplasia, or osteochondritis.
In the older dog rupture of the anterior cruciate ligament of the stifle is a common cause 
of stifle osteoarthritis. In many older dogs the primary cause cannot be determined from 
the history or at necropsy. In many cases, the dog will only show lameness in latter life 
but the initiating cause may have been present much earlier. The joints most often affected 
in the older dog are those in which developmental problems such as osteochondritis 
lesions are common (Amoczky and Marshall, 1981).
The aetiology of osteoarthritis is still uncertain. There is evidence of a genetic 
contribution in man. A defect in cartilage metabolism has been suggested. However, the 
genetic component may be related to differences in the conformation and infrastructure of 
joints, long bones and in soft tissue structures which predispose to osteoarthritic change 
as in hereditary hip dysplasia in the dog. Some hormonal imbalances affect the 
osteoarthritic process. In man, acromegaly, a syndrome caused by excess growth 
hormone production, induces osteoarthritis earlier and with a higher incidence. Diabetes 
mellitus appears to predispose to osteoarthritis. Conversely, osteoporosis due to a fall in 
oestrogen concentrations decreases the incidence of osteoarthritis, possibly because the 
subchondral bone is softened or because of direct hormonal effects (Hough and 
Sokoloff, 1989; Moskowitz, 1989).
2
Chemical theories include primary synovitis, possibly due to immune 
complex formation, and the secondary stimulation of degradative enzymes in cartilage by 
synovial factors. Synovitis is not a consistent finding in osteoarthritic joints (Mankin, 
1985; Hough and Sokoloff, 1989). It has been proposed that the primary defect in 
osteoarthritis is in the synovium and in products of the synovium.Studies of early hip 
dysplasia in dogs suggested that lesions in articular cartilage are preceded by synovitis 
and synovial effusion (Lust and Summers, 1981). Laver-Ruelich and Silberman (1985) 
demonstrated that the surface of articular cartilage is negatively charged and that with age 
the charge density was decreased. A possible relationship with the onset of osteoarthritic 
changes was proposed.
The favoured theories remain those based on a mechanical initiation. Recent 
developments in the knowledge of lubrication and fluid mechanics make previously 
widely accepted views on the importance of synovial viscosity in maintaining low friction 
at the cartilage-cartilage interface untenable (McCutchen, 1978; Davis and others, 1979). 
Pressure application to cartilage causes the surface to "weep". Less tightly bound water 
molecules are forced out of the cartilage matrix. Some of the water content appears to be 
tightly bound to the matrix proteoglycan (Mankin, 1985). The surface of cartilage is 
protected in a "low-shear environment" by undulations and microscopic dimples in the 
cartilage surface which trap synovial fluid. A specific glycoprotein, "Lubricin ", adheres 
to the cartilage and makes it more slippery (Swann, 1978). No deficiency in the 
boundary-lubricating ability of synovial fluid has been demonstrated in osteoarthritis 
(Davis and others, 1978). Although hyaluronic acid appears to have no role in 
cartilage-cartilage interface lubrication, it is an effective lubricant of the periarticular soft 
tissue and is probably the primary lubricant of synovium (Davis and others, 1979; 
Mankin, 1985).
Joint incongruity or instability, or changes in the stiffness of the subchondral 
bone may initiate osteoarthritis. There is evidence that bony changes and repeated impact 
loading are important (Felson and others, 1988). Articular cartilage is much thinner than 
the length of bone available for impact absorption. In experimental and clinical lesions, 
microfractures and sclerosis in the subchondral trabecular bone have been seen to precede 
measurable changes in the cartilage (Roy and Ghadially, 1966; Hough and Sokoloff, 
1989). Cartilage has been found to be mechanically more liable to damage by impact 
loading than by shearing forces (Radin and others, 1973). Sustained pressure on cartilage 
causes a suppression of chondrocyte activity (Crellin and Southwick, 1964). In man, 
some investigators have found a relationship between the increase in body mass 
associated with obesity and the incidence of osteoarthritis of the knee. They proposed 
possible alterations in subchondral bone density as a causative mechanism (Davis and 
others, 1988).
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1*4 Pathogenesis of Osteoarthritis
Whatever the initiating cause, and there may be a combination of factors, the 
changes in the osteoarthritic joint appear to follow a "final common pathway".
Knowledge of some of the various pathways of damage and repair in the osteoarthritic 
joint has increased substantially in the last two decades. However, the relative importance 
of different mechanisms and interactions between them, and the factors which affect the 
progression of the disease and severity of clinical signs associated with osteoarthritis are 
still poorly understood.
The gross changes, which include joint capsule thickening, synovitis, bony 
remodelling, bony end plate sclerosis, osteophyte formation, cartilage softening, 
fibrillation, Assuring and erosion, are paralleled by biochemical changes. The water 
content of osteoarthritic articular cartilage increases, probably due to a decrease in 
proteoglycan content and in proteoglycan aggregation. There appears to be damage to 
proteoglycan and hyaluronate. The number of living chondrocytes does not decrease until 
a late stage in the disease process (Sokoloff, 1969; Mankin, 1985; Hough and Sokoloff, 
1989).
Although it is still possible that most cartilage destruction proceeds 
mechanically (Freeman, 1979; Maroudas, 1980), there is a large amount of evidence that, 
in primary and secondary osteoarthritis, biochemical and mediator effects are very 
important in the disease pathogenesis. Many experimental studies have shown the 
enhancement or inhibition of osteoarthritic changes by various mediators and especially 
the cytokines and various growth factors (see 2.5-2.61. Articular cartilage degradative 
enzyme activity has been reported to be correlated with synovial inflammation and 
synovial inflammation and effusion may precede cartilage changes (Lust and Summers, 
1981). Good correlation has been reported between the disease activity and the active 
metalloproteinase content of articular cartilage in secondary osteoarthritis (see 2.111. 
Some disease modifying drugs have demonstrated marked chondroprotective effects in 
models of secondary osteoarthritis (see 3.71 which suggests that mechanical effects per se 
are not the direct mechanism of cartilage destruction.
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l»4xl Role of the Synovium
Inflammation is associated with up to three-quarters of all cases of 
osteoarthritis in man (Dieppe, 1984). Synovitis is probably important in the pathogenesis 
of osteoarthritis and in the clinical signs of pain and stiffness. Some authors have 
proposed synovial initiation of the osteoarthritic process and there is evidence that 
synovial changes precede changes in cartilage in secondary osteoarthritis (Dingle, 1979; 
Lust and Summers, 1981). The synovium has been shown to liberate a number of 
mediators including interleukin-1 and other cytokines which have effects on the 
chondrocyte and the synovial and fibrous capsule and bony tissues (see 2.51. 
Osteophytes formed at the joint periphery are metaplastic synovial cells and indicate an 
active inflammatory process and synovitis (Mankin, 1985).
1.4*2 Role of the Chondrocyte
In recent years, the increasingly important role of the chondrocyte has been 
recognised. As in other connective tissues, physical and mechanical forces and 
biochemical changes appear to result in a complex pattern of chondrocyte responses 
which react to return the articular cartilage system to normal function. In effect the 
chondrocyte in association with the synovium, the joint capsule, the subchondral bone 
and muscular and ligamentous structures responds to repeated joint trauma or insult or to 
normal or changing loading forces to retain a homeostatic state (Mankin, 1985; Howell, 
1989; Hough and Sokoloff, 1989).
The complex double-diffusion pathway for the nutrition of the chondrocytes 
from the synovium via the synovial fluid means that chondrocytes rely predominantly 
upon anaerobic glycolytic metabolism (Sokoloff, 1969; Mankin, 1985; Hough and 
Sokoloff, 1989). Chondrocytes are extremely resistant to low oxygen tension. In 
response to a reduction in the supply of glucose, chondrocytes respond by switching to 
oxidative (aerobic) metabolism and this is associated with degradation of the surrounding 
intercellular substance. Disturbances in nutrition may involve:
-changes in the synovial blood flow or changes in synovial blood 
vessel structure
-structural changes in synovial tissues, especially fibrosis 
-changes in synovial fluid quantity and quality 
-biochemical and ultrastructural changes in the articular cartilage 
matrix
-subchondral stiffening; cartilage and subchondral deformation under loading are 
reduced and thus a nutrient pumping effect is also reduced (Hough and Sokoloff, 
1989).
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The chondrocyte is sensitive to changes in biochemical environment and the 
disruption of the supply of nutrients may cause changes in the synthesis of matrix 
components by the chondrocytes. In vitro, mechanical stimulation of chondrocyte culture 
increases sulphated glycosaminoglycan ten-fold in the media, and fifty-fold adherent to 
the cell membranes (Sokoloff, 1980). It is now known that chondrocytes are extremely 
active. The glycosaminoglycan content of cartilage is in a continuous cycle of removal 
and replenishment. Collagen is also synthesised and degraded although turnover is much 
slower (Mankin, 1985).
1AA Role of Matrix Components:
Glycosaminoglycans are linear 
polysaccharide chains which, in 
articular cartilage, consist of three types 
of dimeric unit: chondroitin-4 sulphate, 
chondroitin-6 sulphate and keratan 
sulphate synthesised by the 
chondrocyte. Some of the factors 
affecting the synthesis of 
glycosaminoglycan are given in TABLE 
I  (right).
Proteoglycans are formed when 
approximately 100 chondroitin sulphate 
and 60 keratan sulphate chains are bound to a core protein (Molecular weight = 200000). 
Interchain binding of the glycosaminoglycans appears to occur for all glycosaminoglycans 
except hyaluronate, which lacks a S04 group, and keratan sulphate, which lacks a 
carboxyl group. Up to 100 proteoglycan molecules consisting of glycosaminoglycan side 
chains around a core protein aggregate with hyaluronate (Mankin, 1981; Mankin, 1985; 
Hough and Sokoloff, 1989). There is very specific binding between hyaluronate and 
hyaluronate-binding region of the proteoglycan core proteins which suggests a "lock and 
key" mechanism rather than electrostatic interaction (Lindahl and Hook, 1978). 
Proteoglycan aggregates are extremely large (> 2x10s dal tons). The arrangement is 
represented diagrammatically in FIG 1. Glycosaminoglycans bind to collagen by 
electrostatic interaction at physiological pH. There are two collagen binding sites in the 
proteoglycan molecule: one in the core protein, one in the polysaccharide chains (Toole, 
1976). The size and distribution profiles of proteoglycan aggregates is dependent upon the 
quality and quantity of link protein, proteoglycan subunits and hyaluronic acid, and 
probably to the biochemical properties of normal and osteoarthritic cartilage (Buckwater 
and others, 1986; Manicourt and others, 1986; Pita and others, 1986).
s-----------------------------------------------------
TABLE 1: Factors affecting synthesis of 
glycosaminoglycans and proteoglycans
-osteoarthritis 
-laceration injury 
-hydrostatic 
pressure 
-temperature 
-[ substrate ] 
-cortisol 
-cytokines 
-prostaglandins 
-growth hormone
-ascorbic acid 
-vitamin E 
-pH
-calcium concentration
-lipopolysaccharides
-hyaluronate
-salicylate
-other NSAIDs
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Core Protein
Glycosaminoglycan 
Side Chains
Chondroitin 
Sulphate Rich 
Region
Keratan Sulphate 
Rich Region
Link ’A’
Hyaluronate Chain
Link U'
- Hyaluronate 
Binding Region
Oligosaccharides
50-80
disaccharides
Fig 1: Diagrammatic representation of the proteoglycan aggregate structure.
The structure is based on proteoglycan molecules with molecular weights of about 
2 million daltons which are bound by two types of link protein to a hyaluronate 
molecule. The proteoglycan is made up of a core protein to which are attached 
glycosaminoglycan (GAG) side chains. In the area close to the hyaluronate binding 
region keratan sulphate GAG and associated oligosaccharides are most common 
whilst larger chondroitin sulphate GAG chains predominate in the distal region.
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Collagen is formed into an organised lattice which is structured to resist 
compressive and shear forces. In a resting state the collagen network is quite random when 
histologically examined but under mechanical stress the network becomes ordered (Broom, 
1984; Broom, 1986). Glycosaminoglycans are highly electronegative and the proteoglycan 
'gel' traps water. The collagen arcade is normally sealed and the proteoglycan is forced to 
exist in a semi-hydrated state. Collagen retains the form of the articular cartilage, resisting 
the osmotic forces generated by proteoglycans which tend to swell the cartilage and which 
are responsible for the elasticity of normal cartilage (Mankin, 1981; Mankin, 1985; Hough 
and Sokoloff, 1989).
With damage to the collagen arcade, remaining proteoglycan will imbibe water 
and expand, increasing the exposure of proteoglycan and collagen to enzymatic degradation 
and resulting in a decrease in the elasticity and impact load dispersion capacity of the 
articular cartilage, which predisposes to further cell and matrix damage. Unmasking of the 
middle layers of cartilage may be an important pathophysiological event in osteoarthritis 
(Broom, 1984; Broom, 1986). Degenerative, traumatic or enzymatic damage to the 
collagen network will cause common structural transformations. The normal collagen 
cross-linkages are broken and the collagen assumes a soft, parallel configuration (Chrisman 
and others, 1981; Radin, 1983; Howell, 1986). It has been suggested that proteoglycans 
protect interconnecting regions of the collagen network from enzymatic disruption and 
removal of the proteoglycans exposes the linkages of the collagen network to more direct 
attack from collagenases (Broom, 1988).
The nature of the connection between the collagen fibrils is still uncertain. The 
collagen fibrils may link directly or there may be a third matrix component which acts as a 
link. Collagen Type II predominates in cartilage, but there are also small quantities of minor 
collagens Types V, VI, IX, and XI which make up approximately 3% of the total collagen 
content. Collagen Type IX has non-helical regions which give the molecule flexibility and 
is concentrated close to intersections of the fibril network. It has been proposed that 
Collagen Type IX could act as the interfibril linkage molecule (Broom, 1988).
The total proteoglycan content of cartilage is decreased in osteoarthritis. The 
ratio of keratan sulphate and chondroitin 6-sulphate to chondroitin 4-sulphate decreases. 
The length of the proteoglycan subunit core protein is shortened in either the chondroitin 
sulphate or hyaluronic acid binding region. Glycosaminoglycan chains are reduced in 
length and hyaluronic acid polymer size and content decrease (Moskowitz and others,
1979; Howell, 1989; Moskowitz, 1989).
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The capacity to form aggregates with proteoglycan subunits becomes variable. 
The concentration of non-proteoglycan and non-collagen proteins is increased. Degraded 
proteoglycans rapidly diffuse into the synovial fluid or are further degraded by 
chondrocytes. Undamaged proteoglycan subunits may reaggregate (Moskowitz and others, 
1979; Howell, 1989; Moskowitz, 1989). Released proteoglycan fragments have 
demonstrated the potential to cause synovitis and may be an important mediator of 
osteoarthritis pathogenesis (see 2.8).
In natural and experimental osteoarthritis, proteoglycan loss usually precedes 
cartilage erosion (Howell and others, 1986). The mechanism may involve defects in 
chondrocyte repair responses, direct mechanical damage and enzymatic degradation 
(Lowther and others, 1981). Candidates for the enzymes involved include neutral 
metalloproteinases and serine proteases. Several experiments have suggested that serine 
proteases activate latent metalloproteinases (Woessner, 1977; Woessner, 1982; Sapolsky 
and Howell, 1982; see 2.11).
The matrix configuration and charge affect the rate of diffusion of many 
substances through the matrix. The diffusion of larger molecules is particularly sensitive to 
the concentration of proteoglycan (Mankin, 1985). This may be important in the regulation 
of access of various chondrocyte-function mediators to the chondrocyte. The matrix seems 
to inhibit chondrocyte mitosis since the loss of matrix barrier in cartilage erosions is 
associated with clusters of chondrocyte clones (Mankin, 1981; Mankin, 1985; Hough and 
Sokoloff, 1989).
L5 Repair of Cartilage
There is substantial evidence that articular cartilage repair occurs and that the 
cartilage damage in osteoarthritis is potentially reversible (Bland, 1986). Osteoarthritic 
articular cartilage is more active than normal. In osteoarthritis, the microenvironment of the 
chondrocyte changes. Mitosis is stimulated and clone clusters form (Solokoff, 1969; 
Sokoloff, 1980; Hough and Sokoloff, 1989). In chondrocyte cell culture, mature cells 
divide, grow and synthesise phenotypic glycosaminoglycans and collagen. It appears that 
ordinarily, the matrix of cartilage switches off the cell replication mechanism and that 
mitosis can occur when the chondrocytes are released from the matrix (Green, 1971; 
Sokoloff, 1980). Proliferating cells in osteoarthritis not only incorporate Thymidine as a 
marker of DNA synthesis (Havdrup and Telhag, 1980; Hirotani and Ito, 1975) but also 
increase sulphate uptake (Meachin and Collins, 1962).
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In osteoarthritic articular cartilage, chondrocytes become very anabolic, 
increasing production and secretion of glycosaminoglycans and increasing collagen 
synthesis. The collagen that is produced is now believed to be Type II and the repair tissue 
can therefore be considered hyaline type cartilage (Mankin, 1985; Hough and Sokoloff, 
1989). Earlier authors considered tissue produced in experimental cartilage damage and 
repair not to be primary normal hyaline cartilage (Sokoloff, 1974). The rate at which 
articular cartilage repair can occur in vivo is undoubtedly slow, but it may be significant 
over a long period (Mankin, 1981; Bland, 1986). An additional reparative pathway exists 
in the pluripotential granulation tissue which is present in subchondral bone marrow and 
which may become exposed in severe osteoarthritis ( Harrison, 1953; Gay and others, 
1976; Cheung and others, 1980).
In man, it is recognised that there can be extensive damage to articular cartilage 
in a joint without any symptoms. It also appears that osteoarthritis may not be progressive 
in older people. Some cases of advanced and very painful osteoarthritis can become 
painless, or the pain may be intermittent. Spontaneous remission has been reported. In hip 
osteoarthritis in man, marked clinical improvement and radiographic recovery of joint space 
occurred in many cases in one study (Forman and others, 1983; Bland, 1986).
It has been suggested that pharmaceutical or physical stimuli might encourage 
the regeneration of cartilage which is functionally normal (Salter and others, 1980; 
Burkhardt and Ghosh, 1986). Continuous passive motion [the repeated flexion and 
extension of a joint without load by exogenous mechanical means] has been found to be a 
powerful stimulus for cartilage regeneration and healing. Full thickness defects in rabbit 
articular cartilage healed very slowly if the joint was immobilised. If ambulation was 
permitted then healing was more rapid, but the repair was with fibrocartilage and not 
hyaline cartilage. Also, in this group the joints became osteoarthritic within six months. In 
a group treated with continuous passive motion, hyaline cartilage regenerated and the 
cartilage was normal six months later (Salter and others, 1980).
L& Summary
The almost ubiquitous nature of radiographic and anatomical changes in older 
people and the symptomless nature of many cases in man and animals suggests that some 
of these changes are a normal reparative response to joint damage. There are no clinical 
signs and there is essentially full joint function. If, however, damage exceeds repair or if 
clinical effects are mediated for instance by secondary synovial inflammation, then clinical 
osteoarthritis supervenes. The clinician is interested in the factor or factors which tip the 
balance and the potential for modification or reversal of these factors and the osteoarthritic 
process.
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Osteoarthritis is now believed to be a common reaction to different joint insults 
or traumas. The concept of a "final common pathway" is widely accepted (FIG 2). 
Previous theories based on simple "wear and tear" mechanical mechanisms have proved to 
be untenable with new knowledge on the dynamic nature of articular cartilage and other 
joint structures. It now appears that ultra-structural mechanisms and biochemical changes 
play a major role in the regulation of cartilage repair and in the pathogenesis^osteoarthritis. 
The precise interactions and relative importance of these mechanisms is still unclear but 
important advances in our knowledge of the subject have been made in recent years. 
Secondary osteoarthritis in the dog is likely to be initiated by biomechanical overloading. It 
now appears that this induces changes in the chondrocyte or matrix microenvironment 
which mediate alterations in the synthesis and enzymatic degradation of matrix 
proteoglycan. Possible mediators of cartilage and synovial changes are discussed in the 
next chapter.
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Chapter 2
Role of Mediators in the Pathogenesis 
and Clinical Signs of Osteoarthritis
2Role of Mediators in the Pathogenesis 
and Clinical Signs of Osteoarthritis
2d Introduction
It has been suggested that chondrocytes are unlikely to receive and respond to 
humoral messages because of the double diffusion barrier which exists between the 
synovium and the chondrocyte [capillary -> synovium -> synovial fluid -> articular 
cartilage matrix -> chondrocyte] and because of the selectivity of diffusion into the highly 
electronegative proteoglycan matrix. Instead, it is likely that chondrocytes are sensitive to 
alterations in physical forces, for instance pressure and shear forces. However, it does 
appear that many synovium-derived factors including various growth factors and 
cytokines can influence chondrocyte activity (Dingle, 1978; 1979; 1981; Mankin, 1985).
The collagenolytic activity of synovial and cartilage tissues increases in 
osteoarthritis. The collagenolytic activity of cartilage is proportional to the degree of 
inflammation of the synovial membrane and not to the collagenolytic activity in the 
synovium (Pelletier and others, 1985). This suggests that stimulatory mediators may, but 
collagenolytic factors probably do not, diffuse from the synovium to the articular cartilage 
and modulate tissue breakdown. It has been reported that in canine hip dysplasia 
synovitis and effusion precede cartilage damage and bony remodelling (Lust and 
Summers, 1981).
Certain drugs are "chondroprotective" in experimental secondary 
osteoarthritis; others can accelerate degradation (see 3.3.6 and 3.7). Alterations in 
mechanical stresses appear to lead to secondary osteoarthritis by effects on cell-cell 
communication and mediator release. Other mediators may be involved in the 
inflammatory response in the synovium and the clinical signs of pain and stiffness.
It is likely that changes in the synovium and especially in the cartilage matrix 
proteoglycan may reduce the diffusion barrier to mediators to the chondrocyte in 
osteoarthritic cartilage. There are undoubtedly complex inter-relationships between 
different mediators. The stimulation and inhibition feedback network remain poorly 
understood. Possible roles for a number of mediators are discussed in this chapter.
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12 Eicosanoids
Nonspecific cell injury due to mechanical or chemical trauma, ischaemia or cell 
death, or specific receptor-coupled phospholipase release stimulates the liberation of 
unsaturated fatty acids from the plasma membrane or from free triglycerides. These fatty 
acids include arachidonic acid which can be converted into eicosanoids.The eicosanoids 
are molecules which have various actions on the inflammatory process. The arachidonic 
acid biotransformation pathways are represented in diagrammatic form in FIG 3. There 
are two branches to the pathway; the cyclooxygenase pathway leads to the formation of 
the prostanoids including the prostaglandins (PGs), prostacyclin (PGI2) and 
thromboxanes (TBXs). The lipoxygenase pathway leads to the formation of the 
leukotrienes (LTs) and hydroxyeicosotetraenoic acids (HETEs) (Dawson and 
Willoughby, 1985).
Prostaglandin endoperoxide synthetase is present in the microsomes. LTB4 
synthesis occurs in the cytoplasm, whilst LTC4, LTD4 and LTE4 synthesis occurs at the 
plasma membrane. Compartmental localisation may be important in the regulation of 
prostaglandin, leukotriene and HETE production (Kitchen and others, 1985). Different 
prostaglandins and leukotrienes often have antagonistic functions. Many of the effects of 
the prostanoids appear to be antiinflammatory (Dawson and Willoughby, 1985). Some of 
the actions of the eicosanoids are listed in TABLE 2 below. Many of the details of the 
interaction between the eicosanoids and between the eicosanoids and other mediators are 
unclear. Levels of arachidonic acid in articular cartilage increase markedly with age 
(Bonner and others, 1975). A four fold rise in arachidonic acid has been demonstrated 
two hours after experimental cartilage injury (Chrisman and others, 1981). Whether the 
eicosanoids are important in cartilage response to acute trauma is not known.
TABLE 2: SOME KNOWN ACTIONS OF SELECTED EICOSANOIDS
PROSTAGLANDIN E2: PROSTACYCLIN (PGI2):
- vasodilation - vasodilation
- increased capillary permeability - decreased platelet adhesiveness
- enhancement of pain and changes in vasculature - increased vascular permeability
- increase in cyclic adenosine monophosphate ( cAMP) - ? inhibition of chemotaxis
- increase enzyme release
- ? chemotaxis enhancement THROMBOXANE A2:
- increased platelet adhesiveness
PROSTAGLANDIN F2°°:
- vasoconstriction LEUKOTRIENE B4:
- decreased capillary permeability - chemotaxis
- increased cyclic guanosine monophosphate ( cGMP) - increased vascular permeability
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2.2.1 Prostanoids
Cyclooxygenase converts arachidonic acid to PGG2 and further enzyme 
conversion liberates the various prostanoids. The prostaglandins have mediator and 
modulator activity. PGE2 mediates vasodilation. Many of the actions of the prostanoids 
are antagonistic to one another. For instance, thromboxane A2 (TB A2) and prostacyclin 
(PGI2) have antagonistic actions on platelet adherence and aggregation (Ortmann and 
Perkins, 1977; Dawson and Willoughby, 1985). Prostaglandins may have an important 
role in the fine tuning of inflammatory response (Lees and others, 1987).
Prostanoids are not stored in the tissues (Piper and Vane, 1971) but mild 
chemical and mechanical stimulation of tissues will induce their synthesis (Ferriera,
1967). More than twenty prostaglandins have been characterised (Higgins, 1985). 
Prostaglandins act synergistically as with other agents. Prostaglandin E2 and prostacyclin 
enhance pain and vascular permeability responses to kinins. They enhance peripheral pain 
perception (Moncada and Vane, 1977). Both PGEl and PGI2 increase pain sensitivity 
(Higgs and Salmon, 1979). The pain threshold may be so drastically altered that normally 
painless stimuli become painful. Only at very high concentrations (greater than 
physiological concentrations) can prostaglandins cause pain directly. The effect of 
prostaglandins is cumulative and of relatively long duration (Dawson and Willoughby,
1985). Prostaglandins have also been implicated in pain perception in the central nervous 
system. They are produced within the CNS and may sensitise it to painful substances 
such as kinins (Weissman, 1977). Most prostaglandins are eliminated at their first 
passage through the lung, with very low concentrations reaching the systemic circulation. 
They can therefore be regarded primarily as local mediators or modulators (Weissman, 
1977).
Prostaglandins have been identified in the synovial fluid of human patients 
with inflammatory arthritides such as rheumatoid arthritis (Robinson and Granda, 1974; 
Trang and others, 1977; Higgs and others, 1983). Small (pikogram) concentrations have 
been detected in chronic osteoarthritis in horses (Taminini and others, 1980) and in man 
(Brodie and others, 1980).
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In vitro, PGF2oo has been demonstrated to be more potent than either PGE2 or 
PGD2 in enhancing cartilage degradation (Hubbard and others, 1986). Prostaglandins of 
the E series are known to destabilise lysosomal membranes and cause release of enzymes 
in cartilage. Teitz and Chrisman (1975) found that, in rabbits, chloroquine inhibited 
prostaglandin-induced articular cartilage damage but salicylate did not. The short-term 
incubation of intact canine articular cartilage slices with PGEl and PGE2 caused 
significant depletion of hexosamine, a proteoglycan concentration marker, from the 
cartilage matrix compared to control cartilage. Chloroquine, a known inhibitor of DNA 
primer, prevented the prostaglandin-induced hexosamine depletion. The experiment 
suggested that PGE may directly induce cartilage degradation via a DNA-dependent RNA 
controlled synthesis of proteases (Fulkerson and others, 1979). PGE also appears to 
inhibit in vitro production of cartilage ground substance by chondrocytes in culture (Teitz 
and Chrisman, 1975).
2.2.2 Leukotrienes and Hydroxy Arachidonic Acid Products
The role of lipoxygenase products in inflammation remains poorly defined. 
Recent experiments have suggested that leukotrienes C4, D4, and E4 (previously known 
as slow-reacting substance of anaphylaxis or SRS-A) are primarily involved in immediate 
hypersensitivity reactions including bronchospasm and hypotension. LTB4 is a very 
potent chemotaxin, especially for polymorphonuclear leucocytes, can cause smooth 
muscle contraction and affects capillary permeability. LTB4 increases vascular 
permeability and augments prostaglandin effects (Higgins, 1985).
There is little evidence that lipoxygenase products are important mediators in 
chronic inflammation (Dawson and Willoughby, 1985). Lipoxygenase products have not 
been demonstrated in osteoarthritis, although raised concentrations have been identified in 
rheumatoid arthritis, spondylarthritis and psoriasis (Klickstein and others, 1980; 
Hammastrom and others, 1975). LTB4 has been detected at increased concentrations in 
inflamed joints and soft tissues in horses (Higgins, 1985). The blockade of the 
cyclooxygenase pathway with low doses of Non-Steroidal Anti-Inflammatory Drugs 
(NSAIDs) may make available more arachidonate substrate for the uninhibited 
lipoxygenase pathway, and higher concentrations of leukotrienes may be generated 
(Higgs and Vane, 1983). Whether this of any practical significance is not known.
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Though the eicosanoids are undoubtedly important in acute inflammation, 
other mediators are also important. Rats with a deficiency of essential fatty acids, such 
that eicosanoid generation was compromised, showed an acute inflammatory response 
similar to that in normal rats (Bonta and others, 1977). Most authors now consider that 
the eicosanoids are less important in chronic inflammatory conditions than in acute 
inflammation. From the evidence presented above, it can be concluded that the 
prostanoids, particularly PGE and PGF2°°, have effects on cartilage in vitro and may 
have actions in the inflammatory arthritides. However, only small concentrations have 
been detected in osteoarthritic synovial fluid and cyclooxygenase inhibitors do not inhibit 
the progression of disease. It is likely that prostaglandin release is responsible for 
augmenting painful stimuli and is a modulator of the synovitis present in some cases of 
osteoarthritis. This would explain why NSAIDs have proved so useful in controlling the 
symptoms of osteoarthritis.
The prostanoids are important because, currently, they are the most important 
inflammatory mediators which can be affected by drug therapy. The overall blockade of 
prostaglandin biosynthesis by NSAIDs results in the inhibition of anti-inflammatory 
prostanoids as well as pro-inflammatory prostanoids and may not be as useful as first 
thought. A selective inhibition of the formation of pro-inflammatory prostanoids, PGE2 
and TXA2, would apparently be preferable. NSAIDs have not shown any beneficial 
effect on the progression of osteoarthritic changes in joints and many appear to accelerate 
cartilage degradation (see 3.3.6). It is now thought that monocyte and lymphocyte factors 
such as cytokines including interleukin-1 may be more important mediators (Weismann, 
1977; Dawson and Willoughby, 1985; Howell, 1989).
2*2 Platelet Activating Factor
Platelet Activating Factor (PAF) which is derived from membrane 
phosphatidylethanolamine has received much interest and has been the subject of much 
recent study. Its precise role in acute or chronic inflammation is not yet clear but one of 
its effects is the stimulation of generation of reactive oxygen species (see 2.4). Other 
known effects of PAF are chemotactic effects, platelet aggregation and stimulation of 
lysosomal enzyme release (Dawson and Willoughby, 1985; Howell, 1989).
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ZA Reactive Oxygen Species
Reactive Oxygen Species (ROS) or oxygen-derived free radicals are formed 
predominantly by metabolic activity of neutrophils and macrophages. The interconversion 
of the endoperoxide prostaglandins by prostaglandin hydroperoxidase and the 
cyclooxygenase-dependent generation of PGG2 also liberate ROS (Halliwell, 1981; 
Halliwell and Gutteridge, 1984; Hitt, 1988). PAF stimulates ROS release (Dawson and 
Willoughby, 1985). Highly reactive molecules or ions can cause damage to proteins or 
other molecules close to the origin of their formation. It is believed that superoxide and 
secondary radicals probably have considerable significance in inflammatory conditions 
(Higgins, 1985; Hitt, 1988).
Interleukin-1 is known to stimulate ROS generation by chondrocytes which 
may contribute to proteoglycan damage or inhibition of synthesis (Tsukasa and others,
1988). Reactive oxygen species are known to depolymerise hyaluronic acid (Ahlengard, 
1978; Greenwald, 1981) and also mediate an inhibitor of proteoglycan synthesis in 
articular cartilage culture (Bates and others, 1984). Hyaluronic acid and two 
subcomponents of the molecule have been demonstrated to have a ROS-scavenging 
action which increases in synovial fluid from human patients with rheumatoid arthritis 
(Sato and others, 1988).
In rheumatoid arthritis ROS may be an important mechanism of inflammation 
and damage (Hitt, 1988). One possible mechanism of blood-induced arthropathy is the 
iron enhanced generation of hydroxy free radicals which could then cause tissue damage, 
hyaluronic acid degradation and attack of the cartilage surface (Halliwell, 1981; Halliwell 
and Gutteridge, 1984; Madhok and others, 1988). ROS generated by the arachidonic acid 
cascade may be involved in synovial inflammation. Chondrocyte derived ROS may have 
effects on proteoglycan integrity in osteoarthritis.
ZA Cvtokines
The cytokines are a group of structurally different proteins and glycoproteins 
which are produced by cells in response to mitogenic or antigenic stimulation. They are 
classified by their effects on macrophage and lymphocyte target cells and on their origin. 
The biological effects of cytokines have been quite well elucidated and many have been 
sequenced and reproduced synthetically. The cytokines include the interleukins (IL), 
tumour necrosis factors (TNF), interferons (IFN) and osteoclast activating factor (OAF).
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In osteoarthritis, wear particles or free proteoglycans may stimulate synovial 
cell production of cytokines and there is increasing evidence for an important role for 
cytokines in amplifying and controlling cartilage destruction and synovial proliferation 
with special reference to EL-l(oo and 6) and the historically closely-related or 
synonymous factors catabolin (Dingle, 1981; Saklatvala and others, 1984) and 
mononuclear cell factor, and TNF°o (Yocum and others, 1988). The exact role of 
cytokines in cell-cell communication, and the inter-relationships of IL-1, secondary 
messenger systems, final target enzyme responses and/or inhibitors of synthetic 
responses is not entirely understood.
Some of the experimental evidence that cytokines have a role in osteoarthritis 
and other arthritides is given in 2.5.1 to 2.5.7. A diagrammatic representation of some of 
the possible actions and interactions of IL-1 is given in FIG 4.
2.5.1 Joint Inflammation and Pain
When arthritis was induced in rats by the intraarticular administration of 
peptidoglycan-polysaccharide, subsequent intraarticular administration of IL-1 or TNF-«> 
caused acute joint swelling, pain, and histological evidence of an acute inflammatory 
reaction. IL-1 was ten times as potent as TNF-°o. The effect was dose related and heat 
inactivated. The investigators proposed that IL-1 and/or TNF-<» may have an important 
role in chronic synovitis (Stimpson and others, 1988).
2.5.2 Mediator effects
(a) Synovium:
IL-1 induces cyclooxygenase conversion of arachidonic acid acid to PGG2 in 
rheumatoid synovial cells (Mizel and others, 1981). Cyclooxygenase inhibitors decrease 
arachidonic acid conversion in cells stimulated by DL-1. Prostaglandins may be involved 
in IL-1 stimulation of Phospholipase A2 activation (O'Neill and others, 1987). Goddard 
and others (1988) found that PGE2 production by the synovium before IL-1 
administration was similar for osteoarthritis and rheumatoid arthritis. IL-1 administration 
caused a significant increase in PGE2 production in both osteoarthritis and rheumatoid 
arthritis, although the reaction was more marked in the rheumatoid synovial cells.
IL-1, TNF-oo, and TNF-6 stimulate PGE2 production by synovial fibroblasts 
(Dayer and others, 1986; Amento and Hayes, 1988; Linsey, 1988). IL-1 and TNF-©o are 
more potent than TNF-6 (Amento and Hayes, 1988). The cytokine activities have been 
demonstrated to be synergistic (Amento and Hayes, 1988).
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IL-1 and TNF have been found to enhance bradykinin-induced PGE2 release 
from rheumatoid synovial fibroblasts. EL-1<» was more effective than EL-16 or TNF-«» 
and the latter were much more effective than EL-2. Both dexamethasone and indomethacin 
inhibited PGE2 release (93% and 97% respectfully). The study demonstrated that 
cytokines in inflammatory tissues enhance cellular responsiveness to bradykinin and so 
may promote the inflammatory component of arthritis (Batham and Wigley, 1988).
(b) Cartilage:
IL-1 activates Phospholipase A2 activity in rabbit chondrocytes (Chang and 
others, 1986) and induces chondrocyte release of prostaglandins and plasminogen 
activator (McGuire-Goldring and others, 1984; Evequoz and others, 1984a,b). Human 
recombinant EL-16 stimulates chondrocyte production of PGE2, 6-keto-PGFl°°, and 
thromboxane B2 (Chin and Lin, 1988).
2.5.3 Enzvme release from svnovium and chondrocytes
Interleukin-1 (EL-1) has been shown to stimulate the release of collagen and 
proteoglycan-degrading metalloproteinases from both synovial cells and chondrocytes 
(Barret and Saklatvala 1985; Pasternak and others, 1986). EL-1, TNF-<», and TNF-6 
stimulate collagenase production by synovial fibroblasts, EL-1 and TNF-«» being more 
potent than TNF-6. The cytokine activities are synergistic. EFN-gamma inhibits the 
cytokine stimulation of collagenase activity (Amento and Hayes, 1988).
Synovial cells stimulated by EL-1 produce Plasminogen Activator 
(PA)(Lindsey, 1988). Indomethacin and piroxicam inhibit EL-1 stimulated PGE2 
production by 95% and sodium salicylate inhibited production by 80-90%. Indomethacin 
and piroxicam inhibit EL-1 stimulated PA production by over 80% but sodium salicylate 
inhibited production by only 25-50%. PA production is partially restored by the 
concomitant administration of PGE2. It is believed that PA production was inhibited 
partly via inhibition of prostaglandin formation (Lindsley, 1988).
IL-1 or other macrophage products are known to cause the release of 
collagenase and 6-glucoronidase from articular chondrocytes (Evequoz and others, 
1984a&b). IL-1 stimulates cartilage degradation and the production of collagenase and 
proteoglycanase by human chondrocytes in vitro (Gowen and others, 1984). IL-1 is 
specific for the secretion of a specific metalloproteinase from chondrocytes (Schnyder 
and others, 1987).
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2£A  GLycosaminoglvcan Synthesis and Degradation
IL-16 stimulates glycosaminoglycan production in human synovial fibroblast 
cultures (Yaron and others, 1987).Yaron and others (1988) have investigated the 
activities of cytokines in human synovial fibroblasts and articular cartilage cultures. In 
synovial fibroblasts they found that EL-l°o and IL-16 increased hyaluronate production 
up to five fold and TNF-©o increased hyaluronate production 2.5 fold. Production of 
sulphated glycosaminoglycans increased by just under two fold when IL-1 or TNF were 
administered. IFN-gamma had a mild stimulatory effect. Indomethacin had no effect on 
the stimulation of hyaluronate production by cytokines but hydrocortisone caused a 
significant reduction in stimulation (Yaron and others, 1988).
In articular cartilage, cytokines caused a decrease in sulphated 
glycosaminoglycan production (Pettipher and others, 1986). The order of potency was 
IL-16 > IL-loo »  TNF-oo. Neither indomethacin nor hydrocortisone influenced cytokine 
induced inhibition by either IL-1 preparation. The study indicated that cytokines released 
in inflammation may significantly effect glycosaminoglycan synthesis by synoviocytes 
and chondrocytes in joints (Yaron and others, 1988). Lymphokines induce cartilage 
proteoglycan degradation and synovitis in vivo (Taplits and others, 1979). IL-1 induces 
proteoglycan degradation in cultured articular cartilage with a loss of 60-80% of 
proteoglycan from the matrix after 4 days of treatment (Hardingham and others, 1987).
It is believed that IL-1 stimulates cartilage proteoglycan degradation and PGE2 
release, and inhibits proteoglycan synthesis through independent post-receptor 
mechanisms. IL-1 is ten times more potent at inhibiting proteoglycan synthesis as it is at 
stimulating proteoglycan breakdown. The effects of IL-1 on proteoglycan metabolism 
occur before any PGE2 effect. In addition, NSAIDs have no effect on proteoglycan 
synthesis or breakdown at concentrations which totally block IL-1 induced PGE2 release. 
Anti-arthritic drugs which block IL-1 induced breakdown (eg Chloroquine) fail to block 
proteoglycan synthesis inhibition and in fact potentiate the inhibition seen with IL-1 alone 
(Amer and others, 1988).
2.5.5 Tissue anabolic and catabolic effects
IL-1 induces fibroblast proliferation in human synovium (Postlethwaite and 
Kang, 1983) and stimulates collagen and fibronectin synthesis by cultured rheumatoid 
synovial cells (Krane and others, 1985). IL-1 also has a profound but reversible 
cytostatic effect on chondrocytes which is not attributable to prostanoid or polyamine 
synthesis induction (Chin and Lin, 1988). IFN-gamma inhibits collagen synthesis by 
synovial fibroblasts (Amento and Hayes, 1988). Conversely, TNF-6 stimulates synovial 
fibroblast synthesis of collagen (Amento and Hayes, 1988).
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2JL& Free Radical Generation/Immune Mechanism
An immune mechanism of cartilage degradation involving superoxide anions 
has been suggested by Tiku et al.(1988). Chondrocytes are potent cellular sources of 
reactive oxygen species and IL-1 and IFN-gamma cause a dose dependent increase in the 
release of superoxide anions from chondrocytes. These superoxide anions are known to 
alter the functional properties of proteoglycans. It was proposed that the effect of 
superoxide anions may augment the effects of increased collagenase and proteoglycanase 
release by chondrocytes in response to IL-1.
2,5,7 Bone metabolism
Some authors have demonstrated no effect of IL-1 on osteoblasts (Gowen and 
others, 1984). Others have demonstrated IL-l-induced bone resorption and suppression 
of bone collagen and osteocalcin synthesis. Therapeutic concentrations of diflunisal, 
indomethacin, mefenamic acid, naproxen, piroxicam, salicylate and sulindac had no 
effect on this activity. Pharmacologic concentrations of diclofenac, benoxaprofen, 
fenclofenac, indomethacin and sulindac sulphate did block IL-1 activity 
(McGuire-Goldring and others, 1984). IL-1 may modulate bone metabolism via PGE2 
release. It has been stated that lymphokine-mediated bone resorption requires endogenous 
prostaglandin synthesis (Bockman and Repo, 1981).
2.6 Growth Factors
Various factors which stimulate the growth of cartilage have been studied 
(Castor and others, 1985; Davidson and others, 1985; Spom and others, 1986; Castor,
1989). Decreased filtering capacity of the damaged proteoglycan matrix in osteoarthritic 
cartilage may reduce the barrier to the diffusion of growth factors such as connective 
tissue activating peptide (CTAP), platelet-derived growth factor (PDGF), 
pituitary-fibroblast growth factor or insulin growth factor-1 (IGF-1 or somatotrophin C) 
which may amplify repair responses. Insulin appears to be essential for adequate 
synthetic responses in chondrocytes. Insulin growth factor-1 (IGF-1) appears to amplify 
responses and reacts with specific receptors as well as with insulin receptors on 
chondrocytes. IGF-1 has been found to stimulate proteoglycan synthesis in vivo and to 
inhibit catabolism in vitro (Schalkwijk and others, 1988). It may be that IGF-1 levels or 
changes in chondrocyte responsiveness are involved in inflammatory or degenerative 
diseases.
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2iZ Chondrocyte-Derived Proteins
Chondrocytes from human patients with osteoarthritis produce "stress 
proteins" such as SP-70. These proteins are also produced by chondrocytes subjected to 
heat shock or oxygen deprivation. In osteoarthritis, friction may cause local increases in 
temperature or increased chondrocyte metabolism may induce oxygen deprivation in 
chondrocytes and the release of stress proteins. It is known that prolonged exposure of 
cells to stress proteins can cause interferences with nuclear function and this could be a 
mechanism by which chondrocyte metabolism decreases in severe, late-stage 
osteoarthritis. The elimination half life of stress proteins is known to be decreased in 
osteoarthritic cartilage (Kubo and others, 1985).
Fibronectin is a glycoprotein, the function of which is not fully understood. It 
may be involved in opsonisation, cell adhesion, migration, or differentiation. It is present 
in connective tissue matrices, in blood and on cell surfaces (Hynes, 1981; Ruoslahti and 
others, 1982). Fibronectin concentration increases in fibrillated cartilage and synovial 
fluid of osteoarthritic joints (Lust and others, 1986). Fibronectin synthesis is increased 
five-fold in osteoarthritic cartilage in vitro (Wurster and Lust, 1982; 1984). The function 
of fibronectin in damaged cartilage is not known (Brandt, 1986).
2x3 Proteoglycan as a mediator
Mechanical erosion of cartilage in early osteoarthritis leads to the liberation of 
"wear particles" of cartilaginous tissue into the synovial fluid. It appears that these wear 
particles cause cellular activation by either chemical or physical means (Dingle and others,
1979).
Osteoarthritic synovial fluid is known to contain greater than 100 JLig/ml of 
cartilage proteoglycan (Gysen and others, 1982). Elevated levels of proteoglycans have 
been recovered from the synovial fluid of dogs after anterior cruciate ligament transection 
within three weeks of surgery (Heinegard and others, 1985). Exogenous proteoglycan 
subunits suppress the synthesis of collagen by chondrocytes in vitro (Hadley and others
1980). Boniface and others (1988) discovered that when autologous cartilage 
proteoglycan was injected intraarticularly twice a week, synovial hypertrophy, synovitis, 
erosion of the articular surfaces, and loss of articular cartilage metachromasia were 
rapidly induced in rabbits. Neutral collagenases and gelatinase enzymes were produced 
by synoviocytes and chondrocytes and the synoviocytes also produced factor(s) which 
were possibly related to IL-1 and which provoked the activation of chondrocytes. The 
authors proposed that proteoglycan fragments mediate some of the pathophysiological 
changes in arthritis.
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The investigators were uncertain of the mechanism of synoviocyte activation. 
It was thought that an immunological reaction (ie. an antigen-induced arthropathy) was 
unlikely since, first, a reaction to proteoglycan administration was rapidly induced 
although the animal had not received a primary challenge. Second, immunisation is said 
to be poor by the intraarticular route. Third, the uniformity of the response was not 
suggestive of an immune response and, finally, no precipitating antibodies to 
proteoglycans were detected in the sera of rabbits administered intraarticular proteoglycan 
(Boniface and others, 1988). Some evidence of a humoral immune response is 
documented (Kresina and others, 1988).
Proteoglycans may have a more important role in the pathophysiology of 
osteoarthritis, where there are fewer apparent potential biochemical mediators than in 
rheumatoid arthritis where several potential mediator candidates have been identified.
Z2  Immune reaction in osteoarthritis
Partially degraded fragments from damaged cartilage are present in large 
amounts in synovial tissue. More fragments of cartilage are seen in osteoarthritis than in 
rheumatoid arthritis where cartilage lysis is more common. Though the role of 
antibody-antigen complex generation in osteoarthritis pathophysiology is uncertain, the 
exposure of normally hidden and therefore potentially immunogenic autoantigen in 
cartilage may contribute to the pathogenesis of osteoarthritis.
Some authors have found evidence of a humoral immune response to 
autologous cartilage proteoglycan which they proposed could participate in the induction 
of cartilage pathology (Kresina and others, 1988). A 550 kiloDalton glycoprotein 
fragmented in osteoarthritis has been shown to be immunologically cross-reactive (Fife, 
1986).
Immunohistological investigations of phagocytes in osteoarthritic synovial 
fluid have demonstrated collagen Type II in 28% (3-54%) of synovial cells from 
osteoarthritis patients. The data indicated that type II collagen, which is not found in 
normal synovial fluid, is released from cartilage in osteoarthritis (Moreland and others,
1988). Auto-antibodies to canine collagen Types I and II have been detected in dogs with 
spontaneous anterior cruciate ligament rupture and osteoarthritis (Niebauer and Menzel, 
1982; Niebauer and others, 1987; Bari and others, 1989). Autoantibodies to Type I, n, 
IX and XI collagen have been detected in humans with rheumatoid arthritis or 
osteoarthritis. Surprisingly, the autoantibodies were more common in less severe 
osteoarthritis or rheumatoid arthritis, or in early phases of the diseases (Chaniere and 
others, 1988).
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The reactivity of monoclonal anti-Type II collagen antibodies with cartilage 
and synovial tissues in osteoarthritis and rheumatoid arthritis has been investigated 
(Klareskog and others, 1986). Antibody reacted with collagen in cartilage of both the 
osteoarthritis and rheumatoid joint but did not react with normal joint cartilage. Antibody 
also reacted with cartilage fragments in the synovium of both rheumatoid and 
osteoarthritis joints as well as rheumatoid pannus. It was concluded that in the normal 
joint, cartilage antigenic determinants of collagen Type II are not exposed to antibody. 
However, in inflammatory or degenerative joint conditions, proteoglycans are released 
from cartilage and new antigenic determinants are exposed including Type II collagen 
(Gay and others, 1986; Klareskog and others, 1986).
In studies on autoantibody specificities of immune complexes sequestered in 
the articular cartilage of patients with osteoarthritis, Jasin (1985) reported that 
osteoarthritis cartilage contained three times the concentration of IgM and IgG of normal 
articular cartilage. Half the osteoarthritis specimens had significant positive Collagen 
Type II antibody titres. Fifty per cent of osteoarthritis menisci also had significant 
anti-Collagen Type II antibodies. It was suggested that autoimmunity could be a 
mechanism for the self perpetuating and chronic nature of cartilage degradation in 
osteoarthritis.
In horses with secondary osteoarthritis, circulating complement Clq-binding 
immune complexes were present in 82% of cases and in synovial fluid in 77%. Few 
horses had antibody to Type II collagen but anticollagen type I antibody was present in 
25% of sera and 41% of synovial fluid (Niebauer and others, 1988). Immune complexes 
may initiate local tissue damage by activating the complement cascade and secondary 
release of lysosomal enzymes (Cooke and others, 1980; Cooke, 1981; Cooke, 1983). In 
experimentally induced secondary osteoarthritis, immunoglobulin-complement factor C3 
deposition in cartilage has been reported (Moskowitz and Kresina, 1985). These 
complexes were likely to be associated with a secondary synovitis and the investigators 
believed that immune complexes may contribute to osteoarthritis pathology.
1.2.10 Crvstal-induced inflammatory response
Hydroxyapatite crystals are sometimes seen in synovial fluid of osteoarthritic 
joints. It appears that they have the potential to stimulate a secondary inflammatory 
response. The mechanism may involve destabilisation of the synovial fibroblast plasma 
membrane and synthesis or release of PGE2, collagenase and neutral proteases (Mankin, 
1981; Mankin, 1985; Howell, 1989; Hough and Sokoloff, 1989).
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2J1  Enzvmes
There have been many reports on the degradative enzymes and enzyme 
inhibitors present in normal and osteoarthritic articular cartilage (eg. Lack and Ali, 1967; 
Sapolsky and others, 1973; Harris, 1974; Ehrlich and others, 1975; Howell, 1975). A 
correlation between articular cartilage collagenase activity and osteoarthritis has been 
reported (Ehrlich and others, 1978).
Chondrolytic enzymes are both lysosomal and extralysosomal.
Concentrations of cathepsin D, acid phosphatase and aryl sulfatase are raised in 
osteoarthritic cartilage. Acid proteases such as lysosomal enzymes, Cathepsins B, D, and 
F may be involved in terminal matrix protein degradation. They are most probably active 
on or near the chondrocyte plasma membrane since the pH has been found to be more 
acidic (Woessner and Howell, 1983). However, neutral proteoglycanases are now 
thought the primary enzymes responsible for proteoglycan degradation. Proteoglycan 
degrading neutral metalloproteinase (NMP) activity is increased 7-8 fold in fibrillated and 
eroded cartilage. Active NMP is found in highest concentration in the centre of erosions 
and decreases towards the margins. The major form of NMP is a latent form of M.W. 
55,000 (Woessner, 1982). A second form has a M.W. of 24000-27000 (Sapolsky and 
Howell, 1982; Woessner and Selzer, 1984). Neutral metalloproteinase (NMP) and serine 
proteinase activities are also increased in experimentally induced osteoarthritis in dogs 
(Pelletier, 1987). An acid metalloproteinase which also has activity in the neutral pH 
range has been reported (Azzo and Woessner, 1986). The IL-1 stimulation of such 
chondrocyte enzyme production may be the mechanism of cartilage degradation (Evequoz 
and others, 1984a&b; Gowen and others, 1984; Barret and Saklatvala, 1985; Pasternak 
and others, 1986; Schnyder and others, 1987).
Chondrocytes secrete acid and neutral metalloproteinases as proenzymes 
(Woessner, 1982; Dean and others, 1988). These proenzymes then require extra-cellular 
activation. The most likely candidate for proenzyme activator is a serine protease such as 
plasminogen activator. The levels of proenzyme converting enzyme may be increased in 
osteoarthritis. There may be a cascade-type reaction such that the activated enzyme is able 
to catalyse the conversion of proenzymes secreted by the chondrocytes (Morales and 
others, 1983; Sapolsky and others, 1985; Dean and others, 1988).
Concurrently, specific tissue inhibitors of metalloproteinases (TIMPs) are also 
secreted and cover the metalloproteinases (Sapolsky and others, 1981; Killackey and 
others, 1983; Dean and others, 1988). A decrease in TIMPs has been proposed as 
another mechanism responsible for increased enzymatic destruction of the cartilage matrix 
(Dean and others, 1988).
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When the acid and neutral metalloproteinase activities and levels of TIMP in 
osteoarthritic articular cartilage is compared to normal articular cartilage, a number of 
differences are apparent In mild osteoarthritis lesions, there is a disturbance of the 
enzyme profile with an increase in acid metalloproteinase compared to normal cartilage. 
In moderate osteoarthritis, increased enzyme levels (both latent and active) of acid and 
neutral metalloproteinases were present. Although TIMP increases in mild and moderate 
osteoarthritis, the increase was less than that in metalloproteinase activity. In normal 
cartilage there is sufficient TIMP to "cover" the total metalloproteinase. In osteoarthritis, 
the overabundance of metalloproteinases which are not covered by TTMP has been 
postulated as a pathobiochemical phenomenon which makes the cartilage matrix liable to 
attack by activated metalloproteinases (Dean and others, 1988).
Synovial cells are able to synthesise neutral metalloproteinases, Cathepsin D 
and collagenase which may potentiate matrix degradation and may be associated with 
ROS tissue damage in some circumstances (Greenwald, 1981). Synovial fluid contains 
potent enzyme inhibitors including oo-2-macroglobulin and <»-l-antitrypsin. However, 
these inhibitors could be damaged by enzymes secreted by leukocytes in the synovium. 
In the later stages of cartilage erosion, synovial fluid enzyme damage may participate in 
the pathophysiology of osteoarthritis (Amoczky and Marshall, 1981; Howell, 1989).
2,12 Summary
There is overwhelming evidence that mediators and enzymes are involved in 
the pathogenesis of both primary and secondary osteoarthritis. Recent studies have 
indicated that various mediators can promote or provoke osteoarthritic pathology. Certain 
drugs can inhibit experimentally induced and natural secondary osteoarthritis. It is now 
obvious that osteoarthritis is not purely a process of wear and tear.
There is substantial evidence that proteoglycan fragments present in synovial 
fluid can induce synovial inflammation and cartilage damage. The mechanism appears to 
be a mediator-receptor type of effect and not via an immune response. There is evidence 
to suggest that in osteoarthritic joints, collagen type II and others stimulate an immune 
reaction as cartilage fragments sequestered in the synovium and as previously "hidden" 
collagen is exposed as the cartilage is degraded. Hydroxy apatite crystals released from 
subchondral bone may be involved in synovial inflammation.
Research interest has concentrated in recent years on the cytokines. In vitro 
and in vivo experiments have demonstrated that interleukin-1 (IL-1) has actions on the 
synovium and chondrocyte which tend to mimic those of osteoarthritis. IL-1 is known to 
be released from the synovium in response to proteoglycan fragments or wear particles.
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Effects of IL-1 on the synovium include increased synthesis and release of 
prostaglandin E and proteases and the promotion of pain and inflammation. Effects on the 
chondrocyte include a marked inhibition of proteoglycan synthesis and an increase in 
degradative enzyme production. Chondrocyte mitosis is inhibited and cartilage 
degradation increased. Various growth factors including insulin growth factor-1 (IGF-1) 
have stimulatory effects on cartilage. The role of recently discovered chondrocyte "stress 
proteins" and of chondrocyte associated glycoproteins such as fibronectin is still 
uncertain.
Although the prostaglandin inhibitors (NSAIDs) are of benefit in controlling 
some of the symptoms of osteoarthritis (pain and synovitis), they do not inhibit the 
disease process and there is little evidence that prostaglandins or leukotrienes are 
important mediators of the pathogenesis of the disease process in osteoarthritis. 
Prostaglandins are apparently important in the modulation of pain and synovial 
inflammation in clinical osteoarthritis. It is recognised that IL-1 stimulates prostaglandin 
synthesis in the synovium. Reactive species generated by PMNs and the prostaglandin 
interconversion may be involved in tissue damage. IL-1 generated ROS in articular 
cartilage may damage matrix proteoglycan.
Whatever the precise inter-relationships between mediators and between 
biochemical and physical factors, the net result is altered chondrocyte function. 
Alterations in proteoglycan synthesis and increased degradation by neutral 
metalloproteinases, possibly in association with a relative deficiency of tissue inhibitors 
of metalloproteinases (TIMPs) cause damage and loss of proteoglycan. The elasticity of 
the cartilage matrix is lost and the collagen network can be damaged by repeated impact 
loading. Proteoglycan loss may also expose the collagen to enzymatic attack and 
mechanical damage. The net result is cartilage fibrillation and erosion. Some of the 
possible events and interactions in osteoarthritis are represented in a simplified form in 
FIG 5. There is undoubtedly a complex network of interrelationships and mediator 
actions and there has been a temptation in the past to oversimplify the proposed 
mechanisms of the pathogenesis of osteoarthritis.
New ideas on mediator based mechanisms of cartilage damage and synovitis 
may lead to novel mediator-antagonist or agonist drugs which will affect the progression 
of osteoarthritic change and not just the symptoms. Agents may be developed which 
specifically antagonise the activity of cytokines in the joint, which mimic growth factors 
or which stimulate chondrocyte repair mechanisms. Even now, there are drugs available 
which have some of these actions and it is likely that disease-modifying drugs will 
eventually revolutionise the therapy of osteoarthritis.
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Chapter 3
Medical Therapy of Osteoarthritis 
in the Dog
3Medical Therapy of Osteoarthritis in the Dog 
2x1 General Concepts in the Treatment of Osteoarthritis in the Dog
It is important first and foremost to recognise the aims of owner and 
veterinarian in management of the osteoarthritic dog. These aims include pain relief, 
increased mobility and reduced disability, and the prevention of disease progression. It is 
important to recognise differences in the clinical problems and the disease severity 
experienced by the individual dog.
Pain is a major symptom of osteoarthritis in the dog as it is in man. The 
threshold of pain perception seems to be remarkably constant in different species (Vierck, 
1976). Pain tolerance may vary widely between species and between individuals 
according to circumstances. A dog will often manifest the presence of pain by simply 
appearing less lively than usual. Where osteoarthritis affects a joint unilaterally, lameness 
is an almost ubiquitous sign of joint pain. Where an osteoarthritic joint is not apparently 
markedly painful on manipulation, it may still be causing chronic pain (Yoxall, 1978). A 
dog's "quality of life" may improve markedly when analgesics are given. The source of 
pain experienced by osteoarthritis patients has not been determined. Some possible 
causes are listed in TABLE 3. Human patients with osteoarthritis complain of "articular 
gelling" after a period of inactivity. The mechanism may be a subjective perception of 
increased resistance to motion, localised tissue oedema, accumulation of inflammatory 
metabolic products or motion causing muscle pressure on lymphatic or venous 
retum.Weakness is largely the result of disuse muscle atrophy. The decrease in joint 
mobility or range of motion in joints affected by osteoarthritis may have many causes (see 
TABLE 41.
TABLE 2:
Possible Causes o f Pain in the Osteoarthritic Joint
TABLE 4:
Possible intra-articular causes o f  reduced ioint mobility:
•Stimulation o f nerve endings in 
-synovium,
-joint capsule,
-periosteum,
-ligamentous or tendinous tissues by mechanical 
irritation or by inflammation;
•Nerve entrapment;
•Local circulatory disturbances associated with 
subchondral microfractures;
•Capsular tears;
•Impingement o f deformed bone or osteophytes 
on adjacent soft tissues;
•Pressure during muscle spasm on nerves coursing 
through muscular tissue.
•Luxation or subluxation o f the joint;
•Capsular fibrosis, contraction and thickening; 
•Intra-articular adhesions; Fibrous ankylosis;
•A tense effusion;
•Extreme thickening o f  the synovium;
•Intra-articular loose body 
•Late bony ankylosis
Possible extra-articular causes o f  reduced ioint mobility:
•Muscle spasm
•Tendon inflammation/shortening 
•Subchondral bone fractures
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Successful therapy of a case of osteoarthritis depends upon the education of 
the owner. The often progressive, irreversible nature of the disease and the 
unpredictability of the individual case must be explained. The veterinarian should 
differentiate between treating the causes or predisposing/aggravating factors and the use 
of NSAIDs for symptomatic relief. It must be explained that although analgesics can 
affect the symptoms in the short or medium term, the main aim is to change the 
progression or activity of the disease state by reducing further joint damage.
Therapy falls into four broad categories:
1. Corrective treatment for primary pathology
2. Managemental therapy
3. Medical therapy
4. Surgical therapy / salvage
3.1.1 Corrective Treatment
Many cases of canine osteoarthritis have an identifiable cause. The 
progression of secondary osteoarthritis can often be slowed or halted if corrective surgery 
for a primary cause, such as an ununited coronoid process or anterior cruciate ligament 
rupture, is performed early. In all ages of dogs, a full history and careful clinical 
examination often reveals a primary cause of joint instability or incongruity which can be 
ameliorated by surgery.
3xL2 Manageipgntal Therapy
(al Exercise
Carefully thought out and tailored exercise regimes and mechanical 
stimulation of the involved tissues may help to arrest and even reverse the disease process 
(Bland, 1986). Human textbooks emphasise the importance of reducing joint loading in 
the therapy of osteoarthritis patients. Any activities such as running or descending stairs 
which involve excessive impact loading should be avoided. Several short periods of 
standing or walking are preferable to a single prolonged period. Swimming exercise is 
recommended in man, since the muscular tissues are exercised and joint mobility aided 
without impact loading of the joints.
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A reasonable level of exercise is important in preventing stiffness as well as in 
maintaining quality of life. Cyclical loading of joints probably increases the flow of 
nutrients, eg glucose and amino acids to chondrocytes and the removal of metabolites via 
the synovial fluid and matrix. The supply of nutrients and removal of metabolites may be 
compromised if the joint is immobilised. Chondrocytes require mechanical stimulation to 
synthesise matrix components (Sokoloff, 1980). Immobilisation of joints causes the 
rapid development of a marked reduction in proteoglycan synthesis and aggregation 
(Palmoski and others, 1979).
Although hyaline cartilage is an excellent shock absorber, it is present in 
insufficient quantities at the joint surface to make a significant contribution to overall 
shock absorption. Bone is present in larger quantities and has a role in shock absorption. 
However, by far the greatest contribution to shock absorption is the neuromuscular reflex 
mechanism. Indeed, if a person has a short fall such that there is insufficient time for a 
neuromuscular response, he or she can sustain significant injuries. It is thus important to 
maintain musculoskeletal fitness to minimise impact loading damage of articular cartilage 
in cases of osteoarthritis.
Physiotherapy is very useful in man, and can be used in dogs where the dog 
is cooperative and the owner compliant. Heat application often reduces pain and stiffness 
in man, but the use of heat pads has not been assessed in dogs. Sometimes heat 
application intensifies joint pain and ice packs may be used in these cases. The use of 
acupuncture in osteoarthritis has been reported in man (Melzack, 1981) and in the dog 
(Janssens, 1986).
fb) Obesity
Although not confirmed as a cause of osteoarthritis, obesity contributes to 
excessive loading of the articular cartilage and may aggravate symptoms or accelerate 
cartilage breakdown. The difficulty in reducing weight when exercise has been reduced is 
a problem experienced in man as well as in dogs. An increase in weight associated with 
not adjusting dietary requirements when exercise has been reduced can cancel out the 
benefits of changes in exercise regime. Any dog presented with osteoarthritis which is 
obese should be strictly dieted. Many dogs will improve markedly if they are forced to 
adhere to a weight reducing diet Conversely, treatment with exercise restriction and 
analgesics will often have a disappointing effect in a dog which remains or becomes 
obese. The aim is to keep the dog on the low side of the breed average weight.
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3.L2 Medical Management
Even with managements changes, many osteoarthritic dogs will still require 
analgesic therapy. Analgesics provide symptomatic relief and reduce pain and disability 
associated with osteoarthritis. In man, long term use of NSAIDs for osteoarthritis is 
common. The use of these drugs in the dog in conjunction with other forms of treatment 
can greatly enhance the dog's "quality of life" by reducing pain and stiffness and 
increasing mobility. However, they must be used in conjunction with other forms of 
treatment such as owner education and exercise and dietary management. All too often 
veterinarians resort to the convenience of administering oral analgesic treatment in 
isolation without stressing the importance of exercise and dietary management in 
treatment. Owners should be warned that they are responsible for preventing their dog 
from acute trauma to an already damaged joint. Pain relief may cause a dog to over-use a 
damaged joint and cause accelerated disease progression unless the owner controls 
exercise. Beneficial effects of NSAED treatment include:
- pain relief
- decrease the duration and severity of morning stiffness
- decrease tenderness in the joint
- decrease joint swelling, temperature
- increase joint function
(Boardman and Hart, 1967).
3.1.4 Surgery
Arthrotomy and debridement, flushing or synovectomy of an osteoarthritic 
joint can markedly improve clinical signs in the short and medium term if managemental 
and medical therapy fails. Stress-reducing operations in man such as osteotomy have 
been demonstrated to increase the hip joint space, markedly relieve clinical signs, cause 
pseudocyst healing, improvement of bony outline by remodelling and osteophyte 
reduction, and a restoration of normal trabeculae (Bland, 1986). In the most severe cases 
"salvage" surgical procedures such as arthrodesis or femoral head excision may be 
required to ameliorate the clinical signs. Recently, some UK veterinary referral centres 
have begun canine hip joint replacement programmes.
An approach to the therapy of the osteoarthritic dog is given in FIG 6.
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3.2 Symptomatic Medical Treatment of Osteoarthritis in the Dogi
Pure.Analgfisics
3.2.1 Paracetamol (Acetaminophen)
Paracetamol is a weak reversible r , -----------— \
non-competitive cyclooxygenase inhibitor. It /A -A  /
appears to be much more potent in the central H O  -----\ 0 / - A  «snervous system than in the peripheral tissues
(Higgs and Vane, 1983). Standard texts state that
FIG 7: Paracetamol
the analgesic efficacy of paracetamol is equivalent
<
J
to that of aspirin but that paracetamol has no useful 
antiinflammatory effect (Booth, 1982).
However, in a recent study of post-operative pain and inflammation after orthopaedic 
surgery in dogs, paracetamol demonstrated antiinflammatory and analgesic activity 
superior to that of aspirin (Mbum and others, 1988).
Paracetamol is quite safe within the recommended dosage limits. Clinical 
signs of toxicosis (cyanosis, depression, vomiting, facial oedema) are seen in dogs after 
oral administration of 200 mg/kg body weight (Hjelle and Gauer, 1986). Patients 
particularly at risk are those with hepatic microsomal enzyme induction, due to treatment 
with antiepileptiform drugs for example, since they can rapidly form large amounts of the 
toxic metabolic intermediate. Oral methionine or intravenous N-acetylcysteine are 
antidotes after acute paracetamol intoxication. They are converted in vivo to glutathione 
which can then react with the paracetamol metabolite to form non-toxic metabolites 
(Hjelle and Gauer, 1986). Gastric effects of paracetamol are minimal, probably because 
peripheral effects on cyclooxygenase are mild (Rubio and Papich, 1988). There are very 
few reports of hepatotoxicity associated with the therapeutic use of paracetamol (Prescott,
1986).
In man, patients are often treated with paracetamol if the patient is sensitive to 
aspirin since paracetamol is said to give comparative analgesia (Huskisson, 1974; Brandt,
1989) and paracetamol has been stated to be an effective alternative to aspirin for 
analgesic effect in dogs (Rubin and Papich, 1988) although its antiinflammatory activity 
is generally accepted as weak. It seems that paracetamol is potentially useful at a dose rate 
of 15 mg/kg every 8 hours (Jenkins, 1987). A maximum of 25 mg/kg tid has been 
recommended (Taylor, 1987).
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2i2i2* Opiate derivatives
The less potent opioids such as codeine 
and propoxyphene have been used in situations 
where moderate analgesic action is required in 
cases of intransigent pain, especially pain of 
non-inflammatory origin. Codeine has about one 
quarter the potency of morphine but only one tenth 
of the potential for adverse reactions. Constipation 
or slight respiratory depression have been 
recognised side effects of codeine usage (Taylor,
1985).
Propoxyphene is often preferred to codeine because its duration of action is 
longer, it has less side effects and a higher therapeutic ratio than codeine. Medical 
evidence suggests that there is addictive potential in propoxyphene, and discretion should 
be used in dispensing it to owners (Yoxall, 1978). Opioids may cause drowsiness at 
higher doses. Pentazocine may cause hallucinations in small animals and is a Schedule 3 
Controlled Drug.
Hie mixed agonist-antagonist pentazocine is available in tablet form. In 
clinical trials in man, pentazocine tablets were no more effective than paracetamol 
(Huskisson, 1974). In rheumatoid arthritis, pentazocine tablets were not superior to 
placebo (Nuki and others, 1973).
Distalgesic® is a human preparation containing dextropropoxyphene 32.5 mg 
and paracetamol 325 mg. The combination of paracetamol and dextropropoxyphene is 
said to be more effective than the individual component drugs (Messick, 1979).Some 
authors recommend the use of Distalgesic® at 16.5 mg dextropropoxyphene bid for small 
dogs, and up to 32.5 mg tid in large breeds (Yoxall, 1978).
In man, codeine and other narcotic analgesics are rarely required for pain 
control in osteoarthritis and it is advised that, if they are used, the period of use is short 
(Brandt, 1989). Yoxall (1978) advises that veterinarians avoid the use of codeine 
preparations where it is combined with other analgesics. However, some authors have 
recommended that codeine can be used at 2 mg/kg bid alone or in combination with 
aspirin or paracetamol with good effect (Taylor, 1985).
H O
FIG 8: Codeine
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Symptomatic Medical Treatment of Osteoarthritis in the Dog: 
General Properties of Non-Steroidal Anti-Inflammatorv Drugs
i i i i l  Introduction
The Non-Steroidal Anti-Inflammatory Dmgs (NSAIDs) [Anti-Inflammatory 
Analgesics; Non-Narcotic Analgesics; Aspirin-like Drugs] have three major types of 
effect: analgesic; antiinflammatory; and antipyretic. The analgesic efficacy of NSAIDs is 
usually lower than the opioids (Broom and others, 1986), though efficacy varies with 
dose rates and types of peripheral and central pain (McKellar, 1989). However, they do 
not cause dependency. Their antiinflammatory properties can be useful in osteoarthritis 
and other musculoskeletal disorders. Most NSAIDs have analgesic activity, but the 
antiinflammatory activity appears more variable. Some such as aspirin and  ^
indomethacin have potent antiinflammatory activity whilst others such as naproxen and 
meclofenamate have moderate antiinflammatory activity.
NSAIDs have been widely used in the therapy of osteoarthritis in man and 
animals for many years. They relieve pain and may reduce swelling due to secondary 
inflammation but there is tittle evidence that they have any beneficial effects on the 
underlying process. It is not clear at this time whether the activity of NSAIDs in the 
therapy of osteoarthritis is purely analgesic or whether it is a combination of analgesic 
and anti-inflammatory activity. However, antiinflammatory analgesics have been 
demonstrated to be more efficacious in the therapy of osteoarthritis than pure analgesics 
(Doyle and others, 1981). In man, three quarters of osteoarthritic joints show evidence 
of an inflammatory response (Howell, 1981; Dieppe, 1984). It would therefore be 
expected that NSAID treatment would lead to a improvement in many clinical cases. The 
anti-inflammatory effects of aspirin are only apparent at about six times the analgesic 
dose. The dose of many NSAIDs which is required to give an analgesic effect is often 
less than the dose required for anti-inflammatory effect (Dawson and Willoughby, 1985). 
The main differences between the NSAIDs are the incidence of side effects and the 
therapeutic index.
3.3.2 Mechanisms of Action
(a) - Prostaglandin synthesis inhibition
The eicosanoid formation pathway is represented diagrammatically in FIG 
10. Most NSAID activity appears to be due to the inhibition of prostaglandin synthesis 
by reversible or irreversible inhibition of the enzyme cyclooxygenase (Vane, 1971).
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FIG 10: Simplified diagram of the arachidonic acid cascade
and the possible sites of action of NSAIDs, steroids and dual inhibitors
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It is known that aspirin acetylates the cyclooxygenase enzyme at or near the 
active site and so irreversibly inhibits prostaglandin biosynthesis. It appears that most of 
the acidic NSAIDs compete with arachidonic acid for the active site of the 
cyclooxygenase enzyme and, unlike aspirin, reversibly inhibit cyclooxygenase (Ferriera 
and Vane, 1973). Some of the NSAIDs may act on a separate site of the cyclooxygenase 
enzyme [ie reversible non-competative inhibition] (Rainsford, 1984b). The inhibition of 
cyclooxygenase by NSAIDs varies in different tissues as well as between species ( Mills, 
1974; Lewis and Sanford, 1975; Patrono and others, 1976). The reasons are not known. 
This may account for the differences in clinical efficacy between NSAIDs in the treatment 
of different conditions and variations in efficacy between individuals and in different 
species (Higgs and Salmon, 1985).
Some NSAIDs such as alclofenac, azaproprazone, and benoxaprofen are 
weak prostaglandin synthesis inhibitors but still have antiinflammatory activity. Some 
NSAIDs are not cyclooxygenase specific and have effects on lipoxygenase and other 
enzymes (Kitchen and others, 1985). Other actions have been described which, at least in 
some NSAIDs, may have important therapeutic effects.
(bl - Prostaglandin antagonism
Some NSAIDs may have antagonistic actions on theoretical eicosanoid 
receptors (Sanner, 1976). Fenamates, diclofenac, indomethacin and phenylbutazone are 
potent and selective inhibitors of prostaglandin El-induced adenyl cyclase activity 
stimulation (Ortmann and Perkins, 1977). This effect occurred well within therapeutic 
prostaglandin synthesis inhibiting concentrations of the drugs. The fenamates are 
believed to inhibit the action of the prostaglandins at membrane receptors (Dawson and 
Willoughby, 1985).
Many NSAIDs inhibit 15-hydroxy prostaglandin dehydrogenase (PGDH), the 
enzyme responsible for PGE2 and PGF2°° breakdown. However, this effect only occurs 
at very high drug concentrations in most cases (Brooks and others, 1986).
(cl - superoxide dismutase activity
Phenolic compounds can act as scavengers of reactive oxygen species (ROS) 
released in peroxidase conversion of prostaglandin endoperoxide PGG2 (Rainsford, 
1984b). Levels of different individual prostaglandins E2, Fl°°, 12, and D2 can increase or 
decrease depending on direct inhibition or radical scavenging activities (Dewhurst, 1980). 
Copper, zinc and antioxidants such as ascorbic acid and <~-tocopherol inhibit PGE2 
formation (Lands and Rome, 1976).
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(d) - stabilisation of lysosomal membranes
The stabilisation of lysosomal membranes and the inhibition of the release of 
lytic enzymes including phospholipases is a property of some NSAIDs as well as SAIDs. 
The effect is concentration and pH dependent. Changes in prostaglandin concentrations 
and direct drug effects may alter cyclic nucleotide concentrations and so influence 
lysosomal enzyme release. This may be particularly true where LTB4 is inhibited since 
this leukotriene is a potent labilizer of lysosomal membranes. In addition, NSAIDs may 
inhibit free radical generation and so decrease radical induced lysosomal membrane 
damage (Rainsford, 1984b; Dawson and Willoughby, 1985; Kitchen and others, 1985).
(e) - antagonism of histamine/bradvkinin
Most NSAIDs have only mild effects on the early phase of acute inflammation 
where kinins and histamine predominate. There is evidence, however, that these drugs 
may influence the release or action of these mediators (Lewis and Whittle, 1977; 
Rainsford, 1984). They may also inhibit histamine and kinin induced prostaglandin 
release (Kitchen, 1985; Dawson and Willoughby, 1985).
(f) - inhibition of cell chemotaxis and regulation of leukocyte function
Effects on leukocyte migration have been described and have been ascribed to 
effects on the chemotaxin LTB4 or membrane stabilisation effects (Smith, 1978). 
NSAIDs uncouple oxidative phosphorylation. The result is decreased glycogen 
availability and changes in membrane permeability. Increases in intracellular c-AMP 
inhibit leukocyte chemotaxis. NSAIDs may effect the responsiveness of leukocytes to 
chemotaxins (Kitchen and others, 1985). Whether these effects are important in vivo is 
unknown (Rainsford, 1984; Dawson and Willoughby, 1985).
(h) -inhibition of mucopolysaccharide synthesis and collagenase production, and 
uncoupling of oxidative phosphorylation
NSAIDs effect connective tissue metabolism. Most NSAIDs inhibit adenosine 
triphosphate (ATP) synthesis pathways (Kitchen, 1986). This effect and NSAID activity 
on glycosaminoglycan-biosynthetic enzymes and effects of prostaglandins and NSAIDs 
on glycosaminoglycan-degrading enzymes tend towards an overall anti-catabolic and 
anti-anabolic action (Peters and others, 1975; Rainsford, 1984).
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General Pharmacokinetics
Most of the NSAIDs are rapidly absorbed from the proximal small intestine or 
stomach after oral administration. Peak plasma concentrations occur at 1-2 hours after 
administration. Peak concentrations are delayed and reduced when NSAIDs are 
administered with food but feeding generally has no effect on total oral bioavailability 
(Lombardino, 1985). The structure and chemistry of the NSAIDs leads to their 
preferential distribution in inflamed sites. Most of the NSAIDs have a high affinity for 
plasma proteins. In inflamed tissue, the extravas ation of plasma proteins through 
damaged capillaries may concentrate the amount of NSAIDs. Local therapeutic 
concentrations of NSAIDs may be retained after plasma concentrations have declined to 
subtherapeutic levels (Dawson and Willoughby, 1985; Higgins, 1985; Rainsford, 1985; 
Lees and others, 1987). Prolonged effects of NSAIDs have been reported where plasma 
concentrations have become undetectable (Lees and others, 1987).
When drugs have a pKa of between 3 and 7.5, as the acidic NSAIDs, their 
reabsorption from the renal tubule will be sensitive to alterations in urinary pH. Excretion 
of salicylate increases markedly as the urine is alkalinised (Lombardino, 1985). Similar 
findings for other NSAIDs or acidic metabolites may be important in the treatment of 
overdosage or in the adjustment of dosages in performance animals.
Enterohepatic recirculation of 
the NSAIDs is common in the dog 
(Duggan, 1975; Risdall and others, 1978;
Willis and Kendall, 1978; Tsuchia and 
others, 1980; Freh and Rieh, 1981;
Cosenza, 1984; McKellar, 1989).
Conjugates in the bile may be cleaved in the 
gut to regenerate the free acid which can 
then be reabsorbed in the lower intestine.
This regeneration of active drug may cause 
local mucosal irritation and damage and 
prolong the half-life of the drug (FIG 11).
The process appears to be particularly 
important in the dog since, in this species, 
secretion of conjugated metabolites in the 
bile is the main excretory pathway for many NSAIDs. This in part explains the 
gastrointestinal toxicity of a number of NSAIDs which are considerably less damaging in 
people since, for most NSAIDs, renal excretion of conjugates predominates in man 
(Lombardino, 1985). 
t  pKa = pH at which a salt is half ionised
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FIG 11: 
Enterohepatic Recirculation
In addition to species variation in metabolic and excretory pathways, different 
breeds of dogs show different rates of drug clearance. For instance, beagles clear certain 
drugs more quickly than mongrels (Freh and others, 1979). Conversely, they are 
more susceptible to the toxic effects of other drugs (Walker, 1985). Individual variation 
in absorption, distribution and clearance of drugs is also very great in man and in the dog 
(McKellar, 1989; Goetzl and Goldstein, 1989).
3.3>4 Adverse Reactions
The NSAIDs have many adverse effects in common since most side effects 
are attributable to the inhibition of prostanoid biosynthesis (Dearden and Nicholson,
1984).
(a) Gastrointestinal
In human patients admitted to hospital with acute upper intestinal 
haemorrhage, aspirin is implicated in 50% and other NSAIDs in 20%. NSAIDs are 
associated with increased incidence of perforating peptic ulcers, especially in elderly 
patients (Ivey, 1986). Gastrointestinal intolerance appears to be mediated by a 
combination of local and systemic effects (Phillips, 1973; Cosenza, 1984; Rainsford, 
1984a; Brooks and others, 1986; Ivey, 1986; Rubin and Papich, 1988)(FIG_12 & FIG 
12).
The NSAIDs are generally weak organic acids with pKa values of 3-6. At 
lower pH values (ie in the stomach) the drugs are largely unionised and are therefore lipid 
soluble and able to diffuse through biological membranes. In this form the drugs can 
diffuse through the lipid bilayer of the gastric lining cells. Once within these cells, the 
drugs tend to re-ionise at the relatively greater pH in the cytoplasm and can become 
trapped within the cell. The resulting prolonged and relatively high concentrations of 
NSAID within these cells probably contributes to gastrointestinal effects (La Du and 
others, 1972; Rainsford, 1984a; Ivey, 1986). Aspirin which has an irreversible effect on 
cyclooxygenase will have persistent effects in the gastric mucosa after absorption 
whereas reversible inhibitors effects are terminated when the drug has been absorbed. 
Thus drugs which are reversible cyclooxygenase inhibitors and which are rapidly 
absorbed should be better tolerated by the gastric mucosa (Wiseman, 1983).
Mucosal prostaglandins inhibit acid secretion and appear to have a 
"cytopiotective effect" by promoting mucus secretion and strengthening the mucosa 
against back-diffusion of acid from the gastric lumen to the submucosal tissues where it 
can cause damage (Ivey, 1986). PGI2 is produced by cells in the gastric mucosa. It 
inhibits gastric acid production (Whittle and others, 1978).
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Both PGI2 and PGE2 are important in the maintenance of gastric blood flow 
by local vasodilation. NSAIDs which inhibit prostaglandin biosynthesis thus enhance 
vasoconstriction and acid secretion such that ischaemia, necrosis and ulceration can occur 
(Goodman and others, 1980; Ivey, 1986; Jenkins, 1987).
Gastrointestinal intolerance can occur whether the NSAID is given orally or 
systemically. However, gastric effects are worse when drug is administered orally and 
absorption from the stomach is possible since this will result in higher local 
concentrations than if the drug were administered parenterally or in a form which was not 
absorbed from the stomach (Ivey, 1986). To minimise adverse effects, NSAIDs are 
generally given with food in man or are administered in enteric coated preparations which 
reduce the local effects on the gastric mucosa (Booth, 1982; Ivey, 1986). Recent interest 
has been shown in new prodrugs such as fenbufen (see 3.4.6) and sulindac (see 3.4.7) 
which are converted to active metabolites after absorption and should therefore avoid high 
gastric mucosal concentrations and local induction of pathology. Enterohepatic 
recirculation occurs for many NSAIDs in the dog and can cause prolonged local 
concentrations of drug in the intestinal mucosa and so may be an important mechanism of 
gastrointestinal intolerance (see 3.3.3). Chronic blood loss with aspirin treatment is 
apparently common at therapeutic doses in the dog (Phillips, 1981).
(b) Renal toxicity
Prostaglandins are involved in renal blood flow autoregulation, glomerular 
filtration, tubular ion transport, modulation of renin release and water homeostasis. Renal 
prostaglandins do not appear to be important in the control of resting renal blood flow or 
glomerular filtration rate in the normal animal. In contrast, in adverse conditions 
prostaglandins exert a protective effect to preserve renal perfusion where systemic 
vasoconstriction has been induced by mediators such as noradrenaline, alpha adrenergic 
stimulation and angiotensin II (PIG 14). In the normal animal NSAIDs are unlikely to 
have any damaging effects. However, in hypovolaemia and states of decreased renal 
perfusion, inhibition of cyclooxygenase, and hence the inhibition of renal prostaglandin 
synthesis, causes a severe reduction in renal perfusion and reversible or irreversible renal 
insufficiency (TABLE 5) (Kincaid-Smith, 1986; Rubin, 1986).
Prostaglandins in the kidney have an important role in salt and water 
homeostasis. NSAIDs can cause sodium and water retention and oedema. If the retention 
of water is disproportionate, hyponatraemia can develop. Inhibition of the 
renin-angiotensin-aldosterone system can cause hyperkalaemia. NSAIDs reduce the 
diuretic, natriuretic and anti-hypertensive effects of diuretic drugs. NSAIDs also 
counteract the anti-hypertensive effects of the 6-adrenoceptor antagonists, probably via 
their action on renal prostaglandins (Day and others, 1983; Rubin, 1986).
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FIG 14 Possible mechanism of the protective effect of prostaglandins 
in the kidney and the nephrotoxic effects of the NSAIDs
TABLE 5: Pathological Conditions Which Predispose 
to Nephrotoxicity of NSAIDs
1. Reduced circulating blood volume eg. 
-water deprivation
-diuretic therapy 
-haemmorhage 
-nephrotic syndrome
2. Animals in a vasoconstrictive state eg. 
-general anaesthesia
3. Sodium retention eg.
-congestive cardiac disease 
-hepatic cirrhosis
4. Preexisting renal insufficiency
TABLE 6: Pathological Conditions Associated with NSAID Nephrotoxicity
1. - Acute renal insufficiency
(especially in preexeisting congestive cardiac failure, cirrhosis, nephrotic 
syndrome, hypovolaemia secondary to diuresis).
In dogs, high doses of ibuprofen cause acute renal failure.
2. - Papillary necrosis
(described in horses treated with phenylbutazone; associated with 
hypovolaemia due to fluid loss or water deprivation)
3. - Nephrotic sjmdrome and interstitial nephritis 
(possibly T-lyphocyte mediated immune mechanism.
Reversible if treatment is withdrawn)
4. - Sodium and fluid retention
(augment oedema-inducing disease such as congestive cardiac failure; 
decrease efficacy of diuretics eg. frusemide)
5. - Potassium balance
(hyperkalaemia associated with NSAID treatment is reported in man; 
risk increased in sodium depleted patient)
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Acute and chronic clinical syndromes which have been associated with the use of 
NSAIDs are listed in TABLE 6. In man, there is evidence to suggest that uroepithelial 
tumours also occur as a complication of prolonged NSAID use (Kincaid-Smith, 1986).
M  Central nervous system (CNS)
In man, NSAIDs often cause adverse CNS signs including tremors,
weakness, headache, blurred vision, confusion, agitation and ataxia (Dodge, 1979).
Such effects are rarely identified in animals. Dullness is a common reported side effect of ik
NSAIDs buys unclear whether this is due to CNS effects or to abdominal discomfort or 
dyspepsia. Salicylate induced seizures have been reported in a dog (Schubert, 1984).
(d) Hepatotoxicitv
Drugs such as ibufenac, fenclofenac and benoxaprofen have been withdrawn 
from the human market because of hepatotoxicity, and liver damage has been reported on 
occasion for virtually all NSAIDs. Little is known of the mechanisms of hepatotoxicity of 
NSAIDs. Liver enzyme values may be slightly elevated with many NSAIDs in man. 
There may be more potential for hepatotoxicity with certain NSAIDs. In man, these 
include diclofenac, sulindac, pirprofen and phenylbutazone (Prescott, 1986).
(el Dermatological
Rashes, pmritis, and urticaria are common in people treated with NSAIDs 
(Rainsford, 1984; Lombardino, 1985; Brooks, 1986). Skin side effects are poorly 
documented in dogs.
(fl Haemopoetic
The inhibition of platelet aggregation by NSAIDs is due to platelet 
prostacyclin inhibition which reduces platelet aggregation and thromboxane inhibition 
and reduced platelet-capillary wall adhesion. Increased bleeding time may be of 
consequence if there is a preexisting bleeding disorder such as von Willebrands disease, 
other coagulation disorders or gastrointestinal ulceration.
Bone marrow depression has been reported in dogs treated with 
phenylbutazone but is apparently very much rarer than the syndrome in man (Miller and 
Kind, 1962; Ndiritu and Enos, 1977; Schalm, 1979; Watson and others, 1980).
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(g) Pseudoallergic and Hypersensitivity Reactions
Pseudo-allergic adverse reactions to NSAIDs are common in man and are 
probably associated with the protein binding properties of the drugs. Cellular immunity 
usually results in dermatological signs. Asthma and anaphylactic responses are 
documented in man. Extrapolating from work in man, care should be exercised in dogs 
with a known history of hypersensitivity reactions, food allergy or atopy (Szczeklik,
1986).
(hi Pregnancy
Salicylates and other NSAIDs prolong gestation and have demonstrated 
teratogenicity in certain animal studies. Unless treatment is imperative, NSAID treatment 
should be avoided in pregnant animals (Heymann, 1986).
3,3^5 Drug interactions
(al Antacids and Food
Antacids decrease the gastrointestinal side effects of NSAIDs. However, the 
rate and extent of absorption of some NSAIDs can be reduced. Administration of 
NSAIDs and antacids with food may antagonise any antacid-induced reduction in drug 
absorption (Tolbert and others, 1981). Excretion of active drug is only affected by 
urinary pH in selected cases where the NSAID is excreted unchanged eg. salicylate. 
Large doses of oral antacids will raise urinary pH and promote excretion of salicylate (La 
Du and others, 1972; Day and others, 1983).
Administration of NSAIDs with food decreases the incidence and severity of 
gastrointestinal side effects. In general, the administration of NSAIDs with food delays 
and reduces peak plasma concentrations but does not affect total oral bioavailability (Day 
and others, 1983; Rainsford, 1985; Lombardino, 1985; Brooks, 1986).
(b) Anticoagulants
Displacement of warfarin from plasma proteins is not now thought to be the 
primary mechanism by which the activity of coumarin anticoagulants is enhanced by 
phenylbutazone and oxyphenbutazone (Day and others, 1983). Phenylbutazone and 
oxyphenbutazone inhibit the metabolism of the S-isomer of warfarin. The S-isomer is 
five times as potent as the R-isomer. Thus, phenylbutazone and oxyphenbutazone both 
markedly enhance the anticoagulant activity of warfarin (O'Reilly and others, 1980).
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At higher doses salicylates appear to inhibit vitamin K dependent synthesis of 
factors VII, IX, and X but this is not thought clinically significant. Interaction with 
warfarin has not been closely investigated. Earlier reports that other NSAIDs including 
aspirin, diflunisal and meclofenamate potentiated the effect of warfarin-on prothrombin 
complex activity are now believed to be incorrect. In more recent work, none of the 
NSAIDs has shown any effect. NSAIDs will augment any bleeding tendency induced by 
anticoagulant therapy because of their effects on platelets and gastrointestinal bleeding 
(Day and others, 1983). NSAIDs will displace other highly plasma protein bound drugs 
which may have significance where the displaced drug has a narrow therapeutic index 
(McKellar, 1989).
(c) Diuretic and Hypertensive Drugs
The hypotensive effects of propranolol are inhibited by indomethacin, the 
effect possibly due to the inhibition of vasodilatory prostaglandin induction or direct 
sodium retentive effects (Watkins and others, 1980). The hypotensive actions of 
hydralazine, prazosin, captopril or a reduced sodium diet are inhibited by indomethacin in 
man. The diuretic and natriuretic effects of frusemide are inhibited by aspirin or 
indomethacin. The effect may involve the inhibition of prostaglandin-mediated vascular 
effects of frusemide. Where NSAIDs are administered concurrently with 6-blockers, 
antihypertensives or diuretics the doses of the latter drugs may need to be increased to 
have the same desired effect (Day and others, 1983).
(d) Corticosteroids
Patients treated concurrently with corticosteroids and aspirin have higher rates 
of clearance of salicylate. As the dose of steroid is reduced, plasma salicylate 
concentrations may rise (Muirden and Barraclough, 1976). Corticosteroids may 
potentiate the ulcerogenic activity of the NSAIDs (Hamori and others, 1968; Day and 
others, 1983; Cosenza, 1984; Ivey, 1986).
(e) NSAID Combinations
NSAID combinations often increase the incidence of adverse reactions 
without an increase in efficacy. Co-administration of salicylates with other NSAIDs 
reduces the plasma concentrations of the other NSAID. In rare cases the combination 
product may have enhanced activity. Generally, however, it is advised that single 
NSAIDs are used rather than NSAID combinations (Day and others, 1983).
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3i3,6 NSAIDs and Cartilage
In man, indomethacin has been associated with increased joint destruction in 
cases of hip osteoarthritis (Ronningen and Langeland, 1979). Early theories proposed 
that pain relief encouraged increased usage of the joint and so increased further damage.
It has also been suggested that the mechanism of disease promotion was interference with 
the repair of microffactures in the subchondral bone by prostaglandin synthesis 
inhibitors. Aspirin treatment of dogs with experimental anterior cruciate ligament 
transection increases the degeneration of cartilage (Palmoski and Brandt, 1983b).
At concentrations approximating to normal pharmacological plasma levels, 
salicylate had no effect on degradation of proteoglycan in normal cartilage in vitro 
(Palmoski and Brandt, 1979). However, it is believed that inhibitors of prostaglandin 
synthesis may also inhibit proteoglycan biosynthesis. Salicylate and other NSAIDs have 
been found to inhibit proteoglycan synthesis in normal canine articular cartilage (Kalbhen 
and others, 1967). Diclofenac, indomethacin, piroxicam and sulindac sulphide have no 
significant inhibitory effect on proteoglycan synthesis in normal canine articular cartilage 
(Palmoski and Brandt, 1980).
The suppressive effect of salicylates on proteoglycan synthesis have been 
found to be more profound in osteoarthritic cartilage, where basal proteoglycan synthesis 
is 3 to 5 times that in normal cartilage (Palmoski and others, 1980). This was not a 
general chondrocyte toxic effect, since net protein synthesis was not affected. It has been 
suggested that NSAIDs may inhibit enzymes involved in the early stages of chondroitin 
sulphate synthesis such as UDP glucose dehydrogenase. Oral aspirin administration to 
dogs with developing osteoarthritis aggravated the degeneration of articular cartilage. 
There was no apparent effect on normal cartilage in vivo (Palmoski and Brandt,
1983a,b).
In chickens, intraarticular injection of NSAIDs including ibuprofen, 
phenylbutazone, sodium salicylate, fenamic acid and indomethacin causes severe 
osteoarthritic changes (Kalbhen and others, 1978). Oral treatment with aspirin, 
phenylbutazone, indomethacin, ibuprofen and naproxen of mice with a genetic 
predisposition to an osteoarthrosis (C57 black mice) promoted the development of 
osteoarthrosis. Diclofenac showed chondroprotective effects and pirprofen had no effect 
(Maier and Wilhelmi, 1979; 1982).
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The effect of salicylate on degenerative cartilage in vivo with sparing of 
normal cartilage may be related to the proteoglycan concentration of the matrix and the 
resultant decrease in fixed negative charge density of the glycosaminoglycan polymers 
which allows increased diffusion of weakly anionic NSAIDs into the cartilage. 
Proteoglycan depletion rather than cartilage fibrillation determines the effect of salicylate 
and indomethacin on osteoarthritis cartilage (Palmoski and Brandt, 1985). There is no 
evidence that the chondrocyte of osteoarthritic articular cartilage is any more susceptible 
to the effects of salicylate or other NSAIDs on proteoglycan metabolism (Slowman and 
Brandt, 1987). The proteoglycan metabolism effect appears to be unrelated to their 
inhibitory effects on prostaglandin synthesis (Palmoski and Brandt, 1984). In vitro 
experiments have indicated that the variation in the effects of different NSAIDs on joint 
cartilage is related to the drug concentration in synovial fluid which is dependent upon the 
dose administered, which in turn depends upon the potency and toxicity of the drug 
(Palmoski and Brandt, 1985).
Antiinflammatory agents can combine antagonistic effects and in any given 
situation it is hazardous to predict the predominance of anti-anabolic or anti-catabolic 
activity (Wilhelmi, 1983). It has been proposed that aspirin may inhibit the release of 
lysosomal hydrolases and that the beneficial effects of aspirin on synovium may be more 
important than any detrimental effects on articular cartilage (Miller and Smith, 1966). 
Cartilage degeneration has been demonstrated to be inhibited by salicylate by some 
investigators (Simmons and Chrisman, 1965). In Guinea Pigs with osteoarthritis induced 
by transection of the anterior cruciate ligament, neither piroxicam nor indomethacin had 
any positive or negative effect on clinical progression. The protein concentration of the 
cartilage matrix was altered in treated animals (Baragi and Schwartz, 1986).
Normal chondrocyte proteoglycan synthesis is not inhibited by diclofenac, a 
potent inhibitor of cyclooxygenase. This property is not due to partitioning such that 
diclofenac failed to reach the chondrocytes (Brandt and others, 1988). Kalbhen and 
others (1987) have found that diclofenac has a stimulatory effect on chondrocytes in vitro 
and has chondroprotective properties.
The effect of piroxicam on normal articular cartilage has been studied. In 
isolated articular cartilage, piroxicam has no effect on cell proliferation nor on 
incorporation of radiolabelled sulphate into matrix macromolecules. In vivo, dogs treated 
with piroxicam for 8 weeks had no ultrastructural differences to normal controls. At 
concentrations in vitro which are comparable to therapeutic serum levels, piroxicam was 
found to suppress catabolism-inducing factor(s) in osteoarthritis in 11 of 12 specimens. 
There was no inhibition of total protein synthesis: drug-induced suppression was 
selective (Mohr and others, 1984).
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Herman and others (1986) found piroxicam to have no significant effect on 
proteoglycan release from normal cartilage and the investigators proposed that the 
drug-mediated effects were at the level of the synovial tissues. Indomethacin and 
salicylate had no effect on the synthesis of catabolism-inducing factor by osteoarthritic 
synovium. There was no consistent blocking effect on osteoarthritis catabolic factor 
activity using any of the NSAIDs studied. However, the investigators concluded that 
piroxicam may be an effective blocker of catabolism-inducing factor generated in 
rheumatoid arthritis synovium, if not in osteoarthritis synovium (Herman and others, 
1987). Piroxicam does not inhibit sulphate incorporation into proteoglycans or cell 
proliferation (Mohr and others, 1983). Recent studies have demonstrated chondrocyte 
stimulation by piroxicam in vitro (Poriau and others, 1987).
It has been stated by some authors that the inhibitory effects of antirheumatic 
drugs on proteoglycan synthesis are negligible compared with their ability to inhibit 
degradative enzyme damage of cartilage (Chrisman and others, 1981b). Some authors 
have suggested that NSAID effects on serum sulphate concentrations may contribute to 
chondrocyte proteoglycan synthesis inhibition (deVries and others, 1988). Ghosh (1988) 
concludes that the in vivo significance of all the experimental evidence for cartilage 
effects of NSAIDs is still uncertain. However, it may be desirable to use a NSAID which 
has proven chondroprotective or no chondrocyte inhibitory effects (eg diclofenac, 
piroxicam, pirprofen, ketoprofen).
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2A  The Available Data on Individual NSAIDs and their Use in the Dog
3,4,1 Aspirin and Other Salicylates
Aspirin is rapidly hydrolysed in plasma 
to salicylate. Peak concentration of salicylate are 
attained 1 to 2 hours after plain aspirin is 
administered per os. Salicylate is about 60-70% 
plasma protein bound. The half life of the salicylate 
is dose-dependent, increasing as the administered 
dose of salicylate is increasecLAt usual dosages the 
mean plasma half life in the dog is 8 to 9 hours 
(Davis and Westfall, 1973). A decrease in blood pH will lead to a decrease in drug 
ionisation and increased distribution. Synovial fluid concentrations of salicylate are 
approximately one half of the plasma concentrations (Rowland and others, 1967).
Therapeutic plasma concentrations of salicylate are considered to be 100 to 
300 ug/ml by some authors (Yeary and Brandt, 1975) but as little as 50 ug/ml by others 
(Davis, 1980). Twenty-five mg/kg every 8 hours maintains therapeutic concentrations of 
170-190 ug/ml (Yeary and Brandt, 1975). Peak concentrations are attained 4 hours after 
buffered aspirin is given and up to 8 hours after enteric coated aspirin (EC.AS A) is 
given. EC.ASA produces the greatest fluctuations in serum salicylate concentration 
(Lipowitz and others, 1986).
Most dogs tolerate aspirin well. However, any dosage can cause 
gastroduodenal ulceration (Cosenza, 1984). Emesis, gastric haemorrhage and abdominal 
pain have been well documented (Hurley and Crandal, 1964; Taylor and Crawford,
1968; Fisher and others, 1972). Fifty to 100 mg aspirin/kg/day consistently induces 
gastric pathology. Doses over 50 mg/kg often induce emesis (Yeary and Brandt, 1975). 
Overt gastrointestinal haemorrhage can occur after a single dose of aspirin in man. This is 
thought to be an idiosyncratic reaction (Ivey, 1986).
Plain aspirin is most irritating to the gastric mucosa (Lipowitz and others,
1986). Buffered aspirin preparations are associated with reduced epigastric discomfort 
but they do not reduce gastrointestinal damage (Day and others, 1983). Enteric coated 
aspirin (EC.ASA) preparations are associated with less enteric blood loss since the small 
intestine is less affected by local effects than the stomach (Lipowitz and others, 1986).
FIG 15: Aspirin
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Since absorption of aspirin from enteric coated preparations is delayed for six 
hours or more, use is restricted to long-term medication. Food postpones the exit of 
EC.ASA tablets from the stomach and delays peak plasma concentrations of salicylate 
after EC.ASA administration. Multiple meals can cause completely unpredictable patterns 
of plasma salicylate concentration (Nap and others, 1989). Smaller EC.ASA granules 
may not be retained in the stomach and so may allow more predictable and rapid plasma 
concentrations of salicylate to be achieved (Anslow and others, 1984).
Allergy or pseudoallergic intolerance to aspirin occurs in man. No allergies 
are documented in animals. Aspirin has been associated with congestive cardiac failure 
and pulmonary oedema in man. Acute poisoning can occur with aspirin. Clinical signs 
include vomiting, abdominal pain, CNS signs and hypokalaemia in the early stages. In 
the later stages the signs are pyrexia, pulmonary oedema, convulsions, coma, severe 
dehydration and ketosis, and death may occur.
In the dog, it has been reported that therapeutic plasma concentrations of 
salicylate are not maintained by use of plain aspirin at 10 mg/kg every 8 hours. 
Twenty-five mg/kg every eight hours of plain, buffered or enteric coated aspirin are 
effective ( Yeary and Brandt, 1975; Lipowitz and others, 1986). Other authors suggest 
10-20 mg/kg every 12 hours may be clinically effective (Davis, 1980; Haskins, 1987; 
Jenkins, 1987). Clinical experience suggests that the lower dose rate provides analgesic 
effect (Carmichael, 1989). Aspirin is still the most popular drug for the treatment of 
osteoarthritis in man and the standard by which other drugs are judged. It has been stated 
that in the face of more effective and potentially less toxic NSAIDs, the salicylates 
probably have no place in veterinary medicine (Yoxall, 1978).
Diflunisal is a fluorophenyl 
derivative of salicylic acid. Unlike aspirin, it 
does not possess an O-acetyl group and so it 
does not acetylate proteins. The activity of 
diflunisal is intrinsic and not related to in 
vivo conversion to salicylate. Diflunisal has 
approximately three to ten times the 
anti-inflammatory activity of aspirin.
In man, diflunisal has reduced gastric effects and ototoxicity compared with aspirin. 
Cross-allergy with aspirin may occur (Lombardino, 1985). A single dose of 10 mg/kg in 
dogs had no adverse effects on gastric secretion volume or acidity. In the dog, diflunisal 
apparently has similar side effects to aspirin on the gastrointestinal tract and kidney but 
with a higher therapeutic index. In one canine study, oral dosing at 25 mg/kg/day for 3 
months had no toxic effects. It has not been properly evaluated for efficacy and toxicity in 
dogs to date.
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FIG 16: Diflunisal
3«4.2 Phenylbutazone and Other Pyrazolones
Phenylbutazone has been 
withdrawn from general availability on 
prescription for human use in the UK because 
of toxicity; notably fluid retention (sufficient 
to cause cardiac failure), aplastic anaemia, and 
agranulocytosis. In the last twenty years at 
least 1000 people have died from aplastic 
anaemia or neutrop enia associated with the 
use of phenylbutazone or oxyphenbutazone 
(Brooks and others, 1986). It is still licensed 
to treat ankylosing spondylitis under specialist supervision.
Phenylbutazone is rapidly and completely absorbed from the small intestine 
and is extensively protein bound (Brooks and others, 1986). After intramuscular injection 
of phenylbutazone absorption is delayed compared with oral administration, probably 
because of local tissue binding and precipitation. Intramuscular injection is also very 
painful and very irritant, especially to nervous tissue. In man, accidental injection close to 
nerves has been associated with nerve damage (Fowler, 1983).Plasma half life of 
phenylbutazone in the dog has been reported to range from 1.3 to 5.2 hours (McKellar, 
1989).
The pyrazolone derivatives induce drug metabolising microsomal enzymes in 
the liver. As a consequence, tachyphylaxis to phenylbutazone can develop over a period 
and the dose rate required for a beneficial effect may need to be increased. 
Phenylbutazone metabolism is accelerated by hepatic microsomal inducers such as 
phenobarbitone, griseofulvin and phenytoin and is inhibited by the phenylbutazone 
metabolite oxyphenbutazone.
Recognised contraindications to phenylbutazone treatment are existing peptic 
ulceration, liver disease, bleeding disorders and cardiac insufficiency (Fowler, 1983). 
Adverse reactions are widely reported in the dog, including an "idiosyncratic reaction" in 
a Dachshund (Tandy and Thorpe, 1967). Myelotoxicity and blood dyscrasias have been 
reported in the dog, but seem to be less common than in man (Miller and Kind, 1962; 
Ndiritu and Enos, 1977; Schalm, 1979; Watson and others, 1980). Phenylbutazone 
appears less toxic in the dog than in man. This may be associated with the much shorter 
half life in the dog (<6 hours cf. 72 hours in man).
FIG 17: Phenylbutazone
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A dose rate of 22 mg/kg every eight hours has been recommended by some 
authors (Haskins, 1987; Rubin and Papich, 1988). To maintain therapeutic plasma 
concentrations a dose regime of 15 mg/kg qid has been recommended (Nielson and 
others, 1969). Other authors suggest up to 20 mg/kg/day divided is sufficient (Taylor,
1987).
Azaproprazone is reported to have low toxicity, but blood levels are not 
readily achieved in dogs. In man, the dosage of azaproprazone is 10-20 mg/kg/day. In 
the dog, to achieve similar plasma concentrations a daily dosage of 60-120 mg/kg would 
apparently be required (Jones, 1976). This dose rate will cause adverse reactions, at least 
in certain breeds. Beagle dogs treated at 25-100 mg/kg/day rapidly showed toxicity with 
signs including anorexia, rapid weight loss, anaemia, reticulocytosis and leukocytosis, 
blood in faeces, pyloric ulcers, gastrointestinal inflammation and deaths. Azaproprazone 
also had effects on bone marrow. Beagles seem to be particularly sensitive to the 
gastrointestinal effects of azaproprazone since mongrel dogs treated at 50 mg/kg/day for 
12 weeks showed no clinical signs or post mortem pathology (Walker, 1985).
Dipvrone administered at 50 mg/kg orally is rapidly and almost completely 
absorbed to give maximum blood concentrations of about 40 ug/ml 1.5-2 hours after 
dosing. The elimination half life is about 5 hours (Christ and others, 1973). Booth 
(1982) recommends 30 mg/kg sid or bid for chronic treatment In man, skin rashes are 
common but gastrointestinal signs are rare (Brogden, 1986).
3.4.3 Fenamates
The fenamates are N-arylanthranilic acids. Their structure is related to that of 
flunixin and diclofenac (FIG 17). The fenamates inhibit prostaglandin synthesis 
(Scherrer, 1985; Brooks and others, 1986). Meclofenamic acid is one of the most potent 
inhibitors known (Scherrer, 1985). The prostaglandin synthesis inhibitory effects of the 
fenamates are enhanced up to 100 fold in the presence of certain enzyme "cofactors" such 
as phenols and indoles (Egan and others, 1978).
The antiinflammatory activity of the fenamates does not correlate well with 
prostaglandin biosynthesis inhibition and other mechanism of action may be important. 
The fenamates also inhibit some of the actions of some prostaglandins at physiological 
concentrations. It has been suggested that the fenamates inhibit the tissue response to 
prostaglandins by occupying receptor sites. Not all prostaglandins or all actions are 
inhibited and there is variation in potency between species (Scherrer, 1985).
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Mefenamic acid is rapidly absorbed after oral administration with peak plasma 
concentrations in a maximum of 2 to 4 hours. In dogs, most of the drug is excreted in the 
faeces with only small amounts appearing in the urine. Enterohepatic recirculation occurs 
to a varying extent in different species. Oral administration of mefenamic acid to dogs at 
50 mg/kg 5 days per week for 103 consecutive weeks was not associated with any 
adverse clinical signs or tissue reaction. At 100 mg/kg/day, slight hepatic damage was 
reported at histological examination. 300 mg/kg/day divided for four consecutive weeks 
was not associated with clinical signs or tissue reaction (Parke-Davis Veterinary).
Tolfenamic acid is available for use in dogs and cats in France (Tolfedine®). 
A human preparation is also available (Clotan®). It can be administered by subcutaneous, 
intramuscular or oral routes. When administered subcutaneously at 4 mg/kg tolfenamic 
acid had a plasma half life of 6.9 hours (± 1.9 hours) with maximum plasma 
concentrations of 4.4 (±0.6) ug/ml at about 1.5 hours after administration. Serum 
thromboxane levels were inhibited by up to 80% at this dose rate (McKellar and 
Galbraith, 1989). Enterohepatic recirculation has been reported (Vetoquinol Advertising 
Literature; McKellar and Galbraith, 1989).
Haskins (1987) suggests that meclofenamic acid (Arquel®) can be used in 
dogs at a dose rate of 2.2 mg/kg/day. However, the drug manufacturers (Parke-Davis 
Veterinary) and Taylor (1987) suggest that 0.5-1 mg meclofenamic acid/kg/day divided 
for up to 21 days may be more appropriate. Taylor (1987) advises that, for a maintenance 
regime, the dose rate is decreased to every second or third day after 1 to 3 weeks. 
Arquel® is available in sachets for use in horses. Each lOg sachet contains 500 mg which 
is sufficient for a dog weighing between 500 and 1000 kg! Very small quantities will 
require to be weighed out for use in dogs. A 25 kg dog will require between 0.25 and 0.5 
g/day (Parke-Davis Veterinary).
58
Mefenamic acid (Ponstan®) may be useful at 10-40 mg/kg/day in divided 
doses (Taylor, 1987). The manufacturer suggests a dose rate of 40-60 mg/kg divided 
b.i.d. After 1 to 3 weeks, the dosage should be reduced to 10-60 mg/kgin divided daily 
doses on every second or third day (Parke-Davis Veterinary). Ponstan® is available as 25 
mg capsules, a 50 mg/ml suspension or as 250 mg and 500 mg tablets.
A dosage of 4 mg tolfenamic acid/kg/dav divided in two doses is said to 
maintain satisfactory plasma concentrations without accumulation of the product. The 
recommended period of treatment is only 3 to 5 days (Vetoquinol Advertising Literature).
The fenamates are the preferred analgesics of some authors and at some 
veterinary colleges. The main problem associated with their use is diarrhoea. Diarrhoea 
does not seem to be dose related and usually resolves in 3-4 days whilst treatment 
continues. In dogs in which diarrhoea continues, the dose should be reduced or treatment 
withdrawn and reinstituted at a lower dose rate once the diarrhoea resolves. In most cases 
the diarrhoea resolves. Treatment should be withdrawn if diarrhoea is severe or if there is 
blood in the faeces. Vomiting and renal toxicity have been reported (Parke-Davis 
Information).
3.4,4 Flunixin
Flunixin meglumine is a potent NS AID 
which is approved for use in the horse in many 
countries including UK and USA. Oral and 
injectable preparations have recently been approved 
for use in dogs in the UK. Flunixin is a more 
potent analgesic than aspirin or phenylbutazone.
The duration of clinical efficacy of the 
drug in dogs does not correlate with the relatively 
short half life (Rubin and Papich, 1988) of 3.7±
1.2 hours after intravenous injection (Hardie and 
others, 1985). After oral administration at 1.1 mg/kg, flunixin is rapidly absorbed. Peak 
plasma concentrationsof 4 to 6 ug/ml occur about one and a quarter hours after drug 
administration and flunixin has a plasma half life of 2 to 3 hours. (McKellar and Lees, 
1989; McKellar and others, 1989). More recent studies have indicated that the elimination 
half life may be much longer (14-15 hours) than indicated in earlier studies (McKellar and 
Galbraith, 1989). In a clinical trial on an oral formulation in dogs, flunixin was as 
effective as phenylbutazone in the treatment of chronic musculoskeletal pain and 
inflammation (Kelly and Benitz, 1988).
C O O H
FIG 19: Flunixin
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The suggested dose rate of flunixin is 1.1 mg/kg daily for up to 3 days, with 
the course repeated no more often than every 2-3 weeks. Daily treatment intervals can be 
used since flunixin has been shown to persist in inflammatory tissue (Lees and others,
1987). Flunixin has a narrow therapeutic index in the dog but the once a day treatment 
regime will allow almost complete elimination of the drug from plasma and so reduce the 
potential for toxicity and accumulation (Rubin and Papich, 1988). However, flunixin can 
only be used for up to 3 days since longer term use has been shown to cause 
gastrointestinal inflammation and ulceration (Cosenza, 1984). No problem with reduced 
analgesia at the end of the inter-dosing period has been identified in clinical trials (Benitz 
and Lichtenwalner, 1986).
3«4.5 Piroaicam
The oxicams are a novel group of 
NSAIDs which are N-heterocyclic carboxides 
of 1,2-benzothiazine-1,1-dioxide (Brooks and 
others, 1986). Piroxicam is the most popular of 
the oxicam class. In the dog, peak plasma 
concentrations of piroxicam are reached around 
two hours after oral administration. Piroxicam 
has an extended plasma half-life of 37 to 40 
hours in the dog (Lombardino and others, 1973; Wiseman, 1983). It is completely 
absorbed from the gastrointestinal tract and is 99% plasma protein bound. Enterohepatic 
recirculation in man maintains plasma concentrations and extends the half life (Wiseman, 
1983). The similar kinetics in the dog suggest that enterohepatic recirculation occurs. 
Piroxicam accumulates in synovial fluid (Brooks and others, 1986). No clinically 
important interactions with other drugs have been reported in man (Wiseman, 1983; 
Wiseman, 1985).
In man, therapeutic doses of piroxicam are better tolerated than those of 
indomethacin, phenylbutazone or aspirin. In dogs, piroxicam has been used at a dose rate 
of 0.3 mg/kg every 48 hours in clinical cases of osteoarthritis and for analgesic and 
antiinflamnmatory effect post-operatively at Glagow Veterinary School since 1984 with 
an incidence of side effects approximately equivalent to or better than that of other 
NSAIDs. Gastrointestinal intolerance is most common and diarrhoea is more common 
than emesis.
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FIG 20: Piroxicam
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Gastrointestinal ulceration and haemorrhage have been reported in a dog 
treated for ten days with piroxicam at 0.8 mg/kg every 48 hours (Thomas, 1987). In 
dogs treated for 12 to 18 months at 1 mg/kg/day renal papillary necrosis has been reported 
(Wiseman, 1983). Transient rises in liver enzymes are reported in man. The therapeutic 
index of piroxicam is superior to that of aspirin in the dog (Teelman, 1983).
In man, piroxicam has a rapid onset of action. Analgesia is effected in less 
than 2 hours in most cases and the effect of piroxicam fades about 48 hours after 
treatment is withdrawn (Wagenhauser, 1980). The long duration of action of piroxicam 
also means that night time pain relief is often improved in comparison with shorter 
duration NSAIDs, sleep may be more sound and morning stiffness decreased (Wiseman, 
1983). In man, piroxicam has been shown to be a more effective analgesic than aspirin in 
the therapy of osteoarthritis (Gordon and others, 1980). Improved effects are apparent 
when treatment for osteoarthritis is continued for longer periods (Pitts and others, 1982). 
Piroxicam has equivalent efficacy to aspirin, naproxen and indomethacin whilst it is 
generally better tolerated. It is more effective than indomethacin and equivalent to 
phenylbutazone in acute musculoskeletal disorders (Wiseman, 1985).
In the dog, the long half life of piroxicam means that dosing once a day or 
every other day maintains therapeutic concentrations. It has high potency and so a low 
dose of 0.3 mg/kg every 48 hours seems effective and well tolerated. Some authors have 
stated that piroxicam should not be recommended for use in dogs until further safety and 
efficacy studies have been performed (Rubin and Papich, 1988).
2.4*6 Propionic Add Derivatives
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FIG 21: Some of the Propionic Acid Derivatives
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With the exception of Naproxen, the Propionic acid derivatives are 
administered as racemates (mixtures of enantiomers). In most cases only the S (Sinister) 
form is active. In vivo conversion of the R to the S form has been demonstrated for some 
of the propionic acid derivatives and may increase their efficacy in vivo (Brooks and 
others, 1986).
Naproxen
Naproxen is rapidly absorbed after oral administration and peak plasma levels 
occur at 0.5 to 3 hours. Naproxen is 68-100% bioavailable orally (Frey and Rieh, 1981). 
It is 99% plasma protein bound. The half life of naproxen in the dog varies from 35 
(Runkel and others, 1972) to 92 hours (Frey and Rieh, 1981) compared to 6 hours in the 
horse and 12 hours in man. Enterohepatic recirculation is proposed as the mechanism 
which causes the prolonged half life of naproxen in the dog. The dog is the only species 
investigated in which faecal excretion predominates. Slow elimination is not due to 
extensive protein binding since the horse and man have similar degrees of protein affinity 
but much shorter half-lives (Frey and Rieh, 1981).
Naproxen has been used in man (Naprosyn®) and the horse (Equiproxen®) 
without a high incidence of adverse effects (Allison and others, 1985). Although the 
single toxic dose of naproxen in the dog is high (LD50 > lg/kg), dogs are relatively 
intolerant of the gastrointestinal effects of naproxen. Gastrointestinal changes are 
observed in dogs treated at 5 mg/kg/day whilst 15 mg/kg/day is toxic. A dose of 1.5 
mg/kg/day is tolerated for 3 months without signs of toxicity (Hallesy and others, 1973). 
There are many reports of naproxen-induced gastroenteropathy in dogs in the literature 
(eg. Roudebush and Morse, 1981; Steel, 1981; Gilmour and Walshaw, 1987). This is 
apparently related to predominantly biliary excretion and less urinary excretion in the dog 
compared to other species (Segre, 1983).
In various clinical trials in man, naproxen has equivalent or greater efficacy to 
aspirin (Segre, 1983) and has the advantage of requiring only one daily dose. Therapeutic 
concentrations of naproxen (>30 ug/ml) can be maintained when naproxen is 
administered at 1.2-2.8 mg/kg once daily (Frey and Rieh, 1981). It appears that naproxen 
can be used with caution in the dog at a once daily maintenance dose of 2 mg/kg/day with 
or without a single loading dose of 5 mg/kg (Jenkins, 1987; Rubin and Papich, 1988). 
However, the dog appears to be particularly sensitive to gastrointestinal side effects of 
naproxen.
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Ibuorofen
Ibuprofen is rapidly absorbed after oral administration and is 96% plasma 
protein bound. Maximum plasma concentrations are attained between 0.5 and 3 hours 
after oral administration. Its elimination half life in the dog is about 3.5 to 6 hours 
(Scherkl and Frey, 1987). Some authors have reported that ibuprofen is metabolised 
slowly in the dog (Mills and others, 1973).
Ibuprofen is a popular drug in man because it is associated with a lower 
incidence of gastrointestinal adverse reactions than the salicylates (Smith and others,
1985). It is available without prescription in the UK. However, the drug appears to cause 
gastric irritation and ulceration more frequently in dogs. Gastrointestinal toxicity may 
relate to enterohepatic recirculation in this species. It has also been suggested that dogs 
are at increased risk of gastrointestinal ulceration due to ibuprofen treatment because of a 
higher rate of gastrointestinal absorption, longer drug half life, and prolonged blood 
concentrations (Adams and others, 1969).
There are a number of reports of ibuprofen toxicity in dogs. Acute ingestion 
of large doses can cause vomiting, diarrhoea and renal dysfunction (Spyridakis and 
others, 1986). Earlier papers advocated use of ibuprofen at a maintenance dose of 16 
mg/kg/day (Yoxall, 1978). However, treatment with ibuprofen at 12-15 mg/kg/day 
causes repeated and consistent vomiting (Scherkl, 1987). Recent papers suggest a dose 
rate of 8 mg/kg/day may be better tolerated (Taylor, 1987; Rubin and Papich, 1988) or 
that 10 mg/kg every 24 to 48 hours may be useful (Jenkins, 1987). However, Lessel 
(1970) found that dogs treated at 8 mg/kg/day for 30 days developed gastric ulceration.
In an earlier study, dogs treated with ibuprofen at 8 mg/kg/day for 30 days showed no 
clinical signs but intestinal inflammation and gastric ulceration were apparent at necropsy 
(Adams and others, 1969). Haskins (1987) suggests a dose rate of 5 mg/kg/day.
Ibuprofen is generally not recommended for routine use because of its 
gastrointestinal toxicity and because it offers no advantage over less toxic analgesics such 
as aspirin and phenylbutazone (Rubin and Papich, 1988).
Flurbiprofen has a half-life in the dog of 35-40 hours. It is largely excreted in 
the urine unchanged and no metabolites have been detected in canine plasma. 
Enterohepatic recycling is very probable in the dog (Risdall and others, 1978). Severe 
dose related gastrointestinal damage at 1-16 mg/kg has been described. Flurbiprofen is 
much more toxic in dogs than in other species. There have been several reports of severe 
gastrointestinal adverse reactions and nephrotoxicity (Correspondence, 1987). 
Flurbiprofen should not be used in the dog.
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Ketoprofen
a
Ketoprofen is^mixed inhibitor of the cyclooxygenase and lipoxygenase 
pathways and has potent antibradykinin activity ( Julou and others, 1976a,b; Dawson and 
others, 1982; Walker, 1980; Julou and others, 1971). It has structural similarities to 
arachidonic acid and to Leukotriene A4 (Harris and Vavra, 1985). Ketoprofen has potent 
analgesic and antiinflammatory activity. It has not demonstrated any damaging effects on 
articular cartilage.
Studies in the dog at 1 mg/kg have indicated less than 90% absorption with 
peak plasma levels of 1.5 ug/ml at 1 hour. Ketoprofen is eliminated in a complex manner 
and the terminal phase of elimination (half life = 34 hours) accounts for negligible 
amounts of absorbed ketoprofen. Primary and secondary phases of elimination have 
much shorter half lives of 0.85 hours and 4.3 hours respectively. Excretion is primarily 
as conjugates in the urine (Populaire and others, 1973; Heusse and Populaire, 1978; 
Upton and others, 1981). The dose recommended in man is 3-4 mg/kg/day. More rapid 
clearance and lower peak plasma concentrations in the dog suggest that higher and more 
frequent dosages would be required to maintain therapeutic concentrations. In man, 
controlled-release oral preparations allow single daily dosing convenience whilst 
ketoprofen may have increased safety compared to NSAIDs with longer half lives 
because it is rapidly eliminated (Harris and Vavra, 1985). Slow release preparations may 
be of use in the dog. Further study is required on the efficacy and safety of ketoprofen in 
dogs.
Fenbufen
Fenbufen is a prodrug and has no intrinsic inhibitory activity on prostaglandin 
synthesis. After absorption it is converted to the active metabolite biphenylacetic acid 
(BPAA) which is a potent cyclooxygenase inhibitor and has marked antiinflammatory 
activity. The duration of action is much longer than for indomethacin, aspirin or 
phenylbutazone (Greenberg and Bernstein, 1985).
In the dog, fenbufen is rapidly and completely absorbed after oral 
administration and peak plasma concentrations are attained in 1-2 hours. Relatively high 
plasma concentrations of BPAA are maintained for seven hours. Elimination is mainly in 
the urine as diol derivatives. Fenbufen and its metabolites are over 98% protein bound at 
therapeutic concentrations (Chiccarelli and others, 1980). Fenbufen should have less 
gastrointestinal toxicity than other NSAIDs in the dog since there should be no local 
effects on prostaglandin inhibition. Doses of 16 and 40 mg/kg/day for 18 months were 
non-ulcerogenic in dogs. 100 mg/kg/day did induce ulcers (Sloboda and Osterberg, 
1976). Fenbufen may prove a useful drug in the dog.
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2A7 Acetic Acid Derivatives
Indomethacin
Indomethacin is a very effective 
antiinflammatory, analgesic and antipyretic.
However, indomethacin has a high potential 
for gastrointestinal toxicity in carnivores and 
gastrointestinal haemorrhage after its use has 
been widely reported. Extensive enterohepatic 
recirculation may contribute to indomethacin's 
toxicity by repeatedly reexposing the 
gastrointestinal mucosa to high concentrations 
of the drug. A dose of 0.5 mg/kg can be toxic in dogs compared to the toxic dose in man 
of about 20 mg/kg (Duggan, 1975). Authors agree that indomethacin is not suitable for 
use in the dog because of its common and wide ranging side effects (Nicoloff, 1968; 
Ewing, 1972; Duggan, 1975).
Sulindac
Sulindac has a similar structure to indomethacin. It is a pro-drug and is only 
converted to an active metabolite in the body or by gut flora (TTG 221. The active 
sulphide inhibits both cyclooxygenase and lipoxygenase pathways and can act as a free 
radical scavenger. Only small amounts of the active sulphide are excreted in the bile. 
Sulindac and its sulphone metabolite are excreted in the bile and can be converted to 
active sulphide by the gut flora and reabsorbed (enterohepatic recirculation). Thus, the 
gastrointestinal tract is exposed predominantly to prodrug and repeat exposure to active 
sulphide is limited. It would be expected that gastrointestinal effects would be lessened. 
Sulindac demonstrates low activity on renal cyclooxygenase which may be due to an 
inherent lower sensitivity of this isoenzyme to the drug or to differential distribution and 
formation of the sulphide (Rhymer, 1983). Sulindac may therefore be less nephrotoxic 
than other NSAIDs.
Sulindac has been demonstrated to be more effective than aspirin in osteoarthritis 
in man and better tolerated and equivalent to ibuprofen. Gastrointestinal side effects are 
the most common but abnormalities of liver function, dermatological and central nervous 
system signs, oedema, congestive cardiac failure, thrombocytop enia and leucop enia 
have all been reported (Rhymer, 1983; Brooks and others, 1986). Sulindac has not been 
assessed for use in dogs.
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FIG 23: Sulindac and its Metabolites
Diclofenac has a protective effect on cartilage in certain animal models (see 
3.3.61 It is a popular drug in man since gastrointestinal tolerance to diclofenac is greater 
than that for aspirin (Brooks and others, 1986). However, during chronic administration 
to dogs, adverse reactions included gastrointestinal haemorrhage, ulceration and 
perforation and secondary anaemia. Side effects were more common than in studies in 
primates. The increased toxicity in the dog is probably dependent upon the different 
metabolism in this species. In man, hydroxylation and taurine conjugation followed by 
urinary excretion is the main elimination pathway. In the dog up to 80-90% of excretory 
products are direct conjugates in the bile. The direct conjugate is rapidly hydrolysed in the 
gut to yield the active drug which is reabsorbed (ie. enterohepatic recirculation). 
Enterohepatic recirculation prolongs plasma half life and increases the local exposure of 
the intestinal mucosa to active drug and so is most probably responsible for the relative 
intolerance of dogs to gastrointestinal effects (Reiss and others, 1978; Willis and 
Kendall, 1978; Tsuchia and others, 1980).
Alclofenac has central analgesic activity equivalent to codeine and 
antiinflammatory activity equivalent to phenylbutazone. Investigators have reported that 
vomiting may be a problem in clinical cases. It is relatively slowly excreted in the dog and 
in this species a dose rate of 50 mg/kg bid has been suggested (Yoxall, 1978).
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Dual Cyclooxygenase and Lipoxygenase Inhibitors
Some of the NSAIDs already used in man such as benoxaprofen have dual 
inhibitor properties. However, their principal activity is on cyclooxygenase and their 
clinical effects are believed to be mainly due to inhibition of prostanoid synthesis. The 
phenylpyrazoline compound BW755C (3-amino-l-(trifluoromethyl)- phenylpyrazoline) 
has activity against both lipoxygenase and cyclooxygenase. BW755C was as effective as 
phenylbutazone in reducing adjuvant induced arthritis in rats and its beneficial effects 
continued after treatment stopped (Higgs, 1978). In addition, BW755C has no apparent 
effect on PGI2 synthesis in the gastric mucosa following oral administration (Whittle and 
others, 1980) and has not been associated with ulcerogenicity. Antileukotrienes and dual 
inhibitors have not yet been shown to be useful clinically. In some cases (eg. 
benoxaprofen) toxicity has been a problem; others require large doses. Poor penetration 
into inflammed tissue has been reported (Lees, 1987).
Dual inhibitors of both arachidonic conversion pathways may have superior 
efficacy in arthritides where leukotrienes are important mediators. It has been suggested 
that dual inhibitors of 5-lipooxygenase and cyclooxygenase may be more effective than 
selective cyclooxygenase inhibitors in rheumatoid arthritis (Griswold and others, 1988).
M  Application of Symptomatic Treatment of Osteoarthritis in the Dog
Even with managemental changes, many osteoarthritic dogs still require 
analgesic therapy. However, it must be explained to owners that although analgesics can 
affect the symptoms in the short or medium term, the object is to change the progression 
or activity of the disease state by exercise pattern and weight adjustment. Owners should 
be warned that they are responsible for preventing their dog from further traumatising an 
already damaged joint. Pain relief may cause a dog to over-use a damaged joint and cause 
accelerated disease progression unless the owner controls exercise anlobesity.
In contrast to the wide range of analgesic drugs available in man, there are 
relatively few drugs which have been evaluated for efficacy and tolerance in dogs except 
as part of the data for registration for human use. Very few NSAIDs have been registered 
for use in dogs. Registration and marketing may not be considered economically 
justifiable. NS AID manufacturers may not wish to risk the use of their products in dogs 
since adverse reactions in animals may reflect badly on their use in man. However, there 
are a number of NSAIDs which are being tested for use in dogs and other companion 
animals with a view to future registration for veterinary use.
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The non-narcotic analgesics and combinations which are presentiy available 
for use in the dog are listed in TABLE 7. Phenylbutazone and flunixin are the only 
NSAIDs which are formulated without other drugs. Phenylbutazone is the most popular 
analgesic used to control osteoarthritic symptoms in the dog. It has been widely used for 
many years and has a good safety record. Flunixin has only recently been registered for 
use in the dog. It is a potent analgesic but can only be used for a maximum of three days 
since prolonged therapy often results in gastrointestinal intolerance. In osteoarthritis, this 
limits its use to the control of pain and inflammation in acute exacerbations.
Three combination products are available. Predno-Leucotropin® Tablets may 
soon be replaced by PLT ® Tablets. Both contain the NSAID cinchophen in combination 
with prednisolone. In the former product the urinary acidifier hexamine was also present. 
The NSAIDs and steroids act at different levels of the arachidonic acid conversion 
pathways and have complementary actions. Cinchophen and prednisolone may have 
synergistic activity, but prednisolone may also potentiate the ulcerogenic effects of 
cinchophen. Available data on cinchophen and prednisolone in combination is detailed in 
section 5.1.
Paracetamol is available in two combinations. Paracetamol is an analgesic but 
has little demonstrable antiinflammatory activity according to most authors. In 
Budale-V® Tablets it is formulated with butobarbitone and codeine. The combination is 
sedative and so is not appropriate to long term treatment of the osteoarthritic dog. In 
Pardale-V® Tablets, paracetamol is in combination with codeine and caffeine. Since 
paracetamol has peripheral analgesic effects and codeine has central activity the two drugs 
may be synergistic (Messick, 1979; Taylor, 1985). Caffeine is included to potentiate the 
analgesic component. Caffeine increases renal blood flow and may reduce nephrotoxic 
effects of NSAIDs. The mild diuretic effect of the drug may increase the rate of urinary 
excretion. Any action may be due to the general euphoria experienced due to the central 
stimulatory effects of caffeine but there is little evidence that caffeine is an important 
ingredient in these combinations (Burgen and Mitchell, 1978).
Many other NSAIDs which are marketed for human use in the UK have been 
used in the dog. Pharmacokinetic and toxicity studies on NSAIDs have revealed great 
differences between the species. Many of the NSAIDs have much longer half lives in the 
dog and most are excreted in the bile rather than in the urine as in man. Enterohepatic 
recirculation occurs to varying degrees for many of the NSAIDs and prolongs plasma 
half life and increases the exposure of the gastrointestinal tract to local high 
concentrations. It is thus potentially very dangerous to extrapolate dosages or toxicity 
data from one species to another.
68
(As#o
COn
G0>
B
BocJ
<U
©
Q
S i
!>
E
8 .5
S I>0 «<-H 
2 2 n> IU
o  £  2  
■ o  o  u£2 u
.  -  V)
• o  o  3 Q 
•O .
>  a>X (A•a o
•g 8"5b §
S g
8.5
v o  g
8  „ ^  aj
•S
§
6
X 3
I
■£
00
B
•a
£
*s
T3
•?
’•3
>»
f
o
£x:o
C
00
e
<N
VO
iinco
*•a
£
•S•aS
'■3
texo
X3
.1o
oo
s
5
-a
£
1
a>
La
3-taJ
W
**■
3
§
£
°a
£3
£
<U•33
230 3
1 
!§ ■
© ;>
^ 2  
% § l lDa _a
a s
00u,
©cs
2
o
ax:op
‘5
£
£>
3
'oc
E
00 op 00
b b b
8 8 2
00 00 00 
B B BO Ov O
OO 00
£  E
00 0 0  
E E
oo oo
E £
8 8 8 8 8 8cs — '  C N cs
oo 00 00 £ 6 £ o © o 
8 2 ^
OO oo 00
£ E £
oo
3
L .
Q
- Mo 2fi
fl> 4)
s .§ .§ <CO
Z
<D
n
<u o
3
3 3 3
.O JO jO
”> »
S 8 G
K £ £
J§ a s
. Sp S
69
Ta
ble
 
7: 
Or
al 
Pr
ep
ar
at
io
ns
 
Co
nt
ai
ni
ng
 
A
na
lg
es
ic
 
and
 
N
on
-S
te
ro
id
al
 A
nt
iin
fla
m
m
at
or
y 
D
ru
gs
 
Re
gi
ste
re
d 
for
 V
et
er
in
ar
y 
Us
e 
in 
the
 
Un
ite
d 
Ki
ng
do
m
 
(Ju
ne
 
19
89
).
Certain NSAIDs have increased toxicity in the dog. Indomethacin and 
flurbiprofen have shown serious toxicological reactions and should be avoided. 
Therapeutic doses of ibuprofen are potentially toxic and diclofenac has increased toxicity 
in the dog compared to man because it is excreted in the bile. NSAIDs which have been 
used in dogs with some success and without a high incidence of adverse reactions are 
listed with dosage recommendations in TABLE 8. An owner should always be warned 
when the drug used is not registered for use in dogs.
In all NSAID pharmacokinetic studies, one of the most striking findings is the 
massive variation in plasma concentrations in individual animals (McKellar, 1989). In 
addition to individual variation in dose-response characteristics, some patients will 
respond better to one NSAID than to another. The reasons are not known (Kantor,
1983). Since there is such a substantial degree of individual variation in the kinetics, 
clinical response and adverse reactions of a particular drug in any one animal, it is 
important to adjust the dose to the response rather than assuming that an average 
recommended dose or dosage interval are appropriate. The dog should initially be treated 
at a mean recommended dose rate. If the desired effect is not achieved, the dose rate 
should be increased in increments towards the maximum recommended dosage until a 
clinical response is apparent or until side effects occur. If one drug causes side effects or 
is ineffective at the maximum recommended dosage then a second drug should be tried in 
a similar manner. It is rare to find a dog which cannot tolerate treatment with any NSAID.
Treatment should be started with a drug which has a low incidence of adverse 
reactions and preferably with a NSAID which is registered for use in the dog, since this 
will, in the near f u t u r e b e  a guarantee that toxicity and efficacy studies have confirmed 
its safety and effectiveness (Group A: FIG 241. Dogs will respond to NSAED therapy 
within 10 to 14 days, at least in terms of analgesic effect. If there is no response in this 
period or if adverse effects occur, then the NSAID should be discontinued and a different 
NSAID from the same group should be tried. If this also proves unsatisfactory, then 
more potent (mg/kg) but potentially more toxic NSAIDs should be tried (Group B; Group 
C: FIG 24). There is a case for allowing the owner to use a number of the Group A or 
A&B NSAIDs in succession and to then decide which drug is most efficacious. Once the 
clinical condition has been controlled, it is important to review the disease state at 
intervals. In many situations the frequency and/or dose of drug can be reduced or the 
drug withdrawn. The dog should not be under nor overdosed. A dog should not be made 
to suffer unnecessarily because of inappropriate dosage or overlong dosage intervals, but 
neither should the dog run the risk of adverse effects as a result of a dosage that is 
excessive or needlessly frequent. Small breed dogs are often overdosed by owners or by 
veterinarians. Care in calculating dosages is important to avoid either under or 
overdosing.
t  Revised veterinary drug registration procedures
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First Visit (Day 0) Return to Normal
Investigation and Diagnosis- ►  Corrective Surgery
Medication (Group A  [?B]) 
Exercise Control 
Obesity --> Diet Control
Second Visit (14 days) ►  Improved------ ►Reduce or withdraw medication
Continue other controls
N o Change /  Deterioration
Further Investigation Surgery
Change Medication (Group A  or B [?C]) )
Check on Exercise & Diet Controls -----------
Third Visit (28 days]- Medication: Change from 
Group B to Group A
■►Improved
N o Change /  Deterioration... .  ►• Surgery
Change Medication (Group B/C) 
Check Exercise and Diet Controls
Fourth Visit ► Improved
No Change /  Deterioration— ► ? Salvage Surgery
J
GROUP A  
Veterinary Registered
GROUP B 
Tried and Tested
GROUP C
Less experience; seem useful
GROUP D  
AVOID USE
- Phenylbutazone - Aspirin
- Cinchophen +  Prednisolone - Paracetamol
- Paracetamol +  Codeine +  Caffeine
- Carprofen [when available]
- Piroxicam
- Mefenamic Acid
- Meclofenamic Acid
- ? Naproxen
- Indomethacin
- Flurbiprofen
- Ibuprofen
- ? Diclofenac
FIG 24: Management of the Chronically Lame Dog
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Many NSAIDs have a duration of analgesic activity far in excess of that 
predicted by their relatively short plasma half life. There is increasing evidence that drugs 
with short half lives can be given less frequently than would predicted by their plasma 
concentrations without compromising their effectiveness. Pharmacokinetic studies have 
demonstrated that some NSAIDs collect in synovial fluid and may be sustained at 
therapeutic concentrations locally after plasma concentrations have reduced. There is also 
evidence that cyclooxygenase inhibition persists after NSAIDs have become undetectable 
in the synovial fluid. This suggests that NSAIDs can be given less frequently without 
reducing their analgesic or antiinflammatory effectiveness (Brooks and others, 1986).
A number of other factors should be considered when deciding on the NSAID 
and the dosage initially used. Age has effects on absorption, distribution, metabolism and 
excretion of certain NSAIDs which possibly include ketoprofen, piroxicam, and 
naproxen. Salicylate affinity for plasma proteins is reduced in older people and the 
increased free drug concentrations may increase the risk of toxicity. Adverse reactions 
increase in incidence with increasing age (Greenblat and others, 1986).
Genetic factors are known to affect the rate of aspirin metabolism and the 
kinetics of the drug in man (Greenblat and others, 1986). Variations in the rate of 
metabolism, excretion and toxicity of NSAIDs and other drugs have been demonstrated 
between breeds of dog. Beagles generally metabolise and excrete drugs more rapidly 
than mongrel dogs (Freh and others, 1978). Since many of the pharmacokinetic and 
toxicity trials on NSAIDs are performed in beagles, doses may have to be reduced in 
other breeds. Conversely, beagles are more sensitive to the toxic effects of certain 
NSAIDs than mongrel dogs (eg. Azapropazone (Walker, 1985)).
Owners should always be warned of the possible side effects of any treatment 
including the NSAIDs. It should be explained that side effects can occur after a prolonged 
period. If a NSAID has side effects, these effects are more likely to be prolonged if the 
drug has a long half life. The veterinarian should seek the owners cooperation in reducing 
the dose and frequency of NSAID treatment to a minimum by explaining the risks of 
chronic therapy. Many NSAIDs cause fluid retention, interfere with antihypertensive 
effect of 6-blockers and diuretics. Acute renal failure associated with their use has been 
widely reported in man. Care should be exercised in dogs with renal disease, hepatic 
disease, congestive cardiac disease, sodium depletion or on long-term diuretic therapy 
(Hart, 1987). Patients with impaired renal or hepatic function may have a decreased rate 
of clearance of drug and metabolites and the dosage and frequency of dosing of NSAID 
should be decreased accordingly. Prolonged use of NSAIDs may have a direct effect on 
cartilage breakdown and repair and some drugs may reduce proteoglycan synthesis and 
cartilage regeneration.
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In the future the disease modifying drugs (DMDs) described in section 3/7 
are likely to become more important since they affect the progression of osteoarthritis and 
not just its symptoms. However, the NSAIDs will probably remain important drugs since 
the DMDs are generally more expensive, some may require intraarticular injection, and all 
are unlikely to completely ameliorate the symptoms or halt the progression of 
osteoarthritis. When used with managemental adjustment and, where appropriate, 
surgical correction, NSAIDs can greatly benefit the osteoarthritic dog by reducing pain 
and stiffness, and enhancing mobility and "quality of life". It is the responsibility of the 
veterinarian to consider all factors which may effect the efficacy of treatment and the 
probability of side effects (TABLE 9). The use of non-registered drugs should be 
restricted to dogs which have not responded to registered drugs. The non-registered 
NSAIDs should be used with care and at carefully calculated, recommended canine dose 
rates. These dose rates should be taken from the most recent veterinary literature since 
some earlier papers (eg Taylor, 1985) suggest drugs and dose rates now known to be 
potentially harmful. NSAIDs must be used with care and the owner must be made fully 
aware of the potential drawbacks of treatment and how they can be minimised.
TABLE 9: Factors to Consider in Selection of a NS ADD for the Therapy of an
Osteoarthritic Dog
DOG
DISEASE SEVERITY
Age
Other Disease:
Cardiac Insufficiency 
Renal; Hepatic Disease
Other Treatment: 
Diuretics 
B-Blockers 
Anti-Epileptics
DRUG
SAFETY
EFFICACY
Veterinary Registration:
If not
Legal Responsibility;
Warn Owner 
Increased Care 
Adhere to Vet. Literature 
Recommendations
DOSE CALCULATION 
Kinetics /  Interdosing Interval 
[?cartilage effects]
Remember
INDIVIDUAL VARIATION
MINIMUM EFFECTIVE DOSE 
REGULAR REASSESSMENT
OWNER
INFORM
About Osteoarthritis
Symptomatic Treatment 
vs.
Treatment ffecting 
Disease Progression
Importance of Management
-exercise
-obesity
Risks of Chronic Therapy 
with NSAIDs
Side Effects
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2*3 Disease Modifying Drugs TDMPsI
3.8.1 Introduction
In recent years it has become clear that the NSAIDs do not inhibit the 
progression of osteoarthritis and that some of the NSAIDs may promote osteoarthritic 
change by inhibiting chondrocyte proteoglycan production (see 3.3.61. Concurrently, 
research in human and veterinary fields has demonstrated that other drugs can inhibit the 
ultra-structural, biochemical and anatomical changes associated with natural and 
experimentally induced osteoarthritis. These disease modifying drugs (DMDs) may 
become widely used in the therapy of osteoarthritis in the future (DiPasquale and others, 
1986; Doherty, 1989). Some of the drugs investigated are discussed in this section.
2.32. Steroidal Anti-Inflammatory Drugs
Glucocorticoids are known to 
inhibit the release of arachidonate and other 
polyunsaturated fatty acids from cell 
membranes or free triglycerides. More than 
one mechanism has been described.
Glucocorticoids are known to induce the 
production of a protein at the nuclear level.
This protein "lipomodulin " is inhibitory to 
phospholipases A2 (PLA2) and C which are 
responsible for arachidonic acid liberation 
(FIG 26) (Flower and Blackwell, 1979; Blackwell, 1980; Hirata, 1980). Glucocorticoids 
may have a direct effect on PLA2 (Manz and others, 1980) and may also inhibit 
cyclooxygenase (Hawkey, 1982). In osteoarthritis and rheumatoid arthritis an increased 
specificity of PLA2 for arachidonic acid has been reported (Loeser and others, 1988). 
Suppression of endogenous eicosanoid release by corticosteroids only appears to occur in 
a subset of possible steroid-receptor bearing target cell types (Sebalt and others, 1988). 
Other mechanisms have been described and may be important (Green and Lutsky, 1986).
Corticosteroids are well absorbed after oral administration. Ninety percent of 
endogenous corticosteroid is bound to transcortin, a specific corticosteroid-binding 
globulin whilst 5 to 8% is bound to plasma albumin which acts as a low affinity/high 
capacity steroid reservoir. Most of the synthetic steroids, with the exception of 
prednisone/prednisolone, have a low affinity for transcortin and are bound predominantly 
to albumin (Lan and others, 1982).
r S A I D s !
FIG  25: P redn iso lon e [P red n ison e: 11B= O]
75
Steroid
Nucleus...
f  Receptor 
("Steroid")V ^
r mRNA
Ribosome
I n h i b i t i o n
Phospholipase 
A2
Macrocortin /  Lipomodulin 
(? & other regulatory proteins)
Cell Membrane or Free 
Phospholipid
Arachidonic Acid
I
Eicosanoids
FIG  26: Possible mechanism of action of the corticosteroids 
Steroid binds with cytoplasmic receptor and the resulting complex migrates to 
the nucleus where it interacts with the nuclear DNA to induce the formation of 
regulatory proteins responsible for the antiinflammatory and other actions of 
steroids. The regulatory proteins include macrocortin /  lipomodulin which 
inhibits the conversion of phospholipid to arachidonic acid by phospholipase A2.
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Binding properties cause differences in the pharmacokinetics and metabolism 
of the synthetic corticosteroids. There is a large variation in the rate of clearance of 
exogenous steroids between individuals. Corticosteroids are metabolised predominantly 
in the liver but also in other tissues (Dorfman and Ungar, 1965). Within two hours of the 
intraarticular injection of corticosteroids they are present in the cells of synovial fluid or 
the synovial membrane (Zacco and others, 1954). Corticosteroid free in the joint is 
hydrolysed or may proceed to the systemic circulation.
3.8.3 Steroids and the Joint
Intraarticular corticosteroids have been used extensively in human and equine 
osteoarthritis (McKay and Milne, 1976; Friedman and Moore, 1980; Gray and Gottlieb, 
1983). In the horse, texts recommend intraarticular steroids as a way of rapidly reducing 
joint pain associated with traumatic arthritis or osteoarthritis. Steroid treatment is also said 
to reduce synovial effusions in conditions such as bog spavin (tarsal hydrarthrosis) and 
promote the formation of more normal synovial fluid (Hackett, 1982).
Low concentrations of corticosteroids stimulate cell division 
(Macieira-Coelho, 1966). Corticosteroids are very effective in vitro at inhibiting cartilage 
breakdown in synovium stimulated and control cultures (Steinberg and others, 1986). An 
in vivo protective effect has been described for rabbit articular cartilage. Hydrocortisone 
prevented spontaneous and synovium-induced proteoglycan release independently. The 
extent of cartilage degradation and the corticosteroid responsiveness were both dependent 
upon the disease activity and not the type of disease. There was a 24-48 hour lag period 
before proteoglycan breakdown in coculture, suggesting that synovial factors are required 
for initiation or induction of degradation. Contact between the synovium and articular 
cartilage was not required. A brief exposure to synovium caused a major degradative 
response in subsequent cartilage culture (Ackerman and others, 1983). When 
triamcinolone hexacetonide was administered to rabbits at 0.1 mg/kg/day it was found to 
prevent the loss of chondrocytes and matrix proteoglycans from articular cartilage, 
decrease articular surface disruption and decrease the frequency and size of osteophytes 
in chemically induced articular cartilage damage (Williams and Brandt, 1985).
In dogs, oral administration of prednisone at 0.20-0.25 mg/kg/day blocks a 
rise in synovium-induced cartilage neutral metalloproteoglycanase activity in Pond-Nuki 
experimental osteoarthritis (Pelletier and others, 1985a,b). Although prednisone blocks 
the increase in total and active neutral metalloproteinase activity in osteoarthritic cartilage 
and the level of active enzymes is reduced close to levels in control animals, the increase 
in proteoglycan concentration which might be expected does not occur since prednisone 
inhibits the synthesis of proteoglycan by chondrocytes (Silberberg and others, 1966).
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It appears that low dose steroids inhibit the early induction phase of cartilage 
breakdown. Later applications when the breakdown has been activated may be relatively 
ineffectual. Prednisone may inhibit the synthesis or release of soluble factors from the 
synovium or may act by cell receptor or intra-cellular mechanisms on enzyme synthesis in 
chondrocytes (Pelletier and others, 1985a,b). Steroids are known to inhibit some 
activators such as plasminogen activator (Hamilton and others, 1981). Alternatively, 
steroids may promote the synthesis of free endogenous inhibitors (TIMP). Collagen 
degradation is suppressed at physiological levels of corticosteroids. Proteoglycan 
degradation is inhibited only at pharmacologic levels (Steinberg and others, 1986). In 
addition, corticosteroids suppress hyaluronic acid synthesis by synovial villi. This may 
be a mechanism by which steroids reduce the joint hyaluronic acid content and promote 
the resolution of synovial effusion (Colombo and others, 1983).
The use of larger doses of corticosteroids systemically or intraarticularly is 
associated with well documented adverse reactions in man and animals. Long term 
systemic steroids in man have been associated with osteoporosis, pathological fracture, 
aseptic necrosis, growth plate disturbances and stunting, as well as the effects on other 
body systems. To avoid these effects, intraarticular steroids have been used since 1951. 
The first reports of adverse joint effects were reported in 1958, and since that time many 
doctors have reported accelerated joint destruction. Corticosteroids are known to promote 
degeneration of articular cartilage (Bentley and Goodfellow, 1969; Chandler and Wright, 
1958; Miller and Restiffo, 1966; Moskowitz and others, 1970; Goldberg and others,
1976). In experiments in vivo , changes have been induced by local steroid treatment 
(Greenwald and others, 1986). Multiple steroid injections into joints causes a 
"corticosteroid arthropathy" with fibrillation, chondrocyte degeneration, loss of matrix 
proteoglycans and cyst formation (Goldberg and others, 1976). Corticosteroid 
arthropathy is reported in horses treated with intraarticular corticosteroids for 
osteoarthritis and in chip fractures. Early theories proposed that the acceleration of 
osteoarthritic changes seen were a result of analgesia and consequent overuse. Other 
theories have included mechanical trauma from crystalline preparations, vasculitis, 
subchondral osteoporosis and microfractures, and chondrocyte metabolism effects.
Experiments have demonstrated that corticosteroids inhibit chondrocyte 
production of proteoglycans by up to 60% and of collagen by up to 80%, and decrease 
osteoblast activity in subchondral bone. It seems that corticosteroids adversely effect the 
synthesis of matrix macromolecules and reduce cartilage turn-over. Subchondral bone 
effects may result in microfractures and promote joint damage.
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Septic arthritis is a potentially disastrous complication of intraarticular steroid 
injection. It usually arises from arthrocentesis but can result from the haematogenous 
seeding into the immunosuppressed joint. In experimental animals it has been 
demonstrated that both intraarticular and systemic steroid treatment reduces the number of 
bacteria required to establish infection in a joint. Corticosteroids also promote bacterial 
joint destruction and may mask the early signs of septic arthritis. Clinical signs may be 
apparent within 24 hours or may take weeks or months to develop, depending on the 
initial bacterial load and type and the subsequent inflammatory reaction.
In the horse, the intraarticular use of steroids has been recommended to be 
confined to temporary palliative treatment of joint disease. They are used to prolong the 
performance career in cases such as the racehorse with a progressive osteoarthritis. Their 
use in acute traumatic synovitis may also be indicated. Intraarticular steroids may be 
beneficial when lesions are confined to soft tissues of the joint, except in injuries 
involving joint laxity. The minimum dose and frequency for effect is recommended 
(Hackett, 1982). In man, intervals of 4-6 months between intraarticular steroid injections 
are recommended. It is advised in man and the horse that joint loading is minimised for at 
least two weeks after injection (Owen, 1978; Hackett, 1982; Brandt, 1989).
Though the incidence of steroid arthropathy and septic arthritis in people 
treated with intraarticular steroids is low, many physicians are doubtful of their 
usefulness. Modem texts of rheumatic disease in man state that there is no place for 
systemic corticosteroid or adrenocorticotrophic hormones in the management of 
osteoarthritis since the side effects associated with the prolonged use of these drugs 
outweigh any potential beneficial effects (McKay and Milne, 1976; Hart, 1983; Brandt, 
1989).
3.8.4 Glvcosaminoglvcan Polvsulphate Esters fGAGPSI
When the evidence that proteoglycan fragments can induce synovitis (see 2.81 
is considered, it is perhaps surprising that polysulphated glycosaminoglycans such as 
Adequan®, Arteparon and pentosampolysulfate have anti-arthritic effects in experimental 
models of osteoarthritis in animals. The proposed explanation is that the lower molecular 
weights of these compounds, (2000-12000 daltons), are below that which is required to 
mediate the inflammatory reactions demonstrated by larger sulphated polysaccharides. It 
has been shown that low molecular weight polyanions will inhibit the activation of 
macrophages by high molecular weight anions (Schlorlemmer and others, 1980; 
Steinberg and others, 1980).
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A number of possible mechanisms of action for GAGPS have been proposed. 
GAGPS has been reported to stimulate glycosaminoglycan synthesis in certain cell 
systems (Verbruggen and Veys, 1977; Verbruggen and Veys, 1979; Von der Mark,
1979) Although GAGPS stimulates glycosaminoglycan synthesis in chondrocytes (Nevo 
and Dorfman, 1972; Huang, 1974) it only does so at high concentrations. GAGPS 
inhibits collagen and proteoglycan catabolism in human articular cartilage (Adam, 1980). 
Leukocyte accumulation is reduced in experimental models of cartilage degradation. This 
may be important in vivo since cartilage exposure to PMN-derived metalloproteinases or 
chondrocyte-active mediators may be reduced (Francis and others, 1989).
Glycosaminoglycan polysulphate ester has been found to be a potent inhibitor of 
a variety of enzymes including cathepsin B l, serine proteases such as cathepsin G and 
elastase (Kruze and others, 1976; Stephens and others, 1980) and B-glucuronidase, 
N-acetylglucosaminidase, hyaluronidase and stromolysin ( Kalbhen, 1970; Greiling and 
Kaneko, 1973; Lees, 1989). Most known protease inhibitors are toxic in vivo or 
suppress cellular synthetic function and most agents administered systemically or 
intraarticuarly fail to concentrate in cartilage for a sufficient period. However, following 
intramuscular injection, GAGPS concentrates in articular cartilage to give concentrations 
of 10-6 M: sufficient to inhibit serine proteases and metalloproteinases in vitro. It is 
retained in effective concentrations for up to 8 days. It is distributed diffusely throughout 
the cartilage when 3H-GAGPS studies have been performed (Ghosh, 1985).
GAGPS may bind to proteoglycans and glycoprotein in the matrix and protect 
the substrate from enzymatic degradation. GAGPS is known to stimulate hyaluronate 
synthesis. GAGPS inhibition of hyaluronidase may rectify hyaluronate metabolism and 
allow the regeneration of proteoglycan aggregates of normal size (Howell, 1986).
Twice weekly intraarticular injections of GAGPS at 1 mg/kg had a significant 
beneficial effect on morphological parameters of disease severity in experimentally 
induced osteoarthritis in rabbits. In osteoarthritic controls, there were 5-10 fold increases 
in active neutral metalloproteinase at 12 and 20 weeks, and 10 fold increases in neutral 
serine proteases at 20 weeks. No thiol pro tease activity was detected. GAGPS injections 
suppressed the enzyme activity levels to normal or below normal range values. GAGPS 
either directly at chondrocyte level or via synovial cell mediator actions suppressed net 
neutral protease activity. In addition GAGPS treated animals had chondrocyte cell counts 
double those of controls. Unlike the osteoarthritis controls they were not located in brood 
capsules. GAGPS used prophylactically and therapeutically prevented the 35-40% 
reduction in hexuronate incorporation seen in untreated osteoarthritis controls (Howell 
and others, 1986).
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In dogs with experimentally induced osteoarthritis, glycosaminoglycan 
polysulfuric acid ester (GAGPS) administered intramuscularly at 4 mg/kg twice 
weekly was found to substantially protect the cartilage. Cartilage swelling was increased 
in the untreated control group but remained near normal in the group treated with 
GAGPS, suggesting that GAGPS treatment preserved the collagen network. Total and 
active metalloproteinases were elevated in the untreated controls but only the total 
metalloproteinase content was increased in the GAGPS treated group (Altman, 1988). 
These findings have also been demonstrated after intraarticular use in dogs (Altman and 
others, 1989). GAGPS treatment was associated with a reduction in cartilage pathology, 
decreased collagen disruption and decreased collagenase activity.
GAGPS has been widely used and is licensed for use in horses (Adequan®) 
by intramuscular and intraarticular routes and various studies have demonstrated its 
clinical efficacy (Tew, 1982; Snow, 1983; Hamm and other, 1984; Collins, 1989).
3,8,5. Hyaluronic Acid / Hyaluronate
Hyaluronic acid is a 
constituent of normal synovial fluid 
which is secreted by synoviocytes 
and which has lubricant and shock 
absorption properties (TIG 271. It is 
also a component of a thin, 
filamentous layer which is present 
on the surface of normal cartilage 
(Balazs and others, 1966; Balazs and 
Darzynkiewicz, 1973).
Synovectomy appears to lead to the 
loss of this layer and degenerative 
changes in articular cartilage.
Hyaluronate injection of synovectomised rabbits restores the filamentous layer and 
prevents further damage (Toyoshima, 1978).
In vitro studies have suggested that hyaluronate may have a 
chondrocyte-regulatory function such that it influences the synthesis or release of 
proteoglycans (PGs). Hyaluronate is a potent inhibitor of proteoglycan synthesis. 
Depolymerised hyaluronate retains activity on chondrocyte PG synthesis but not on 
fibroblasts (Sommarin and Heinegard, 1983; Abatangelo and others, 1989).
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FIG 27: Sodium Hyaluronate
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It appears that hyaluronate binds to specific sites on the chondrocyte surface. 
Hyaluronate thereby inhibits PG synthesis by blocking glycosaminoglycan chain 
initiation by specific inhibition of either normal core protein synthesis or the 
xylosyl-transferase which initiates chondroitin sulphate chain synthesis. This mechanism 
seems important in the control of cartilage matrix proteoglycan (Sommarin and 
Heinegard, 1983; Abatangelo and others, 1989). Hyaluronate may also effect the release 
of enzymes or mediators from the synovium (Schiavinato, 1989). Sodium hyaluronate 
does not apparently modify joint inflammation (Hilbert, 1985). It appears that hyaluronic 
acid improves the intraarticular environment rather than having any anti-inflammatory or 
analgesic action (Higgins, 1985).
Hyaluronic acid was first reported to be useful in an intraarticular combination 
with corticosteroids (Rydell, 1970). The intraarticular use of hyaluronic acid has proved 
to be useful in the therapy of osteoarthritis in man and in the horse (Rydell, 1971; 
Asheim, 1976; Wigren, 1978; Rose RJ, 1979). Severe cases are often unresponsive to 
therapy. Sodium hyaluronate has been found to significantly delay osteoarthritic changes 
if administered soon after joint instability occurs or reduce disease progression if given 
up to seven weeks after initiation of experimental stifle osteoarthritis in the dog 
(Schiavinato and others, 1989).
3.8.6 Glucosamine
Glucosamine is a proteoglycan/glycosaminoglycan precursor. Glucosamine 
promotes chondrocyte proteoglycan synthesis (Karzel and Domenjoz, 1968 ; Vidal y 
Plana and others, 1978; Vidal y Plana and others, 1980). It is under study in man but 
appears to be chondroprotective when used orally and has proven therapeutic benefit in 
osteoarthritis equivalent to or even greater than that of NS AIDs (Vidal y Plana and others, 
1978; Drovanti and others, 1980; Vaz, 1982).
3.8.7 Orgotein
Orgotein is the generic name adopted in 1971 for Cu-Zn superoxide 
dismutases (SOD). Orgotein is derived from bovine liver and has a molecular weight of 
about 31,500.
Orgotein catalyses the reaction:
° 2“ + 02" + 2 H ------------ > H2O2 + O 2 ------------- > H2O + V2 °2
and suppresses the reaction:
0 2 “ + H2O2 ------------ > OH- + OH- + O2
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It is proposed that Orgotein is a scavenger of free radicals, and so prevents 
lysosomal membrane destabilisation. Orgotein is a potent anti-inflammatory at an 
effective dose of > 0.5 mg/kg. In the dog, orgotein displays first order kinetics. It is 
rapidly cleared from plasma. Two hours after administration 55% is present in the urine 
and 29% in the kidney (Huber and others, 1980). Orgotein is digested if given by mouth. 
If given parenterally, it is cleared rapidly be the kidneys. However, when given 
subcutaneously or intramuscularly in the dog it has a long duration of effects (Huber and 
others, 1980).
Orgotein has very low toxicity. A single dose twenty thousand times the 
clinical dose is safe as is administration at 160 times the therapeutic dose for 30 days 
(Huber and others, 1983). Orgotein has very low immunogenicity despite its bovine 
derivation. The copper and zinc in orgotein are tightly bound to the polypeptide and have 
no clinical effect. The safety of the drug is believed to be due to its extracellular 
distribution and rapid accumulation and clearance by the kidney (Huber and others, 1980; 
Huber and others, 1983). Orgotein does not interfere with other drug actions.
Some authors have reported the effect of orgotein in osteoarthritis as 
disappointing (Huber and others, 1980). However, many authors have reported its 
usefulness in traumatic and soft tissue injuries in the horse (Decker and others, 1974; 
Faull and others, 1976; Linton, 1976). Ahlengard et al (1981) found it to have good 
efficacy in horses that had been lame for shorter periods, if no intraarticular fractures 
were present In man, injection of orgotein into arthritic knee joints caused statistically 
significant improvement clinically, in pain and joint use parameters. Orgotein is 
apparently as effective as gold or steroids in the treatment of rheumatoid arthritis in man 
(Menander-Huber, 1981; Goebel and Storck, 1983). Orgotein has been used in dogs 
with locomotor dysfunction and was found to significantly improve many cases 
(Breshears and others, 1974).
The estimated dosage, extrapolated from studies in man, is 2-4 mg 
intraarticularly every 7-14 days for up to 5 treatments or 0.1 to 0.3 mg/kg in 1 ml saline 
intramuscularly every other day for up to several weeks.
3.8.8 PimethvlsulDhoxide (DMSO)
DMSO is a highly polar organic solvent. It is well absorbed through the skin. 
DMSO scavenges free radicals and particularly hydroxy radicals (Wong and Reinertson, 
1985). There is some evidence of beneficial action in post-traumatic inflammation. The 
mechanism and benefits are controversial however and medical texts advise against its 
use (Brandt, 1989).
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3,8.2 Ascorbic Acid
Ascorbic acid (Vitamin C) has anabolic effects on cartilage. In man and 
rabbits, ascorbic acid is required for chondrocyte protein synthesis (Krystal and others, 
1982). Also, it stimulates chondrocyte proliferation and proteoglycan synthesis in vitro. 
Vitamin C may protect against cartilage erosion by increasing chondrocyte synthesis 
(Schwartz, 1981). However, it is believed that dogs do not require exogenous vitamin C 
in addition to that synthesised endogenously and dietary supplementation would probably 
not be appropriate or necessary.
3.8.10 Cvtokine Effectors
The compound CP-66,248 which has biological activity against Leukotriene 
B4 and Interleukin-1 biosynthesis in vitro and in vivo, has been found to be more 
efficacious in the treatment of human osteoarthritis than a placebo treatment but had a 
similar incidence of side effects (Davis, 1988).
3.9 Summary
The recent evidence that steroids have a chondroprotective role when used in 
early osteoarthritis at low doses contrasts with the wealth of data that at higher doses 
administered intraarticularly they can induce osteoarthritic changes in normal joints or 
promote damage in osteoarthritic joint If steroids have protective effects at doses which 
do not suppress adrenal function significantly, their oral use at low doses may be useful 
in early osteoarthritis. The use of higher doses of steroids intraarticularly is of doubtful 
value. The potential for adverse effects on the joint is great. Greater benefits are attainable 
with some of the newer DMAs without the same risk of septic arthritis or articular 
cartilage damage.
Both hyaluronic acid and glycosaminoglycan poly sulphate (GAGPS) esters 
have proven chondroprotective effects in experimental models of osteoarthritis. 
Hyaluronic acid appears to effect chondocyte synthesis of proteoglycan and may be 
involved in proteoglycan aggregation and the maintainence of a diffusion barrier between 
the synovium and the chondrocyte. GAGPS has effects on chondrocyte proteoglycan 
synthesis, and on degradative enzyme production and activation. Both GAGPS and 
hyaluronate are licenced for use in equidae and have been used with some success. 
Experimental studies in dogs have shown that they markedly delay the progression of 
secondary osteoathritis.
8 4
GAGPS has the advantage that when administered intramuscularly it 
concentrates in articular cartilage. Hyaluronate must be administered intraarticularly. The 
GAG precursor glucosamine appears to have chondroprotective properties. It may be 
very useful since it can be administered by mouth. There is an urgent need for clinical 
efficacy studies in naturally occurring osteoarthritis in dogs, particularly with GAGPS 
but also with hyaluronic acid and glucoasamine.
There is conflicting evidence on the efficacy of the reactive oxygen species 
scavenger orgotein in osteoarthritis. It may be more useful in rheumatoid arthritis where 
there is more evidence that ROS are important in the inflammatory reaction. The use of 
dimethylsulphoxide (DMSO) is generally not recommended.
In the near future, it is likely that DMDs will be used increasingly in man and 
in animals. Other drugs which have effects on the mediators of osteoarthritis 
pathogenesis such as IL-1 or which mimic growth factors or chondroprotective mediators 
will probably augment the symptomatic treatment of osteoarthritis with NS AIDs which 
do not have antagonistic activity on chondrocyte metabolism. At present, when used 
appropriately the NSAIDs are extremely useful in the amelioration of the symtoms of 
osteoarthritis whilst factors which predispose to further damage are corrected and similar 
drugs will probably remain important in the future.
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Chapter 4
The NSAIP Carprofen and its Use 
in the Therapy of Canine Osteoarthritis
4The NSAID Carprofen and its Use in the 
Therapy of Canine Osteoarthritis
4J. Carprofen
4.1.1 Structure and Chemistry
Carprofen ad us. vet contains 
the substance known chemically as 
alpha-methyl-6-chlorocarbazole-2-acetic 
acid. It is a tricyclic compound (a 
carbazole) and a propionic acid 
derivative. Carprofen (Ro-20-5720) was 
originated at Hoffman-La Roche 
Research Laboratories. Carprofen, like most other propionic acid derivatives, is a racemic 
compound. Carprofen has a pKa of 4.7.
4.1.2 Activity and Mechanism of Action
Carprofen inhibits prostaglandin synthesis by reversible inhibition of 
cyclooxygenase. However, carprofen is a much less potent cyclooxygenase inhibitor than 
indomethacin in vitro and in vivo (indomethacin IC50M).50 fiM; carprofen IC50=48 
|iM). The approximate order of potency of cyclooxygenase inhibition is:
Indomethacin, tolmetin Na, naproxen > carprofen = piroxicam > ibuprofen 
»benoxaprofen.
(Baruth and others, 1985).
Carprofen is a potent inhibitor of prostanoid biosynthesis in rheumatoid 
synovial cell culture (chronic inflammation) and in rat peritoneal polymorphonuclear 
leucocytes (PMN). Carprofen is less potent than indomethacin in synovial culture but 
equipotent in the rat peritoneal PMN model and is twice as potent as benoxaprofen in 
both models (Dayer and others, 1977; Dayer and others, 1980). Carprofen is apparently 
inactive against lipoxygenase in vitro. However, carprofen is a moderately potent 
phospholipase inhibitor in vitro (IC50=120 fiM; cf. indomethacin 370 jjM, benoxaprofen 
440 |iM). These concentrations are quite high and the in vivo significance of these 
findings is uncertain.
Cl
C H C O O H
FIG 28: Carprofen
t  IC50 = Concentration of drug which inhibits cyclooxygenase activity by 50%.
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Carprofen is a more potent inhibitor of the release of arachidonic acid from 
cellular lipid than many other NSAIDs (about 100 p.M). High in vitro concentrations of 
carprofen inhibit complement activation in man (DiPerri and others, 1982). Carprofen 
may have effects on neutrophil chemotaxis (Tursi and others, 1982). In animal models, 
carprofen has demonstrated potent antiinflammatory and analgesic activity and is well 
tolerated. The antiinflammatory activity of carprofen is greater than that expected from its 
effects on cyclooxygenase. Carprofen has activity superior to aspirin and equivalent to 
indomethacin in both acute (carrageenan-induced oedema, acute adjuvant arthritis) and 
chronic (established adjuvant arthritis) inflammatory models. In acute inflammatory 
models in the rat, 2 mg/kg carprofen is equivalent to 68 mg/kg aspirin. The 
antiinflammatory activity of carprofen is equipotent to indomethacin in acute adjuvant 
arthritis in rats. In general, the order of antiinflammatory potency of the common 
NSAIDs is:
carprofen « indomethacin, piroxicam, diclofenac > phenylbutazone > ibuprofen > aspirin
(Maeda and others, 1977; Strub and others, 1982; Jeunet, 1982).
The analgesic activity of carprofen is similar to that of indomethacin and 
greater than that of aspirin (Randall and Baruth, 1976; Strub and others, 1982).
4.1.3 Pharmacokinetics in the Dog
After oral administration, carprofen is very rapidly absorbed. Peak 
concentrations are proportional to the administered dose. In beagle studies with doses of 
1, 5, and 25 mg/kg, peak plasma levels were attained after 2 hours (Roche Internal Data). 
Carprofen's elimination half-life (ti/26) in the dog has been reported as 12-24 hours. 
Plasma concentrations show a biphasic or multiphasic decline. There is no evidence of 
either drug accumulation or of microsomal enzyme induction or tachyphylaxis (Rubio and 
others, 1980). In a pharmacokinetic study by the author carprofen at 4 mg/kg 
administered orally was rapidly absorbed to give peak plasma concentrations between
26.1 and 44.3 qg/ml and a mean elimination half life (ti/26) of about 9 hours (6.5 to 13.7 
hours) (see 4.21.
In man, absorption of carprofen is delayed by administration with food but 
total bioavailability is not affected. An oral dose of 100 mg produces plasma 
concentrations of 6 to 16 ug/ml (Ray and Wade, 1982) and multiple daily doses of 150 
mg (ie. approximately 2 mg/kg) orally produce plasma concentrations between 3 and 20 
ug/ml (Crevoisier, 1982). The elimination half life in man is 13 to 27 hours (Ray and 
Wade, 1982).
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Carprofen readily diffuses into the synovial fluid although peak 
concentrations are lower and are reached about 6 hours after peak plasma concentrations 
(Ray and others, 1979). Concentrations in synovial fluid in man are 30 to 103% of serum 
concentrations (Enthoven and others, 1987). The plasma half life in older people is 
reduced although clearance is not affected (Blumenthal and others, 1980). In man, 
hepatic cirrhosis does not effect pharmacokinetics (Holazo and others, 1985).
In the dog, the elimination of carprofen is primarily by biotransformation. 
Biliary secretion and faecal excretion account for 60-70% of the administered dose. The 
main metabolic pathways are direct conjugation of carprofen to an ester glucoronide and 
oxidation of carprofen to C7 and C8 phenols and subsequent glucoronyl conjugation.
The metabolites are rapidly eliminated and do not accumulate (Rubio and others, 1980). 
In man, urinary excretion of the glucoronide ester predominates (Maeda and others,
1977). In man, enterohepatic recirculation of carprofen occurs (Ray and Wade, 1982). 
There is no evidence of enterohepatic recirculation in the dog (Rubio and others, 1980).
4.1.4 Use in Man
Carprofen (Imadyl®; Rimadyl®) is available for use in man in a number of 
countries but not in the UK. Indications for the use of carprofen in man have included 
osteoarthritis; rheumatoid arthritis; ankylosing spondylitis; capsulitis; extra-articular 
rheumatic conditions such as tendonitis, bursitis, synovitis and soft tissue injuries; and 
the relief of pain following acute trauma. In man, carprofen has proven beneficial in 
symptomatic relief in rheumatoid arthritis (Dickey and Huleatt, 1980; Standell, 1982) and 
osteoarthritis (Dickey and others, 1979; Klein, 1982; Stein and others, 1983). Carprofen 
has a rapid onset of action and a longer duration of action than aspirin. It has equivalent 
efficacy to indomethacin in the therapy of osteoarthritis in man (Dickey and others,
1979). In man, carprofen is used at approximately 5 mg/kg/day in two divided doses 
(Jeunet, 1982; Baruth and others, 1985; Lombardino, 1985). Once a satisfactory 
response is seen, the dosage is reduced to the minimum effective dose.
4.1.5 Dosage and Administration
The preliminary recommendations from Hoffman-La Roche were that 
carprofen be used in all species at 0.5-0.7 mg/kg/day for a maximum of 3 months.
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4.1.6 Tolerance and Toxicity
The following side effects have been reported in man:
-Gastrointestinal: epigastric discomfort, nausea, heartburn, diarrhoea.
-CNS: Dizziness, headaches, drowsiness.
-Skin: Rash, pruritis, erythema, urticaria.
-Others: dysuria, increased frequency of urination, visual disturbances, mild
peripheral oedema.
Side effects in man are usually mild and transient Where a skin rash occurs, 
it is advised that treatment is withdrawn, as for other NS AIDs.Transient abnormalities in 
liver function tests have been reported.Treatment of overdosage is symptomatic. There is 
no specific antidote to carprofen overdosage.
Carprofen, like other NSAIDs will produce gastric irritation when 
administered at sufficiently high doses. However, the safety ratio (therapeutic dose: 
ulcerogenic dose) is much greater for carprofen than for many other NSAIDs. In the rat, 
the safety ratios are:
Carprofen * 32
Indomethacin ~ 2
Aspirin « 0.9
Carprofen is very much less ulcerogenic than indomethacin in rats [carprofen 
MED§ = 64 mg/kg p.o.; indomethacin MED = 4 mg/kg p.o.] (Roche Internal Data;
Baruth and others, 1985).
Experimental studies have indicated that the dog is particularly resistant to the 
ulcerogenic activity of carprofen (Maeda, and others, 1977). Carprofen is not ulcerogenic 
in the dog at doses which would be expected to have an effect. In tests for occult blood in 
the faeces of dogs receiving various NSAIDs, carprofen has been shown to be tolerated 
orally at 3 to 30 mg/kg/day whereas indomethacin, aspirin, piroxicam and 
phenylbutazone administration was associated with occult faecal blood. The latter drugs 
were often active even after a single dose. Studies on the role of hepatic function and 
B-glucoronidase function on the ulcerogenicity of carprofen in rats have suggested that 
intestinal glucoronidase activity is an important factor but variations in biliary excretion 
and hepatic metabolism are not (Dairman and others, 1976; McClain, 1976).
§ MED = Minimum effect dosage which induces ulcers in experimental animals
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No adverse clinical or pathological effects on the gastrointestinal tract were 
seen in dogs treated with carprofen orally at 25 mg/kg/day for a year (Roche Internal 
Data; Baruth and others, 1985). The low incidence of gastrointestinal intolerance may be 
due to tissue specific cyclooxygenase inhibition or to the pharmacokineticsand distribution 
of carprofen (Baruth and others, 1985). Carprofen appears to have a greater therapeutic 
index in the dog than most other NSAIDs (Teelman, 1983). A short tolerance study in 
dogs at 9 mg/kg/day is documented in Section 4.3.
Carprofen has shown no evidence of renal toxicity in the dog (Baruth and 
others, 1985). No central nervous, cardiovascular or respiratory side effects have been 
demonstrated in animal tests at doses far in excess of therapeutic doses. Mild 
dermatological effects were seen in some experimental dogs treated chronically (Maeda 
and others, 1977).
4.1.7 Contraindications and Drug Interactions
The recommendations from Hoffman-La Roche are that active peptic 
ulceration or previous hypersensitivity to carprofen are contraindications to its use. 
Precautions included care in the use of carprofen in patients with a history of peptic 
ulceration, severe renal or hepatic insufficiency or previous sensitivity to aspirin or other 
NSA1D. Since carprofen is highly protein-bound, it has been suggested that dosages of 
other highly protein-bound drugs such as anticoagulants, sulphonamides, phenytoin, 
certain potent diuretics and hypoglycaemic agents may require adjustment when 
administered concurrently. However, there are no known interactions between carprofen 
and anticoagulants. Co-administration of carprofen and antacids has no effect on 
carprofen bioavailability (Jeunet, 1982; Roche Internal Data).
4.1.8 Summary
Carprofen is propionic acid derivative. It is a cyclooxygenase inhibitor and 
also has effects on cellular lipid release, neutrophil chemotaxis and on phospholipase 
which may be significant in vivo. It has no action on lipoxygenase. Carprofen has potent 
antiinflammatory activity and significant but less potent analgesic activity. It is rapidly 
absorbed after oral administration to give peak plasma concentrations in less than two 
hours. Carprofen is highly plasma protein bound. It is eliminated primarily by 
biotransformation and is mostly excreted in the bile and faeces. Enterohepatic 
recirculation occurs in man but has not been described in the dog. Elimination is biphasic
it
or multiphasic according to some studies. In a study by the authorAcould be described in a 
monophasic fashion with anelimination half life of 6 to 13 hours. Roche Internal Data 
reports an elimination half life of 12-24 hours.
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Carprofen has relatively low ulcerogenic activity in animal tests. The dog is 
particularly resistant to ulcerogenic effects. Long term tolerance studies in dogs at 25 
mg/kg/day did not cause any adverse effects. Gastrointestinal intolerance does occur at 
higher doses. Mild dermatological signs have been reported in some dogs treated 
chronically. No evidence of renal toxicity is reported. The therapeutic index for carprofen 
in the dog is superior to most other NSAIDs. Carprofen has less potential for interaction 
with anticoagulants and antacids than many NSAIDs. Carprofen has proven efficacy in 
the treatment of musculoskeletal disorders in man including osteoarthritis. The high 
therapeutic index of the drug in acute and chronic administration studies in the dog 
suggests that, at the appropriate dose rate, it may be the NS AID of choice for chronic 
therapy of osteoarthritis in dogs.
± 2  Study on the Pharmacokinetics of Carprofen 17,5 mg Tablets in 
Dogs when Administered as a Single 4 mg/kg Oral Dose
4.2.1 Objective
The objective of the investigation was to determine the plasma pharmacokinetics 
of a single oral dose of 4 mg/kg carprofen (Ro 20-5720/659) in beagle dogs.
Materials and-Metiimte
{a} Animals:
The test animals were three male and three female beagle dogs aged between 2 
and 3 years old. The animals received no medication in the 14 days before the experiment 
began. The dogs were fed a complete cereal based diet and water was available ad 
libitum. Details of the dogs are given in TABLE 10.
TABLE 10: Experimental Animal Details
Dog Number Sex Weight prior to drug Calculated Actual dose
administration (kg) Dose (mg') Admin.
(mg) (mg/kg)
1 F 14.5 58.00 58.00 4.00
2 M 17.0 68.00 68.02 4.00
3 F 12.0 48.00 47.98 4.00
4 F 13.0 52.00 51.97 4.00
5 M 18.5 74.00 74.12 4.01
6 M 15.0 60.00 59.92 4.00
(b) Test Drug:
Carprofen ad us vet. (Roche Ro 20-5720/659); Lot No. MZ 626 B 01; 
Expiry date: 07/91.
Tablet formulation: 17.5 mg carprofen per tablet;
Supplied by Hoffman-La Roche via Grampian Holdings Ltd.
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(c) Reagents:
unwashed an alar grade (Rathbum Chemicals Ltd)
Redistilled analar grade (Rathbum Chemicals Ltd)
Permanganate distilled water. Impurities capable of degrading the 
HPLC column are present in undistilled water 
Citrate/phosphate buffer (pH 3);
20.5% M/5 Na2HP04 :79.5% M/10 Citric acid
(dl Trial Design:
The six beagles were weighed on the day prior to the day of drug 
administration. The 17.5 mg tablets were weighed to establish the mean weight of one 
tablet. Tablets were shaved to obtain a dosage such that carprofen was administered to all 
dogs at 4 mg/kg body weight (TABLE 101. All six dogs were given the oral dosage at the 
same time on the same date.
Blood was collected from the left jugular vein with a 20 gauge needle and 10 
ml syringe before drug administration ('Pre'), and at 15 minutes, 30 minutes, 1 , 1.5, 2 , 
4, 8 , 12, 24,48 and 96 hours after drug administration. Samples were placed in 
heparinised Sarstedt monovettes for plasma drug concentration estimations.
(e) Carprofen Analysis:
The heparinised blood sample from each dog was centrifuged and the plasma 
decanted and frozen. Each plasma sample was defrosted at room temperature and a 2 ml 
plasma aliquot was placed in a 50 ml stoppered tube. 0.6 ml of phosphate-citrate buffer 
(pH 3) and 20 ml of diethyl ether were added and the mixture was shaken for ten minutes 
on a rotary mixer. 15 ml of the upper ether layer was recovered and placed in a 50 ml thin 
walled glass boiling tube.
A further aliquot of 20 ml of diethyl ether was added to each stoppered tube. 
The tube was shaken for a further ten minutes and 20 ml of the upper ether fraction 
recovered and added to the 15 ml already obtained. The combined diethyl ether volumes 
were evaporated on a Dri-Block at 50°C under airstream until about 5 ml remained. The 
diethyl ether extract was transferred to a conical tube. The walls of the 50 ml tube were 
rinsed with 1 ml of ether three times and the washings combined with the extract The 
extracts were evaporated to dryness in the Dri-Block at 50°C under airstream. Again, the 
walls were rinsed with about 1 ml of ether and evaporated to dryness.
Diethyl ether:
Methanol:
Water:
pH 3 Buffer:
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Samples were reconstituted in methanol (minimum volume of methanol= 150 
ul) prior to injection into an HPLC (High Pressure Liquid Chromatography) system (FIG 
29 and 301. HPLC was performed using the materials listed below:
HPLC Apparatus:
Pump: Gilson 302
Detector Cecil Instruments UV Detector CE 2012
Column: 100 x 5 mm Shandon Southern Ltd.
Packing: ODS-Hypersil 5 pm Shandon Southern Ltd.
Wavelength: 254 nm
Absorbance: 0.05 a.u.f.s. units
Solvent: 70 Redistilled methanol: 30 Perchloric acid
(50 ul of V55 dilution of 70% solution) 
Flow Rate: 1 ml/minute
Recorder: Vitatron 2001R
Loop volume: 20 pi
Injection volume: 20 pi
Standard: Carprofen 2 pg/1 in methanol
The plasma concentration of carprofen in the test animals was determined by 
comparing the UV absorption of the sample with that of a 2 pg/1 standard solution in 
methanol and adjusting the ratio for the expected 95% recovery.
(fl Drug Recovery and Calculations:
Known concentrations of carprofen were added to blank plasma. "Spiked" plasma 
samples with known concentrations of carprofen of 0.25, 1, 10, 20, and 50 pg/ml were 
extracted to find the mean recovery in every batch of extractions that were performed. The 
expected proportion of carprofen extracted in ether would be 0.95 since in the first extraction 
15 of 20 ml were recovered (0.75) and in the second extract 0.2 was removed and the 
remaining 0.05 was discarded.
The concentration of carprofen recovered in the 'spikes' after extraction was 
calculated using the formula below:
Recovery = concentration recovered 
actual concentration
= UV abSQrp sample x [standard] x Analysis VQlums xlQQ /actual conc.
UV absorp standard Plasma sample vol. 95
= Sample peak height* x [standard] x Analysis volume x I0Q /actual conc.
Standard peak height* Plasma sample vol. 95
(* = Chromatogram peak heights)
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The plasma concentration of carprofen in the test samples was calculated in a 
similar fashion. A conversion factor (the reciprocal of the recovery determined from the 
analysis of the 'spikes') was used to adjust the calculated concentration in the extracted 
sample to derive the actual plasma drug concentration:
Plasma = UV absorp sample x [standard] x Analysis volume x 100 x ___1___
[carprofen] UV absorp standard Plasma sample vol. 95 recovery
Plasma = Sample peak height x[standard] x Analysis volume x 100 x ___1___
[carprofen] Standard peak height Plasma sample vol. 95 recovery
Examples of 'spike' recoveries and calculations are given in TABLE 11 below.
TABLE 11: Examples of Spike Recoveries and Plasma Carprofen Concentrations
Examples o f Carprofen Spike Sample Recovery Calculation
Samole Sample
Peak
Height
Standard
Peak
Height
Sample P kH t x Standard x  Residual vol 100 
x -----
95
+ Actual 
Concentration 
[10 Jig/ml]
RFCOVFRY
Conc.
Standard Pk Ht Plasma vol
Spike S4 
[10 |lg/ml] 41.25 43.5
41.25
7 T T x 2 =  L82fiS
10 ml
-  9.4828
2 ml
9-981? 0.9819 0.9982
Examples of Test Sample Carprofen Concentration Calculation
Sample Sample
Peak
Height
Standard
Peak
Height
Sample PkH t x Standard Residual volT 100 x ___
95
x Conversion 
Factor*
[1.042]
PTASMA
CARPROFEN
CONCN.
Conc.
Standard Pk Ht Plasma vol
DOG 4
37.0 46.0
37.0
t 2 =  1.609
16 ml
= 12.8696 9.9819 13.547 14,116
pg/ml
8 hour 
sample 46.0 2 ml
♦Conversion Factor = 1 + Mean Spike Recovery
Pharmacokinetics
Standard models and equations were used to calculate pharmacokinetic parameters 
(Sedman and Wagner, 1976; Baggot, 1977).
Results
All six dogs were clinically normal prior to the trial and remained healthy 
throughout. Food and water intake were normal.
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Plasma Carprofen Concentrations
The concentrations of carprofen in the plasma of the individual dogs and the mean 
concentrations are given in Appendix A l. Pharmacokinetic parameters are listed in TABLE 12 
below. Mean concentrations and standard errors from the mean for the six dogs are 
represented graphically in FIG 31 and FIG 32.
Carprofen was rapidly absorbed after oral administration in all dogs. Peak plasma 
concentrations ranging from 26.1 to 44.3 (ig/ml (mean 35.3 ug/ml) were attained between 0.5 
and 2 hours after administration (mean 1.25 hours). The elimination half life (ti/2 6) ranged 
from 6.5 to 13.7 hours (mean 9.3 hours). The area under the curve (AUC observed) ranged 
from 171 to 460 (mean 310).
TABLE 12:
Pharmacokinetic Parameters for Carprofen After Oral Administration 
of a Single 4 mg/kg Dose
Dog 1 Dog 2 Dog 3 Dog 4 Dog 5 Dog 6 Mean ±SEM
No. of 
exponentials 3 3 3 3 3 3
tV2 (ab)(hrs)
(absorption)
0.4 0.5 0.6 0.3 0.2 0.3 0.4 0.06
1 V2 (alpha) (hrs) 
(distribution)
3.0 2.3 7.5 1.4 2.5 1.1 3.0 1.0
1 1 / 2  (6) (hrs) 
(excretion)
9.3 7.6 13.7 8.6 9.9 6.5 93 1.0
AUC
(observed)
171 460 428 353 247 198 310 50
Cmax.
[ug/ml]
31.8 44.3 26.1 31.6 40.7 37.4 35.3 2.7
Tmax.
[hrs]
1 2 2 1 0.5 1 1.25 0.25
Kev: 1 1/2 (ab): Absorption half-life (ie. 0.693/ apparent first-order absorption rate constant)
1 1/2 (alpha): Distribution half-life
1 Vl (B): Elimination half life (Biological /Plasma half life of drug)
A U C : Total area under the plasma drug concentration vs. time curve from t=0 to t=°
after administration of a single dose.
Cmax.: Maximum plasma drug concentration after administration of a single dose.
Tmax.: Time after oral administration when Cmax. was attained.
SEM: Standard error from the mean
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4.2.4 Conclusions and Discussion
Oral absorption was more uniform than in studies at 0.7 mg/kg with a paste 
formulation (McKellar, 1989). Peak concentrations were attained in less than two hours. 
Peak plasma concentration and excretion rate showed some individual variation. Peak 
concentration were higher than those reported by some authors (Roche Internal Data). 
Peak concentrations were in agreement with extrapolations of blood concentrations in 
radioimmunoassay studies at lmg/kg in beagles (Rubio and others, 1980). Extrapolation 
was valid since plasma levels are directly proportional to dose in the range 1-10 mg/kg 
(Rubio and others, 1980).
No results for intravenous administration of carprofen at 4 mg/kg are available 
to estimate bioavailability. However, the AUC varied quite markedly between 
individuals. The elimination half life (ti^B) calculated was shorter than that estimated by 
other studies (Rubio and others, 1980) and by the manufacturer (12-24 hours: Roche 
Internal Data). However, these authors describe two phases of excretion (Rubio and 
others, 1980; Roche Internal Data). In this study there was good correlation with single 
exponential elimination kinetics. The elimination half life was similar to that calculated by 
other authors (McKellar, 1989). In dog 3, the absorption, distribution and elimination 
half lives were prolonged. The reason is not known. There was no evidence of 
enterohepatic recirculation. Plasma concentrations above 3.3 Jig/111! were maintained in all 
dogs for 12 hours and in dogs 2, 3, and 4 for 24 hours after drug administration.
The disagreement with previous studies in the peak plasma concentrations 
attained may relate to the difference in the oral preparation used, differences in the assay 
method used and differences in the statement of the concentrations. In previous studies 
kinetics are expressed in "blood concentration" rather than the "plasma concentration". 
This will include the cellular component of blood. Since carprofen is highly plasma 
protein bound (Rubio and others, 1980), and assuming that cell binding is minimal, the 
concentration in plasma will be significantly greater than that in whole blood. There is 
also variation in peak concentrations in different dogs within the study. Variation is likely 
between dogs in different studies and under different management conditions.The dogs 
used in some previous studies had been fasted for shorter periods than the dogs in this 
study and were receiving a different feedstuff (Roche Internal Data).
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Tolerance Study in Dogs with Carprofen Administered Orally at a 
Dose Rate of 9 mg/kg Once Daily For Fourteen Davs
4.3.1 Summary
The study indicated that at 9 mg/kg body weight carprofen is well tolerated 
by normal dogs when administered once daily for fourteen days. No dog showed 
any abnormal clinical signs. There were no biochemical changes suggestive of hepatic or 
renal toxicity. There were no biochemical or haematological signs suggestive of 
gastrointestinal ulceration and no blood was detected at consistent or significant levels in 
faeces. Typical haematological or biochemical signs of NSAID toxicity such as 
hypoproteinaemia, hypoalbuminaemia, or anaemia did not occur.
The aetiology of high C-reactive protein (CRP) concentrations and 
eosinophilia in Dog 5 remains obscure but on the evidence available the changes were not 
associated with carprofen administration or venipuncture. With the exception of increased 
numbers of Target Cells in all dogs of unknown pathogenesis and the eosinophilia in Dog 
5, there were no significant variations in haematological parameters.
It was concluded that at a dose of 9 mg/kg body weight administered once 
daily over 14 consecutive days, carprofen was well tolerated by clinically healthy, young 
adult Beagle dogs.
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4uL2 Objective
To assess the tolerance of dogs to carprofen at a dose rate of 9 mg/kg body 
weight administered orally once daily for 14 consecutive days. Specifically, to determine 
any clinical, blood biochemical or haematological effects of carprofen at this dose.
4i2J. Materials and Methods
(al Test Animals
Six two year old beagle dogs, 3 male and 3 female, were used in the study. 
The dogs had not received any medication in the fourteen days before the trial 
commenced. The dogs were fed a complete cereal based diet.
(bl Test Drug
Carprofen [Ro 20-5720/ 659]; Lot No. GMZ 626 B 01; Expiry date: July 1991]
Tablet formulation: 17.5 mg carprofen per tablet;
Supplied by Hoffman-La Roche via Grampian Holdings Ltd.
{c) Drug Administration
Carprofen was administered orally. The dose for each dog was calculated at 9 
mg/kg based on the weight of the dogs on the day before the trial commenced. The 
number of whole and half tablets required to give a daily dose of 9 mg/kg or greater was 
calculated rAppendix B ll. The tablets were administered in a single daily dose. The dogs 
were fed at approximately 9 am each day and tablet administration and sampling carried 
out between 12 and 3 pm [ie. approx. 3 - 6  hours after feeding].
(dl Trial Design
The six dogs were weighed and a pretrial blood sample was taken at 2 pm on
the day before the trial commenced. Blood samples were subsequently taken on days 3,
5, 8 ,11,14, and 17 [the first day of drug administration was considered day 0]. 
Sampling by venipuncture was performed between 12 and 3 pm, just prior to carprofen 
administration.
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Blood was placed in Lithium-Heparin biochemistry tubes which were 
centrifuged for 15 minutes and the plasma supernatant decanted for biochemical assay 
including C-reactive protein estimations. Urea, creatinine, cholesterol, alkaline 
phosphatase, aspartate transaminase, and alanine transaminase concentrations were 
measured using a Cobas Mira Discrete Analyser. Sodium and potassium concentrations 
were measured using flame photometry. Chloride concentration was measured using a 
chloride meter. Calcium and magnesium concentrations were measured by atomic 
absorption. Total protein concentration was measured by a standard biuret method using 
an autoanalyser. Albumin was measured by a standard Bromopresil Green method using 
an autoanalyser. CRP estimations were performed using a specific enzyme-linked 
immunoadsorbant assay (ELISA). The analyses were carried out by Glasgow University 
Veterinary Biochemistry Department.
Blood was placed in potassium-EDTA haematology tubes and was submitted 
for full haematological profile including differential leucocyte count and film analysis. 
White and red blood cell counts and haemoglobin estimations were performed using a 
Coulter Counter S-Plus IV. Differential white blood cell counts were performed 
microscopically. Analyses took place at University of Glasgow Veterinary Pathology 
Department
Clotting times were assessed on sampling days. Free flowing blood was 
collected from the venipuncture needle using three capillary tubes. These tubes were 
placed in a tray with a warm water sleeve at 37 C. The time taken for the blood in each 
tube to clot was noted. The mean clotting time for each dog was calculated, as was the 
mean clotting time for the six dogs. Faecal samples were taken on sample days and tested 
for the presence of occult blood using a Colo-Rectal Test kit [Roche]. The dogs were 
kept in pens in pairs. Two samples were taken from each pen. Results were recorded for 
each sample in each of the three pens.
4-3.4 Results
Clinical Observations
At no time during the trial did clinical examination of the six dogs demonstrate 
any signs of illness. Appetite remained good and faeces of normal consistency were 
passed. None of the dogs was seen to vomit at any time and water intake remained 
normal.
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Biochemistry
Blood biochemical parameters were measured on the day before the trial 
began and on days 3, 5, 8, 11, 14, and 17. Dogs 5 and 6 were also sampled on day 47 
when results of the C-reactive protein assays during the trial period were returned. 
Appendix B2 gives the normal value ranges for healthy young adult dogs. Individual 
results are shown in Appendices B3-B5 and mean blood biochemical values are given in 
Appendix B5. Mean values for most biochemical parameters were within the normal 
range on all occasions with the following exceptions:
Mean urea concentrations [normal 0 -7.47 mmol/1] were raised on days 3, 5, 
11, and 17. However, this range of normal values is for fasted animals and since 
sampling occurred 3-6 hours after feeding the levels of urea can be considered normal.
Mean serum inorganic phosphate [normal 1.29 - 2.9 mmol/1] was low in the 
pretrial sample and on day 14. The mean phosphate was low in the pre sample because all 
dogs except Dog 4 had serum phosphate levels below 1.29 mmol/1. On day 14, Dogs 1, 
5, and 6 showed low levels. Dog 6 had sub-normal phosphate levels in the Pre, and day 
3,5,11,14, and 47 samples. Concentrations were particularly low in the Pre sample 
[0.81 mmol/1 n= 1.29 - 2.9 mmol/1] , on day 5 [0.92 mmol/1 n= 1.29 - 2.9 mmol/1] and 
on day 47 [ 0.88 mmol/1 n=1.29 -2.9 mmol/1]. On days 8 and 17, Dog 6 had normal 
serum phosphate concentrations.
In most cases, the disparate mean values were the result of high or low values 
in a number of animals rather than extremes in a particular individual. However, Dog 5 
and Dog 6 showed more particular changes. Mean C-reactive protein values were raised 
on days 5, 8, and 14 [normal <10 mg/1]. These values were due to high levels in samples 
from Dog 5. In Dog 5, CRP values were consistently above normal and on days 5 and 14 
exceeded 100 mg/1 indicating extensive tissue damage [normal= < 10 mg/1, Dog 5 range
16.5 to >100 mg/1]. The Pre sample also had high CRP levels. At no time did Dog 5 
show any clinical signs of illness. The CRP on Day 47 was back in the normal range, 
indicating that there was not an active inflammatory process occurring at this date. Dog 6 
had a high CRP titre on Day 8 [49.1 mg/1, n=<10 mg/1] but all other values of CRP were 
within the normal range. Total plasma protein was low [normal 50-77 g/1] in Dog 5 on 
days 5,11,14, and 17, mainly due to a hypoglobulinaemia [ globulin = 13 g/1 on day 5, 
normal 18-35 ].
Other results outwith the normal expected limits in individual animals were 
minor and transitory, generally returning to normal range values on subsequent sampling 
occasions.
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Haematology
Blood samples were taken for haematological examination on the day before 
the first day of carprofen administration and subsequently on Days 3, 5, 8, 11, 14, and 
17. Individual results are given in Appendices B6-B9. mean values in Appendix B9 and 
ranges of expected normal values in Appendix B2.
Mean haematological parameters measured were within the expected normal 
limits except for slightly depressed percentage of neutrophils in the differential leucocyte 
counts on Day 3 and Day 11 [normal =60-77 %]. These values were due to a number of 
individuals with lower neutrophil percentages and not to a very low level in any 
individual. The reduction was slight Individual results were on occasion outwith the 
expected normal range of values but these were generally marginal and transitory.
Dog 5 had a relative eosinophilia on days 3,5 and 17 [ normal <10% ] and an 
absolute eosinophilia on days 3, 5, 8 and 17 [ normal 0.1-1.25 x 10 /I ]. All dogs were 
reported as having increased numbers of Codocytes ["Target Cells"] on film examination 
on Days 5, 8,11,14 and 17.
Clotting Times
Clotting times were measured on the day before the first administration of 
carprofen and on days 3, 5, 8,11, 14 and 17. Individual mean results and the mean 
clotting time for the six dogs on each of the sample days is recorded in Appendix BIO. 
All mean clotting times were within the range of expected normal values and there was no 
significant increase in clotting time between the Pre sample and samples taken during the 
administration of carprofen.
Occult Faecal Blood
Occult faecal blood was assessed on the day before the first administration of 
carprofen and on Days 3, 5, 8, 11, 14, and 17. Results are given for each of the pairs of 
dogs on test days in Appendix BIO. Occult blood in faeces was only detected in one of 
the two samples from Pen 3 [Dogs 5 & 6] on Day 14. Occasional positive results can be 
expected in normal dogs not receiving NSAIDs (McKellar, 1989).
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4.3.5 Discussion and Conclusions
Carprofen tablets were well accepted orally by all the dogs. At the dose rate of 
9 mg/kg body weight once daily for 14 days, no adverse clinical signs were shown by 
any of the dogs.
Marginal elevations in urea levels in many of the dogs at various sampling 
times were almost certainly a result of feeding. The low serum phosphate concentrations 
were transitory in all dogs except Dog 6 where they were low in a number of samples. 
Consistent low levels of serum phosphate can occur in Rickets, Osteomalacia and 
Primary Hyperparathyroidism. However, Alkaline Phosphatase levels were not raised 
and phosphate levels were within expected normal values on Day 8 and Day 17. These 
conditions are very rare and no clinical signs were shown by Dog 6 at any time. 
Whatever the aetiological or physiological basis of the low serum phosphate in Dog 6, it 
appears unrelated to and unaffected by carprofen administration since pretrial and Day 47 
(33 days after the last dose of carprofen) samples also have depressed levels of serum 
phosphate. Mild hypophosphataemia may have been related to the cereal based diet
The raised C-reactive protein (CRP) values in Dog 5 on all days before and 
during the trial could have a number of causes. CRP is virtually absent from serum 
before tissue damage and is only produced as part of the Acute Phase Reaction in 
response to tissue damage events such as vasodilation, inflammation, and movement of 
leucocytes to the area of damage. CRP has been shown to be present at high 
concentrations in serum for about 4 days following surgery and in a variety of 
inflammatory conditions including Systemic lupus erythematosus, polyarthritis, 
Pemphigus, Thrombocytop enia, osteoarthritis and acute orthopaedic injuries and in 
response to the administration of endotoxin. The levels of CRP rapidly decline when the 
inflammatory response abates (Eckersall and others, 1985; Caspi and others, 1987). 
Thus, Dog 5 had an unidentified inflammatory condition on the day before the start of 
carprofen administration and during the trial but not on day 47, 33 days after the last dose 
of carprofen. The levels of CRP were over 100 mg/1 on Days 5 and 14 which is 
indicative of extensive tissue damage. However, at no time did Dog 5 show any clinical 
signs of pathology. There were no other significant changes in the blood biochemistry of 
Dog 5 except the low total protein and Globulin levels. Dog 5 also had an eosinophilia in 
a number of haematology samples. These findings may or may not have been related to 
the inflammatory process elucidated by the CRP assay.
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Whatever the aetiology of the condition, it does not appear to have involved 
hepatic, renal or gastrointestinal pathology which would have caused changes in 
biochemical parameters other than CRP. Neither carprofen nor venipuncture initiated the 
inflammatory process since elevated pretrial CRP levels indicated that tissue damage was 
present on the day before the first administration of carprofen. The rises in CRP on days 
5 and 14 to over 100 mg/1 [ normal= <10 mg/1 ] may have been precipitated by carprofen 
or venipuncture or may have been part of the progression of the inflammatory process. 
The process had apparently resolved by Day 47 when CRP levels were within normal 
expected values. The single high CRP value in Dog 6 on Day 8 was transient, all other 
samples having normal values. It could have been due to any mild acute inflammatory 
response.
Most of the haematological values outwith the normal range of expected 
figures were marginal and transitory. The two findings of concern were the elevated 
numbers of Codocytes or Target Cells in all the Dogs' blood films on Days 5,11, and 
17 and the eosinophilia shown by Dog 5 on Days 3, 5, 8 and 17. Codocytes or Target 
Cells are thin, cup-shaped erythrocytes with a dense central area of haemoglobin that is 
separated partially or completely by a colourless or pale zone from the peripheral 
haemoglobinised region. This is a result of the redistribution of haemoglobin within the 
cell, probably as a consequence of excessive cell membrane or a decrease in haemoglobin 
content, or both. In man, Codocytes are found in hypochromic anaemias, liver disease 
with cholestasis, a rare deficiency of the enzyme lecithin-cholesterol acyltransferase 
(LCAT), certain haemoglobinopathies and after splenectomy. In hypertonic plasma they 
may be seen as an artefact. Target Cells have been found in dogs with conditions similar 
to humans except for haemoglobinopathies and LCAT-deficiency which have not been 
described in animal species. In this case, a possible cause of increased numbers of Target 
Cells associated with NSAID administration would be liver damage. However, there was 
no consistent or significant rise in enzymes associated with hepatic damage or 
cholestasis, or in bilirubin or CRP. There was no consistent hypoproteinaemia or 
hypoalbuminaemia and no anaemia. It seems very unlikely that liver damage could cause 
Target Cell formation in isolation.
The absolute and relative eosinophilia in Dog 5 could have a number of 
causes. Eosinophilia is most often associated with disease involving antigen, IgE 
antibody and Mast Cell response. Diseases which may be included in this are parasitic 
infections eg. gastrointestinal parasitism, flea bite allergy/dermatitis, allergic respiratory 
disease, dermatoses, allergic responses to drugs and any disease condition involving the 
continuous degranulation of Mast Cells such as eosinophilic enteritis. The cause in this 
case is uncertain. No other indications of any possible allergic reaction to the carprofen 
were apparent during the trial. Whether the eosinophilia and high CRP in Dog 5 were 
linked is conjecture.
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The clotting time studies during the period of carprofen administration 
demonstrated no increase in mean clotting time outwith the normal range expected in 
untreated dogs [normal range 1.53-4.03 minutes (mean +/-2 S.D.)]. The negative faecal 
blood results provide some evidence against gastrointestinal haemorrhage during 
carprofen administration at 9 mg/kg body weight.
In this study, carprofen was well tolerated by normal dogs when 
administered orally at 9 mg/kg once daily for fourteen days. No dog showed any 
abnormal clinical signs and there were no biochemical changes suggestive of hepatic or 
renal toxicity. There were no biochemical or haematological signs suggestive of 
gastrointestinal ulceration and blood was not detected at significant levels in 
faeces.Typical haematological or biochemical signs of NSAID toxicity such as 
hypoproteinaemia, hypoalbuminaemia, or anaemia did not occur.
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4A  Clinical Trial of the Efficacy of Carprofen 17.5 mg Tablets
in the Therapy of Canine Osteoarthritis
4.4.1 Summary
The aim of the trial was to establish the clinical efficacy of carprofen tablets in the 
therapy of clinical osteoarthritis in the dog. This was under taken by comparing the effect of 
carprofen tablets with the effect of a previous treatment for the condition in the same animal 
and by comparing the effect of treatment in a group of carprofen treated dogs with the effect of 
treatment in a group of phenylbutazone treated dogs. Ten dogs received one drug and then the 
other in a form of cross-over trial.
Carprofen tablets were efficacious in the therapy of 49 of 74 cases of clinical 
osteoarthritis (66%). Carprofen was as efficacious or superior to previous treatment in 32 of 
46 cases (70%) where the veterinarian stated comparative efficacy. Phenylbutazone treatment 
was considered satisfactory in only 10 of 21 dogs treated (48%). However, there was no 
significant difference between efficacy of treatment in the carprofen treated and 
phenylbutazone treated groups or in the effect of carprofen and phenylbutazone in the ten 
cases which received both drugs. In carprofen treated cases there were reported side effects 
such as vomiting, diarrhoea, constipation and inappetance which may have been associated 
with gastrointestinal disturbance. There was no evidence of increased toxicity in a limited 
number of dogs with concurrent cardiac or renal disease.
From the limited numbers of dogs treated during the trial, carprofen appears to be 
effective in the therapy of many cases of clinical osteoarthritis when used at 0.71 to 3.50 
mg/kg/day. There was a correlation between the treatment dose and effect within this dose 
range. Carprofen seemed to be very much more effective when used at over 2 mg/kg/day sid 
or bid than when used at lower dose rates. For the duration of treatment, carprofen was well 
tolerated in most dogs. The incidence of side effects and treatment withdrawal were 
comparable with other non-steroidal anti-inflammatory drugs (NS AIDs). Treatment was 
withdrawn because of side effects in only 2 dogs. In many cases the reported side effects 
were thought to be coincidental and unconnected to carprofen therapy.
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4.4.2 Objective
1) To compare carprofen tablets:
(a) with previous medical treatment in existing cases
(b) with the standard drug phenylbutazone in new cases 
in the control of the signs of clinical osteoarthritis in the dog.
2) To determine and record the incidence and nature of any unwanted side effects.
4.4.3 Materials and Method
Test Drugs
Carprofen tablets
[ Ro 20-5720/659; Lot No. G MZ 626 B 01; Expiry date: July 1991]
(each tablet containing 17.5 mg Carprofen)
Flexazone Tablets® 100 mg [Batch No. 80302A-1; Expiry Date: April 1993]
(each tablet containing 100 mg Phenylbutazone BP)
Trial Design
The aim of the trial was to establish the clinical efficacy of carprofen tablets in the 
therapy of osteoarthritis in the dog. This was undertaken by comparing the effect of carprofen 
tablets with the effect of a previous treatment for the condition in the same animal and by 
comparing the effect of treatment in a group of carprofen treated dogs with the effect of 
treatment in a group of phenylbutazone treated dogs. Thus the trial was based on a form of 
Positive Control design. A Placebo Control design would not have been acceptable to owners 
or veterinary practitioners and would also have been ethically unsound. It was not considered 
practical to perform a "cross-over" type trial because of the possible lack of compliance of 
veterinary practitioners and owners. However, veterinarians were encouraged to use both 
drugs in the same dog where possible. It was hoped that the carprofen and phenylbutazone 
treated groups would be large enough to be comparable.
The number of cases required to assess the efficacy of the drug was greater than 
would be seen in a reasonable period of time at Glasgow University Veterinary Hospital and 
veterinarians in general practice were asked to use carprofen and phenylbutazone in cases 
requiring NSAID treatment for osteoarthritis. No financial or other inducements were offered 
or given to veterinarians or practices involved in the trial.
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Investigator Selection
Veterinary practitioners who were known personally by the authors, by Dr. Q. 
McKellar, of the Department of Veterinary Pharmacology, or by Mr. S. Carmichael of the 
Department of Veterinary Surgery, University of Glasgow were contacted by letter and asked 
to participate in the clinical trial. Further correspondence and telephone conversations led to 
the recruitment of 26 practices, 16 of which returned results information sheets. Each practice 
was supplied with information on the product, and instructions on case selection, dose 
recommendation and condition scoring [~Appendices Cl: C2: C31. Approximately 20 sets of 
results information sheets ["Patient Information", "Efficacy Assessment" and "Clinical 
Assessment" sheets; Appendices C4; C5: C61 were also delivered to each practice. Carprofen
17.5 mg tablets and Flexazone Tablets® 100 mg (each tablet containing 100 mg 
Phenylbutazone BP) were supplied.
Dose Recommendations
The Dose Recommendations sheet supplied to practitioners \Appendix C21 
recommended that carprofen tablets be administered orally based on a theoretical minimum of
0.7 mg per kilogram body weight per day in a single daily dose. Due to the set quantity per 
tablet the recommendations would give a daily dosage of between 0.7 and 1.75 mg carprofen 
per kilogram bodyweight (minimum bodyweight 5 kg). The initial treatment period was to be 
5 to 7 days, subject to clinical response.
After two months, the author wrote to participating veterinarians advising that the 
dose rate of carprofen was adjusted such that dogs would receive a theoretical minimum of 2 
mg/kg/day. Due to the set quantity per tablet, the recommendations would give a daily dosage 
of between 2 and 5.25 mg carprofen per kilogram bodyweight (minimum bodyweight 5 kg).
With the 100 mg tablets provided, a dose rate in tablets was calculated such that 
phenylbutazone would be administered at a suggested dose rate of between 8 and 16 mg/kg 
bodyweight/day in two divided doses. It was stated that phenylbutazone should not be used in 
animals with cardiac, renal or hepatic insufficiency or in animals showing signs of or with a 
history of anaemia, as recommended in the Data Sheet for the product.
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Case Selection and Protocol
Carprofen tablets were to be assessed for therapeutic effect in cases of clinical 
osteoarthritis. Diagnosis was made by the history and clinical presentation. In some cases 
radiography was performed and radiographic findings consistent with a clinical diagnosis of 
osteoarthritis reported. Since no financial incentives or remuneration were offered to any 
veterinarian it was not possible to insist that diagnostic radiography was performed in all 
cases.
Cases were of two groups:
- existing cases (dogs already receiving medical therapy for osteoarthritis);
- new cases (dogs at first presentation to the practitioner or for which the previous
history was not known).
The protocol for the trial was as follows:
1. Existing Cases:
i) Information on the owner and the dog was recorded. The joints affected were 
noted. In most cases, a brief summary of the clinical history was given. The dose, 
regime, duration and effect of the previous treatment was noted and the previous 
treatment was withdrawn.
ii) Where possible, dependent upon the wishes of the owner and the veterinary 
surgeon, the time taken for the signs of the painful condition to reappear was 
monitored.
iii) The clinical condition was scored for lameness [0 to 4], 
weightbearing [0 to 2] and joint mobility [0 to 2] according to 
the condition scoring sheet fAppendix C31.
iv) Therapy was instituted with carprofen tablets at the recommended dose rate.
v) The effect of treatment was monitored, i.e. the dog was re-examined after a 
period of treatment (5 to 7 days was the recommendation) and the clinical 
condition was rescored. Where possible, the owner was to be questioned as to the 
efficacy of the treatment and the time taken for the treatment to have an effect, if 
any.
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vi) At the end of the treatment period, the "Clinical Assessment" sheet was to be 
completed with the veterinary practitioners' subjective opinion on whether the 
treatment had been satisfactory and how the treatment compared to the previous 
treatment. Any side effects could also be noted on the "Clinical Assessment" sheet. 
Provision was made on the first sheet ["Patient Information"] for noting 
premature withdrawal and its cause or any change of dose rate.
2. New Cases:
i) Osteoarthritis was confirmed clinically and in some cases radiographically.
Patient information and the joint(s) affected were noted. A brief summary of the 
history was also to be given.
ii) The clinical condition was scored for lameness [0 to 4], 
weightbearing [0 to 2], and joint mobility [0 to 2] according to the 
condition scoring sheet [Appendix C31.
iv) Therapy was instituted with carprofen tablets or phenylbutazone (Flexazone 
Tablets) at the recommended dose rate on an "alternate case" basis, i.e. treating dog 1 
with carprofen tablets, dog 2 with phenylbutazone, dog 3 with carprofen tablets etc.
v) The effect of treatment was monitored, ie. the dog was re-examined after a 
period of treatment (5 to 7 days was the recommendation) and the clinical 
condition was rescored. Where possible, the owner was to be questioned as to the 
efficacy of the treatment and the time taken for the treatment to have an effect, if 
any.
vi) At the end of the treatment period, the "Clinical Assessment" sheet was to be 
completed with the veterinary practitioners' subjective opinion on whether the 
treatment was satisfactory. Any side effects could also be noted on the "Clinical 
Assessment" sheet. Provision was made on the first sheet ["Patient Information"] 
for noting premature withdrawal and its cause or any change of dose rate.
It was suggested that, where possible, new cases should be treated firstly with one 
of the two test drugs and then, after an interval, the drug used could be switched to the second 
drug. This would allow comparison of the effects of carprofen and phenylbutazone tablets in 
the same animal.
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Exclusions
Dogs which were concurrently receiving treatment with a drug with 
antiinflammatory or analgesic effect were excluded from the results analysis. Incomplete or 
totally illegible results forms were also excluded. Dogs which were not diagnosed as having 
osteoarthritis or with a history not consistent with such a diagnosis were not included in the 
results analysis. It was considered reasonable to consider results valid in cases where the full 
address of the owner or the dog name was omitted from the "Patient Information" form.
Results Analysis
Five statistical analysis methods were used: unpaired "Students" t -test; paired 
f-test; Wilcoxon Signed Rank test; Chi squared (X 2) test; Kendall Correlation (Weisbrot, 
1985; Wardlaw, 1985).
The Student's r-test or r-independent test compares the means and standard 
deviations of two independent samples; each standard deviation is presumed to be from the 
same population. This test was used to compare the differences in the total condition scores in 
the phenylbutazone and carprofen treated groups.
The paired r-test analyses the average differences between a series of paired 
observations. It is considered more rigorous and useful than the unpaired "Students" r-test 
since it allows isolation of the effects of manipulation on otherwise identical samples. 
However, the paired r-test, like the Student's r-test, does assume a parametric or normal 
distribution of data which could not be guaranteed for the parameters measured during the trial 
(lameness, weightbearing, joint mobility, and total condition scores), especially when the 
sample size was so small.
The Wilcoxon Signed Rank test is the non-parametric homologue of the parametric 
r-test. Thus, if the data was non-parametric, any statistical significance in differences between 
pre and post-treatment condition scores would still be assessed.
The Chi squared (X  2) test is frequently used in epidemiology and therapeutics to 
compare categorical data (lived/died, improved/not improved). It was used in this trial to 
compare the response rates to carprofen and previous treatment or phenylbutazone treatment, 
and to compare groups with or without advice to reduce exercise.
Kendall Correlation is a non-parametric rank-order correlation. This test was used 
to assess whether there was any statistically significant linear correlation between the dose rate 
of carprofen administered and the improvement in the overall condition of the patient
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The effect of treatment in carprofen and phenylbutazone groups was assessed by 
the comparison of pretreatment and post-treatment condition scores for lameness, 
weightbearing, joint mobility, and the total condition score (Lameness + weightbearing + joint 
mobility). The condition scores before and after treatment were compared using a paired r-test 
and by a Wilcoxon Signed Rank test.
Treatment with carprofen and phenylbutazone was compared by the differences in 
pre and post-treatment condition score within the two treatment groups. The differences in pre 
and post condition scores between carprofen tablet and phenylbutazone treatment were 
compared using a Student's t -test and the overall effect of treatment (Improved /  Not 
Improved) compared with a X  2 test. The veterinary practitioner gave a subjective opinion of 
whether Carprofen Tablets were more or less efficacious than the previous treatment
4.4.4 Results
One hundred and four sets of case results sheets were returned. Nineteen sets of 
results were completely excluded. In 5 cases the results were incomplete. In 8 cases the dog 
had received concurrent treatment with a drug preparation with possible anti-inflammatory or 
analgesic activity and which therefore might interfere with the results obtained for the test 
drugs. A further 6 cases were treated which were not diagnosed as suffering from clinical 
osteoarthritis.
After the exclusion of these results, there were a total of 85 dogs reported. The 
mean number of case reports per practitioner was 5. However, the number of usable results 
per practitioner ranged from 1 to 18 cases f Appendix C8\
Seventy four dogs were treated with carprofen tablets; twenty one dogs were 
treated with phenylbutazone (Flexazone® 100 mg Tablets); ten dogs were treated with 
carprofen tablets and phenylbutazone consecutively: 8 dogs were treated with carprofen and 
then phenylbutazone; 2 dogs were treated with phenylbutazone and then carprofen.
Trial Animal Details
Animal details are tabulated in Appendices C9 & CIO.
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Age Distribution \Appendix Cl 11
Most dogs clinically affected were in the 7 to 12 years old range (Mean age = 8.3 
years; Standard deviation [S.D.] = 4.4 years). The age of one dog was not specified. The 
mean age of the phenylbutazone treated dogs was 7.8 years (S.D.= 3.5 years). The mean age 
of the carprofen treated dogs was 8.3 years (S.D. 4.6 years). These findings were similar to 
those for the PLT ® Tablet clinical trial in Section 5.2.4.
Breed Distribution f Appendix C l21
The breed distribution was similar to that seen in the PLT clinical trial (see 5.2.4) 
with a high proportion of the dogs being Labrador Retrievers (26 of 85 dogs, 31%). There 
were also more German Shepherd Dogs and Golden Retriever and Border Collies than other 
breeds. Breed distribution was similar in the carprofen and phenylbutazone treated groups, 
although there were relatively fewer Golden Retrievers, Border Collies and German Shepherd 
Dogs in the phenylbutazone treated group.
Sex Distribution f Appendix Cl 31
There was no significant sex predeliction for clinical osteoarthritis although 
slightly greater numbers of males than females were present in the sample population (47 of 
85 dogs; 55 %). The sex distribution in the carprofen and phenylbutazone treated groups was 
similar.
Bodyweight Distribution \Appendix C l41
The body weight of cases ranged from 1.5 kg to 75 kg (Mean 26.3 kg; S.D. 12.1 
kg). Most dogs (56 of 85; 66%) were between 16 and 35 kg in weight. The bodyweight of 
the dogs treated with phenylbutazone ranged from 6 kg to 45 kg with a mean of 26.6 kg (S.D.
11.3 kg). The bodyweight of the carprofen treated dogs varied from 1.5 kg to 75 kg with a 
mean of 26.1 kg (S.D. 12.4 kg).
Jointfs) Affected \Appendices C15: C l6: C171
The joint(s) affected and a brief history as recorded by the veterinary practitioner 
are listed for each case in Appendices C15 & C16. Thirty four dogs (40 %) had osteoarthritis 
of one or more often of both hips. In addition, 5 dogs had "hind limb" problems. Thirty three 
dogs had osteoarthritis affecting one or both elbows (39 %). Twenty eight dogs had 
osteoarthritis of one or both stifles (33 %). Sixteen dogs had shoulder osteoarthritis (19 %).
In 21 dogs (25 %) more than one joint type was stated to be affected (eg. both hips, one 
stifle).
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The joints affected in the carprofen treated dogs are similar to the total trial sample. 
There were no bilateral stifle, carpal or tarsal osteoarthritis cases in the phenylbutazone treated 
group.
Case History [Summary: Appendix Cl 71
No history was given in 26 cases. In most cases little history was given. Seven 
dogs had had previous surgery. One dog received a femoral head excision 5 weeks before the 
trial. Two dogs had elbow arthrotomies to remove osteochondrosis lesions two months before 
the trial period. Two dogs had a trochleoplasty of one or both stifles to correct a patellar 
subluxation in one case 2 months and in the other 19 months before the trial period. One dog 
had an elbow arthrotomy to remove ununited anconeal processes 5 months before the trial 
period. In 18 dogs the history gave firm evidence that the osteoarthritis had developed 
secondary to injury, developmental or conformational abnormalities. In twelve new cases, it 
was stated that the diagnosis had been confirmed by radiography. Where the duration of the 
clinical problem was stated it was months or years.
Previous Treatment
Details of previous treatments administered, dose rates, durations of treatment and 
effect of treatment is given in Appendices C34 - C36.
Fifty dogs had been previously treated. A total of 60 previous treatments had been 
given. One dog was treated with antimicrobials post-operatively with a reported "marked 
improvement". In the remaining 59 cases, NSAIDs or steroids were used in therapy. Previous 
treatment had no effect on the painful condition in 9 cases (9 of 60; 15%). In 30 cases the 
previous treatment had some effect (50%). In 18 cases, treatment had a marked effect (30%). 
In one case treated with Predno-Leucotropin Tablets, the dog was said to be "sound" whilst 
on treatment. In one case the effect of treatment was not stated.
The time for signs of the painful condition to reappear after the withdrawal of the 
previous treatment was stated in 28 cases. The period ranged from 2 days in a number of 
cases to one dog which had not been treated for 2 or 3 months. Where the time taken for the 
recurrence of painful signs was stated, the mean period was 7 days (S.D. 12 days). However, 
in the majority of cases, the period was 2 to 7 days. In one case it was stated that treatment 
was not withdrawn between the previous treatment and Carprofen treatment. In 18 cases, the 
"Time taken for return of painful condition" was not completed.
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Carprofen Treatment
Dose Rates and Regimes:f Appendices Cl 8-201
The initial dose rate used by the practitioners ranged from 0.71 to 2.85 
mg/kg/day. Overall, the minimum daily dosage administered was 0.39 mg/kg/day and the 
maximum dosage administered was 3.50 mg/kg/day. [Details Appendices C18-C20 and 
represented graphically in Appendix C201.
The treatment regime was once a day dosing (s.i.d.) in 62 of 99 treatments (63%). 
A divided daily dose (b.i.d.) was the regime in 32 of 99 treatments (32%). The initial 
treatment dose was divided into three administrations per day (ti.d.) in 4 cases (4%). In one 
dog, the regime was reduced from s.i.d. to every other day treatment. The total duration of 
treatment ranged from a maximum of 70 days to a minimum of one day in a dog which 
vomited when treated with Carprofen. The mean treatment period before reexamination was 
16 days (S.D. 12 days). For details see Appendices C l8-20.
Other advice was reported as given to the owners in 38 cases (51%). In 30 cases 
the owner was advised to reduce the exercise which the dog received or change the exercise to 
frequent short walks or lead exercise. In two cases normal exercise was recommended. It was 
stated in only 6 cases that weight reduction was advised (Details in Appendices C l8-201.
Twenty dogs were reported to be receiving other treatment or be suffering from 
other disease. Eight dogs were receiving treatments for cardiac disease, including the diuretic 
Frusemide in 5 cases. Five dogs were being treated with Millophyline-V (Etamiphyline 
camsylate). Three dogs were receiving treatment with digoxin. Case 21 suffered from 
incontinence but was not receiving any treatment. Case 23 had a femoral head excision 7 days 
before treatment. Case 26 had skin disease, conjunctivitis, and rhinitis. Case 34 had an 
abscess and was treated with antimicrobials; the antimicrobial was not stated. Case 36 was 
reported to suffer occasional bouts of colitis which were controlled by dietary changes.
Case 52 was treated with Ampicillin after the surgical removal of a superficial growth. Case 
54 had polydipsia for which Hills k/d® had been prescribed. Case 60 was treated with the 
anthelmintic Piperazine on the first day of trial treatment. Case 110 had a chronic nephritis. 
Case 201 had a conjunctivitis and lymphadenopathy and was treated with Ampicillin. Case 
202 had a chronic nephritis and was treated with Ceporex® tablets.
It was hoped that none of the preexisting diseases would interfere with the actions 
of carprofen therapy. Since none of the concurrent treatments have any significant known 
direct anti-inflammatory or analgesic actions, it was not thought that these treatments would 
affect the efficacy of the carprofen treatment.
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No specific information on the interaction of carprofen and diuretics such as 
frusemide, or the effect of carprofen in dogs with preexisting cardiac or renal disease was 
previously known to the author.
Palatability was reported as "Good" in 47 cases (47 of 66; 71 %), "Average" in 19 
cases (19 of 66; 29 %) and "Poor" in no cases [66 cases Palatability reported].
Condition Scores:
The pretreatment, post-treatment and difference in condition scores for lameness, 
weightbearing, and joint mobility are given for each case in Appendices C21 & 22. A 
graphical representation is given in Appendices C23-26.
Lameness f Appendices C21: 22: 231
One dog was not lame before treatment Carprofen treated dogs demonstrated a 
reduction in lameness score of between 1 and 3 units in 49 of the 73 cases which were lame 
before treatment (67%). In three cases (4%) the lameness score was worse at reexamination. 
In 22 cases (30%) there was no change in lameness score at reexamination. Eleven dogs 
(15%) were not lame after treatment and a further 35 dogs (47%) were normal when standing 
and walking (score i) . The mean pre treatment lameness score was 2.4 (S.D. 0.8). The mean 
post treatment lameness score was 1.5 (S.D. 1.0). The mean reduction in lameness score 
between the pre and post treatment examinations was 0.92 units (S.D. 0.90). The pre and 
post treatment lameness scores are represented graphically in Appendix C23.
A paired t -test showed a significant improvement in lameness score between the 
pre and post treatment examinations (p < 0.001). A Wilcoxon Signed Rank Test showed a 
significant improvement in lameness score between the pre and post treatment examinations (p 
< 0.001).
Weightbearing [Appendices C21: C22: C241
Weightbearing was reduced in 44 cases (44 of 74; 59%) before treatment. In 30 
dogs weightbearing was not reduced (41%). Carprofen treated dogs showed an improvement 
in weightbearing score in 18 cases where weightbearing had been affected (18 of 44; 41%). In 
one case, the weightbearing score after treatment was worse than before treatment The mean 
pre treatment weightbearing score was 0.7 (S.D. 0.6). The mean post treatment weightbearing 
score was 0.5 (S.D. 0.6). The mean reduction in weightbearing score between the pre and 
post treatment examinations where weightbearing was affected was 0.4 units (S.D. 0.5). The 
pre and post treatment weightbearing scores are represented graphically in Appendix C24.
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A paired t-test showed a significant improvement in weightbearing score between 
the pre and post treatment examinations (p < 0.001). A Wilcoxon Signed Rank Test showed 
a significant improvement in weightbearing score between the pre and post treatment 
examinations (p < 0.001).
Joint Mobility \Appendices C21: C22: C251
Joint mobility was reduced in 62 cases (62 of 74; 84%) before treatment In 12 
dogs joint mobility was not reduced (16%). Carprofen treated dogs showed an improvement 
in joint mobility score in 13 cases where joint mobility had been affected (13 of 62; 21%). In 
three cases, the joint mobility score was worse after treatment than before treatment. The mean 
pre treatment joint mobility score was 1.0 (S.D. 0.6). The mean post treatment joint mobility 
score was 0.8 (S.D. 0.6). The mean reduction in joint mobility score between the pre and post 
treatment examinations where joint mobility was affected was 0.2 units (S.D. 0.6). The pre 
and post treatment joint mobility scores are represented graphically in Appendix C25.
A paired t -test showed a significant improvement in joint mobility score between 
the pre and post treatment examinations (p < 0.01). A Wilcoxon Signed Rank Test showed a 
significant improvement in joint mobility score between the pre and post treatment 
examinations (p < 0.01).
Total Condition Score \Appendices C21: C22: C261
Seven dogs had a zero score after carprofen treatment (7 of 74; 9%). Fifty one 
dogs showed an improvement in condition score at reexamination after treatment with 
carprofen (51 of 74; 69%). In twenty dogs, the condition score was unchanged by carprofen 
treatment In 3 dogs, the condition score was worse at reexamination. The mean total 
condition score before treatment was 4.1 (S.D. 1.5). The mean post treatment total condition 
score was 2.8 (S.D. 1.7). The mean reduction in total condition score between the pre and 
post treatment examinations was 1.4 units (S.D. 1.5). Pre and post treatment total condition 
score is represented graphically in Appendix C26.
A paired t -test showed a significant improvement in total condition score between 
the pre and post treatment examinations (p < 0.001). A Wilcoxon Signed Rank Test showed 
a significant improvement in total condition score between the pre and post treatment 
examinations (p < 0.001).
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To try to assess whether advice on exercise had made a difference, the 
improvement in the total condition scores of dogs where the owner was told to reduce exercise 
was compared with the scores from dogs where no exercise advice was stated. The difference 
between the two groups was not significant when the Reduced Exercise and No Advice 
Groups were analysed by aX 2 test or Students r-test The improvement in total condition 
score between dogs which were judged to be overweight by the veterinarians was less than 
that in dogs which were not considered overweight. However, because the number of dogs 
which were of "ideal weight" was small and the difference in mean improvement was also 
sm all, the difference between the two groups was not statistically significant. No significant 
differences in treatment response were found for different breeds or for different affected 
joints.
Veterinarian Satisfaction:
The effect of carprofen treatment was considered satisfactory by the veterinary 
practitioner in 49 of the 74 cases (66%) and to have been unsatisfactory in 25 cases (34%).
Renorted Side Effects and Treatment Withdrawals
Case 1 John: 8 month old Golden Retriever Male 30 kg. Bilateral elbow osteoarthritis.
Carprofen 2 x 17.5 mg b.i.d. [2.33 mg/kg/day]
After two days, good analgesia caused the dog to over-exercise and lameness increased. 
Treatment was temporarily withdrawn.
Case 2 John: 8 month old Golden Retriever Male; 30 kg. Bilateral elbow osteoarthritis, 
secondary to osteochondrosis lesions. Also hip dysplasia. Littermate of Case 1. 
Carprofen 2 x 17.5 mg b.i.d. [2.33 mg/kg/day]
After two days, good analgesia caused the dog to over-exercise and lameness increased. 
Treatment was temporarily withdrawn.
Case 6 Cornelius: 4 year old Collie Spayed Female; 23 kg. Bilateral elbow osteoarthritis.
Carprofen 17.5 mg s.i.d. [0.76 mg/kg/day]
Veterinary surgeon reported:" Owner thought drug caused excessive drowsiness and was 
distressed by this". However, treatment was continued.
Case 15 Glass: 12 year old Chihuahua Male; 6.5 kg (Ideal weight approximately 4 
kg). Bilateral elbow O.A. Previous treatment with Phenylbutazone 
at 15.4 mg/kg/day and Prednisolone at 0.15 mg/kg/day.
Carprofen 0.75 x 17.5 mg s.i.d. [2.02 mg/kg/day]
Veterinary surgeon reported" Slight inappetance". However, treatment was more effective 
than previous treatment and was continued without any further adverse effects.
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Case 23 Knowles: 9 month old Jack Russell Terrier Male; 6 kg. Left hip:
Avascular Necrosis of the Femoral Head; Femoral head excision performed 5 weeks 
before treatment with phenylbutazone. Later cross-over treatment with carprofen. 
Carprofen 0.5 x 17.5 mg b.i.d. [2.92 mg/kg/day]
Veterinarian reported: Vomited on second and third days of treatment. Treatment withdrawn. 
Vomiting stopped. No time-scale or indication of severity was given.
Case 24 Miller: 14 year old Labrador Retriever F/N; 27 kg. Stiff on all legs but
lame left fore when examined. Previously treated with Phenylbutazone at 11.1 
mg/kg/day for 18 months. Also suffering from mild renal failure and proteinuria. 
Carprofen 1.5 x 17.5 mg s.i.d. [0.97 mg/kg/day]
Veterinarian reported: Slight increase in thirst ? However, previous renal failure/proteinuria 
was already causing polydipsia. Treatment was continued.
Case 27 Gadsby: 6 year old Bearded Collie F/N; 30 kg. Right shoulder and elbow 
osteoarthritis.
Carprofen 1.5 x 17.5 mg s.i.d. [0.875 mg/kg/day]
Owner reported that the dog "smelt funny" for the first ten days of treatment Treatment was 
continued.
Case 36 Flanagan: 12.5 year old Golden Retriever Male; 34 kg (Ideal weight * 30 kg). 
Bilateral stifle secondary osteoarthritis. Previously treated with Phenylbutazone at
17.6 mg/kg/day and Predno-Leucotropin Tablets.
Carprofen 3 x 17.5 mg s.i.d. [1.54 mg/kg/day]
Veterinarian reported that after two days the dog had diarrhoea containing mucus. The dog 
had had previous bouts of colitis controlled by dietary changes. The veterinarian considered it 
doubtful that the mucoid diarrhoea was a true side effect and was more probably coincidental 
with treatment However, treatment was withdrawn.
Case 48 Molloy: 7 year old German Shepherd Dog Female; 35 kg. Elbow osteoarthritis 
Carprofen 1.5 x 17.5 mg daily [0.75 mg/kg/day]
Veterinarian reported that the dog showed inappetance on days 5 to 7 of treatment and 
increased salivation whilst on treatment. Treatment had little effect and the dog had two 
painful episodes during the treatment period. Treatment was not withdrawn.
Case 59 Walls: 10 year old German Shepherd Dog Male; 45 kg (Ideal weight = 35 kg).
Bilateral hip osteoarthritis. Previously treated with Phenylbutazone at 8.89 mg/kg/day. 
Carprofen 1 x 17.5 mg b.i.d. [0.77 mg/kg/day]
Veterinarian reported that the dog had diarrhoea on days 2 to 5 of treatment Owner thought 
that the diarrhoea might have been dietary in origin. Dietary control was advised and the 
carprofen dosage was reduced by one half and later increased. Treatment was not withdrawn.
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Case 64 Jagielko: 13 month old Mastiff Male; 75 kg. Bilateral elbow osteoarthritis 
secondary to ununited anconeal processes.
Carprofen 8 x 17.5 mg daily [1.86 mg/kg/day]
Veterinarian reported that the dog vomited three times. Thought that this may have been 
related to an Upper Respiratory Tract infection. Treatment was not withdrawn. Vomiting 
ceased.
Case 65 Jack: 8 year old Golden Retriever Male; 35 kg. Stifle osteoarthritis. Previously 
treated with Phenylbutazone at 17.1 mg/kg/day.
Carprofen 1.5 x 17.5 mg s.i.d. [0.75 mg/kg/day]
Veterinarian reported: Diarrhoea from 7 to 14 days. Reported that the dog was "prone to 
diarrhoea". Treatment was not withdrawn.
Case 67 Osbourne: 2 year old Labrador Retriever Female; 23 kg. Elbow/Shoulder.
Carprofen 1.5 x 17.5 mg b.i.d. [2.28 mg/kg/day]
"Vomiting" reported. No details given. Treatment not withdrawn.
Case 110 Barker: 14 year old Crossbred Male; 17 kg. All joints affected.
Previously treated with Predno-Leucotropin Tablets and Phenylbutazone.
Concurrent "chronic nephritis".
Carprofen 17.5 mg b.i.d. [2.06 mg/kg/day]
Variable thirst reported. Treatment not withdrawn.
g
Case 203 Edwards: 12 year old Pekinese Male; 5 kg. Stifle osteoarthritis. Previously treated 
with Predno-Leucotropin Tablets. Also on Digitalis.
Carprofen 0.25 x 17.5 mg b.i.d. [1.75 mg/kg/day]
Veterinarian reported increased thirst and constipation. Peridale granules prescribed for 
constipation. Carprofen was stated to be more effective and to cause less nausea and 
polyphagia than the previous treatment. Treatment was not withdrawn.
Case 211 Stalker: 8 year old Shetland Sheepdog Male; 10 kg. Right hind leg 
affected. Previously treated with Opticorten Tablets. Concurrent therapy 
with "Heart Tonic and Stimulant" and Frusemide.
Carprofen 0.5 x 17.5 mg daily [0.88 mg/kg/day]
Veterinarian reported thirst. Thought to be due to diuretic therapy. Treatment not withdrawn.
Case 212 Scott: 16 year old Standard Poodle; 23 kg. Hip osteoarthritis. Concurrent therapy 
with Millophyline.
Carprofen 3 x 17.5 mg s.i.d. [2.28 mg/kg/day]
Veterinarian reported dog suffered from constipation and restlessness. However, dog said to 
be much happier and livelier on treatment and treatment was not withdrawn.
123
Phenvlhutazone Treatment
Dose Rates and Regimes \Appendix C271
The initial dose rate used by the practitioners ranged from 5.7 to 33.3 mg 
phenylbutazone/kg/day with a mean of 12.4 mg/kg/day (S.D. 5.7). The regime was s.i.d. in 
two phenylbutazone treatments, b.i.d. in 13 treatments and Li.d. in 4 cases. In two cases the 
regime was not stated. The duration of treatment before the dog was re-presented ranged from 
4 to 50 days (mean = 16.5 days; S.D. 10.9). Other advice was reported as given to the 
owners in 5 cases. In five cases the owner was advised to reduce the dogs’ exercise and in 
two cases weight loss was advised.
Two dogs were reported to be receiving other treatment or to be suffering from 
other disease. Case 204 was receiving treatment with Heart Tonic and Stimulant Tablets® and 
Case 205 was receiving treatment with Lasix® during the trial. Presumably both of these dogs 
had cardiac disease. It was not thought that these diseases or treatments would affect the 
efficacy of the treatment. However, the use of phenylbutazone in animals suffering from 
cardiac disease increases the risks of nephrotoxicity. Phenylbutazone is reported to cause fluid 
retention in man. It is also known that the concurrent administration of NSAIDs with 
frusemide reduces the diuretic action of the latter.
Palatability of the sugar-coated Flexazone 100 mg Tablets® was reported as 
"good" in 8 cases and "average" in 10 cases. In 3 cases the palatability of the tablets was not 
stated.
Condition Scores
The phenylbutazone group pretreatment, post-treatment and difference in condition 
scores for lameness, weightbearing, and joint mobility are given for each case in Appendix 
C28. A graphical representation is given in Appendices C29-32.
Lameness f Appendices C28 & C291
Phenylbutazone treated dogs showed a reduction in lameness score of between 1 
and 3 units in 8 of the 21 cases which were lame before treatment (38%). In 13 cases (62%) 
there was no change in lameness score at reexamination. Three dogs (14%) were not lame 
after treatment and a further 8 dogs (38%) were normal when standing and walking (score 1). 
The mean pre treatment lameness score was 2.6 (S.D. 0.9). The mean post treatment 
lameness score was 1.8 (S.D. 1.1). The mean reduction in lameness score between the pre 
and post treatment examinations was 0.77 units (S.D. 0.91). The pre and post treatment 
lameness scores are represented graphically in Appendix C29.
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A paired r -test showed a significant improvement in lameness score between the 
pre and post treatment examinations (p < 0.01). A Wilcoxon Signed Rank Test showed a 
significant improvement in lameness score between the pre and post treatment examinations (p 
< 0.02).
Weightbearing \Appendices C28 & C301
Weightbearing was reduced in 13 cases (13 of 21; 62%) before treatment. In 8 
dogs weightbearing was not reduced (38%). Phenylbutazone treated dogs showed an 
improvement in weightbearing score in 2 cases where weightbearing had been affected (2 of 
13; 15%). In two cases, the weightbearing score after treatment was worse than before 
treatment. The mean pre treatment weightbearing score was 0.8 (S.D. 0.7). The mean post 
treatment weightbearing score was 0.8 (S.D. 0.6). The mean reduction in weightbearing score 
between the pre and post treatment examinations where weightbearing was affected was zero 
(S.D. 0.5). The pre and post treatment weightbearing scores are represented graphically in 
Appendix C30.
A paired t -test demonstrated no statistically significant improvement in 
weightbearing score between the pre and post treatment examinations (p = 1.0). A Wilcoxon 
Signed Rank Test showed no statistically significant improvement in weightbearing score 
between the pre and post treatment examinations (p = 0.5).
Joint Mobility \Appendices C28 & 311
Joint mobility was reduced in 18 cases (18 of 21; 86%) before treatment In 3 
dogs joint mobility was not reduced (14%). Phenylbutazone treated dogs showed an 
improvement in joint mobility score in one case where joint mobility had been affected (1 of 
18; 6%). In two cases, the joint mobility score was worse after treatment than before 
treatment. The mean pre treatment joint mobility score was 1.0 (S.D. 0.5). The mean post 
treatment joint mobility score was also 1.0 (S.D. 0.6). There was a mean increase in joint 
mobility score between the pre and post treatment examinations where joint mobility was 
affected of 0.05 units (S.D. 0.08). The pre and post treatment joint mobility scores are 
represented graphically in Appendix C31.
A paired t -test showed no significant improvement in joint mobility score between 
the pre and post treatment examinations (p = 0.6). A Wilcoxon Signed Rank Test showed no 
significant improvement in joint mobility score between the pre and post treatment 
examinations (p = 0.5).
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Total Condition Score [Appendices C28 & C321
One dog had a zero score after phenylbutazone treatment (1 of 21; 5%). Nine dogs 
showed an improvement in condition score at reexamination after treatment with 
Phenylbutazone (9 of 21; 43%). In nine dogs, the condition score was unchanged by 
Phenylbutazone treatment (9 of 21; 43%). In 3 dogs (3 of 21; 14%), the condition score was 
worse at reexamination. The mean total condition score before treatment was 4.3 (S.D. 1.5). 
The mean post treatment total condition score was 3.6 (S.D. 1.8). The mean reduction in total 
condition score between the pre and post treatment examinations was 0.7 units (S.D. 1.3).
Pre and post treatment total condition score is represented graphically in Appendix C32.
A paired t -test showed a significant improvement in total condition score between the 
pre and post treatment examinations (p < 0.02). A Wilcoxon Signed Rank Test showed a 
significant improvement in total condition score between the pre and post treatment 
examinations (p < 0.02).
Veterinarian Satisfaction:
The effect of treatment with phenylbutazone was considered to have been satisfactory 
by the veterinary practitioner in only 10 of the 21 cases (48%), to have been unsatisfactory in 
8 cases (38%). In 3 cases (14%), the veterinarian said that the effect of treatment was not 
completely satisfactory but there was an effect on the condition.
Reported Side Effects
Case 204 Sharpies; 9 year old Crossbred Male; 12 kg. Stifle/hip osteoarthritis. Concurrent 
therapy with Heart Tonic and Stimulant Tablets.
Phenylbutazone 100 mg b.i.d. [16.7 mg/kg/day]
Vomiting and inappetance after 12 days treatment Treatment not withdrawn.
Comparison Between Treatments
Carprofen Tablet Treatment and Previous Treatment
Fifty dogs had been previously treated with a total of 60 treatments. In four cases, 
these previously treated dogs were treated with phenylbutazone during the trial period. The 
remaining 56 dogs were treated with carprofen during the trial [Appendices 34-361. The 
investigating veterinarian stated the relative effectiveness of carprofen and the previous 
treatment on the Clinical Assessment Form for 46 of the 56 previous treatments. The stated 
comparison with all previous analgesic and anti-inflammatory therapy is represented in tabular 
form in Appendices C37 & C38.
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Carprofen was judged to be superior to the previous treatment in 26 cases (26 of 
46; 57%), to be equivalent to the previous treatment in 6 cases (13%) and to be inferior to the 
previous treatment in 14 cases (30%). Compared to previous treatment of 21 dogs with 
phenylbutazone at 6 to 27 mg/kg/day, where a comparative efficacy was stated, carprofen 
treatment was stated to be more effective in 12 cases (57%), equivalent in 3 cases (14%) and 
inferior in 6 cases (29%). Compared to previous treatment of 11 dogs with 
Predno-Leucotropin® Tablets at 5-40 mg cinchophen and 0.03-0.20 mg prednisolone/kg/day, 
where the comparative efficacy was stated, in five cases (5 of 11; 45%) carprofen was 
considered more efficacious, and in 6 cases (55%) Predno-Leucotropin® Tablets were 
considered more efficacious.
Seven previous treatments had no effect on clinical presentation (Score 0). Five of 
these cases improved when treated with carprofen. In two of these cases carprofen did not 
have any effect Twenty one previous treatments had "some effect" (Score 1) on the clinical 
condition. In fifteen cases the efficacy of Carprofen was considered superior to the previous 
treatment and in a further two cases was considered of equivalent effect. In four cases where 
the previous treatment had some effect, the efficacy of carprofen was considered inferior. 
Eighteen previous treatments gave a "marked improvement" (Score 2) in the clinical condition. 
In six cases the efficacy of carprofen was considered superior to the previous treatment and in 
a further two cases was considered of equivalent effect. In nine cases where the previous 
treatment had a marked effect, the efficacy of carprofen was considered inferior. One case was 
considered "sound" whilst on treatment with Predno-Leucotropin Tablets® and in this case 
carprofen was considered to be less beneficial.
The above findings are tabulated fullv in Appendices C34-36 and are summarised
below:
Previous Treatment Subiective ComDarative Effect of Camrofen Treatment
Effect
Worse Same Better
No Effect 0 2 (29%) 5 (71%)
Some Effect 4 (19%) 2 (10%) 15 (71%)
Marked Improvement 9 (53%) 2 (12%) 6 (35%)
Sound 1 (100%) 0 0
Carprofen efficacy cf : 14 (30%) 6 (13%) 26 (57%)
all previous treatments
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Carprofen Tablet Treatment and Phenylbutazone Treatment
The pre treatment condition scores for lameness, weightbearing, joint mobility 
and total condition score for the carprofen treated and phenylbutazone treated groups 
were not significantly different when analysed by a Students t-test. There was no 
statistically significant difference in the reduction in lameness score or in the post 
treatment lameness scores between the carprofen and phenylbutazone treated groups 
when the scores were compared by a Students t -test.
The improvement in weightbearing score was significantly greater in the 
carprofen treated group than in the phenylbutazone treated group when the differences in 
pre and post treatment scores were compared by a Students t -test (p <0.01).
The improvement in joint mobility score was significandy greater in the 
carprofen treated group than in the phenylbutazone treated group when the differences in 
joint mobility scores pre and post treatment were compared by a Students Mest (p 
<0.05).
There was no statistically significant difference between the improvement in 
total condition score for the carprofen and phenylbutazone treated groups when the scores 
were compared by a Students r-test. However, the post treatment total condition scores 
for the carprofen treated group were significantly lower than those for the 
phenylbutazone treated group when compared by a Students r-test (p <0.05).
Both carprofen and phenylbutazone were used in ten cases. Eight cases were 
treated with carprofen at 0.92 to 2.92 mg/kg/day for between 7 and 21 days followed by 
phenylbutazone at 8.26 to 15.4 mg/kg/day for between 7 and 21 days. In two cases, the 
dogs were treated with phenylbutazone at 10.5 mg/kg/day in one case and at 33.3 
mg/kg/day in the other, both for 7 days, followed by carprofen at 0.92 mg/kg/day for 14 
days in Case 22 and at 2.92 mg/kg/day on one day in Case 23 (dog vomited on second 
and third days of treatment and carprofen was withdrawn). In four cases neither treatment 
was considered satisfactory. In four cases carprofen was considered the more efficacious 
of the two treatments. In two cases phenylbutazone was considered the more efficacious 
treatment. When the difference in total condition score pre and post treatment for the two 
treatments was compared by a paired Mest and Wilcoxon Signed Rank test there was no 
statistically significant difference between the two treatments in these ten dogs.
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Carprofen Dose and Effect
The recommended range of treatment doses was changed to 2 to 4 mg/kg/day 
after 2 months of the trial period because a number of the investigating veterinarians 
stated that the effect of carprofen at the 0.7 mg/kg/day recommended was disappointing. 
When a Kendall Rank Order Correlation test was applied to the data, there was a 
significant positive correlation between the dose rate of carprofen and the improvement in 
total condition score (p <0.05). The effect of treatment was compared for the group of 
dogs treated at less than 2 mg/kg/day to those treated at 2 mg/kg/day or over by 
expressing the improvement in total condition score as a percentage of the pre treatment 
total condition score, as below:
Post treatment total condition score - Pre treatment total condition score x jqq %
Pre treatment condition score
The percentage improvement in total condition score is represented graphically 
for the two dose ranges in Appendix C33. The number of dogs with a zero improvement 
or worse on carprofen is 11 of 46 (28%) for the <2 mg/kg/day group but only 5 of 28 
(18%) for the >2 mg/kg/day group. Also, the number of dogs with a 50-100% 
improvement in total condition score is only 14 of 46 (30%) for the lower dose range but 
is 13 of 28 (46%) for the higher dose rate. However, these differences are not statistically 
significant when compared by a X  2 test.
Eighteen dogs were treated at a higher dose rate when treatment with 
carprofen at a lower rate failed to have a satisfactory effect The dose rates and effects are 
tabulated in Appendix C37. The effect of treatment with the two dose rates on the 
difference in pre and post treatment total condition score is represented graphically in 
Appendix C33. In seven cases when the low dose rate had failed to improve the 
condition, the higher dose rate was also ineffective (7 of 18; 39%). In two cases the 
increased dose rate had the same effect as the lower dose rate (11%). In the remaining 
nine cases (50%) the higher dose rate was considered appreciably more efficacious.
The lower treatment doses ranged from 0.71 to 1.84 mg/kg/day (mean 1.1 mg/kg/day; 
S.D. 0.36). The higher treatment doses ranged from 1.46 to 3.50 mg/kg/day (mean 2.11 
mg/kg/day; S.D. 0.54). The lower dose rate gave a mean improvement in total condition 
score of 0.3 units (S.D. 0.8). The higher dose rate gave a mean improvement in total 
condition score of 1.2 units (S.D. 1.0). When the differences in pre and post treatment 
total condition scores for the two doses were compared by a paired r-test, the 
improvement in total condition score at the higher dose rate was significantly greater than 
for the lower dose rate (p <0.001). The number of dogs showing improvement was 
significantly greater at the higher dosage range when an X  2 test was performed.
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4.4.5 Conclusions
Efficacy of Treatment
The efficacy of carprofen in the therapy of dogs with clinical osteoarthritis 
was judged to have been satisfactory in 49 of 74 treated dogs (66%). The post carprofen 
treatment examination showed statistically significant improvements in subjective scores 
for lameness, weightbearing and joint mobility.
The efficacy of phenylbutazone in the therapy of dogs with clinical 
osteoarthritis was judged to have been satisfactory in 10 of 21 treated dogs (48%). The 
post phenylbutazone treatment examination showed statistically significant improvements 
in subjective scores for lameness but not for weightbearing or joint mobility.
Carprofen had a satisfactory effect in 49 of 74 cases treated (66%) whilst 
phenylbutazone had a satisfactory effect in only 10 of 21 (48%). Improvements in 
condition score parameters were seen in more cases treated with carprofen than in dogs 
treated with phenylbutazone. However, there was no significant difference between the 
mean improvements in total condition scores for the carprofen and phenylbutazone treated 
groups. In the ten cases where a form of cross-over trial was undertaken there was no 
statistically significant difference between improvement in total condition scores for the 
two treatments when compared by a paired r-test. No statistically significant differences 
in efficacy were found for different joints or under different reported management 
changes.
Carprofen was considered more effective than previous treatment in 26 (57%) 
and of equivalent efficacy in 6 (13%) of 46 cases where the veterinarian stated the 
comparative efficacy.
There was a correlation between the improvement in total condition score and 
dose rate of carprofen administered. The number of dogs which had improved after 
carprofen therapy was greater for dogs treated at over 2 mg/kg/day than at less than 2 
mg/kg/day. Also, a larger ' number of dogs improved by a greater amount when treated 
at the higher dose range.
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Adverse Reactions
The veterinarian entered details in the "Side Effects" section for fifteen dogs 
treated with carprofen (15 of 74 cases; 20%). In seven cases there was another likely 
cause of the observed signs. In eight cases an adverse reaction was suspected (8 of 74 
cases; 11%). However, it was unclear whether the reports of side effects were 
volunteered or were elicited by questioning.
Treatment was withdrawn because of suspected adverse reactions in only 2 
cases (2 of 74 cases; 3%). In Case 23, treatment was withdrawn because the dog vomited 
on the second and third days of carprofen treatment Vomiting could have been due to 
gastritis or nausea.
In Case 36 treatment was withdrawn when the dog developed diarrhoea. 
However, this dog had a previous history of colitis and diarrhoea. The veterinarian 
believed that the bout of diarrhoea was probably coincidental. In two cases, Cases 1 and 
2, treatment was withdrawn because analgesia was causing the dogs to over-use their 
damaged joints.
Gastrointestinal disturbances were reported in a further six cases. Two dogs 
vomited but treatment was not withdrawn. Case 64 had a coincidental upper respiratory 
tract infection. Two dogs became diarrhoeic. In case 59 the diarrhoea was thought to be 
dietary in origin. Treatment was maintained at a lower dose rate and the diarrhoea 
resolved. Case 65 had a previous history of diarrhoeic episodes. Constipation was 
reported in two cases. Inappetance was reported in case 15, and inappetance and 
increased salivation in case 48. These signs may have been due to nausea. Polydipsia 
was reported in 4 cases. However, in 2 cases concurrent renal disease was thought to be 
responsible; in one case concurrent diuretic therapy was thought responsible. Drowsiness 
was reported in Case 6.
Side effects were reported for carprofen at a range of doses from 0.75 to 2.92 
mg/kg/day. No relationship between dose rate and side effects was apparent although the 
three dogs which vomited whilst on treatment were all treated at over 1.86 mg/kg/day. 
The trial sample is too small to assess whether the incidence of vomiting or diarrhoea are 
related to dose rate. Concurrent renal or cardiac disease was not apparently associated 
with increased drug toxicity or with an increased incidence of suspected adverse 
reactions.
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One dog treated with phenylbutazone had reported side effects (1 of 21; 5%). 
Case 204 vomited after 12 days of phenylbutazone treatment but treatment was 
continued. Vomiting could have been due to nausea, gastritis, or gastrointestinal 
ulceration. The trial sample is too small to be an accurate prediction of the incidence of 
adverse reactions in dogs treated with phenylbutazone.
The clinical trial was limited by practical constraints and the absence of any 
form of remuneration for participating veterinarians. This led to the unblinded, positive 
control trial design, no radiological confirmation of the diagnosis in all cases, and a 
limited number of cases. The subjective nature of condition assessment and variation 
between veterinarians in scoring the condition and in other advice given on exercise 
undoubtedly affects the validity of the trial results. However, with the exception of 
flexion and extension angle measurement, there are no objective measurable parameters 
of the severity of osteoarthritis or of any improvement with analgesic or antiinflammatory 
treatment. Little relationship has been detected between objective indicators and the 
degree of pain and functional loss experienced in human osteoarthritis patients (Berry, 
1983; Kramer, 1983; Harkness, 1984). Summers reported that radiographic assessment 
was poorly correlated with the degree of pain or of functional impairment in osteoarthritis 
of the knee or hip in man (Summers, 1988).
There were differences in the carprofen and phenylbutazone treated groups in 
age distribution, breed distribution and joint affected. The differences were partly due to 
the limited size of the trial population. However, for a disease like osteoarthritis variance 
within and between groups is inevitable unless the sample population is very large. 
Although the two groups are not completely comparable, the trends indicated in the trial 
are probably valid.
Carprofen appears to be efficacious in the therapy of many cases of 
osteoarthritis when used at a dose rate of 0.71 to 3.50 mg/kg/day. There was a 
correlation between dose rate and effect within this dose range. A dosage range of 2.00 to 
3.50 mg/kg/day improved efficacy without an apparent increase in toxicity or adverse 
reactions.
Carprofen was well tolerated in most dogs. The incidence of suspected 
adverse reactions was comparable to that of other non-steroidal anti-inflammatory drugs. 
The subjectively assessed improvement in the clinical condition in carprofen treated dogs 
was equivalent or superior to that in phenylbutazone treated dogs and carprofen compared 
favourably with the treatments previously prescribed.
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Results Summary:
Total number of dogs treated 
Dose rate (mg/kg/day)
Reported side effects (all) 
Probable adverse reaction 
Treatment withdrawn because 
of adverse reaction
Lameness reduced 
Weightbearing increased 
Joint mobility increased 
50-100% improvement:
< 2 mg/kg/day 
> 2 mg/kg/day
Treatment considered satisfactory
Carprofen Phenylbutazone
74 21
0.39 - 3.5 5.7 - 33.3
15 (20%) 1 (5%)
8(11%) 1 (5%)
2 (3%) 0
49/73 (67%) 8/21 (38%)
18/44 (41%) 2/13 (15%)
13/62 (21%) 1/18 (6%)
14/46 (30%) -
13/46 (46%) -
49/74 (66%) 10/21 (48%)
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Chapter 5
The NSAID-Steroid Combination PLT ® Tablet
and its Use in the 
Therapy of Canine Osteoarthritis
5The N^SAID-Steroid Combination Preparation PLT© Tablet
andit&Usfc inthe. Therapy. of .Canine Osteoarthritis
L l  General Available Data on PLT® Tablets and Related Preparations
5.1.1 Preparation
PLT ® Tablets are a fixed combination product containing:
Cinchophen 200 mg
Prednisolone BP 1 mg per tablet.
The product has been developed by BK Veterinary Products to replace 
Predno-Leucotropin Tablets® which have been available for veterinary use in the United 
Kingdom for 22 years. Predno-Leucotropin Tablets contain 100 mg Hexamine per tablet 
in addition to cinchophen and prednisolone BP.
Hexamine is a surface acting urinary antiseptic. It is believed that antibacterial 
activity of the compound is due to its conversion to formaldehyde in a slighdy acidic 
environment Hexamine was removed from the product because at the suggested dose 
rate of approximately 10 mg/kg in Predno-Leucotropin Tablets, hexamine has little 
anti-inflammatory activity.
The effect of urinary acidification on the excretion of cinchophen or its 
metabolites is not documented. If  the excretion of cinchophen depends upon urinary 
excretion of the active drug, the low pKa of cinchophen may mean that acidification of 
the urine could delay excretion and prolong plasma concentrations (La Du and others, 
1972).
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5,1,2 Active Ingredients. Properties and Mechanisms of Activity
CiochQph.en
Cinchophen (chemical name:
2-phenylquinolone-4-carboxylic acid or 
2-phenylcinchoninic acid) is a non-steroidal 
anti-inflammatory drug (NSAID) with 
anti-inflammatory, analgesic and uricosuric 
properties (Hueper, 1948). The 
anti-inflammatory and analgesic actions of 
cinchophen are thought to be due to 
reversible inhibition of the enzyme complex 
cyclooxygenase which reduces the tissue 
production of the inflammatory prostanoids (McKellar, 1989). Little is known about the 
pharmacology of cinchophen since it has not been used in man for many years. Other 
quinolones have antimicrobial and inhibitory effects on DNA transcription (Booth,
1982).
Unpublished studies in beagles carried out in the Department of Veterinary 
Pharmacology, University of Glasgow have indicated that cinchophen administered at
12.5 mg/kg in a single dose has an elimination half life of about 8-9 hours and an average 
oral availability of 85 to 90%. Cinchophen was generally rapidly absorbed. Maximum 
plasma concentrations of between 44.7 and 99.5 ug/ml were attained between 45 minutes 
and eight hours after administration. However, since effective plasma concentrations are 
not documented, the significance of kinetic data cannot be determined.
No LD50 values are documented for cinchophen in the dog. Oral toxicity 
studies have been limited because cinchophen consistently causes vomiting at oral doses 
over 500 mg/kg. 620 mg/kg by subcutaneous injection is lethal (Risi, 1932). 500 mg/kg 
for 2-3 days is fatal (Starkenstein, 1924). In man, dermatological, cardiovascular, 
hepatic, and renal toxicity have been described (Biberfeld, 1913; Hanzlik, 1921; 1927; 
Sutton, 1928; Chen, 1936; Stalker and others, 1937; Hueper, 1948). Doses of 50-400 
mg/kg have caused renal and liver pathology (Hueper, 1948). Cinchophen was 
withdrawn from use in man because of a high incidence of hepatotoxicity, which is 
thought to be much less common in the dog.
C O O H
FIG 33: Cinchophen
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Cinchophen causes gastrointestinal ulceration (Bollman and others, 1937; 
Stewart and others, 1980). The mechanisms of gastrointestinal pathology may be local 
although some authors have demonstrated hypothalamic effects (Nagamichi, 1977). At 
higher than therapeutic doses, gastric mucosal inflammation is apparent by 24 hours after 
the ingestion of the first dose of cinchophen. Gastritis is reversible if treatment is 
withdrawn. Gastric ulceration appears to be dose related and the incidence increases with 
the number of treatments given. Even at relatively low doses such as 22 mg/kg it is 
thought that gastrointestinal ulceration will develop with chronic use (Van Wagoner and 
Churchill, 1931). At 50 mg/kg bid, protein losing gastroenteropathy will probably 
develop. It is thought that 25 mg/kg/day is well tolerated for the proposed 14 day 
treatment period. It has been advised that a maximum dose of 25 mg/kg/day for up to 14 
days is not exceeded (McKellar, 1989).
Cinchophen can cause tinnitus, dizziness and vertigo in man (Hanzlik, 1929). 
No effect has been demonstrated on prothrombin clotting time in dogs fed a normal diet 
(Hueper, 1946) but cinchophen could affect the platelet component of the clotting
mechanism which may be important in animals with preexisting clotting deficiencies or 
where gastrointestinal haemorrhage occurs.
Prednisolone
Prednisolone is a synthetic corticosteroid with an intermediate duration of 
activity. The double bond in the steroid 'A' ring protects the ring from metabolic 
deactivation and increases the drug half life. It has 0.8 times the mineralocorticoid activity 
and 4 times the glucocorticoid activity of cortisol (Haynes and Murad, 1980; McDonald, 
1982). Prednisolone is less expensive than more derivatised steroids and has good 
antiinflammatory, antiallergic and immunosuppressive activity. The increased therapeutic 
ratio of prednisolone/prednisone and their usefulness in alternate day therapy makes them 
the steroids of choice for chronic oral use (Green and Lutsky, 1986).
The antiinflammatory action of steroids may be partly due to the induction of 
translation of a protein (macrocortin or lipomodulin) which inhibits phospholipase A2, 
the enzyme responsible for catalysis of the conversion of membrane or free phospholipid 
into arachidonic acid. This may reduce the substrate available for the lipoxygenase and 
cyclooxygenase pathways and reduce the synthesis of inflammatory mediators (Flower 
and Blackwell, 1979). However, recent experiments have cast doubt on the in vivo 
importance of this mechanism (Lees, 1989). Other mechanisms of steroid activity are 
believed to be important but have not been elucidated (Green and Lutsky, 1985).
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The side effects of chronic exogenous steroid administration have been widely 
reported and include: accelerated carbohydrate, protein and fat catabolism; 
immunosuppression; reversible hepatopathy; iatrogenic hyperadrenocorticism (Cushing's 
Syndrome); and iatrogenic secondary adrenocortical insufficiency (Liddle, 1971; Irvine 
and Barnes, 1972; Scott and Greene, 1974; Chastain and Graham, 1979; Haynes and 
Murad, 1980; McDonald, 1982). It is believed that the minimum dose required to 
suppress the hypothalamic-pituitary-adrenal axis is approximately 0.3 mg/kg/day which 
is equivalent to 1 mg/kg/day of hydrocortisone (Mulnix, 1979). This is greater than the 
dose of prednisolone available at the proposed dose rate of PLT Tablets. Corticosteroids 
decrease gastric mucus secretion and viscosity and increase secretion of acid and pepsin. 
Used alone corticosteroids can occasionally cause gastrointestinal ulceration (Rogers and 
Ruebner, 1977) but they may potentiate the effects of NSAIDs on the gastric mucosa 
(Cosenza, 1984). Prednisolone at higher dose rates has been shown to enhance the 
ulcerogenic activity of cinchophen (Hamori and others, 1968). Side effects to steroid 
administration show a marked variation in individual response to the same dosage.
High doses of corticosteroids have adverse effects on the joint. However, a 
number of studies have demonstrated a cartilage protective and disease inhibiting effect of 
corticosteroids at lower doses similar to those in PLT Tablets.
Cinchophen and Prednisolone Combination
There are a number of satisfactory arguments for the potential advantages for 
a cinchophen-prednisolone combination. The prednisolone may promote absorption of 
cinchophen, may compete for plasma protein binding sites, or may prolong plasma 
concentration of cinchophen by antagonising excretion. Because cinchophen and 
prednisolone act by different antiinflammatory mechanisms, synergy may exist between 
the two drugs. However, the dose of prednisolone in PLT Tablets is lower than doses 
usually considered to have therapeutic antiinflammatory activity (Haynes and Murad, 
1980; McDonald, 1982). At the higher limits of the dose range, the dosage of 
prednisolone is similar to dosages which inhibit early articular cartilage degenerative 
changes in experimental osteoarthritis in dogs.
5,1.3 Clinical Efficacy Data on PLT Tablets and Related Drugs
Unfortunately, neither cinchophen nor the drug preparations of which it is a 
constituent are included in standard veterinary or human pharmacology and therapeutics 
texts (eg. Alexander, 1969; Goodman, 1980; Booth, 1982; Chandler, 1984). Most 
reports on cinchophen which have appeared in medical journals in the last 35 years 
concern its use at high doses to induce the formation of gastric ulceration. Recent texts 
mention the anti-inflammatory and uricosuric activity of cinchophen (Shen, 1979).
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In the last 40 years, the only published data on the veterinary use of 
cinchophen containing products are two anecdotal reports on the use of "Leucotropin", an 
injectable fixed-combination of cinchophen and hexamine or of cinchophen, hexamine 
and sodium salicylate and caffeine (Lustig-Lendva, 1949; Frost, 1949). The only data 
available on cinchophen and prednisolone in fixed combination is the data on 
Predno-Leucotropin Tablets® and the clinical trial documented in section 5.2.
5.1.4 Efficacy of Predno-Leucotropin in the Therapy of Canine 
Musculoskeletal Pain
There are no documented studies on the clinical efficacy of 
Predno-Leucotropin Tablets® in the dog or other species. However, it is unlikely that 
Predno-Leucotropin Tablets would have continued to be such a popular veterinary 
product if they were not efficacious in the therapy of osteoarthritis in the dog. Between 
January 1984 and June 1988, 51 million Predno-Leucotropin Tablets were sold in the 
UK.
5.1.5 Adverse Reactions to Predno-Leucotropin Tablets
No serious adverse reactions have been reported in man when hexamine has 
been used at doses much greater than those in Predno-Leucotropin Tablets. Nausea, 
vomiting, rashes and urinary irritation have occasionally occurred. However, reported 
adverse reactions to Predno-Leucotropin Tablets are probably attributable to cinchophen 
or prednisolone. It is probable that a similar spectrum and incidence of side effects will 
occur for PLT Tablets.
In the period January 1984 to June 1988, sixteen adverse reactions and 10 
deaths in dogs receiving Predno-Leucotropin Tablets were reported by veterinarians. 
Unfortunately, all the details of the animals or treatments in all cases (eg. ages, dose 
rates, treatment period before reaction/death) are unavailable.
Where the age of the dog was stated, in both fatal and non-fatal adverse 
reaction cases it was between 4 and 11 years. There was no obvious breed or sex 
predisposition except that 3 Dachshunds and 2 Chows were among the total. Calculating 
daily dosages based on estimated breed weight, daily dose rates ranged from 23 to 50 
mg/kg/day. Both adverse reactions and deaths occurred in dogs treated at dosages within 
the proposed range. Suspected adverse reactions began between 1 day and 4 months after 
treatment started. However, in the majority of cases, clinical signs were seen within 2-4 
days of the start of treatment. Where mortality was reported, death occurred between a 
few hours and ten days after the first clinical signs.
135
Adverse reactions included vomiting, gastritis, gastric ulceration, abdominal 
pain, diarrhoea and melaena in cases which subsequently recovered and vomiting, 
melaena, haemorrhagic enteritis, diarrhoea, lethargy, collapse, seizures, bilirubinuria and 
proteinuria, and haemorrhage from the nares and gingiva in animals which died, 
Necropsy findings included a perforated gastric ulcer, gastrointestinal ulceration, and 
findings consistent with a diagnosis of "post-anaesthetic death".
In summary, suspected adverse reactions (SARs) occurred in a range of 
breeds and ages of dogs. The dose rate was within the recommended dosage range in 
most cases. S ARs and deaths occurred mostly in the first week of treatment. The most 
common clinical signs could be attributed to gastrointestinal irritation or ulceration 
although some cases showed evidence of nephropathy or a defective clotting mechanism.
The number of reported adverse reactions and deaths in dogs receiving 
treatment with Predno-Leucotropin Tablets is small when compared to the number of 
dogs treated with the preparation. However, the number of reported adverse reactions is 
certainly very much lower than the actual incidence of side effects since veterinarians 
seldom report non-fatal S ARs. It is also possible that adverse reactions in dogs treated 
chronically with Predno-Leucotropin Tablets are not always correctly attributed to the 
drug preparation. Weight loss and subclinical anaemia may be consequences of chronic 
gastrointestinal ulceration and protein losing enteropathy although the loss of blood and 
protein may not be sufficient to cause acute distress. Such reactions may not be 
diagnosed.
5.1.6 Dose Recommendations:
Proposed Dose Rate
Bodvweight fkgl Suggested dosage
Ttabletsl
8 bid
9-16 1 bid
17-24 1.5 bid
25-32 2 bid
Daily Dosermg/kg/davl 
Minimum Maximum
Cine. Predn. Cine. Predn,
25 0.125 25 0.125
25 0.125 44.4 0.222
25 0.125 35.3 0.176
25 0.125 32 0.160
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54,7  Conclusions
To determine what oral dose rate and regime is appropriate for PLT ® Tablets, 
efficacy data and minimum effective plasma concentrations are required. This will require i n  
vitro and in vivo measurement of antiinflammatory effects and inhibition of prostanoid 
synthesis. There are arguments for a combination product containing NSAID and steroid. The 
most convincing is that the two drugs act synergistically by exerting complementary activities 
on inflammatory mechanisms. However, it is possible that the analgesic or antiinflammatory 
efficacy of PLT Tablets is entirely due to their cinchophen content. Further studies are 
required to assess the effect of prednisolone on cinchophen pharmacokinetics, and the effect 
of the component drugs compared with the effect of their combination.
From data available, PLT Tablets are probably well tolerated for up to 14 days at 
20-30 mg/kg/day divided. Longer term treatment at the recommended dose rates may cause 
gastrointestinal inflammation and ulceration. The spectrum and incidence of side effects to 
cinchophen are similar to those of other NSAIDs, principally gastrointestinal intolerance. 
Clinical efficacy data was required and a clinical trial of the efficacy of PLT Tablets in the 
therapy of canine osteoarthritis was instigated (see section 5.21.
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Clinical Trial of the Efficacy of PLT Tablets in the Therapy of 
Canine Osteoarthritis
5.2.1 Summary
The aim of the trial was to establish the clinical efficacy of PLT Tablets in the 
therapy of clinical osteoarthritis in the dog. This was under-taken by comparing the effect 
of PLT Tablets with the effect of a previous treatment for the condition in the same animal 
and by comparing the effect of treatment in a group of PLT treated dogs with the effect of 
treatment in a group of phenylbutazone treated dogs.
PLT Tablets were efficacious in the therapy of 31 of 36 (86%) cases of 
clinical osteoarthritis. Phenylbutazone was efficacious in the therapy of 12 of 15 cases 
treated (80%). PLT was generally as efficacious or superior to previous treatment and 
there was no significant difference between the PLT treated and Phenylbutazone treated 
groups. In the thirty-six PLT treated cases there were mild reported side effects such as 
dullness, increased thirst and mild diarrhoea in 6 cases (17%). In two cases vomiting was 
a side effect and treatment was withdrawn (6%). Of the fifteen phenylbutazone treated 
cases, there was dullness for the first few days of treatment in one case (7%). Vomiting 
was a side effect in one case and treatment was withdrawn (7%).
From the limited numbers of dogs treated during the trial, PLT appears to be 
effective in the therapy of many cases of clinical osteoarthritis when used at 8-46 mg 
cinchophen/kg body weight/day [0.04-0.23 mg prednisolone/kg body weight/day]. There 
was correlation between treatment dose and effect within this dose range. For the 
duration of treatment, PLT was well tolerated in most dogs. The incidence of adverse 
reactions and treatment withdrawal were comparable with other non-steroidal 
anti-inflammatory drugs.
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LLZ Objective
i) To compare PLT Tablets, a fixed combination preparation containing 200 mg 
cinchophen and 1 mg prednisolone per tablet:
(a) with previous medical treatment in existing cases
(b) with the standard drug phenylbutazone in new cases
in the control of the signs of clinical osteoarthritis in the dog.
ii) To determine and record the incidence and nature of any unwanted side effects. 
5 ^ .2  Method and Materials
Test Drugs
1. PLT Tablets: cinchophen 200 mg
prednisolone BP 1 mg per tablet
[Batch No. 88T2918; Expiry Date: January 1991]
2. Flexazone® Tablets: phenylbutazone BP 100 mg per tablet 
[Batch No. 80302A-1; Expiry Date: December 1990]
Trial Design
The aim of the trial was to establish the clinical efficacy of PLT Tablets in the 
therapy of clinical osteoarthritis in the dog. This was undertaken by comparing the effect 
of PLT Tablets with the effect of a previous treatment for the condition in the same animal 
and by comparing the effect of treatment in a group of PLT treated dogs with the effect of 
treatment in a group of phenylbutazone treated dogs. Thus the trial was based on a form 
of positive control design. It was not considered practical to perform a "cross-over" type 
trial because of the possible lack of compliance of veterinary practitioners and owners. A 
blind placebo control design would not have been acceptable to owners or veterinary 
practitioners and would also have been ethically unsound. It was hoped that the PLT and 
phenylbutazone treated groups would be comparable. No financial or other inducements 
were offered to any participating veterinary surgeon.
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Investigator Selection
Veterinary practitioners who were known personally by the author, by Dr. Q. 
McKellar of the Department of Veterinary Pharmacology, or by Mr. S. Carmichael of the 
Department of Veterinary Surgery, University of Glasgow, or by Mr. Graeme Bell of 
C-Vet Limited were contacted by letter and asked to participate in the clinical trial. Further 
correspondence and telephone conversations led to the recruitment of 20 practices, 14 of 
which returned results information sheets. Each practice was supplied with information 
on the product, and instructions on case selection, dose recommendation and condition 
scoring [Appendices Dl-31. Approximately 15 sets of results information sheets ["Patient 
Information", "Efficacy Assessment" and "Clinical Assessment" sheets] were also posted 
to each practice. These sheets were similar to those used in the previous clinical trial on 
the efficacy of carprofen [Appendices C4-61 except that a fourth parameter "stiffness" 
was added to those of lameness, weightbearing and joint mobility. This category was 
included because a number of practitioners involved in the previous trial commented that 
stiffness had markedly improved in a number of cases where lameness was still apparent. 
It was hoped that, by distinguishing between lameness and stiffness, scoring the 
condition would be simpler. PLT Tablets and Flexazone® 100 mg tablets were supplied.
Dose Recommendations
The Dose Recommendations sheet supplied to practitioners \Appendix D21 
recommended that PLT Tablets be administered orally in a divided dose based on a 
theoretical minimum of 25 mg cinchophen and 0.125 mg prednisolone per kilogram 
bodyweight per day. Due to the fixed combination and set quantity per tablet the 
recommendations would give a daily dosage of between 25 and 44 mg/kg/day 
cinchophen and between 0.125 and 0.22 mg/kg/day prednisolone. The initial treatment 
period was to be 14 days, subject to clinical response.
With the 100 mg tablets provided, a dose rate in tablets was calculated such 
that phenylbutazone would be administered at a suggested dose rate of between 8 and 16 
mg/kg bodyweight/day divided into two doses daily. It was stated that phenylbutazone 
should not be used in animals with cardiac, renal or hepatic insufficiency or in animals 
showing signs of or with a history of anaemia, as recommended in the Data Sheet for the 
product.
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Case Selection and Protocol
PLT Tablets were to be assessed for therapeutic effect in cases of clinical 
osteoarthritis. Diagnosis was made by the history and clinical presentation. Confirmation 
of the clinical diagnosis with radiographic diagnosis would have been preferable but since 
no payment or inducements were offered to participating veterinarians, it was not 
considered reasonable or practical to insist on radiographic confirmation of diagnosis. 
Cases were of two groups:
1. existing cases (dogs already receiving medical therapy for osteoarthritis);
2. new cases (dogs at first presentation to the practitioner or for which the previous 
history was not known).
The protocol for the trial was as follows:
1. Existing Cases:
i) Information on the owner and the dog was recorded. The joints affected 
were noted. In most cases, a brief summary of the clinical history was 
taken. The dose, regime, duration and effect of the previous treatment 
was noted and the previous treatment was withdrawn.
ii) Where possible, dependent upon the wishes of the owner and the 
veterinary surgeon, the time taken for the signs of the painful condition to 
reappear was monitored.
iii) The clinical condition was scored for lameness [0 to 4], 
weightbearing [0 to 2], joint mobility [0 to 2], and stiffness [0 to 4] 
according to the condition scoring sheet rAppendix D31.
iv) Therapy was instituted with PLT Tablets at the recommended dose rate 
f Appendix D21.
v) The effect of treatment was monitored, i.e. the dog was re-examined 
after a period of treatment (14 days was the recommendation) and the 
clinical condition was re-scored. Where possible, the owner was to be 
questioned as to the efficacy of the treatment and the time taken for the 
treatment to have an effect, if any.
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vi) At the end of the treatment period, the "Clinical Assessment" sheet was 
to be completed with the veterinary practitioners' subjective opinion on 
whether the treatment had been satisfactory and how PLT treatment 
compared to the previous treatment. Any adverse reactions could be noted 
on the "Clinical Assessment" sheet. Provision was made on the first sheet 
["Patient Information"] for noting premature treatment withdrawal and its 
cause or any change of dose rate.
2. New Cases:
i) Osteoarthritis was confirmed clinically and in four cases 
radiographically. Patient information and the joint(s) affected were noted.
A brief summary of the history was taken.
ii) The clinical condition was scored for lameness [0 to 4], weightbearing 
[0 to 2], joint mobility [0 to 2], and stiffness [0 to 4] according to the 
condition scoring sheet rAppendix D31.
iv) Therapy was instituted with PLT Tablets or phenylbutazone 
(Flexazone® Tablets) at the recommended dose rate \Appendix D21 on 
an "alternate case" basis, i.e. treating dog 1 with PLT Tablets, dog 2 with 
Flexazone Tablets, dog 3 with PLT Tablets etc.
v) The effect of treatment was monitored, i.e. the dog was re-examined 
after a period of treatment (14 days was the recommendation) and the 
clinical condition was re-scored. Where possible, the owner was to be 
questioned as to the efficacy of the treatment and the time taken for the 
treatment to have an effect, if any.
vi) At the end of the treatment period, the "Clinical Assessment" sheet was 
completed with the veterinary practitioners' subjective opinion on 
whether the treatment was satisfactory. Any adverse reactions could be 
noted on the "Clinical Assessment" sheet. Provision was made on the first 
sheet ["Patient Information"] for noting premature withdrawal and its 
cause or any change of dose rate.
It was suggested that, where possible, new cases should be treated firstly 
with one of the two test drugs and then, after an interval, the drug used could be switched 
to the second drug. This would allow comparison of the effects of PLT and 
phenylbutazone in the same animal.
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Exclusions
Dogs which were concurrently receiving treatment with a drug with 
anti-inflammatory or analgesic effect were excluded from the results analysis. Incomplete 
or totally illegible results forms were also excluded. Dogs which were not diagnosed as 
having osteoarthritis or with a history not consistent with such a diagnosis were not 
included in the results analysis. It was considered reasonable to consider results valid in 
cases where the full address of the owner or the dogsname was omitted from the "Patient 
Information" form. Dogs treated with PLT Tablets or phenylbutazone outwith the 
recommended dose rate were included.
Results Analysis
The case results were divided by the treatment received into PLT Tablet 
treated and phenylbutazone treated groups. The PLT treated group was further divided 
into previously treated/ existing cases and non-treated/ new cases.
Five statistical analysis methods were used: unpaired "Students" r-test; paired 
r-test; Wilcoxon Signed Rank test; Chi squared (.X 2) test; Kendall Correlation (Weisbrot, 
1985).
The Student's r-test or r-independent test compares the means and standard 
deviations of two independent samples; each standard deviation is presumed to be from 
the same population. This test was used to compare the differences in the total condition 
scores in the phenylbutazone and PLT treated groups.
The paired r-test analyses the average differences between a series of paired 
observations. It is considered more rigorous and useful than the unpaired "Students" 
r-test since it allows isolation of the effects of manipulation on otherwise identical 
samples. However, the paired r-test, like the Student's r-test, does assume a parametric or 
normal distribution of data which could not be guaranteed for the parameters measured 
during the trial (lameness, weightbearing, joint mobility, stiffness and total condition 
scores), especially when the sample size was so small.
The Wilcoxon Signed Rank test is the non-parametric homologue of the 
parametric r-test. Thus, if the data was non-parametric, any statistical significance in 
differences between pre and post-treatment condition scores would still be assessed.
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The Chi squared (X 2) test is frequently used in epidemiology and 
therapeutics to compare categorical data (lived/died, improved/not improved). It was used 
in this trial to compare the response rates to PLT and previous treatment or 
phenylbutazone treatment, and to compare groups with or without advice to reduce 
exercise.
Kendall Correlation is a non-parametric rank-order correlation. This test was 
used to assess whether there was any statistically significant linear correlation between 
the dose rate of PLT administered and the improvement in the overall condition of the 
patient.
The effect of treatment in PLT and phenylbutazone groups was assessed by 
the comparison of pretreatment and post-treatment condition scores for lameness, 
weightbearing, joint mobility and stiffness, and the total condition score (Lameness + 
weightbearing + joint mobility + stiffness). The condition scores before and after 
treatment were compared using a paired r-test and by a Wilcoxon Signed Rank test.
Treatment with PLT and phenylbutazone was compared by the differences in 
pie and post-treatment condition score within the two treatment groups, and by the 
assignment of "Improvement" scores based on the improvement in condition score, the 
comments of the veterinary practitioner and the comparison of the effect of treatment with 
any previous treatment (see below). The overall effect of treatment was rated as:
0 = No Effect
1 = Some Effect
2 -  Marked Improvement
3 = Sound
The differences in pre and post condition scores between PLT Tablet and 
phenylbutazone treatment were compared using a Student's r-test and the overall effect 
of treatment compared with a X  2 test
The effect of PLT Tablets was compared with the effect of previous treatment 
using the same system of "Improvement" scores. The "Improvement" scores for the PLT 
treatment and the previous treatment were compared using a paired r-test and X  2 test. In 
addition, the veterinary practitioner gave a subjective opinion of whether PLT Tablets 
were more or less efficacious than the previous treatment.
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5.2.4 Results
Sixty-nine sets of case results sheets were returned. Twenty cases were 
completely excluded. In 4 cases the results were incomplete. In 3 cases the dog had 
received concurrent treatment with a drug preparation with possible anti-inflammatory or 
analgesic activity and which therefore might interfere with the results obtained for the test 
drugs. One dog was concurrently receiving prednisolone 5 mg bid for eczema. One dog 
was receiving treatment with Otema ® Ear Drops which contain betamethasone. One dog 
was receiving treatment with Sesoral ® tablets which contain ethinyloestradiol and 
methyltestosterone. A further 13 cases were treated which were not diagnosed as 
suffering from clinical osteoarthritis.
After excluding these results, there were a total of 49 dogs which were 
diagnosed as suffering from clinical osteoarthritis. The mean number of case reports per 
practitioner was 3.5. However, the number of usable results per practitioner ranged from 
1 to 9 cases (Appendix D 4\
Thirty-four dogs were treated with PLT Tablets only; thirteen dogs were 
treated with phenylbutazone only; two dogs were treated with PLT Tablets and 
phenylbutazone consecutively: one dog received PLT for 14 days then phenylbutazone 
for 14 days; one dog received phenylbutazone for 14 days and then received PLT for a 
similar period.
Trial Animal Details
Animal details are summarised in Appendices D5 & D6.
Age Distribution \Appendix D71
The age distribution of the cases of osteoarthritis was similar to that seen in 
the carprofen clinical trial with most dogs clinically affected in the 7 to 12 years old 
range. The age of three dogs was not specified. The mean age of all the osteoarthritic 
dogs was 8.5 years (standard deviation (S.D.) 3.8 years). The mean age of the 
Phenylbutazone treated dogs was 8.4 years (S.D 2.4 years). The mean age of the PLT 
treated dogs was 8.6 years (S.D. 4.2 years).
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Breed Distribution rAppendix D81
The breed distribution was similar to that seen in the carprofen trial with a 
high proportion of the dogs being Labrador Retrievers (16 of 49 dogs, 33%). There were 
also more German Shepherd Dogs, Golden Retriever and Border Collies than other 
breeds.
Sex Distribution \ Appendix D91
There were slightly more bitches than dogs with clinical osteoarthritis in the 
trial sample (22 male:27 female (45%: 55%)). In the PLT treated group, the ratio was 
50:50 but in the phenylbutazone treated group it was 33% male: 66% female. It was not 
thought likely that there would be sex differences in the efficacy of treatment
Bodvweight Distribution \Appendix D101
The body weight of cases ranged from 13 kg to 52 kg. Most dogs (34 of 49: 
69%) were between 25 and 40 kg in weight. The mean body weight was 31.6 kg (S.D.
9.2 kg). The animal weight was mostly associated with the breed. However, twenty five 
dogs were considered to be greater than their "ideal" weight by the veterinary practitioner 
(25 of 49: 51%). The bodyweight distribution of dogs treated with PLT Tablets and 
phenylbutazone were similar to those of the whole trial group.
Jointfsi Affected [Appendices D11-131
The joint(s) affected and a brief history as recorded by the veterinary practitioner 
arc listed for each case in Appendices D12 & D13.
Osteoarthritis of one or both hips was most prevalent (21 of 49 dogs: 43%). The 
stifle (15 of 49: 31%) and elbow (6 Of 49: 12%) were the other joints more often 
affected. In 5 cases (10%) more than one joint type is affected (eg. Case 1 both hips, one 
stifle). The joints affected in dogs receiving PLT or phenylbutazone is represented 
graphically in Appendix D l l . There are differences between the two treatment groups 
because of the small sample size.
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Case History [Summary: Appendices D 12 & D 131
In seven cases the veterinary practitioner provided almost no history. In 
general, there was little history given. In 5 cases, osteoarthritis was thought to have 
developed secondary to previous surgical repair of ruptured anterior (cranial) cruciate 
ligament(s). Where stated, the history duration was months or years in most cases. In 
Cases 10, 16, 21, 46,48, 55 and 56 radiography was performed and radiographic 
findings consistent with a clinical diagnosis of osteoarthritis were reported.
Previous Treatment
Details of previous treatments administered, dose rates, durations of treatment 
and effect of treatment is given in Appendix D31. The effect of treatment is also 
represented graphically in Appendix D32.
Twenty-two dogs were treated with a total of twenty-four treatments. In 
Cases 36 and 54 previous Predno-Leucotropin® treatment had no effect. In case 56, 
phenylbutazone had no effect. Seven (of 16) treatments had some effect.Twelve (of 22) 
previous treatments had a marked effect. Cases 36,48, 54 and 58 were treated with 
phenylbutazone during the trial. Case 10 was treated with both phenylbutazone and PLT 
Tablets consecutively. The remaining 17 dogs were treated with PLT Tablets.
The time for signs of the painful condition to reappear after the withdrawal of 
the previous treatment was stated in only 5 cases. The period ranged from "a few days" 
or "several days" to 10 days, 6 weeks and 6 to 8 weeks. In 3 cases it was stated that 
treatment was not withdrawn between the previous treatment and PLT treatment In 14 
cases, the "Time taken for return of painful condition" was not completed.
PLT Treatment
Dose Rates and Regimes \Appendices D14 & D151
The initial dose rate used by the practitioners ranged from 8 to 46.2 mg 
cinchophen/kg/day (0.04 to 0.23 mg prednisolone/kg/day)[Graph: Appendix D171 and 
are summarised below:
Initial Treatment Dose (mg/kg/dav) Number of dogs:
Cinchophen Prednisolone
8.0-46.2 0.04 - 0.23 36
8-20 0.04-0.10 12 [33%]
20-30 0.10-0.15 22 [61%]
30-47 0.15-0.23 2 [6%]
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The initial regime was once a day dosing in two cases only (Case 6 and case 
49). A divided daily dose (bid) was the initial regime in 26 cases (72%). The initial 
treatment dose was divided into three administrations per day in 7 cases (19%). Four times 
a day dosing was prescribed initially in one case (case 45).
In only five cases was the recommendation to reduce the treatment dose 
gradually followed by the veterinary practitioner. However, in 13 cases the treatment was 
not discontinued and the practitioner reported that treatment with PLT Tablets was to 
continue indefinitely. In other cases treatment stopped abruptly. The duration of PLT Tablet 
treatment before the dog was re-presented ranged from 5 to 28 days. The mean treatment 
period before reexamination was 13 days (S.D. 6 days). The total duration of trial PLT 
treatment with monitoring and result completion ranged from less than a week in cases 
where vomiting occurred to 90 days in case 49 (mean=19 days S.D. 17 days).
Other advice was reported as given to the owners in 28 cases. In 17 cases the 
owner was advised to reduce the exercise which the dog received or change the exercise to 
frequent short walks or lead exercise. In 4 cases normal exercise was recommended. In one 
case, a gradual increase in exercise was advised. In 10 of the 25 cases which the 
veterinarian considered overweight, it was reported that weight reduction was advised.
to
Five dogs were reported to be receiving other treatment or^be suffering from 
other disease. Case 21 was pruritic. PLT was said to benefit the condition. Case 30 had a 
dermatitis and was being treated with Pevidine baths. Case 32 had a history of a mild 
"stroke" four weeks previously. True "strokes" or intracranial vascular accidents are 
believed to be rare in the dog. The term "stroke” in veterinary usage is usually applied to 
cases of spontaneous "Vestibular Syndrome". In addition this dog also had bilateral 
cataracts. Case 37 had gingivitis and was on treatment with Metronidazole. Case 42 was 
being treated with Theocardin®(Diprophylline) and presumably had cardiac disease but 
unfortunately this was not stated. Case 44 was treated with Kaobiotic and Buscopan® for 
diarrhoea after 6 weeks of PLT treatment The effect of the antacids in kaolin and of 
hyoscine N-butylbromide in Buscopan® on gastrointestinal absorption of cinchophen, and 
the effect of the NSAID dipyrone in Buscopan® in case 44 was not known. However, 
treatment was only administered once with these drugs and the remainder of the treatment 
period would be unaffected. It was not thought that the other diseases or treatments would 
affect the efficacy of the treatment. [Details Appendices D14 & D151.
Palatability was reported as "Good" in 14 cases, "Average" in 17 cases and 
"Poor" in 3 cases [ Palatability reported in 34 cases ].
1 4 8
Condition Scores
The pretreatment, post-treatment and difference in condition scores for 
lameness, weightbearing, joint mobility and stiffness are given for each case in Appendix 
D18. A graphical representation is given in Appendices D2Q-23. One dog was not 
reassessed because treatment was withdrawn and therapy with aspirin instituted.
Lameness \Appendices D18 & D201
In four cases, the dog was not lame before treatment PLT Tablets caused a 
reduction in lameness score of between 1 and 4 units in 25 of the 31 cases which were lame 
before treatment (81%). In 6 of these 31 lame cases (19%) there was no reduction in the 
lameness score. In 13 of the dogs lame before treatment, there was no detectable lameness 
after treatment (13 of 31: 42%). The mean lameness score before treatment was 2.2 (S.D. 
1.3). The mean score after treatment was 0.7(S.D. 0.9). A paired r-test showed a 
significant improvement in lameness score (p <0.001). A Wilcoxon Signed Rank Test 
showed a significant post PLT treatment improvement in lameness score (p <0.001).
Weightbearing f Appendices D18 &D211
Weightbearing was not reduced in 19 dogs (54%). Of the 16 dogs with reduced 
weightbearing, 13 had normal weightbearing at the post treatment reexamination (81%), 
whilst 3 dogs did not improve (19%). The mean pretreatment weightbearing score was 0.5 
(S.D. 0.5). The mean score after treatment was 0.1 (S.D. 0.3). A paired r-test indicated a 
significant reduction in weightbearing score after treatment (p<0.001). A Wilcoxon Signed 
Rank Test showed a difference in weightbearing score post treatment which was significant 
despite the small sample size (p<0.005).
Joint Mobility f Appendices D18 & D221
Joint mobility was reduced before treatment in 24 of 35 dogs (69%). Treatment 
with PLT Tablets was associated with an improvement in joint mobility in 8 of these 24 
dogs (33%). The mean joint mobility score before PLT treatment was 0.9 (S.D. 0.7) and 
after treatment was 0.6 (S.D. 0.6). There was a statistically significant change in joint 
mobility after PLT treatment when the scores were compared by paired r-test (p <0.01). 
Though the sample size was small there was a statistically significant difference in joint 
mobility score between the pre and post treatment examinations when analysed by a 
Wilcoxon Signed Rank Test (p<0.01).
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Stiffness [Appendices D18 & D231
Thirty-two dogs had stiffness before PLT treatment. In 27 of these 32, there 
was a reduction in stiffness score at the post treatment reexamination (84%).The mean 
stiffness score before PLT treatment was 2.4 (S.D. 1.2) and after treatment was 1.0 (S.D.
1.0). There was a significant decrease in stiffness score after PLT treatment by analysis 
using a paired r-test (p <0.001) and when analysed by a Wilcoxon Signed Rank Test (p 
<0.001).
Total Condition Score \Appendices D19 & D241
Appendix D19 gives the pre and post PLT treatment and difference in total 
condition scores ie. the sums of the lameness, weightbearing, joint mobility and stiffness 
scores. Appendix D24 shows the pre and post PLT total condition scores and the change in 
total score between the pre and post treatment examination. In one dog (Case 21)the total 
score was zero before PLT treatment This dog was receiving treatment 
(Predno-Leucotropin®) when the first examination took place. In 29 of 35 dogs (83%), 
PLT treatment was associated with a reduction in total condition score of between 1 and 9 
units. Twenty-three dogs (23 of 36: 64%) had a 50 to 100% improvement in total condition 
score.
The mean total condition score before PLT treatment was 5.9 (S.D. 2.6) and 
after treatment was 2.5 (S.D. 2.0). There was a significant decrease in the total condition 
score after treatment with PLT when the scores were analysed by paired r-test (p < 0.001). 
A Wilcoxon Signed Rank Test also revealed a significant decrease in the total condition 
score post treatment (p <0.001)
Improvement Rating \Appendices D19 & D331
The improvement rating was assigned to each case result based upon the 
improvements in condition score but also considering the veterinary practitioners comments 
on the effect of treatment and the relative efficacy of PLT treatment compared with the 
previous treatment, for which the veterinary practitioner had assigned an improvement 
score (0=No effect, l=Some Effect, 2=Marked Improvement, 3=Sound).
In Case 2, the dogs' condition deteriorated during treatment with PLT. The dog 
was euthanased because of the severity of the condition. In case 19, treatment with PLT 
gave no improvement and side effects were reported (see below). Case 43 did not improve 
on treatment. In case 50 treatment was withdrawn because of vomiting.
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In 6 cases (17%) PLT treatment had some effect. In 21 of 36 cases (58%) PLT 
treatment had a marked effect. In 4 cases (11%) PLT treatment made the dog sound 
according to the veterinary practitioner.
Treatment was considered satisfactory by the veterinary practitioner in 31 cases 
(86%). The exceptions were Cases 2,19, 43, 50, and 57.
Reported Side Effects
Case 12
Gooch: 3.5 year old M/N Golden Retriever; 52.5 kg (Ideal 40 kg). Left hock.
No previous treatment
PLT Tablets: 22.9 mg cinchophen/kg/day; 0.11 mg prednisolone/kg/day 
Veterinary surgeon reported: "Both polydipsia and polyphagia were noticed by the owner 
after a few days treatment; neither were severe enough to cause owner concern". The dog 
was also on a strict diet.
Case 19
Fowler: 9 year old M/N Labrador Crossbred; 35 kg (Ideal 25 kg). Hips, especially
left No previous treatment.
PLT Tablets: 22.9 mg cinchophen/kg/day; 0.11 mg prednisolone/kg/day. 
Veterinary surgeon reported vomiting after 3 days. The dose rate was halved to 11.4 mg 
cinchophen/kg/day; 0.06 mg prednisolone/kg/day but the dog vomited after 4 days on this 
lower dose rate. Treatment was then withdrawn.
Case 24
Lomas: 11 year old M Labrador, 30 kg. Hips; concurrent pruritis.
Previously treated with phenylbutazone long term (20 mg/kg/day).
PLT Tablets: 20 mg cinchophen/kg/day; 0.1 mg prednisolone/kg/day.
Veterinary surgeon reported the dog had slightly increased thirst whilst on treatment.
Case 26
Giles: 14 year old M Collie; 18 kg. "Pain in back legs and spine".
No previous treatment
PLT Tablets: 22.2 mg cinchophen/kg/day; 0.11 mg prednisolone/kg/day. 
Veterinary surgeon reported: "Slight dullness for few days, then O.K.".
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Case 34
Love: 8 year old F Labrador, 25-30 kg. Hips. No previous treatment.
PLT Tablets: 14.8 mg cinchophen/kg/day; 0.07 mg prednisolone/kg/day. 
Veterinary surgeon reported: "Slight diarrhoea problem which cleared up once off PLT". 
Occasional diarrhoea, from about 18 days of treatment. Treatment not continued after 
veterinary surgeon re-examined the dog.
Case 38
Duncan: 10 year old F/N Corgi; 13 kg (Ideal 11 kg). Shoulder.
PLT Tablets: 46.2 mg cinchophen/kg/day; 0.23 mg prednisolone/kg/day 
Veterinary surgeon reported: "Polyuric. Wets in house at night. Previously clean". Thirst 
reported at 7 day reexamination. Dose reduced to 30.8 mg cinchophen; 0.15 mg 
prednisolone/kg/day.
Case 44
Young: 12 year old M Bearded Collie; 33 kg. Shoulder, carpal and spinal problems.
PLT Tablets: 12.1 mg cinchophen/kg/day; 0.06 mg prednisolone/kg/day 
Treated previously with phenylbutazone 12 mg/kg/day for 1 month.
Veterinary surgeon reported that the dog was presented with diarrhoea after 41 days on 
PLT Tablets. Treated with Kaobiotic and Buscopan. Diarrhoea not thought connected to 
PLT. PLT therapy continued.
Case 50
Campbell: 11 year old M Border Collie; 35 kg (Ideal 25 kg). Bilateral stifle.
PLT Tablets: 17.1 mg cinchophen/kg/day; 0.09 mg prednisolone/kg/day 
Veterinary surgeon reported that dog had vomited and treatment withdrawn. Neither the 
number of treatments nor the severity or frequency of vomiting were reported.
There were no adverse reactions reported on abrupt withdrawal of PLT treatment.
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Phenylbutazone Treatment
Dose Rates and Regimes \Appendix D161
The initial dose rate used by the practitioners ranged from 5.0 to 11.4 mg 
phenylbutazone/kg/day with a mean of 8.4 mg/kg/day. The regime was sid in two cases, 
bid in 10 cases and tid in 3 cases. The duration of treatment before the dog was 
re-presented was 14 days in most dogs but ranged from 7 to 18 days. The duration of trial 
treatment with phenylbutazone ranged from 3 to 60 days. In case 16 an adverse reaction 
caused treatment to be withdrawn after three days.
Other advice was reported as given to the owners in 13 cases. In 10 cases the 
owner was advised to reduce the exercise which the dog received or change the exercise to 
frequent short walks or lead exercise. In 6 cases, weight reduction was advised.
Three dogs were reported to be receiving other treatment or be suffering from 
other disease. Case 3 was diagnosed as suffering from Chronic Degenerative 
Radiculo-Myelopathy and the associated ataxia was said to confuse the gait abnormality due 
to hip dysplasia and osteoarthritis. During the first seven days of phenylbutazone treatment, 
Case 4 was receiving treatment with a trimethoprim-sulphonamide preparation for a urinary 
tract infection. Case 54 was treated at ten day intervals with an insecticidal spray to reduce 
flea dermatitis. It was not thought that these diseases or treatments would affect the efficacy 
of the treatment
Palatability of the sugar-coated Flexazone 100 mg Tablets® was reported as 
"Good" in 13 and "Average" in two cases.
Condition Scores
The phenylbutazone group pretreatment, post-treatment and difference in 
condition scores for lameness, weightbearing, joint mobility and stiffness are given for 
each case in Appendix D25. A graphical representation is given in Appendices D26-30.
Lameness f Appendices D25 & D261
Thirteen of the 15 dogs treated were lame before treatment In case 16, the dog 
was more severely lame after treatment with phenylbutazone: in this case treatment had 
been withdrawn because of vomiting. Two of the thirteen lame dogs did not improve with 
treatment (13%). Ten dogs had reduced lameness after treatment (67%).
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The mean lameness score before phenylbutazone treatment was 2.2 (S.D. 1.3) 
and after treatment was 1.1 (S.D. 1.2). There was a statistically significant improvement in 
lameness score after treatment when assessed using a paired r-test (p <0.005). By a. 
Wilcoxon Signed Rank Test, the post treatment lameness score was significantly different 
from the pretreatment score (p<0.005) despite the small sample size.
Weightbearing rAppendices D25 & D271
Eleven of the fifteen treated dogs had reduced weightbearing before treatment.
In 9 of the 11, there was an improvement in weightbearing score after treatment (82%).
The mean weightbearing score was 0.9 (S.D. 0.6) before treatment and 0.3 
(S.D. 0.5)after treatment. There was statistical significance in the improvement between 
pretreatment and post-treatment weightbearing scores with a paired r-test (p<0.001). By a 
Wilcoxon Signed Rank Test, there was a statistically significant improvement in 
weightbearing score after treatment (p<0.005) despite the small sample size.
Joint Mobility f Appendices D25 & D281
Joint mobility pre treatment was reduced in 14 of the 15 dogs. In 7 of the 14, 
there was an improvement in joint mobility at the post treatment reexamination (50%).
The mean joint mobility score was 1.4 (S.D. 0.6) before and 0.9 (S.D. 0.8) 
after treatment. There was a statistically significant improvement in joint mobility score 
after treatment with a paired r-test (p<0.005) and by a Wilcoxon Signed Rank Test 
(p<0.01) despite the small sample size.
Stiffness \Appendices D25 & D291
Stiffness was a feature in 14 of the 15 dogs before treatment In 12 of these 14
knt
dogs, stiffness score had improved at the post treatment reexamination (86%).
The mean stiffness score was 2.6 (S.D. 1.0) before treatment and 1.1 (S.D.
1.1) after treatment There was a statistically significant reduction in the stiffness score after 
treatment when the data was analysed by a paired r-test (p<0.001) and a Wilcoxon Signed 
Rank Test (p<0.002) despite the small sample size.
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Total Condition Score [Appendices D25 & D301
In case 16 the total condition score was worse at reexamination than before 
treatment. This was the dog which had treatment withdrawn because of a suspected adverse 
reaction. In case 3 there was no change in the condition score after treatment. The condition 
of this dog deteriorated during the trial period and it was later euthanased. In 13 of 15 
treated dogs there was a reduction in total condition score of between 1 and 7 units (87%). 
The percentage improvement in total condition score is shown graphically in Appendix 
7(ii). In 9 cases (9 of 15: 60%) there was a 50 to 100% improvement in total condition 
score.
The mean total score before treatment was 7.0 (S.D. 2.5) and after treatment 
was 3.5 (S.D. 2.9). There was a statistically significant reduction in total condition scores 
between the pre and post phenylbutazone treatment examinations when they were submitted 
to a paired r-test (p<0.001)and a Wilcoxon Signed Rank Test (p <0.002). Despite the small 
sample size there was a very low probability that this could have occurred by chance.
Improvement Rating [Appendices D25 & D331
The improvement rating was assigned to each case result subjectively based 
upon the improvements in condition score but also considering the veterinary practitioners 
comments on the effect of treatment In two cases, Cases 3 and 16, the condition was 
assessed as being worse after treatment than before (13%). In Case 3 the dog was later 
euthanased. In Case 16 treatment was withdrawn after three days because of a suspected 
adverse reaction. In six cases treatment was stated to have had some effect (40%). In six 
cases treatment was said to have had a marked effect (40%). In one case the dog was said 
to be sound after treatment (7%).
Treatment was considered satisfactory by the veterinary practitioner in 12 of the 
15 cases treated (80%).
Reported Side Effects
Cass. 14
Avemell: 4 year old F/N Labrador, 30 kg. Bad hip dysplasia, especially right hip.
No previous treatment 
Phenylbutazone: 10 mg/kg/day for 10 days.
Veterinary surgeon reported dullness: "Dog seemed rather quiet".
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Case 16
Edmunds: 8 year old M German Shepherd Dog.; 40 kg. Left hip. Previously treated with 
Predno-Leucotropin at 15 mg cinchophen/kg/day. Marked improvement. 
Phenylbutazone: 10 mg/kg/day.
Veterinary surgeon reported:" Within 12 hours of first tablets: Vomiting-H-; would not eat 
or get up. Stopped PBZ after 3 days. Better in 24 hours. Reinstituted therapy with 
Predno-Leucotropin®".
Comparison Between Treatments
PLT Tablet Treatment and Previous Treatment
There was no statistically significant difference in the "improvement scores" for 
PLT and the previous treatments when compared by either paired or Student's r-test. 
However, when the number of dogs showing a "Marked Improvement" or "Sound" score 
(+2 or +3) was compared with dogs showing no effect or only some effect (-1,0, or +1), 
there were significantly more dogs with the +2 or +3 scores in the PLT treatment than in 
the previous treatment group when the data was analysed by aX 2 test In addition, the 
veterinary surgeon was required to state how the PLT treatment compared to the previous 
treatment This was stated for 18 previous treatments in 17 dogs. In the 5 dogs which had 
previously received Predno-Leucotropin®, the PLT treatment was said to be of equivalent 
efficacy. In one case, a previous treatment with Predno-Leucotropin® had been more 
effective. The PLT treatment was said to be superior to 11 previous treatments and 
equivalent to phenylbutazone in one case [Appendix D32].
PLT Tablet Treatment and Phenylbutazone Treatment
Both drugs were used at separate times in the same case in only 2 dogs. In one, 
PLT and phenylbutazone were said to be of equivalent efficacy. In the other case, PLT was 
said to give a better effect and reduced the condition scores more than phenylbutazone. 
When the effect of treatment on condition scores and the percentage improvement in total 
condition score were compared for the PLT and phenylbutazone groups, there was no 
statistically significant difference between the two groups by X 2 test or by Student’s r-test.
PLT Dose and Effect
a
Analysis of the PLT Tablet treatment dose and the effect of treatment by^Kendall 
Correlation Test revealed a significant correlation between dose and percentage reduction in 
total condition score within the treatment dose range of 8 to 47 mg cinchophen:0.04 to 0.23 
mg prednisolone/kg/day (p<0.002).
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5.2.5 Conclusions
There were differences in the PLT and phenylbutazone treated groups in sex 
distribution, breed distribution, joint affected and the severity of the disease. The 
differences were partly due to the small size of the trial population. However, variance 
within and between the groups was inevitable. Although the two groups are not truly 
comparable, the trends indicated in the trial are probably valid.
Eight cases had reported adverse reactions whilst receiving PLT treatment 
(22%). It is not clear whether all these effects were volunteered or were elicited by 
questioning. The reported polyphagia was more likely a consequence of a weight reducing 
diet than the low dose prednisolone treatment The slight increase in thirst reported in 2 
cases was unlikely to have been due to the low dose of prednisolone. It may have been 
suggested by questioning or might be indicative of nausea. In one case receiving a higher 
dose of PLT polyuria was reported. The "slight dullness" reported in case 26 may have 
been due to nausea or gastric irritation.
Vomiting, inappetance and depression from 3 to 9 days on 22.9 mg 
cinchophen: 0.11 mg prednisolone/kg/day in case 19 and after a "few days" on 17.1 mg 
cinchophen/kg/day: 0.09 mg prednisolone/kg/day in case 50 were reported. Treatment was 
withdrawn in both cases and the dogs recovered. These signs may have been due to 
nausea, gastric irritation or ulceration. In case 34 mild diarrhoea was a side effect after 18 
days of treatment Treatment was discontinued at the next veterinary examination. 
Diarrhoea after six weeks of treatment in case 44 was thought by the veterinarian to be 
coincidental. Treatment was continued and the diarrhoea resolved. Adverse reactions were 
apparently unrelated to higher PLT Tablet dose rates.
Adverse reactions were reported in two phenylbutazone treated dogs (13%). 
Dullness was reported in case 14 and may have indicated nausea. Vomiting, inappetance 
and depression were side effects in case 16. These signs may have been due to nausea, 
gastric initation or ulceration. Treatment was withdrawn.
From the limited numbers of dogs treated during the trial, PLT appears to be 
effective in the therapy of many cases of clinical osteoarthritis when used at 8-46 mg 
cinchophen/kg bodyweight/day [0.04-0.23 mg prednisolone/kg bodyweight/day] for 
between 5 and 90 days. There was correlation between treatment dose and effect within this 
dose range. For the duration of treatment, PLT was well tolerated in most dogs. The 
incidence and type of reported adverse reactions and treatment withdrawal were comparable 
with other non-steroidal anti-inflammatory drugs. No correlation between dose rate or 
treatment duration and the incidence or severity of adverse reactions was apparent.
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The clinical trial suggested that PLT Tablets may be effective at lower dose rates 
or less frequent dosing than is recommended by the manufacturer. It appears that the 
dosage recommendations from the manufacturer for Predno-Leucotropin Tablets and for 
PLT Tablets are not followed by veterinary practitioners.
On the basis of currently available information, including the clinical trial 
described in this section, PLT Tablets appear to have a good therapeutic effect in cases of 
canine osteoarthritis. From the clinical trial, PLT Tablets are probably equivalent to or of 
greater efficacy than phenylbutazone. Based upon the S AR information reported for the 
closely related combination Predno-Leucotropin Tablets, and the clinical trial data, the 
available evidence suggests that the proposed 25-44 mg cinchophen and 0.125-0.22 mg 
prednisolone/kg/day as two divided daily doses is effective and well tolerated for at least 14 
days with an incidence of adverse reactions similar to that of other NSAEDs.
The trial design was limited by practical constraints. This led to the use of a 
positive control design. Unfortunately, the limited time available and a poor response by 
some veterinarians has meant that only 49 cases of clinical osteoarthritis were treated during 
the trial. The small size of the phenylbutazone treated group limits the comparability of the 
two groups. In addition, the use of subjective measurements and the lack of blinding at the 
level of the practitioner also reduce the significance that can be attributed to the results. 
Performing a cross-over design and insisting on radiographic confirmation of osteoarthritic 
changes would have severely affected recruitment of practices, investigator compliance and 
the number of results returned.
It would have been more useful to have a smaller number of dogs which were 
diagnosed osteoarthritic radiographically in addition to clinically, treated blind with both 
test drug and positive control in a cross-over type design. The two drugs could then be 
compared in therapy of the same condition in the same animal and a preference stated by the 
owner. This approach would reduce the potential errors involved in the present trial due to 
the possibility of incorrect diagnosis and inappropriate treatment, lack of group 
comparability and bias in favour of one of the treatments by the veterinarian (Harris 
and Fitzgerald, 1970). However, the extra requirements in time and materials would 
necessitate the use of financial compensation for the veterinarians involved.
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Results Summary:
Total no. of dogs treated 
Dose rate (mg/kg/day)
Reported adverse reactions 
Treatment withdrawal
Lameness reduced 
Weightbearing increased 
Joint mobility increased 
Total condition score improved 
50-100% Improvement in total score
Treatment considered satisfactory
PLT PBZ
36 15
8 -4 6  cinchophen 5-11 .4
0.04- 0.23 predn.
8 (22%) 2 (13%)
2 (5.5%) 1 (6.7%)
25/31 (81%) 10/13 (67%)
13/16 (81%) 9/11 (82%)
8/24 (33%) 7/14 (50%)
31/36 (86%) 13/15 (87%)
23/36 (64%) 9/15 (60%)
31/36 (86%) 12/15 (80%)
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APPENDIX
TABLE Al: Plasma Carprofen Concentration l~ug/mll measured after
oral administration of a single 4 mg/kg dose
Plasma Carprofen Concentration lug/mll
Time (hours') Doe 1 Dog 2 Dog 3 Doe 4 Dog 5 Doe 6 Mean ±SEM
Pre 0 0 0 0 0 0 0 0
0.25 2.02 9.25 NS 8.65 24.71 17.97 12.52 3.96
0.5 19.57 17.17 13.63 24.11 40.74 28.39 23.94 3.97
1 31.84 33.57 16.69 31.58 35.41 37.38 31.08 3.01
1.5 29.73 38.28 20.44 29.13 31.75 30.80 30.02 2.34
2 25.93 44.30 26.13 24.98 25.19 20.02 27.76 3.43
4 17.33 32.02 21.61 21.94 19.49 11.89 20.71 2.71
8 7.27 19.85 17.82 14.12 11.16 8.93 13.19 2.03
12 3.33 13.94 11.42 10.40 3.85 3.74 7.78 1.91
24 0.42 3.33 5.78 3.35 1.18 1.10 2.53 0.82
48 0.07 0.49 1.26 0.48 0.22 0.09 0.44 0.18
72 0 0.05 0.30 0.10 0.05 0 0.083 0.046
96 0 0 0.11 0 0 0 0.018 0.018
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APPENDIX
Calculations of Dosage Schedule
Each dog was weighed on the day previous to the start of the trial. The number of tablets 
and half tablets [17.5mg] required to give a dose of 9mg/kg/day or greater was calculated as 
below:
Dog Numher Weight fkgl x 9mg/kg tabs req. Admin,
1 13.5 121.5 6.9
2 16.3 146.7 8.4
3 12.3 110.7 6.3
4 13.5 121.5 6.9
5 16.5 148.5 8.5
6 15.5 139.5 8.0
Thus the actual daily doses were as follows:
DOG 1: 9.07 mg/kg orally once a day for fourteen days
DOG 2: 9.13 mg/kg «
DOG 3: 9.25 mg/kg
DOG 4: 9.07 mg/kg it
DOG 5: 9.02 mg/kg tt
DOG 6: 9.03 mg/kg it
B1
BIOCHEMISTRY PROFILES:
NORMAL CANINE VALUES 
r S .I .  units!
UREA (mmol/1) 0-7.47
SODIUM 136-160
POTASSIUM " 3.4-5.8
CHLORIDE 95-115
CALCIUM 2.34-3.03
MAGNESIUM " 0.61-1.19
PHOSPHATE 1.29-2.9
CHOLESTEROL " 1.8-6.96
CREATININE " 44-132
BILIRUBIN (umol/1) 0-10.26
ALKPHOS (LU.) 0 -130
AS T (I.U.) 0 -4 0
A LT (LU.) 0 -5 0
TOTAL PROTEIN (g/1) 50-78
ALBUMIN (g/1) 36
GLOBULIN (g/1) 27
C R P  (mg/1) 0-10
[10-100 reflects degree of tissue damage, 
>100= extensive tissue damage]
HAEMATOLOGY PROFILES:
NORMAL CANINE VALUES
WBC (xl09/ l ) 6.0-17.0
RBC (xl012/l) 5.5 -8.5
Hb (g/dl) 12-18
Hct (VI) 0.370 - 0.550
MCV (A) 60-70
NEUTROPHILS (%) 60-77
LYMPHOCYTES t i 12-30
MONOCYTES i t 3 -1 0
EOSINOPHILS n 2 -1 0
NORMOBLASTS i i <1
PLATELETS ( x 109/1) 100 - 350
B2
BIOCHEMISTRY PROFILES: DAY: Pre
DOG NTJMRF.R:
1 2
UREA (mmol/1) 7.9 7.0
SODIUM 146 146
POTASSIUM 3.8 3.9
CHLORIDE 103 108
CALCIUM 2.61 2.63
MAGNESIUM 0.76 0.72
PHOSPHATE 1.17 1.12
CHOLESTEROL " 4.82 3.02
CREATININE 96 80
BILIRUBIN (umol/1) 1 0
ALKPHOS (LU.) 55 59
A ST (LU.) 22 34
ALT (LU.) 29 66
TOTAL PROTEIN (g/1) 54 54
ALBUMIN (g/1) 38 34
GLOBULIN (g/1) 16 20
C R P (mg/1) 5.6 3.8
BIOCHEMISTRY PROFILES: 
DOG NUMBER:
1 1
UREA (mmol/1) 11.6 10.8
SODIUM 146 142
POTASSIUM 4.4 4.2
CHLORIDE 101 107
CALCIUM 2.69 2.65
MAGNESIUM 0.85 0.71
PHOSPHATE 1.51 1.22
CHOLESTEROL " 5.19 3.08
CREATININE 94 82
BILIRUBIN (umol/1) 1 0
ALKPHOS ( L U .) 63 76
AS T (LU.) 23 32
A LT ( L U .) 26 61
TOTAL PROTEIN (g/1) 57 58
ALBUMIN (g/1) 34 34
GLOBULIN (g/1) 22 24
C R P  (mg/1) 0 0
BIOCHEMISTRY PROFILES:
DOG NUMBER:
1 Z
UREA (mmol/1) 9.4 8.8
SODIUM 146 150
POTASSIUM 4.4 3.9
CHLORIDE 106 109
CALCIUM 2.63 2.60
MAGNESIUM 0.85 0.79
PHOSPHATE 1.68 1.39
CHOLESTEROL " 4.97 3.43
CREATININE 89 82
BILIRUBIN (umol/1) 1 0
ALKPHOS (LU.) 59 56
A ST (LU.) 22 34
A LT (LU.) 28 63
TOTAL PROTEIN (g/1) 54 58
ALBUMIN (g/1) 36 33
GLOBULIN (g/1) 28 25
C R P  (mg/1) 3.6 0
1 4 5 £
5.5 8.6 6.7 3.9
144 145 147 146
3.9 4.0 4.1 3.9
108 101 102 104
2.58 2.79 2.63 2.58
0.75 0.69 0.66 0.60
1.12 1.34 1.15 0.81
3.54 4.64 2.48 4.04
89 93 96 83
1 1 1 1
71 76 52 70
24 25 41 20
35 51 84 35
57 59 51 59
32 33 34 28
25 26 17 31
6.5 0 24.8 2
DAY:3
1 4 £ £
8.3 11.1 11.8 9.4
147 149 150 146
5.1 4.7 4.5 4.2
109 104 108 104
2.78 2.78 2.80 2.64
0.81 0.84 0.81 0.76
1.78 1.88 1.63 1.24
3.53 4.89 Z46 4.15
90 92 89 80
1 0 0 0
70 75 60 68
24 26 30 17
34 53 46 33
58 63 54 62
32 37 36 28
26 26 18 34
2.8 0 31.6 2
DAY:5
1 4 i £
8.6 9.1 9.1 7.3
145 145 147 148
4.8 4.7 4.5 4.3
104 108 109 106
2.51 2.66 2.46 2.68
0.76 0.74 0.74 0.72
1.30 1.61 1.36 0.92
3.68 4.46 2.61 4.20
84 82 97 81
1 0 0 1
62 70 46 67
27 34 24 19
34 50 37 37
58 58 47 63
32 34 34 26
26 24 13 37
0 0 >100 6.1
B3
BIOCHEMISTRY PROFILES;
HOC. NUMBER:
1 Z
UREA (mmol/1) 7.3 6.7
SODIUM 151 152
POTASSIUM 4.2 4.1
CHLORIDE 109 113
CALCIUM 2.60 2.60
MAGNESIUM 0.70 0.76
PHOSPHATE 1.66 1.43
CHOLESTEROL " 5.06 3.44
CREATININE 79 63
BILIRUBIN (umol/1) 1 0
ALKPHOS (LU.) 53 45
AST (LU.) 27 30
ALT (LU.) 27 57
TOTAL PROTEIN (g/1) 53 56
ALBUMIN (g/1) 31 30
GLOBULIN (g/1) 22 26
C R P  (mg/1) 0 0
1 ± a £
6.3 7.5 8.5 4.7
149 149 148 148
4.0 4.2 4.4 3.9
112 109 109 109
2.65 2.70 2.68 2.70
0.82 0.68 0.76 0.79
1.26 1.31 1.59 1.48
3.79 4.62 2.32 5.21
81 86 89 67
1 2 0 1
62 65 52 115
26 31 32 16
35 54 31 32
57 56 51 64
32 32 25 35
35 24 26 29
0 0 67.9 49.1
BIOCHEMISTRY PROFILES: DAY:11
n o r .  NUMBER-,
1 Z 1 1 a a
UREA (mmol/1) 11.9 9.0 7.0 9.4 9.2 7.5
SODIUM 143 146 144 146 144 145
POTASSIUM 4.4 4.2 4.6 4.4 4.6 4.0
CHLORIDE 103 109 108 108 107 105
CALCIUM 2.62 2.59 2.68 2.65 2.54 2.69
MAGNESIUM 0.85 0.74 0.74 0.72 0.74 0.74
PHOSPHATE 1.73 1.61 1.73 1.86 1.38 1.23
CHOLESTEROL " 4.92 3.22 3.61 4.85 2.72 4.87
CREATININE 88 70 73 77 82 74
BILIRUBIN (umol/1) 0 0 1 0 0 0
ALKPHOS (LU.) 67 51 67 64 46 96
AST (LU.) 27 36 27 27 37 20
ALT (LU.) 24 54 34 49 37 33
TOTAL PROTEIN (g/1) 52 54 55 59 49 61
ALBUMIN (g/1) 31 30 32 32 25 34
GLOBULIN (g/1) 21 24 23 23 24 27
C R P  (mg/1) 0 0 0 0 16.5 9.1
BIOCHEMISTRY PROFILES; DAY:14
HOC, NUMBER-.
1 Z 1 1 a a
UREA (mmol/I) 7.4 5.7 4.3 5.3 5.1 2.8
SODIUM 145 148 144 145 141 144
POTASSIUM 3.9 3.7 4.8 4.2 4.4 3.9
CHLORIDE 102 105 105 103 104 104
CALCIUM 2.62 2.55 2.72 2.70 2.32 2.64
MAGNESIUM 0.66 0.60 0.76 0.66 0.80 0.69
PHOSPHATE 1.21 1.33 1.38 1.49 1.22 1.07
CHOLESTEROL " 4.72 3.28 4.04 5.08 2.74 4.83
CREATININE 85 82 83 90 83 73
BILIRUBIN (umol/1) 1 1 1 2 1 1
ALKPHOS (LU.) 50 51 78 78 66 100
A ST (LU.) 24 30 29 32 28 14
ALT (LU.) 31 58 40 55 33 33
TOTAL PROTEIN (g/1) 50 50 58 59 44 61
ALBUMIN (g/1) 30 28 32 33 23 33
GLOBULIN (g/1) 20 22 26 26 21 28
C R P  (mg/1) 5.5 0 0 5.4 >100 7.3
B4
BIOCHEMISTRY PROFILES: DAY: 17
DOG NUMBER:
1 z 1 ± i 6
UREA (mmol/1) 11.6 9.5 8.5 11.2 8.4 8.4
SODIUM 149 148 145 146 143 146
POTASSIUM 4.3 3.9 4.8 4.5 4.4 4.0
CHLORIDE 104 107 107 102 103 104
CALCIUM 2.68 2.58 2.61 2.67 2.50 2.71
MAGNESIUM 0.62 0.76 0.68 0.74 0.72 0.68
PHOSPHATE 1.70 1.25 1.39 1.72 1.54 1.67
CHOLESTEROL " 5.05 3.36 3.71 4.76 2.14 4.56
CREATININE 96 80 86 90 94 73
BILIRUBIN (umol/1) 1 0 1 0 0 0
ALKPHOS (LU.) 60 52 82 74 42 105
AS T (LU.) 22 26 23 22 35 24
A LT (LU.) 31 72 38 53 35 34
TOTAL PROTEIN (g/1) 54 55 58 57 Al 63
ALBUMIN (g/1) 32 31 33 31 24 34
GLOBULIN (g/1) 22 24 25 26 23 29
C R P  (mg/1) 3.8 5.8 0 3.3 34.1 0
BIOCHEMISTRY PROFILES: M EA N  V A LU ES
PRE 3 5 8 11 14 17
UREA (mmol/1) 6.6 10.5 8.7 6.8 9.0 5.1 9.6
SODIUM 146 147 147 150 145 145 146
POTASSIUM " 3.93 4.52 4.43 4.13 4.37 4.15 4.32
CHLORIDE 104 106 107 110 107 104 105
CALCIUM 2.64 2.72 2.59 2.66 2.63 2.59 2.63
MAGNESIUM " 0.70 0.80 0.77 0.76 0.76 0.70 0.70
PHOSPHATE " 1.12 1.54 1.38 1.46 1.59 1.28 1.55
CHOLESTEROL" 3.76 3.88 3.89 4.07 4.03 4.12 3.93
CREATININE " 90 88 86 78 77 83 87
BILIRUBIN (umol/1) 0.8 0.3 0.5 0.8 0.2 1.2 0.3
ALKPHOS (LU.) 64 69 60 65 65 70 69
A ST (L U .) 28 25 27 27 29 26 25
A LT (L U .) 50 42 42 39 39 42 44
TOTAL PROTEIN (g/1) 56 59 56 56 55 54 56
ALBUMIN (g/1) 33 29 32 31 31 30 31
GLOBULIN (g/1) 23 25 25 27 24 24 25
C R P  (mg/1) 7.1 6.1 18.3 >19.5 4.3 >19.7 7.8
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Haematology Results: ERE
Dog 1 Doe 2 Dog 3 Dog 4 Dog 5 Dog 6
WBC (xl09/l)
RBC (x 1012/1)
Hb (g/dl)
Hct m
MCV (fl)
Neutrophils (%)
Lymphocytes If
Monocytes II
Eosinophils II
Platelets (xl09/l)
Haematology Results:
WBC (xl09/l)
RBC (x 1012A)
Hb (g/dl)
Hct (VI)
MCV (A)
Neutrophils (%)
Lymphocytes i f
Monocytes i f
Eosinophils i f
Platelets (xlO9/!)
13.2 15.0 12.6
7.0 6.8 6.2
15.6 16.9 15.4
0.475 0.496 0.452
68 73 73
68 61 57
26 33 35
0 1 2
6 5 6
510 450 380
Pay 3
PogJ. Dog 2 Dog 3
14.6 18.8 13.1
7.0 6.9 6.3
15.2 16.9 15.4
0.480 0.506 0.406
69 73 73
59 62 43
28 32 52
1 1 0
12 5 5
420 460 280
12.5 18.0 14.5
7.3 6.7 7.0
18.1 14.0 17.0
0.540 0.425 0.498
74 64 71
72 78 71
22 14 26
4 1 0
2 7 3
270 510 380
Dog 4 Dog 5 Dog 6
14.2 18.0 13.5
7.7 6.6 7.4
19.0 14.2 17.7
0.573 0.417 0.535
74 63 72
57 52 59
35 21 33
3 2 3
5 25 5
250 450 400
B6
Haematology Results; D.a.Y-5
Dog 1 Dog 2 Dog 3 Dog 4 Dog 5 Dog 6
WBC (xl09/l) 11.6 14.3 12.4 11.5 16.6 12.2
RBC (x 1012A) 6.8 6.9 6.3 7.2 6.5 7.5
Hb (g/dl) 14.7 16.8 15.7 18.1 14.2 18.6
Hct (VI) 0.462 0.501 0.459 0.530 0.408 0.534
MCV (A) 68 73 73 74 63 71
Neutrophils (%) 64 55 61 55 65 61.5
Lymphocytes »t 26 27 31.5 38 15.5 25
Monocytes i t 2 7 2.5 4 7 6.5
Eosinophils t» 8 11 5 3 12 6
Platelets (xlCP/1) 410 400 370 250 470 320
Film Report:
Increased numbers of target cells in all dogs in this batch.
Haematology Results: Day 8
Dog 1 Doe 2 Dog 3 Dog 4 Dog 5 Dog 6
WBC (xiosyi) 13.3 15.7 12.8 10.9 19.2 18.2
RBC (X 1012/1) 6.6 6.6 6.3 7.0 6.5 7.9
Hb (g/dl) 15.5 16.4 16.1 17.8 14.2 19.7
Hct (VI) 0.445 0.474 0.450 0.517 0.405 0.559
MCV (fl) 67 72 72 74 62 71
Neutrophils (%) 67 73 75 80 77 87
Lymphocytes I I 27 15 18 14 11 10
Monocytes I t 2 3 1 3 2 1
Eosinophils t t 4 9 6 3 10 2
Platelets (xl09/l) 400 390 300 210 490 310
B7
Haematology Results: Dav 11
D ogl DoS 2 Doe 3 Doe 4 Dog 5 Dog 6
WBC (xl09/l) 15.2 20.0 C C C 13.6
RBC (x 1012A) 6.5 6.6 L L L 7.7
Hb (g/dl) 14.8 16.4 O O O 18.6
Hct (VI) 0.441 0.480 T T T 0.554
MCV (A) 68 73 T T T 72
Neutrophils (%) 52 52.5 E E E 53
Lymphocytes vv 40 35 D D D 36
Monocytes tv 3 6 - - - 7
Eosinophils t t 5 6 - - - 3
Normoblasts tv 0 0.5 - - - 1
Platelets (xl09A) 370 350 - - - 330
Film Report:
Films from 1,2, and 6 show target cells
Haematology Results: Pav 14
Doe 1 Dog 2
WBC (xl09/l) 11.7 15.3
RBC (x 1012/1) 6.4 6.3
Hb (g/dl) 15.0 16.0
Hct (VO 0.419 0.449
MCV (A) 66 71
Neutrophils (%) 58 64
Lymphocytes tv 31 24
Monocytes vv 7 4
Eosinophils vv 4 7
Normoblasts VI 0 0
Platelets (xl09/l) 430 420
Dog 3 Dog 4 Dog 5 Dog 6
12.3 11.1 15.8 12.4
7.3 6.5 6.8 7.1
19.0 16.5 14.5 18.1
0.531 0.462 0.411 0.493
73 71 60 69
69 61 74 64
25.5 29 16 28
4 2 6 1
1 8 4 6
0 0 0 1
260 380 510 340
B8
Haematology Results: Dav 17
D ogl Dog 2 Doe 3 Dog 4 Dog 5 Dog 6
WBC (xl09A) 15.4 19.3 13.1 14.7 20.4 10.2
RBC (x 1012/1) 6.8 6.8 6.3 7.4 6.7 6.7
Hb (g/dl) 15.5 16.8 15.5 18.6 13.7 16.1
Hct (VI) 0.462 0.494 0.459 0.542 0.409 0.475
MCV (fl) 68 73 73 73 61 71
Neutrophils (%) 57 58 64 65 55.5 66
Lymphocytes tv 34.5 31 28 26.5 10.5 24.5
Monocytes tv 5.5 6.5 4 6.5 2 3
Eosinophils tv 2.5 4 4 2 32 3.5
Platelets (xl09A) 386 450 350 
Film Report:
All dogs still have increased numbers of Target Cells.
240 490 220
Haematology Results: Mean values
Pre sL2 45 m d!4 m
WBC (xl09/ l ) 14.3 15.4 13.1 15.0 16.3 13.1 15.5
RBC (xl012/l) 6.8 7.0 6.9 6.8 6.9 6.7 6.8
Hb (g/dl) 16.2 16.4 16.4 16.6 16.6 16.5 16.0
Hct m .481 .495 .482 .475 .492 .461 .474
MCV (fi) 71 71 70 70 71 68 70
Neutophils (%) 68 55 60 77 53 65 61
Lymphocytes vv 26 34 27 16 37 26 26
Monocytes V9 1.3 1.7 4.8 2.0 5.3 4.0 4.6
Eosinophils tv 4.8 9.5 7.5 5.7 4.7 5.0 8.0
Normoblasts I t 0 0 0.25 0 0.5 0.17 0.17
Platelets (xl09/l) 417 377 370 350 350 390 356
Clotting Timesfminutesl
PRE Day 3 Qay_5
DOG 1 2.50 2.13 3.00
DOG 2 3.47 2.18 3.50
DOG 3 1.88 4.02 2.50
DOG 4 3.15 1.23 2.83
DOG 5 2.60 3.22 2.33
DOG 6 3.12 3.08 2.58
MEAN: 2.79 2.64 2.79
SEM +/- : 0.23 0.40 0.17
Normal range [Mean ± 2x S.D] = 1.
Day 8 Day 11 Day 14 Day 17
2.79 3.33 2.55 3.42
2.74 2.93 2.61 3.50
3.33 3.38 3.92 2.33
2.28 3.18 2.17 2.58
4.03 2.35 3.08 1.50
3.48 3.80 1.83 3.00
3.11 3.16 2.69 2.72
0.26 0.20 0.30 0.31
:o 4.03 minutes (mean = 2.78 minutes)
Faecal Blood Test [Colo-Rectal Test Kits: Roche]
PRE Day 3 5 8 11 14 17
DOG 1 ............................................................................
+
DOG 2 - -
DOG 3 
+
DOG 4
DOG 5 - - +
+
DOG 6 ...............................................................
BIO
APPENDIX
C
CARPROFEN
Carprofen is a non-steroidal anti-inflammatory compound registered for use in humans 
in several countries but not so far registered for veterinary use. Pharmacokinetic studies in 
Beagles treated at 0.7mg/kg have shown that Carprofen has a prolonged half life as compared 
with Phenylbutazone. Extensive toxicology studies have been carried out, where Carprofen was 
administered orally to dogs at 35 times the proposed dose rate daily for one year with no clinical 
or pathological side effects. Pharmacological trials in various species have shown it to be an 
analgesic and an anti-inflammatory. It is available at present for dogs as a tablet formulation.
Rycovet are developing Carprofen as a product for use in animals [ horses, dogs, and 
cattle ]. As part of this development programme we are asking selected veterinary surgeons to 
assess the efficacy of the drug in reducing pain and discomfort associated with osteoarthritis or 
degenerative joint disease. Approximately 300 dogs of various ages and breeds will be used in the 
trial overall.
Your assessments will be recorded on the standard forms noting patient information, 
treatment and the effect of treatment on lameness, weight bearing and joint mobility using the 
condition scoring sheet provided. The information from all the reports will be analysed and used 
in the application to register Carprofen for the treatment of dogs.
Case Selection:
1 .Existing Cases:
These dogs will already be receiving treatment with non-steroidal 
anti-inflammatory drugs or other drugs. The protocol will be as follows:
1. Take the dog off the present drug, noting the regime and efficacy of treatment on the 
"Patient Information" form.
2. If appropriate and possible, monitor the time taken for the signs of the painful 
condition to recurr.
3. Note joints affected and score condition for lameness, weight bearing and joint
mobility.
4. Start Carprofen treatment if the pain recurrs.
5. Monitor the effects of Carprofen therapy.
£.  New Cases:
These will be dogs newly diagnosed as suffering from osteoarthritis or dogs 
for which the previous history or treatment is not known.
1. Confirm clinically osteoarthritis/ degenerative joint disease and
(a) note joints affected
(b) score condition for lameness, weight bearing and joint mobility.
2. Institute treatment with Carprofen or Phenylbutazone on an alternate dog basis.
3. Monitor the effects of treatment.
C l
Carprofen:
Dose Recommendation:
The recommended dose rate for Carprofen is an initial regime of
0.7mg/kg once a day for 7 days administered orally. Depending on clinical response, 
treatment may be discontinued, repeated for another week, or the dose rate increased up to 
2mg/kg in 2 daily treatments. As with other NSAIDs, give at approximately 1 hour before or 
after a meal to reduce the possibility of gastro-intestinal irritation but preferably not with food 
as this can reduce the effective dose and alters the pharmacokinetics.
Each tablet contains 17.5mg carprofen. At the proposed dose rate of 0.7mg/kg, the dose 
band will be as follows:
Body Weight f kg 1 No. of Tablets
Up to 12.5 0.5
13 to 25 1
26 to 37.5 1.5
38 to 50 2
etc.
Contra-indications/Precautions: DO NOT USE CONCURRENT ANTI-INFLAMMATORY MEDICATION
Phenylbutazone: (Flexazone [bk])
The suggested dose rate will be ca. 8mg/kg administered in two daily doses for
7 days. As with other NSAIDs, give at approximately 1 hour before or after a meal to reduce the 
possibility of gastro-intestinal irritation but preferably not with food as this can reduce the 
effective dose and alters the pharmacokinetics.
The tablets supplied contain 100mg and the dose band will be:
Body Weight f kg 1 No. of Tablets
Up to 12.5 1 [2 x 0 .5 ]
13 to 25 2 [ 2 x 1 ]
26 to 37.5 3 [ 2 x 1.5 ]
38 to50 4 [ 2 x 2 ]
etc.
If you have any queries or problems, please contact:
Tim Pearson BVMS MRCVS 
Dept, of Veterinary Pharmacology 
University of Glasgow Veterinary Hospital 
Bearsden Road
Bearsden Telephone: 041-339-8855, Extn. 5790.
Glasgow. G61 1QH [Evenings: 041-339-8242]
C2
CONDITION SCORING:
Lameness: [ L]
0 = Clinically NORMAL
1 = STANDS normally;
WALKS normally;
LAME after vigorous exercise or slight stiffness after rest.
2 = Stands normally;
SLIGHT LAMENESS when walking and stiffness after rest.
3 = Careful when standing;
OBVIOUS LAMENESS when walking.
4 = NOT standing normally.
SEVERE LAMENESS when walking and unwilling to run.
Weightbearing: [ W.B. ] [where appropriate ie. limb joints affected]
0 = NORMAL weightbearing on all limbs.
1 = Weight only applied temporarily on affected limb.
2 = NO WEIGHT applied on affected limb.
Mobility of Affected Joint(s): [ J.M. ]
0 = NO LIMITATION of joint movement.
No evidence of pain shown by dog during manipulation.
1 = SOME REDUCTION in joint movement.
Dog shows reluctance during manipulation.
2 = OBVIOUS REDUCTION in joint movement.
Dog shows evidence of pain during manipulation plus crepitus.
C3
PATIENT INFORMATION
Owner: Name:__________________________________  Date:_________
Address:____________________________________________________________
Postcode: Telephone No.:________________________
Dog Identification: Name:__________________ Age:_________  Sex:M/F/Neu/Preo.
Breed:________________________ Approx. weight (kg):_________Ideal weight (kg):_______
Joint(s) Affected:. 
Brief History:___
Previous Treatment(s) [in the last 3 months] for the condition:
Product [name + co.] Dosefma+no. tabs! Regime and Duration
1 . __________________________________________*
2 . __________________________________________*
3 ._______________________ *
Effect of Treatment on the condition:
[tick as applicable]
Time taken for return of painful 
condition after treatment withdrawal:
TREATMENT: Date treatment started:___________
Product: Dose[tabs]: Regime: Duration:
Carprofen/ Phenylbutazone:________ * _________________ *________________
[Delete as applicable]
Other Advice Given [eg. re exercise or weight]_________________________________
Any concurrent disease or medication:
Dose Chanaes:Date:_______ Dose and Regime:.
Reason for Dose Change:_________________
Premature Treatment Withdrawal? Why?___
i l l
i) No Effect: __ __ __
ii) Some Effect: __ __ __
iii) Marked Improvement:   __ __
iv) Sound: __ __ __
C4
EFFICACY ASSESSMENT: (see Condition Scoring)
1 .Veterinary Surgeon: Name:__________
Before Treatment:
Date:
After Treatment:
Date:________ Date:________ Date:_______
Dose:______________ Dose:______________ Dose:_______
Lameness:____ Lameness:____ Lameness:.
W/ B :  ____ W/ B:  ____ W/ B:  ___
J /  M: _____ J / M:___ _____ J /  M:__ ____
Improved:____ Improved:____ Improved:__
Comments: _______________________________________________
Lameness ( 0 to 4): 
Weight Bearing ( 0 to 2): 
Joint Mobility ( 0 to 2): _
PTO if extra comment
2.Qwner ( as questioned by the Veterinary Surgeon )
Date:_______ improved
After treatment the dog: deteriorated
did not change
[Time taken for improvement, if any:________]
Date:_______ improved
Since the last visit, the dog has: deteriorated
not changed
Date:_______ improved
Since the last visit, the dog has: deteriorated
not changed
Owner's comments: __________________  ________________________
C5
CLINICAL ASSESSMENT:
1. Did the treatment work satisfactorily? [Please give details, if possible]
2. How did the test drug compare with the previous treatment? [ If applicable ]
3. Did the dog show any side effects at any time? Yes  No__
If "Yes", did any of the following occur? Yes » >  Date
Vomiting ____ ________
Diarrhoea ____ ________
Constipation ____ ________
Thirst__________ ____ ________
Inappetance ____ ________
Dullness________ ____ ________
Faecal blood ____ ________
Other__________ ____ ________
Please give details: [eg. signs, course, duration, any treatments etc]
4. Palatabilitv: Good:_ Average:___  Poor:
Other Comments:
Veterinary Surgeon:
Signed:_______________________________  Date:
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Veterinarians and Practices Participating in Carorofen Ginical Trial
Miss M. Flanagan 
Abbeycraig Park 
Causewayhead 
Stirling
Mr. N. McIntosh
Andrew, Alladyce, Love & Lealy
71, Canal Street
Paisley
Mr. J. Gartside 
48, Saville Road 
Dewsbury 
West Yorkshire
Mrs. R. Gilbert 
18, Leonard Street 
Keswick 
Cumbria
Ashworth and Rodger
Craigforth
Union Terrace
Crieff
Perthshire
Mr. D. Longley 
7, Preston Street 
Camforth 
Lancashire
Mr. C. Barker 
Glasgow University 
Lanark Practice 
Lanark
Mr G. Barr
16, Kilmarnock Road
Mauchline
Ayrshire
L. Gray
183, Main Street
Uddingston
Glasgow
Murphy and Collier 
42, Barassie Street 
Troon 
Ayrshire
Mr. D. Watson
Batchelor, Davidson and Watson 
19, Hillhouse Road 
Blackball 
Edinburgh
Mr. P. Frost 
Rushton and Browne 
Broughton-in-Fumess 
Cumbria
Mr. F. Nind
5, Riccarton Mains Road
Currie
Midlothian
Mr. R. McConville 
Archway Veterinary Group 
Grange-over-Sands 
Cumbria
Miss L. Carmichael University of Glasgow Veterinary Hospital
1A Lee Crescent Bearsden Road
Portabello Bearsden
Edinburgh Glasgow
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Number of Case Reports Returned bv 
Veterinary Practitioners in Carprofen Trial
McConville 
McIntosh 
Gray 
Gilbert 
Nind 
Longley 
Ashworth 
Flanagan  
W atson  
Gartside 
Frost 
Collier 
Barr 
Carmichael 
G.U. Lanark 
G.U.V.S.
VS/SJ/SSSSSSAWS///SJ Total of 85 cases
$ZB2ZZ
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c
a  18
1
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20
No. of usable reports returned
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Animal Details of Osteoathritis Cases
C ase
No.
Owner Age
(yrs)
Sex Breed W eiqht
ftgl
Previous
T reatm ent
Iria i
Treatment
1 John 0.8 M G.Ret. 30 PBZ, Pirox. Carprofen
2 John 0.8 M G.Ret. 30 PBZ, Pirox. Carprofen
3 Sneddon 0.7 F Rott. 29 - Carprofen
4 Harpwood 0.6 F WHound 50 A.S.A. Carprofen
5 Dick 9 M/N Lab. 45+ A.S.A., Ibupro Carprofen&PBZ
6 Cornelius 4 F/N B.Collie 23 - Carprofen
8 Murchison 3.5 M Lab. 36 - Carprofen
9 Weir 0.9 M RetX 20 Paracetamol Carprofen
10 Keirs 2.5 F Lab. 30 PBZ Carprofen
11 Freid 4 M B.Collie 18 - Carprofen
12 McRobert 7 F/N Dobe. 31.4 PBZ Carprofen
13 MacIntyre 3 F/N Lab. 28.4 - Carprofen&PBZ
14 Eggo 3 F/N Lab. 25 - Carprofen
15 Glass 12 M Chihuahua 6.5 PBZ, Pred. Carprofen
18 Young 11 F/N Lab. 34.4 PLT Carprofen
19 Sloan 11 M PoodleX 9 - Carprofen&PBZ
20 Stewart 13 M WHW 9 - Carprofen
21 Wilson 14 F R.Collie 24 PBZ Carprofen
22 Frost 8 F/N Sp.Spaniel 19 - PBZ & Carprofen
23 Knowles 0.9 M J.R.T. 6 - PBZ & Carprofen
24 Miller 14 F/N Lab. 27 PBZ Carprofen
25 Toone 6 M Lab. 28 Piroxicam Carprofen
26 Todd 9 M G.S.D. 35 - Carprofen&PBZ
27 Gadsby 6 F/N Be. Collie 30 - Carprofen
28 Perschke 6 M Pointer 32 PBZ PBZ
29 McKay 0.8 M Lab. 23 PBZ Carprofen
31 Nicol 12 F/N Lab. 30.4 PBZ Carprofen
32 Nisbet 11 M B.Collie 30 - Carprofen
33 White 6 F Lab. 30 PLT PBZ
34 Scott 9 F/N Lab. 40 PBZ, PLT, Pirox. Carprofen
35 Brown 4 F GHound 30 PBZ Carprofen
36 Flanagan 12 M G.Ret. 34 PBZ, PLT Carprofen
37 Hogg 10 F/N B.Collie 25 Piroxicam Carprofen
38 Lyle 12 F Lab. 34 - Carprofen
39 MacDonald 12 M Shet. Shd. 15 PBZ, PLT Carprofen
40 Garret 12 M WHW 11 PBZ Carprofen
41 Fraser 8 F C.Spaniel 14 - Carprofen
42 Dawes 3.6 F Toy Poodle 1.5 Optic, Pardale Carprofen
43 Dawes 0.6 F Toy Poodle 1.5 - Carprofen
44 Potts 5 M Shet. Shpd. 20 - PBZ
45 Gilchrist 12 F R.Collie 26 PLT PBZ
46 Neild 13 F O.E.S. 30 A.S.A. Carprofen
47 Howell 8 F G.Ret. 35 - PBZ
48 Molloy 7 F G.S.D. 35 - Carprofen
49 Sykes 9 F Lab. 30 PLT PBZ
51 Taylor 12 M Lab. 32.4 - Carprofen
52 Finlay 14 M Lab. 39 - Carprofen&PBZ
54 Lambie 11 M Lab. 29.4 Pred. Carprofen&PBZ
55 Stewart 7 M G.Pointer 35.8 - PBZ
58 Rowcroft 8 F Lab. 40 - PBZ
59 Wally 10 M G.S.D. 45 PBZ Carprofen
60 Taylor 8 M G.S.D. 30 - Carprofen
61 Hall 14 M X 22 Pardale Carprofen
63 Graham 8 M X 27 PLT, PBZ Carprofen
64 Jagielko 
Key overleaf
1.1 M Mastiff 75 Ceporex, Flagyl Carprofen
C9
C ase
No.
65
66
67
68
69
70
71
72
73
101
102
103
104
106
107
108
109
110
201
202
203
204
205
206
208
209
210
211
212
213
Kev:
Animal Details of Osteoathritis Cases
O wner Age Sex Breed W eight P revious Trial
(yr§) &gl T reatm ent T reatm en t
Jack 8 M G.Ret. 35 PBZ Carprofen
Irwin 8 M B.Collie 22 PBZ Carprofen
Osbourne 2 F Lab. 23 - Carprofen
Clark ? F/N X 31 PBZ Carprofen&PBZ
Storrie 3 M G.S.D. 45 - Carprofen
McCallum 11 F/N Lab. 35 PBZ Carprofen
Talbot 11 M Cairn T. 9.2 - Carprofen
Johnson 8 F/N Lab. 27.4 PLT Carprofen
Arnot 7 F/N G.Ret. 37.5 PLT Carprofen
Bradley 13 M Lab. 31 PLT Carprofen
Long 8 M Lab. 33 PBZ Carprofen
Crawford 10 M Lab. 35 - PBZ
Upton 8 F Dalm. 26 - Carprofen
Baines 16 M X 16 - Carprofen
McCaffrey 8 F C.K.C.S. 10 - PBZ
Peel 13 F O.E.S. 30 PBZ Carprofen
Pearse 14 M G.Ret. 31 PBZ Carprofen
Barker 14 M X 17 PLT, PBZ Carprofen
Smith 12 M Lab. 45 - Carprofen
Sharpies 7 M Scot. T. 19 PBZ, PLT Carprofen
Edwards 12 M Peke 5 PLT Carprofen
Sharpies 9 M X 12 Dexafort PBZ
Plenderleith 10 M Cairn 13 PBZ Carprofen&PBZ
Taylor 15 M Poodle 7.5 - Carprofen
Jackson 5 F/N C.K.C.S. 11 PLT, Pardale Carprofen
Buntin 10 M C.K.C.S. 17 - Carprofen
Sarginson 14 F Weim. 25 PBZ, PLT Carprofen
Stalker 8 M Shet. Shpd. 10 Opticorten Carprofen
Scott 16 M St. Poodle 23 - Carprofen
Clark 12 F/N Lab. 30 PBZ Carprofen
Sex: M = Male; F = Female; N = Neutered.
Breed: G.Ret. = Golden Retriever; Rott. = Rottweiler; WHound = Wolfhound; Lab. = 
Labrador; B. Collie = Border Collie; RetX = Retriever Crossbred; Dobe. = Dobermann; 
PoodleX = Poodle Croosbred; WHW = W est Highland White Terrier; R. Collie = Rough 
Collie; Sp. Spaniel = Springer Spaniel; J.R.T. = Jack Russell Terrier; G.S.D. = German 
Shepherd Dog; Be. Collie = Bearded Collie; GHound = Greyhound; S h e t Shpd. = Shetland 
Sheepdog; C.Spaniel = Cocker Spaniel; O.E.S. = Old English Sheepdog; G.Pointer = 
German Pointer; X = Cro ssbred; Caim T. = Caim Terrier; Dalm. = Dalmatian;
C.K.C.S. = Cavalier King Charles Spaniel, Weim. = W eimaraner; St. Poodle = Standard 
Poodle.
Previous Treatments:
PBZ = Phenylbutazone;
Pirox. = Piroxicam (Feldene ®; 10 mg Tablets or Capsules);
A.S.A. = Acetyl salicylic acid or Aspirin;
Ibupro = Ibuprofen;
Pred. = Prednisolone;
PLT = Predno-Leucotropin Tablets ® [BK Veterinary Products Ltd]
containing Cinchophen 200 mg, Prednisolone 1 mg, Hexamine 100 mg.
Optic. = Opticorten ® Tablets 0.25mg [Ciba-Geigy Agrochemicals] 
containing Dexamethazone 0.25 mg 
Pardale = Pardale-V Tablets ® [Arnolds Veterinary Products]
containing Paracetamol 400 mg, Codeine phosphate 9 mg, Caffeine hydrate 10 mg. 
Dexafort = Dexafort ® injection [Intervet UK Ltd] containing Dexamethazone 3 mg/ml. 
Ceporex = Ceporex ® Tablets [Glaxovet Ltd] containing Cephalexin 250 mg 
Flagyl = Flagyl ® Tablets [RMB Animal Health Ltd] containing Metronidazole 200 mg.
Trial Treatments:
Carprofen = Carprofen 17.5 mg Tablets [Ro 20-5720/659; Lot No. G MZ 626 B 01;
Expiry date: 07.91]
PBZ = Flexazone ® Tablets 100 mg [BK Veterinary Products Ltd], Batch no. 80302A/1
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Breed Distribution of All Treated Doas
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Weight Distribution of All Treated Doas
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Joints Affected in All Osteoarthritis Cases
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Jo in ts  A ffe c te d  and K n o w n  H is to ry
C ase  Jo in tfs l R eported Brief H istory (if given)
Affected
1 EE Severe O.A. both elbows. Radiographic confirmation. O.C.D. lesions in both
elbows found at surgery performed on both elbows 2 months before start 
of treatment for severe 2° O.A.
2 EB-H Severe O.A. in both elbows and hips. Radiographic confirmation. Surgery
for O.C.D. elbows. Treatment started 2 months post-op. for severe 2°
O.A.
3  E Elbow instabilty and O.A. 2° to radius/ulna shortening.
4  ShSh Bilateral O.C.D. Right shoulder operated on 5 w eeks before trial. Left
shoulder: radiographic lesions but no pain until 7 days before start of 
treatment.
5 Hind limbs Creaks/Stiff for about 2 years. Inability to rise & NSAIDs for 12 months.
6 EE None
8 Hock Intermittent lam eness for 2 years after acute onset joint pain and
swelling at about 9 months old (Probably O.C.D.).
9  ffl-BH Three bouts of lam eness in right fore and both hind legs. Slight when
presented.
10 S Injury 1 year previously. Hairline fracture of distal femur and exostosis
distal medial femur.
11 S Lame for about 2 years.
12 Sh Lame for about 2 weeks. Radiography:"Slight roughening of shoulder joint
surface".
13 Sh Lame for 4 months. Radiograph: N.A.D.
14 Sh Chronic lam eness. Radiography: N.A.D.
15 EE Chronic obesity. 2° osteoarthritis and breathing difficulties.
18 E O.A. for 14 months.
19 H indlegs Old age arthritis.
20 Sh Fall one year before trial. Stiff on rising for 2 months.
21 PH Right hip more severely affected.
22 SS None
23 H Avascular necrosis of left hip and excision arthroplasty one month before
trial.
24 Sh Lame left fore when examined. However, stiff on all legs. PBZ for 18
months.
25 PH Right hip more severe. NSAIDs for over 18 months.
26 PH Left hip most affected.
27 ShE[C?] Discomfort after exercise.
28 S None
29 E [Sh?] May be Osteochondrosis.
31 BHH None
32 C Intermittent lam eness and pain in carpal joint for 3-4 years.
33 BE 6 months before trial: intermittent forelimb lam eness. Bilateral elbow
problem diagnosed. Radiography confirmed O.A. ++. ? Old O.C.D. lesions.
34 PH Mild hip dysplasia and O.A. Difficulty in rising. Very lame after exercise.
35 C Old racing injury. Possibly fractured accessory carpal bone.
Radiographic confirmation.
36 SS A.C.L. ruptures when younger. Joints thickened and stable but severe 2°
O.A.
37 BHH Hindlimb stiffness/mild lam eness. Right elbow: severe intermittent
lam eness and joint swelling, crepitus ++ and poor range of movement.
38 E Had had very occasional slight stiffness previously. Presented quite lame.
39 E First lame 4 months before trial. No history of any injury.
40 S PBZ for 3 months.
41 SS None
42 SS Both stifles operated on for subluxating patellas 19 months before trial.
43 Hind limbs Standing in crouched position.
44 S None
45 All None
46 All joints None
47 HH Radiography: Arthritic changes.
48 E None
49 E [All] None
51 B-H Gradually increasing stiffness over the last year.
Key overleaf
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C ase
52
54
55
58
59
60
61
63
64
65
66
67
68
69
70
71
72
73
101
102
103
104
106
107
108
109
110
201
202
203
204
205
206
208
209
210
211
212
213
Kev:
Jo in ts  A ffec ted  and K no w n H is to ry
Jo in tfsf R eported Brief H istory (if a iven l
Affected
EEHH Increasing difficulty rising over the last 2 years.
EE Three year history
H Lame after rest. Stiffness right hind for 2 weeks,
m  None
l-H Right hip more severely affected.
HH Injury to right hip as a  pup. Lame on and off since. W orse now. Hip
dyspasia/O.A.
HH Stiffness and difficulty jumping. Recently, exercise pain a s  well.
HHSS O.A. for 4 months
EE Bilateral ununited coronoid process. Surgery 5 months before trial.
S Lame. W orse after post-exercise rest.
S Muscle wasting, stifle pain, much worse after exercise. 2 year history.
E Lame for more than a  year.
S A.C.L. rupture. Surgery performed. Still very lame & d isuse m usde
atrophy.
E Lame intermittently for 6 months.
HHSSEEHoHo Old age, chronic arthritis.
S Acute bout of lam eness.
E Gun dog. Lame for 2 months.
S None
Sh None
BE None
ShHH
HH None
SS None
HH None
All None
All None
All Especially hind legs.
HHSSHoHo Previous problems, worsened by age.
EESS None
S [All] None
US None
l-H 18 month history. Deteriorating despite chronic PBZ treatm ent.
Hind legs "Cold" lam eness.
S Severe 2° O.A. due to patellar luxation. Trochleoplasty 2 months before
trial.
HHSh One year right fore stiffness. Also cardiac d isease.
All Especially right stifle.
Right hind None
HH Gradually stiffening after rest for 18 months. E ases off with exercise.
EBHH Right fore stiffness for over 3 years. Hip problems for 4  months.
Joints Affected:
E = Elbow; EE = Both elbows; H = Hip; HH = Both hips; Sh = Shoulder; ShSh = Both 
shoulders; S = Stifle; SS  = Both stifles; C = Carpus; Ho = Hock; HoHo = Both hocks; 
All = All joints stated a s  affected.
History Abbreviations:
O.A. = Osteoarthritis; O.C.D. = Osteochondrosis dissecans;
NSAID = Non-Steroidal Anti-Inflammatory Drug; N.A.D. = No Abnormality Detected; 
PBZ = Phenylbutazone; A.C.L. = Anterior Cruciate Ligament.
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Carprofen Treatm ents:
C ase D osaae R eaim e Duration O ther Advice O ther d isea se /tre a tm en t
No.
1
rm a/ka/davl
2.33 bid
Tdavsl
2* Lead exercise
2 2.33 bid 2* Lead exercise -
3 2.41 bid 14 Lead exercise -
4 1.75 bid 7 Restrict exercise -
5 2.33 bid 10 - -
6 0.76 sid 14 Strict rest and diet -
8 1.94 sid 28 Lead exercise -
9 2.19 sid 28 Lead exercise -
10 0.88 sid 7 - -
11 0.97 sid 7 Lead exercise -
1.94 sid 8 Lead exercise -
12 1.11 sid 10 Walking only -
13 1.23 bid 10 Restrict exercise
14 1.40 bid 10
Reduce weight
15 1.35 sid 7 - -
2.02 sid 13 - -
18 0.76 sid 7 Walking only -
19 0.97 sid 21 - -
20 0.97 sid 7 Walking only -
21 0.73 sid 7 - Incontinence
22 0.92 sid 14 - -
23 2.92 bid n Physiotherapy Femoral Head Excision 7 d pre-T.
24 0.97 sid 7 - -
25 0.94 sid 7 - -
26 2.00 bid 7 - Pre-T skin d isease, conjunctivitis
27 0.88 sid 14 Strict rest 1 week
and rhinitis.
2.33 bid 28 Walking exercise -
1.75 bid 28 Walking exercise -
29 0.76 sid 12 Restrict exercise -
31 0.86 sid 7 Hills r/d; Weight loss -
0.86 eod 21 ■ ■ " -
32 0.88 sid 7 - -
34 1.75 sid 14 Strict diet A bscess: Abe treatm ent
35 2.04 sid 14 Rest. Support
36 1.54 sid 7
bandage for 2-3 days 
Restrict exercise O ccasional bout of colitis, usually
37 1.40 sid 4A Decrease exercise
treated  by dietary changes.
38 2.06 sid 7 - -
39 1.17 sid 10 - -
40 0.80 sid 14 - -
1.59 bid 7 -
41 1.25 bid 7 - -
2.50 bid 16 - -
42 0.97 sid 19 - -
43 0.73 sid 8 - -
46 2.33 bid 21 - -
48 0.75 sid 7 - -
sid = one treatm ent daily; bid = two treatm ents daily; tid = three treatm ents daily;
eod = treatm ent every other day.
pre-T. = Pre treatm ent; Abe = Antibiotic;
*»  overuse due to analgesia. Treatm ent withdrawn, 
t  = Vomited. Treatm ent withdrawn.
A -  Treatment withdrawn because condition deteriorating.
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C a rp ro fe n  T re a tm e n ts :
Case
No.
51
52
54
59
60
61
63
64
65
66
67
68
69
70
71
72
73
101
102
104
106
108
109
110
201
202
203
Kev:
D osaae
Tma/ka/davl
Reaim e Duration 
Tdaysl
O ther Advice O ther d isea se /tre a tm en t
2.16 bid 14 Regular light exercise -
2.69 tid 9 Amp.19mg/kg/day post-op. after 
removal of superficial growth on 
left fore.
0.89 sid 7 - Polydipsia; Hills k/d prescribed.
0.78 bid 24 - -
0.39# bid 3 - -
0.58 tid 18 - -
0.73 sid 7 - Piperazine (Verocid®x6) on dayl
1.46 sid 7 - -
0.80 sid 6 Regular light exercise -
1.59 bid 60 M II H -
1.30 sid 7 Weight loss -
1.94 sid 4 " M -
1.17 sid 26 Restricted exercise -
1.87 sid 7 H 1. -
0.75 sid 7 Lead exercise -
1.50 sid 14 Lead exercise -
1.19 sid 10 Reduce weight slightly 
Frequent short walks .
2.28 bid 9 Continue a s  normal -
1.13 bid 19 Gentle exercise 
Encourage use of leg
1.17 sid 7 Restrict exercise -
2.00 sid 10 Reduce weight
1.50 sid 7 N M -
2.85 tid 7 Limited exercise -
2.55 bid 7 Reduce exercise -
0.93 sid 7 Reduce weight -
1.87 bid 7 Reduce weight -
0.71 sid 14 - -
2.11 sid 14 - -
0.79 sid 7 - -
1.59 sid 7 - -
1.35 sid 14 Split exercise -
2.19 sid 14 Restrict exercise -
2.33 bid 40 - -
2.25 bid 14 - -
2.05 bid 7 - Chronic nephritis
3.09 bid 7 - ■ "
1.16 sid 7 Moderate exercise Conjuctivitis, Lymphadenopathy: 
Ampicillin given
1.16 sid 20 Short, frequent walks ?Lymphosarcoma; 
Aural haem atom a
1.84 bid 7 - Chronic nephritis: Ceporex tablets
2.76 tid 7 - H
1.84 bid 7 - .
1.75 bid 14 - CVS d isease: Digitalis 0.5/day.
3.50 bid 14 -
sid = one treatment daily; bid = two treatm ents daily; tid = three treatm ents daily;
Abe = Antibiotic; Amp. = 
CVS = Cardiovascular.
Ampicillin; Post-op. = Post-operatively;
# = Dose reduced when diarrhoea present and increased when diarrhoea stopped.
Digitalis = Digitalis Tablets [Veterinary Drug Co. PLC]; contain Digitalis BP 30 or 60 mg.
C19
No
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gs
C arp ro fe n  T re a tm e n ts :
C ase D osaae Reaim e Duration O ther Advice
No. Im a/ka/davl fdavsl
205 1.35 sid 7
2.69 sid 4 -
206 1.16 sid 8 -
208 2.39 sid 21 Regular light exercise
209 1.03 sid 21 Reduced exercise
210 2.10 bid 21 .
211 0.88 sid 31 -
212 2.28 sid 21 -
213 0.88 sid 7 -
2.63 sid 7 -
O ther d isease /trea tm en t
CVS disease: Frusemide
"Wheeze*1: Millophyline 
Bronchitis,CCF: Fruse, Millophyline 
CCF & Bronchitis:
Millophyline 2 bid; Fruse. 1.5 sid 
HTS tablets, Vit. B12 inj.
HTS tablets, Frusemide 
CVS disease: Millophyline.
CVS disease: Millophyline, 
Frusemide.
Key;
sid = one treatm ent daily; bid = two treatm ents daily; tid = three treatm ents daily;
CVS = Cardiovascular
CCF = Congestive Cardiac Failure
Vit. B12 inj. = Vitamin B12 Injection
Fruse. = Frusemide or Lasix® Tablets [Hoechst Animal Health].
Millophyline = Millophyline-V ® Tablets [Arnolds Veterinary Products];
contain Etamiphylline cam sylate 100 mg.
HTS Tablets = Heart Tonic and Stimulant Tablets [Duphar Veterinary Ltd];
contain Digitalis BP 30 mg, Belladonna Dry Extract BP 0.25 mg & Glyceryl trinitrate 0.32 mg.
Carprofen Treated Doas: Dose Rates
Total of 74 dogs
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Dose rate [mg/kg/day]
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Carprofen Treatm ent: Pre and Post Treatm ent Condition Scores
C ase L am eness W eiahtbearina Jo in t Mobilitv Total Conditio
No. Pre P o st Pre P ost Pre P o st Pre P ost
1 3 1 1 0 2 2 6 3
2 3 1 1 0 2 2 6 3
3 2 1 1 0 2 2 5 3
4 2.5 1.5 1 1 1 0.5 4.5 3
5 3 2 1 1 1 1 5 4
6 2 1 0 0 1 1 3 2
8 0 0.5 1 0 1 1 2 1.5
9 1.5 0 0 0 1 1 2.5 0.5
10 3 1 1 0 1 0 5 2
11 3 1 1 0 0 0 4 1
12 2 2 0 0 0 0 2 2
13 2 2 0 0 1 1 3 3
14 1 0 0 0 0 0 1 0
15 4 2 1 1 1 1 6 4
18 4 2 1 1 2 1 7 4
19 1 0 0 0 0 0 1 0
20 2 1 0 0 0 0 2 1
21 1 1 0 0 1 1 2 2
22 1 1 0 0 1 1 2 2
23 4 3 1.5 1.5 1.5 1 7 5.5
24 3 2.5 1 1 1 1 5 4.5
25 2.5 1.5 1 0.5 1 0.5 4.5 2.5
26 2 1 0 0 1 1 3 2
27 2 0.5 2 2 2 2 6 4.5
29 2 0 0 0 1 0 3 0
31 2 0 0 0 1 0 3 0
32 2 2 0 0 1 1 3 3
34 2 1 0 0 1 1 3 2
35 4 1 1 0 2 0 7 1
36 2 2 0 0 1 1 3 3
37 2 4 0 1 2 2 4 7
38 3 2.5 1 0.5 2 1 6 4
39 2 1 0.5 0 1 1 3.5 2
40 3 1 1 1 1 0 5 2
41 3 2 1 1 1 1 5 4
42 3 3 1 1 1 1 5 5
43 2 1 1 1 0 0 3 2
46 2 1 1 0 1 0 4 1
48 2 2 1 1 1 1 4 4
51 3 3 0 0 1 1 4 4
52 3 4 0 1 1 2 4 7
54 3 3 1 1 1 2 5 6
59 3 2 1 1 1 1 5 4
60 2 1 0 0 1 1 3 2
61 2 1 0 0 2 0 4 1
63 2 2 0 0 1 1 3 3
64 3 3 1 1 2 2 6 6
65 2 1 0 0 0 0.5 2 1.5
66 2 1 0 0 1 1 3 2
67 2 1 0 0 0 0 2 1
68 4 4 2 1 0 0 6 5
69 2 0 0 0 1 0 3 0
70 3 2 1 1 2 2 6 5
71 3 0 1 0 1 1 5 1
72 3 3 0 0 1 1 4 4
73 2 2 1 1 1 0.5 4 3.5
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C arp ro fe n  T re a tm e n t: Pre and P ost T re a tm e n t C o n d itio n  S c o re s
C ase L am en ess W eiahtbearina Jo in t Mobilitv Total Condition Score
No. Pre P o st Pre P ost Pre P o st Pre P ost
101 1.5 1 2 2 1 1 4.5 4
102 2 2 1 1 1 1 4 4
104 1 1 2 2 2 2 5 4
106 1 0 2 2 2 2 5 4
108 3 1 1 0 1 1 5 2
109 2 1 1 0 0 0 3 1
110 2 1 1 0 1 1 4 2
201 3 1 1 1 1 1 5 3
202 2 1 1 0 1 1 4 2
203 2 1 1 0 1 1 4 2
205 3 3 1 1 1 1 5 5
206 2 0 0 0 0 2 0
208 3 3 1 1 1 1 5 5
209 3 1 1 0 1 0 5 1
210 4 2 2 1 2 1 8 4
211 3 1 1 0 0 0 4 1
212 2 1 0 0 2 1 4 2
213 2 1 0 0 2 2 4 3
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C a r p r o fe n  T r e a te d  D o a s :
P re  T re a tm e n t L a m e n e s s  S c o re
40 n Total of 74 dogs treated
30 -
20  -
10 -
41 2 30
Lam eness Score
C arprofen T reated  D o a s:
P o s t  T reatm ent L a m e n e ss  S c o r e
Total of 74 dogs treated40 -i
30 -
20 -
10 -
42 30 1
Lameness Score
C arprofen T reated  D o a s:  D ifferen ce  in 
Pre and P o s t  T reatm ent L a m e n e ss  S c o r e s
40 n
Total of 74 dogs treated
2 1 0 -1 -2  -3
Difference in Pre and Post Treatment Lameness Score
Im provem ent  ^
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C a r p r o fe n  T r e a te d  D o a s :
P r e  T r e a t m e n t  W e ig h t b e a r in g  S c o r e s
50 -i
Total of 74 d o g s  t re a te d
40 -
30 -
20 -
10 -
0 21
W eig h tb ea rin g  S c o re
C arprofen  T reated  D o a s:
P o s t  T rea tm en t W eig h tb ea r in g  S c o r e
Total of 74 d o g s  tre a te d
W eig h tb ea rin g  S c o re
C arprofen  T reated  D o a s: D ifferen ce  in
Pre and  P o s t  T reatm en t W eigh tb earin g  S c o r e s
30 -i
Total of 46 d o g s  in w hich  
w e ig h tb e a r in g  re d u c e d
20 -
10 -
0 / / / /
1 0 1
Difference in Pre and P ost Treatment W eightbearing S core
Im p ro v em en t ---------------------^
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C a r p r o fe n  T r e a te d  D o a s :
P re  T r e a t m e n t  J o in t  M o b i l i t y  S c o r e s
55 -i Total of 74 dogs
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35 -
30 -
25 -
20 -
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Joint Mobility Score
C arprofen  T reated  D o a s:
P o s t  T rea tm en t J o in t  M obility  S c o r e s
Total of 74 dogs
Joint Mobilty Score
C arprofen  T reated  D o a s:  D ifferen ce  in
Pre and P o s t  T reatm en t J o in t M obiltv S c o r e s
Total of 63 dogs where
Joint mobility initially restricted
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Difference in Pre and P ost Treatm ent Joint Mobility Score
Im p ro v em en t ------------------------------^
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C a r p r o fe n  T r e a te d  D o a s :
P re  T r e a tm e n t  T o ta l  C o n d i t io n  S c o r e
25 -i Total of 74 dogs
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10  -
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Total Condition Score
C arprofen  T reated  D o a s:
P o s t  T reatm ent T otal C o n d itio n  S c o r e
25 -i Total of 74 dogs
2 0 -
15-
10 -
0 6 7 82 4 51 3
Total Condition S core
C arprofen  T reated D o a s: D iffe r e n c e  in
Pre and P o st T reatm ent T otal C o n d itio n  S c o r e s
Total of 74 dogs30 -i
20  -
10 -
6E$
1 3 4 5 63 2 0 1 2
Difference in Pre and Post Treatm ent Total C ondition S co res
Im p rovem en t _________________^
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P h e n y lb u ta z o n e  T re a tm e n ts :
C ase
No.
D osaae
rm a/ka/davl
R eaim e Duration
rdavsl
O ther A dvice
5 13.3 tid 7 .
13 8.26 bid NS Restrict exercise; 
reduce weight
19 11.1 NS 10 -
22 10.5 bid 7 -
23 33.3 bid 7 -
26 11.4 bid 21 -
28 18.8 tid 8 Restrict exercise
33 10.0 tid 10 Restrict exercise; 
reduce weight
44 10.0 bid 28 -
45 11.5 tid 21 -
47 8.57 bid 21 -
49 13.3 NS 7 -
10.0 NS 7 -
6.67 NS 7 -
52 7.69 bid 14 Minimise exercise
54 10.2 bid 7 Diet
55 11.1 bid 17 15 mins. exercise/day-
58 10.0 bid 26 -
68 12.9 bid 14 Light exercise
103 5.71 sid 4 -
107 10.0 sid 50 -
204 16.7 bid 21 -
205 15.4 bid 7 -
O ther d isease /trea tm en t
HTS Tablets 
Lasix
Kev:
sid = one  treatm ent daily; bid = two treatm ents daily; tid = three treatm ents daily;
HTS Tablets = Heart Tonic and Stimulant Tablets [Duphar Veterinary Ltd];
contain Digitalis BP 30 mg, Belladonna Dry Extract BP 0.25 mg & Glyceryl trinitrate 0.32 mg.
Lasix = Lasix® Tablets [Hoechst Animal Health].
NS -  Mot SbteL
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P h e n y lb u ta zo n e  T re a tm e n t: Pre and Post T re a tm e n t C o n d itio n  S co res
C ase L am en ess W eiahtbearina Jo in t Mobility
No. Pre P ost Pre P ost Ess £ o s i
5 3 2.5 1 1 1 1
13 2 0 0 0 1 1
19 1 0.5 0 0
22 1 1 0 0 1 1
23 4 3.5 1.5 1.5 1.5 1.5
26 2 1.5 0 0 1 1
28 3 3 2 1 2 2
33 2 1 0 0 2 1
44 3 1 1 1 1 1
45 3 1 1 1 1 1
47 4 1 1 1 1 1
49 3 1 1 0 1 1
52 3 3 0 1 1 2
54 3 3 1 1 1 2
55 2 2 0 1 1 1
58 2 1 0 0 1 1
68 4 4 2 2
103 2 2 1 1 1 1
107 1 0.75 2 2
204 3 2 1 1 0 0
205 3 3 1 1 1 1
Total Condition Score 
Pre P ost
4.5 
1
0.5
2
6.5
2.5 
6
2
3
3
3 
2 
6 
6
4 
2 
6
4
3.75
3
5
C28
No
. 
of 
do
gs
 
No 
of 
do
gs
P h e n y lb u ta z o n e  T r e a te d  D o a s :
P re  T r e a tm e n t  L a m e n e s s  S c o r e s
1 Total of 21 d ogs
2-
0 1 2 3 4
L am eness Score
P h en y lb u ta zo n e  T reated  D o a s:  
P o s t  T reatm ent L a m e n e ss  S c o r e s
10 - i Total of 21 dogs
0 1 2 3 4
L am eness Score
P h en y lb u ta zo n e  T reated  D o g s:  D ifferen ce  in 
Pre and P o st T reatm ent L a m e n e ss  S c o r e s
2 0  - i
Total of 21 dogs
10 -
0 1 2 3
Difference in Pre and P ost Treatm ent L am en ess S core
Im p rovem en t ►
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P h e n y lb u ta z o n e  T r e a te d  D o a s :
P re  T r e a tm e n t  W e ig h t b e a r in g  S c o r e
15 -i Total of 21 d o g s
1 0 -
0 1 2
W eightbearing Score
P h en y lb u ta zo n e  T reated  D o a s:
P o s t  T reatm en t W eig h tb ea r in g  S c o r e s
15 -|
Total of 21 dogs
10
0 1
W eightbearing Score
P h e n y lb u ta z o n e  T reated  D o a s: D ifferen ce  in 
Pre and  P o s t  T reatm ent W eig h tb ea r in g  S c o r e s
14 -i Total of 15 dogs where 
w eigh tbearing  w as affected
12 -
10 -
1 0 1
Difference in Pre and Post Treatment W eightbearing S co res
Im p rovem en t ------------------------ ►
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P h e n y lb u t a z o n e  T r e a te d  D o g s :
P r e  T r e a t m e n t  J o in t  M o b i l i t y  S c o r e s
20 - \ Total of 21 dogs
20 1
Jo in t Mobility Score
P h e n y lb u ta z o n e  T reated  D o a s:
P o s t  T rea tm en t J o in t  M obility S c o r e s
2 0  - i Total of 21 dogs
10 -
0 21
Jo in t Mobility Score
P h e n y lb u ta z o n e  T reated  D oas: D ifferen ce  In 
Pre an d  P o s t  T reatm en t Jo in t M obility S c o r e s
20 i Total of 18 dogs in which 
Join t Mobility w as affected
10 -
1 0 -1
Difference in Pre and Post Treatment Joint Mobility S c o res
Im p ro v e m en t  ^
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P h e n y lb u ta z o n e  T r e a t e d  D o a s :
P re  T r e a t m e n t  T o ta l  C o n d it io n  S c o r e
8 Total of 21 dogs
6
4
2
0
75 60 2 3 41
Total Condition Scora
P h e n y lb u ta z o n e  T rea ted  D o a s:
P o s t  T reatm en t T otal C on d itio n  S c o r e
Total of 21 dogs
4 -
75 60 2 3 41
Total Condition Scora
P h en y lb u ta zo n e  T reated  D o a s: D ifferen ce  In 
Pre and  P o s t  T reatm en t T otal C ondition  S c o r e
Total of 21 dogs10  - i
2 1 0 -1 -2 -3
Difference in Pre and P ost Treatm ent Total Condition Score
Im p ro v em en t  ^
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C a s e s  T r e a te d  w ith  T w o  D o s e s  o f C a r p r o fe n :
E f fe c t  o n  T o ta l  C o n d it io n  S c o r e
Total of 18 dogs
10 -
Low dose 
High dose
2 1 0 2 31
Difference in pre and poet treatm ent condition sc o res
C arprofen  T reated  D o a s: P e r c e n ta g e  im p ro v em en t in 
tc ta l c c n d it io n  s c o r e  in d o a s  trea ted  at < 2 m q/ka/dav
Total of 46 dogs
%age improvement in total condition sco re
C arp rofen  T reated  D o a s :P e r c e n ta a e  im p r o v e m e n t in tota l 
c o n d it io n  s c o r e  in d o a s  trea ted  at > 2 m a /k g /d a v
Total of 28 dogs
O O O O O O O O o O O O O O O O O O O  o o r ^ ( D i r ) T f c o c M v -  v— c \ 4 o r> ^ t f > c o f ,s» o o o > o
% age improvement in total condition sco re
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P re v io u s  T re a tm e n ts  a n d  E ffe c ts
C a se
N o.
Drua P reparation D o sa q e
Tma/ka/davl
1 Piroxicam 0.33  e.o .d .
2 Piroxicam 0.33  e .o .d .
4 Aspirin 3 0 0  mg 12
5 Ent. Coat. A .S.A. 6 0 0  mg 
Ibuprofen 4 0 0  mg
27
18
9 Paracetam ol NS
10 P henylbutazone 13
12 Phenylbutazone 12.7
15 P henylbutazone
P rednisolone
15
0.15
18 Predno-Leucotropin Tabs. 
C inchophen 2 0 0  mg 
P rednisolone 1 mg
17.4
0.09
21 P henylbutazone 8 .3
2 4 P henylbutazone 11 a s  req.
25 Piroxicam 0.36  e .o .d .
28 P henylbutazone 19
29 P henylbutazone 26
31 P henylbutazone 20
33 Predno-Leucotropin Tabs. 
C inchophen 2 0 0  mg 
P rednisolone 1 mg
13
0.07
34 P henybutazone  
Predno-Leucotropin Tabs. 
C inchophen 2 0 0  mg 
P rednisolone 1 mg 
Piroxicam
15
30
0.15
0.33  e .o .d .
35 P henylbutazone 20
3 6 P henylbutazone  
Predno-Leucotropin Tabs. 
C inchophen 2 0 0  mg 
P rednisolone 1 mg
18
17.6
0.09
37 Piroxicam 0.40  e .o .d .
39 Phenylbutazone  
Predno-Leucotropin Tabs. 
C inchophen 2 0 0  mg 
Prednisolone 1 mg
27
27
0.13
D uration E;ffect T im e for oainfu l
TO to  31 s ia n s  to  recurr
7  d ays 1 NS
7  d ays 1 NS
5  w e e k s 1 Swift
_ 1
6 m onths 1* Few d ays
NS NS NS
NS 1 t E xercise depen dent
7  d ays 2 2  w eek s
NS 1 NS
NS 0 N/A
"Constant" 1 NS
2 .5  years 1-2 Not withdrawn
18 m onths 1 2  days
6  m onths 1 7  days
8  d ays 1 NS
10  d a y s 2 3  days
10 d a y s 1 2  days
A s req. 1 NS
3 -4  w e e k s 1 -
14 2 -
7  d ays 2A NS
10 d ays 2 3 w eek s/ E xercise
A s req. 1 NS
NS 2 NS
14 d ays 2 No T. 2 -3  months
4  w eek s 2 -
10 d ays 2 7  days
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P re v io u s  T r e a tm e n ts  a n d  E f fe c ts
C a se
No.
Drua P reparation D o sa q e
[m g/kg/day]
D uration E ffect  
r o to  ?1
T im e for painful 
s ia n s  to  recurr
40 P henylbutazone 9 4  m onths 1 3 days
42 Opticorten [D exam eth.] 
Pardale-V [Paracetam ol +]
0 .08
267
14  d ays  
2 8  d ays
0
0 N/A
45 Predno-Leucotropin T abs. NS 7 days 2 2 days
46 Aspirin 500  mg 16.7 NS 1 NS
49 Predno-Leucotropin T abs. 
C inchophen 2 0 0  mg  
Prednisolone 1 mg
13
0.07
NS 1 2 days
54 Prednisolone 0.51 e .o .d . NS 1 NS
59 Phenylbutazone 9 5 m onths 2 7 days
61 Pardale-V [Paracetam ol +] 72 10 d ays 1 2  days
63 Predno-Leucotropin T abs. 
C inchophen 2 0 0  mg 
Prednisolone 1 mg 
Phenylbutazone
30
0.15
15
7  d ays  
6 w eek s
0
1
N/A
NS
64 C eporex [Cephalexin]
& Flagyl [M etronidazole]
27
21
10 d ays 2 -
65 P henylbutazonem 1711
7 d ays  
10 d ays
2
2 5 days
66 P henylbutazone 18 14 d ays 2 3 days
68 P henylbutazone 13 2 8  d ays 0 N/A
70 P henylbutazone 17 NS 0 N/A
72 Predno-Leucotropin T abs. 
Cinchophen 2 0 0  mg 
Prednisolone 1 mg
22
0.11
NS 2 NS
73 Predno-Leucotropin T abs. 
Cinchophen 2 0 0  mg 
Prednisolone 1 mg
5
0.03
NS 1 2-3 d ays
101 Predno-Leucotropin T abs. 
C inchophen 2 0 0  mg 
P rednisolone 1 mg
13
0.06
18 d ays 3 7 days
102 P henylbutazone 6 NS 2 4 days
108 Phenylbutazone 10 NS 0 N/A
109 P henylbutazone 10 NS 1 2 days
110 P henylbutazone 
Predno-Leucotropin T abs. 
Cinchophen 2 0 0  mg 
Prednisolone 1 mg
12
23
0.12
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4 -5  m onths 
3 4  d ays
1
2 2 days
P r e v io u s  T r e a tm e n ts  a n d  E f fe c ts
C a se
No.
202
203
2 0 4
205  
208
210
211
213
K ev:
D ru g  P r e p a r a t io n
Phenylbutazone 
Predno-Leucotropin T abs. 
C inchophen 20 0  mg 
Prednisolone 1 mg
D o s a g e  Duration
fm g/k g /d av l
11 NS
21 NS
0.11
E ffect T im e for painful
f0 to  31 s ig n s  to  recurr
2  NS
1 NS
Predno-Leucotropin T abs.
Cinchophen 20 0  mg 
Prednisolone 1 mg
40
0 .20
7 days 1 2  d ays
Dexafort Inj.[Dexameth.] 0 .1 2 5 1 d o se 0 N/A
Phenylbutazone 15 "Constant" 1 2-3  d ays
Predno-Leucotropin T abs.
Cinchophen 2 0 0  mg 
Prednisolone 1 mg
2 7
0 .1 4
10 days 0 N/A
Pardale-V [Paracetam ol +] 55 4  days 1 -
Phenylbutazone 
Predno-Leucotropin T abs.
12 7  days 1 -
Cinchophen 2 0 0  mg 
Prednisolone 1 mg
24
0.12
21 days 1 2-3  d ays
Opticorten [Dexam eth.] 0 .0 2 5  occasionally 1 4  d ays
Phenylbutazone 7 NS 2 NS
Drug Preparations:
Ent. Coat. A.S.A. = Enteric C oated  Aspirin;
Opticorten [Dexam eth.] = Opticorten ® T ablets 0 .25  mg [Ciba-Geigy Agrochem icals];
contain D exam ethazone BP 0 .2 5  mg.
Pardale-V [Paracetam ol +] = Pardale-V ® T ablets [Arnolds Veterinary Products];
contain Paracetam ol BP 40 0  mg, C od ein e p h osp h ate BP 9 mg 
& Caffeine hydrate BP 10 mg per tablet. 
Ceporex = C eporex ® T ablets [G laxovet Ltd]; contain 50  or 25 0  mg C ephalexin .
Flagyl = Flagyl ® T ablets [RMB Animal Health Ltd]; contain M etronidazole BP 20 0  mg. 
Dexafort Inj. = Dexafort ® [Intervet UK Ltd]; contains D exam ethazone 3  mg.
Other Abbreviations:
e.o .d . = every other day; a s  req. = a s  required; N S = Not stated; N/A = Not applicable;
* = C aused diarrhoea.and constipation; f  = cau sed  vomiting; A = G astroenteritis.
Effect of Treatment:
0 = No Effect
1 = S om e Effect
2 = Marked Improvement
3 = Sound
R ecom m ended Daily D o sa g e s  for Previous Treatments:
Aspirin/ Enteric C oated Aspirin = 25  mg/kg every 8 hours [50-75 mg/kg/day]
Phenylbutazone = 2 -20  m g/kg/day divided [ 8 -16  mg/kg/day usually used]
Predno-Leucotropin T ablets = 20 -40  mg Cinchophen; 0 .1 -0 .2  mg Prednisolone/kg/day. 
Piroxicam = 0 .3  mg/kg every 4 8  hours
Pardale-V = 0 .5 -3  tablets every 8 hours [equivalent to about 4 0 -8 0  mg 
Paracetamol/kg/day]
Ibuprofen = Not recom m ended
Opticorten T abs. = 1-8 tab lets daily [equivalent to about 0 .0 5  mg D exam ethazone/kg/day] 
Dexafort = 0.5-1 ml [3mg/ml]
Ceporex = 20-30  m g/kg/day.
Flagyl = 20  m g/kg/day for 10-20  days.
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Carprofen C om pared  to P rev ious T reatm en ts
[Where the veterinary surgeon stated the comparative effect of the previous treatm ent and 
Carprofen treatment]
C arprofen
Better S am e W orse
cf. All P rev ious T rea tm en ts 26 6 14
cf. P heny lbu tazone 12 3 6
cf. P redno-L eucotrop in 5 0 6
cf. Piroxicam 2 1 2
cf. Aspirin 3 0 0
cf. Pardale-V 1 1 0
cf. Ibuprofen 1 0 0
cf. O pticorten 1 1 0
cf. P redn iso lone 1 0 0
C arprofen and  P heny lbu tazone T reatm en ts in the Sam e Doa: C om parative 
Efficacy
C ase PBZ D ose T.C.S. Diff. C arorofen d o se T.C.S. Diff. M ost effective
No. rm a/ka/davl rm a/ka/davl T reatm en t
5 13.3 0.5 2.33 1 Carprofen
13 8.26 2 1.23 0 Phenylbutazone
19 11.1 0.5 0.97 1 Carprofen
22 10.5 0 0.92 0 Neither
23 33.3 0.5 2.92 1.25 Neither
26 11.4 0.5 2.00 1 Carprofen
52 7.69 -2 2.69 -3 Neither
54 10.2 -1 0.89 -1 Neither
68 12.9 0 1.13 1 Carprofen
205 15.4 0 1.35 0 Phenylbutazone
C arprofen D ose Rate C h an g es  in the  S am e Doa: C om parative Efficacy
C ase D ose 1 T.C.S. Diff. D ose 2 T.C.S. Diff. M ost Effective
No. rm a/ka/davl rm a/ka/davl D ose Rate
11 0.97 1 1.94 3 1.94
15 1.35 1 2.02 2 2.02
27 0.88 1 2.33 2 2.33
40 0.80 1 1.59 2 1.59
41 1.25 0 2.50 1 2.50
60 0.73 0 1.46 1 1.46
61 0.80 0 1.59 3 1.59
63 1.30 0 1.94 0 Neither
64 1.17 0 1.87 0 Neither
65 0.75 1 1.50 1 Not stated
70 1.50 1 2.00 1 Sam e
73 0.93 -2 1.87 0.5 Neither
101 0.71 0 2.11 0.5 Neither
102 0.79 0.5 1.59 0.5 Neither
202 1.84 0 2.76 2 2.76
203 1.75 1 3.50 2 3.50
205 1.35 0 2.69 0 Neither
213 0.88 0 2.63 1 2.63/Neither
T.C.S. Diff. = Total Condition Score Difference between Pre and Post Treatm ent Examinations
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Carprofen Treatm ents Compared to Previous Treatm ents
Case. Previous  Effect Carprofen D osage Carprofen cf. Previous Treatment
Treatm ent tog/K g/cfey] W orse Sam e Better
Phenylbutazone
68 - 0 1.13 6
70 " 0 2.00 0
108 " 0 2.33 6
10 M 1f 0.88 6
24 " 1 0.97 0
34 H 1 1.75 0
63 " 1 1.94 6
15 " 1 2.02 0
205 " 1 2.69 6
110 " 1 3.09 6
21 " 1-2 0.73 6
29 N 2 0.76 6
59 " 2 0.78 6
12 " 2 1.11 6
39 " 2 1.17 6
66 " 2 1.19 6
65 " 2 1.50 6
102 " 2 1.59 6
35 M 2 2.04 6
213 " 2 2.63 6
202 " 2 2.76 0
Predno-Leucotropin Tablets
63 M 0 1.94 6
18 " 1 0.76 o
73 " 1 1.87 6
202 M 1 2.76 6
203 1 3.50 0
39 M 2 1.17 o
36 " 2 1.54 6
34 " 2 1.75 6
72 " 2 2.55 6
110 M 2 3.09 6
101 M 3 2.11 6
25 Piroxicam 1 0.94 ------6 ? -- -
1 Piroxicam 1 2.33 6
2 Piroxicam 1 2.33 6
37 Piroxicam 2 1.40 6
73 Piroxicam 2 1.87 6
4 Aspirin 1 1.79 6
5 Aspirin 1 2.33 6
46 Aspirin 1 2.33 0
42 Pardale-V 0 0.97 6
61 Pardale-V 1 1.59 6
42 Opticorten 0 0.97 6
211 Opticorten 1 0.88 6
5 Ibuprofen 1* 2.33 6
15 Prednisolone 0 2.02 6
t  = caused  vomiting; * = caused diarrhoea and constipation
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APPENDIX
D
PLT
PLT tablets are a developm ent of Prednoleucotropin tablets which have b een  w idely u sed  
in veterinary practice for 20 years.
Prednoleucotropin tablets contain 3 active constituents:
Cinchophen 20 0  m g/ tablet
Hexam ine 100 m g/ tablet
Prednisolone 1 m g/ tablet
Experimental stud ies in laboratory anim als have show n that the anti-inflammatory 
activity of cinchophen and prednisolone is not en h an ced  by the addition of hexam ine. T he purpose  
of this study is to determ ine the clinical efficacy of the cincophen / prednisolone com bination  
a lone (ie. PLT tablets) in the therapy of osteoarthritis in the dog.
PLT tablets contain:
Cinchophen 20 0  m g/ tablet
Prednisolone 1 m g/tab let
and will b e  administered in a divided d o se  on a  theroretical 25  mg cinchophen and 0 .1 2 5  mg 
prednisolone per kg body weight.
You, the veterinary surgeon, are ask ed  to treat suitable c a s e s  of clinical osteoarthritis.
Treatm ent of existing c a s e s  will allow com parison of efficacy betw een two treatm ents in the sa m e  
animal. N ew  c a s e s  will be treated with PLT tablets or F lexazone ( phenylbutazone ) tab lets on an  
alternate c a s e  basis. N ew  c a s e s  may alternatively b e  treated with a  14 day cou rse  of o n e  drug 
then, after a  short interval of 3 to 4  d ays to allow the return of clinical signs, sw itched to th e  
other drug.
C a s e  S e le c t io n
1. EXISTING CASES
T h ese  are anim als already receiving treatment for osteoarthritis using  
Non-Steroidal Anti-Inflammatory Drugs.
i) Take the animal off the drug
ii) Monitor the time taken for the return of the painful condition
iii) Score  the clinical condition
iv) Institute PLT treatment
iv) Monitor effects of treatment eg . at 2  w eek s, re-exam ine the dog and re-score
2. NEW CASES
i) Confirm osteoathritis (as distinct from traumatic, septic or immune b a sed  arthritis)
Identify the joint(s) affected  
S core the clinical condition
ii) Institute PLT or P henylbutazone treatm ent on an "alternate dog" b asis
iii) Monitor effects of treatment eg . at 2  w eek s, re-exam ine the dog and re-score
Your a sse ssm e n t should be recorded on the standard form using the condition scoring  
table provided. W here possible, the ow ner should b e  questioned a s  to the efficacy of the  
treatment. At the end of the treatment period, fill in the EFFICACY A SSESSM E N T  sh e e t  provided.
T he information from all the reports will b e  analysed  and u sed  in the application to 
register PLT for u se  in the treatment of osteoarthritis in the dog.
D1
D o s e  R e c o m m e n d a t io n
ELI
PLT tablets contain:
Cinchophen 20 0  m g/ tablet
Prednisolone 1 m g /tab le t
and will b e  adm inistered in a  divided d o se  on a  theroretical 25  mg cinchophen and 0 .125  mg 
prednisolone per kg body w eight.
In practical term s, due to the fixed combination and se t  quantity per tablet, the d o se  rates will 
be:
B p d y w eig h t [ k g l T a b le ts C in ch oD h en
[mg/kg]
P r e d n iso lo n e
[mg/kg]
8 1/2 tab le t tw ic e  da ily 25 0 .125
9 - 1 6 1 tab let tw ice  daily 2 5 - 4 4 0 .1 2 5 - 0 .2 2
1 7 - 2 4 1.5 ta b le ts  tw ice  d aily 2 5 - 3 5 0 .1 2 5 -0 .1 7 6
2 5 - 3 2 2 ta b le ts  tw ice  daily 2 5 - 3 2 0 .1 2 5 - 0 .1 6 0
D ue to the prednisolone content, treatment should b e  reduced gradually.
T he initial treatm ent period will b e  14 days, subject to clinical resp on se .
P h e n v lb u ta z o n e : [F lexazone (BKY|
S u g g e ste d  d o se  rate is 8 to 16 mg/kg body w eight in two divided daily d o se s . With the 
100 mg tab lets provided, the table below  g ives guideline d o se  rates:
B o d v w e ia h t Tkal T ab lets P hen v lb u tazon efm a/k a l
Up to  12 .5 1 [ 2  x 0 .5  ] 8  to 16+
13 to  25 2 [ 2 x 1 ] 8  to 16
2 6  to  3 7 .5 3 [ 2 x 1 . 5 ] 8  to 11.5
3 8  to  50 4 [ 2 x 2 ] 8  to 10 .5
etc.
C ontra-indications/ Warnings:
Cardiac, renal or hepatic insufficiency and in anim als show ing  
sign s of or having a  history of anaem ia.
If you h ave  any q ueries or problem s, p lease  contact m e at the te lep h on e num bers below:
Tim Pearson: Work: 041 -339-8855  extn. 5 7 9 0
Home: 041-339 -8242
D2
C O N D IT IO N  S C O R IN G :
W here p ossib le , sco re  the dog's clinical condition as below . If the clinical s ig n s  do not fit the 
sco res  given p le a se  d escrib e  them in the " Comments" section .
L am en ess : [ L ]
0 = Clinically NORMAL
1 = STA N D S normally;
WALKS normally;
LAME after vigorous exercise
2 = S tan d s normally;
SLIGHT LAMENESS w hen walking
3  = Careful w hen standing;
OBVIOUS LAMENESS when walking.
4  = NOT standing normally.
SEVER E LAMENESS w hen walking and unwilling to  run.
W eigh tb earin g: [ W .B. ] [where appropriate ie. limb joints affected]
0 = NORMAL weightbearing on all limbs.
1 = W eight only applied temporarily on affected  limb.
2 = NO WEIGHT applied on affected limb.
M obility o f A ffec ted  Jo in tfs ) : [ J.M . ]
0 = NO LIMITATION of joint m ovem ent.
No ev id en ce  of pain show n by dog during manipulation.
1 = SOM E REDUCTION in joint m ovem ent.
D og sh o w s reluctance during manipulation.
2 = OBVIOUS REDUCTION in joint m ovem ent.
D og sh o w s ev id en ce of pain during manipulation plus crepitus.
Stiffness: fSI
0  = NO ST IFFN E SS at any time
1 =  SLIGHT STIFFNESS after post-exercise rest or first thing in the morning
2 =  MODERATE S T I F F N E S S ......................................................................................
3  = MARKED STIFFNESS after rest plus SLIGHTLY STIFF GAIT w hen walking
4 = SEVERE STIFFNESS after rest and  MARKEDLY STIFF w hen walking
D3
Number Of Usable Case Results Returned by Veterinarians
McKee
Wray
Leslie
W olfensohn
Stockton
Southerden
Orhan
Murdoch
Martin
Gawne
Brown
Boyce
Bardsley
Ballantine
Total of
7 7 7 7 7 7
77777/ /
' / / / / / / .
/  / 7 7 7 / / / / / / / / / / / / / / / / / / / / / $
777W
{/ / / / / / / / / / / / / / $
• ' / / / / / / >
777
/ / / / / / / / 7 7 7
—1
10
No. of cases
49 cases
□  PLT 
0  PBZ 
■  Both
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A n im a l  D eta i ls  of Clin ica l O s te o a th r i t is  C a s e s
CASE-NQ, OWNER NAME AGErvrsi  BREED WEIGHTfkql PREV. T. TRIAL TREATMENT
1 Hannington 10 M Dalm. 30 PLT
2 Matthews 11 M Lab. 35 Predn. PLT
3 Baxter 11 F/N G.S.D 45 PBZ
4 Martin 9 M G.S.D 45 PBZ
5 Sharm an 9 F/N Lab. 35 Piroxicam PLT
6 Kerr 7 F/N Lab. 40 PLT
7 Gould 8 F/N Lab. 35 PLT & PBZ
10 Hook 6 M G.Ret. 35 Voren Susp PLT & PBZ
11 Murton 7 M G.S.D. 46 PBZ
12 Gooch 3 M/N G.Ret. 52 PLT
14 Avenell 4 F/N Lab. 30 PBZ
16 Edmunds 8 M G.S.D. 40 PrLT PBZ
18 Ricketts 10 F/N Lab. 35 PLT
19 Fowler 9 M/N LabX 35 PLT
20 Dowdall 10 F/N CollieX 20 PrLT PLT
21 Holt 13 M Eng Sett 35 PrLT PLT
22 Timberlake 12 F Lab. 35 PrLT PLT
23 Dykins ? M B.Collie 25 PBZ/Optic. PLT
24 Lomas 11 M Lab. 30 PBZ PLT
25 Greenhough 2 F Rott. 35 PLT
26 Giles 14 M B.Collie 18 PLT
27 Laybourne 9 F B.Collie 20 PBZ/Predn. PLT
29 Joynsohn 4 M Dobe. 45 PLT
30 Bowman 8 M Lab. 40 Fluvet PLT
31 Johnston 15 F/N G.S.D.X 15 PBZ PLT
32 Thorpe 12 F/N St.Poodle 35 PLT
33 Booth royd 12 F J.R.T. 13 PLT
34 Love 8 F Lab. 27 PLT
36 Reynolds 7 F G.Ret. 30 PrLT, A.S.A. PBZ
37 Holwerda 12 F/N Dobe. 30 A.S.A. PLT
38 Duncan 10 F/N Corgi 13 PLT
41 Dunton 12 F/N O.E.S. 40 PrLT,
PBZ/Predn.
PLT
42 Andrews 16 M G.Ret. 28 PLT
43 Marshall 5 M Lab. 35 PLT
44 Young 12 M Be. Collie 33 PBZ PLT
45 Shar ? F/N Boxer 35 PLT
46 Love 9 M Lab. X 20 p Tl t PLT
47 Hobbs 9 F/N G.S.D. 37 PLT
48 Jerem iah 10 F/N Lab. 36 Pri_T PBZ
49 Ramsden 11 M/N X 25 A.S.A. PLT
50 Campbell 11 M Collie 35 PLT
51 McNiven 12 F/N Lab. 40 PBZ
52 Shivaes 7 F/N Lab. 40 PBZ
53 Robertson 7 F X 20 PBZ
54 Kerr 12 M K.B. Terr. 20 PrLT PBZ
55 McNeish 11 F/N G.Ret. 25 PBZ
56 Donaldson 13 F CollieX 16 PBZ PLT
57 Burchell 10 M Lab. 25 PrLT PLT
58 Gaston 7 F/N Lab. 32 PBZ PBZ
(Key overleaf)
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Key: S ex : M = Male, F = Female, M/N = Castrated Male, F/N = Spayed Female
B re ed : Dalm. = Dalmatian, Lab. = Labrador Retriever, G.S.D. = German Shepherd Dog 
[Alsatian], G.Ret. = Golden Retriever, LabX = Labrador Retriever Crossbred,
CollieX = Collie Type C rossbred , Eng Sett = English Setter, B.Collie = Border Collie,
Rott. = Rottweiler, Dobe. = Doberm ann, G.S.D.X = German Shepherd Dog Crossbred, 
St.Poodle = S tandard  Poodle, J.R.T. =Jack  Russell Terrier, O.E.S. = Old English Sheepdog, 
K.B.Terr. = Kerry Blue Terrier.
Previous Treatm ent:
Predn. = Prednisolone.
Voren S u sp . = Voren Suspension  [Boehringer Ingelheim Ltd] Dexamethasone.
PrLT = Predno-Leucotropin Tablets[BK Veterinary Products] Cinchophen, hexamine, 
Prednisolone.
PBZ = Phenylbutazone
Optic. = Opticorten Tablets 0.25 mg [Ciba-Geigy Agrochemicals] Dexamethasone.
Fluvet = Fluvet Tablets [Syntex Animal Health] Flum ethasone.
A.S.A. = Acetylsalicylic acid [Aspirin]
Trial Treatment:
PLT = PLT Tablets [BK Veterinary Products] Cinchophen, Prednisolone.
PBZ = Flexazone Tablets 10Omg [BK Veterinary Products] Phenylbutazone
D6
A a e  D i s t r i b u t i o n  o f  P L T  T r i a l  O s t e o a r t h r i t i s  C a s e s
Total of 46 dogs of known age10 i
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AGE[y rs]
Age Distribution: PLT Treated Doas
10 n Total of 34 dogs of known age
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A G E[yrs]
Age Distribution: PBZ Treated Doas
10 n Total of 14 dogs of known age
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A GE(yrs]
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B r e e d  D i s t r i b u t i o n :  O s t e o a r t h r i t i s  C a s e s
K.B.Terr. Total of 49 dogs
B e. Collie
Boxer
Corgi
J .R .T .
S t. P o o d le
Rott. 
E n g  S e tte r  
Dalm . 
O .E .S .
Dobe.
B.Collie
C ro ssb re d
G .R et.
G .S.D .
Lab
20100
No. of dogs
Breed Distribution: PLT Treated Doas
K.B.Terr. 37 dogsTotal
Be. Collie
B oxer
SL P o o d le
Rott.
E ng  S e tte r  
Dalm . 
O.E.S. 
Dobe.
B.Collie
C ro ssb re d
£ 2G.S.D.
Lab
121 082 60 4
No. of dogs treated with PLT tablets
Breed Distribution: Phenylbutazone Treated Doas
K.B.Terr. 
B e. Collie 
B oxer 
Corgi 
J .R .T . 
S t. P o o d le  
Rott. 
E ng  S e tte r  
Dalm . 
O .E.S. 
Dobe. 
B.Collie 
C ro ssb re d  
G .R et. 
G .S.D .
I ah
Total of 14 dogs
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No. of dogs treated with phenylbutazone
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Sex Distribution: Osteoarthritis Cases
T otal of 49 c a s e s25 -i
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Weight Distribution: Osteoarthritis Cases
Total of 49 c a s e s
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Weight Distribution: PLT Treated Dogs
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Joints Affected in All Osteoarthritis Cases
"Fore leg" 
"Hind legs" 
M /Carpal-P1 
Hock[1] 
Carpi[2] 
Carpus[1] 
Shoulder[Bilat] 
Shoulder[Unilat] 
Elbow[Bilat] 
Elbow[Unilat] 
Stifle[Bilat] 
Stifle[Unilat] 
Hip[Bilat] 
Hip[Unilat]
Total of 49 d o g s
20
20
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No. of d o g s  a ffected
Joints Affected: PLT Treated Doas
"Fore leg" 
"Hind legs" 
M /Carpal-P1 
Hock[1 ] 
Carpi[2] 
C arpus[1] 
Shoulder[Bilat] 
Shoulder[Unilat] 
Elbow[Bilat] 
Elbow[Unilat] 
Stifle[Bilat] 
StiflefUnilat] 
Hip[Bilat] 
Hip[Unilat]
v /s S /S A
T7777. Total of 36 d o g s
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No. of d o g s  affected
Joints Affected; Phenylbutazone Treated Doas
"Fore leg" 
"Hind legs" 
M /Carpal-P1 
Hock[1] 
Carpi[2] 
Carpus[1 ] 
Shoulder(Bilat] 
ShoulderfUnilal] 
Elbow[Bilat] 
Elbow[Unilat] 
Stifle[Bilat] 
Stifle[Unilat] 
Hip[Bilat] 
Hip[Unilat]
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Total of 15 d o g s
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No. of d o g s  affected
C lin ica l  O s te o a r th r i t is  C a s e s :  J o in ts  A f fec ted  and  K n o w n  H is to ry
CASE NO. JOINTS] AFFECTED BRIEF HISTORY IF GIVEN
1 HHS Arthritis for several months. No previous treatm ent.
2 FH No history given. 14 months of prednisolone treatm ent.
3 fh Chronic arthritis. Gradual onset over 3 years. Also C.D.R.M.
4 FH Gradual onset stiffness especially after resting. W orsened with 
recent febrile illness.
5 s s Right stifle A.C.L. rupture and sugicaJ replacement 12/86. Left stifle 
arthritis and cranial instability developing over 7 months.
6 s s Surgery for A.C.L. rupture on both stifles 1983 and 1985.
7 s A.C.L. rupture repair and medial meniscectomy. Also Hip Dysplasia.
8 sh R.T.A. Lame left fore plus proprioceptive deficit. ?Brachial plexus 
injury.
9 Spine "Spondylitis"
10 E Acute exas erbation of chronic O.A. Radiographic confirmation.
11 FH Gradually increasing stiffness in hind quarters.
12 Hock Swollen left hock. Lameness, stiffness after exercise, history of 
injury a s  a  puppy.
14 FH Especially right hip. Very bad Hip Dysplasia. Gradual onset lam eness 
in right hind. Sudden onset collapse.
15 Digit V Acute onset lam eness 3 days ago. Localised to Digit V, Phalanx 1.
16 H Hind leg lam eness/w eakness for 1 year. Radiographic confirmation of 
Hip Dysplasia 4/88. Predno-Leucotropin treatm ent since 4/88.
18 FH Right hip worse than left. Increasing stiffness over last 6 months,
19 FH Especially left.
20 FH Severe hip dysplasia since a  few weeks old.
21 HHSS Arthritic hips and stifles. Radiographic confirmation.
22 SS An overweight dog with arthritic stifles.
23 Hind legs No history. Long term medical therapy.
24 FH Also severe pruritis.
25 SS Bad conformation. One stifle A.C.L. rupture and surgical replacem ent.
26 Hind legs Pain in back legs and spine.
27 FH 7 year history of Hip Dysplasia. Long term therapy with PBZ & 
Prednisolone.
29 Carpus Carpal valgus and crepitation.
30 E Long standing O.A. of left elbow.
31 FH Increasing stiffness since 9/86. Pain/stiffness on rising.
32 FH Worsening over 6 months.
33 FH Always been overweight. Recently unwilling to walk a s  much.
34 FH Stiffness and slight discomfort.
36 E 6/88 Slight stiffness. N.A.D. on examination. 9/88 detected stiffness 
in elbow. Slowly deteriorating.
37 S [HH?] Stiff on rising. Unable to jump into car.
38 sh Lame for 2 months. Worse on exercise.
41 shshEECCHH Longstanding Hip Dysplasia. Responded well to PBZ in 1985. 
9/88 presented with severe forelimb stiffness.
42 HH [S?] Stiff and mild ataxia.
43 Hock Old R.T.A.
44 shC Right fore intermittent lam eness for 7 years.
45 S OA. Problem for last 4 days.
46 Metacarpal-P1 Cut foot stitched 12/88. Pain increased by 29/12. Arthritic changes 
in joint confirmed by radiography.
47 SS Gradual lam eness in both hind legs for 1 year. Crepitus in both stifles.
48 Hock 5/87 swollen and painful. Radiography: severe O.A. changes. 
18 months PrLT. Lame at presentation.
49 EHH 11/88 Pain in fore leg. Reluctant to walk.? hips also affected.
50 SS Left stifle A.C.L. rupture and repair 1982.
51 S Chronic lam eness
52 Right fore "Limping on right fore for 6 months. All joints in leg"
53 Right fore Lame for 14 days. Chronic problem.
54 HH R.T.A. som e years ago. 6 months hip pain and stiffness.
55 S Lame after rest for two weeks. Radiography: marked arthritis.
56 S Gradual onset lam eness from 9/88. O.A. confirmed on radiography.
57 E Slight lam eness left fore increasing since 10/87.
58 S Stiff left hind after rest for 4 months. No stifle instability reported.
Key overleaf
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Kev:
H = Unilateral hip; HH = Bilateral hip; S = Unilateral stifle; SS  = Bilateral stifle; E = Unilateral elbow; 
EE = Bilateral elbow; sh = Unilateral shoulder; shsh = Bilateral shoulder; C = Carpus; CC = Carpi; 
P1=Phalanx 1.
C.D.R.M. = Chronic Degenerative Radiculo-Myelopathy
A.C.L. = Anterior (Cranial) Cruciate Ligament
O.A. = Osteoarthritis
PBZ = Phenylbutazone
PrLT=Predn-Leucotropin®
NAD = No Abnormalities Detected 
R.T.A. = Road Traffic Accident
D13
PLT T r e a tm e n ts :
CASE NO. Dosaqe[mq/kq/dav] Reqime Duration Other advice
Cinch. Pred, [days]
1 20.0 0.10 tid 28 Restrict exercise
2 22.8 0.11 bid 5 Restrict exercise
5 22.8 0.11 bid 14 R est
6 10.0 0.05 sid 14 Reduce weight
12 22.8 0.11 bid 5 R educe weight
16.5 0.08 bid 5 Reduce exercise
8.8 0.04 bid 5
18 22.9 0.11 bid 14 R educe weight
19 22.9 0.11 bid 3 Reduce weight
11.4 0.06 bid 4* M N
20 20.0 0.10 bid 21 Normal exercise
21 11.4 0.06 bid 14 Normal exercise
22 17.1 0.09 tid 7 -
23 16.0 0.08 bid 12 -
24 20.0 0.10 tid 7 .
13.3 0.07 bid 7 -
25 11.4 0.06 bid 7 Increase exercise slowly
26 22.2 0.11 bid 8 -
27 20.0 0.10 bid 7 -
29 13.3 0.07 tid 7 Reduce weight
30 20.0 0.10 bid 28 -
31 26.7 0.13 bid 14 Freq. short walks
32 22.9 0.11 bid 14 Reduce weight
33 30.8 0.15 bid 14 Reduce weight
34 14.8 0.07 bid 14 Lead exercise
37 20.0 0.10 bid 12 Normal exercise
38 46.2 0.23 tid 7 Reduce exercise
30.8 0.15 bid 7 N M
* Treatm ent withdrawn because of vomiting
Other d isease/treatm ent
Pruritis
Pevidine baths-dermatitis
Mild "stroke" 4wks ago 
Bilateral cataracts
Metronidazole-Gingivitis
D14
P L T  T r e a t m e n t s :
CASE NO. Dosaae[mg/kg/dav1 
Cinch. Pred,
Regime Duration Other advice 
[days]
Other disease/treatm ent
41 20.0 0.10 bid 14 - -
42 21.4 0.11 tid 10 Normal exercise Theocardin 1 tid
14.3 0.07 bid 28 M H "
43 11.4 0.06 bid 14 Limited exercise -
44 12.1 0.06 bid 45 Regular short walks Diarrhoea at 6 weeks I 
- Kaobiotic, Buscopan.
45 22.9 0.11 qid 14 Diet advised. Walking 
exercise only.
-
11.4 0.06 bid NS -
46 20.0 0.10 bid 10 Rest -
10.0 0.05 sid 50 Increase exercise -
47 21.6 0.11 bid 21 Lead exercise 
Reduce weight
-
49 8.0 0.04 sid 90 Reduce excessive exercise
50 17.1 0.09 tid 10* - -
56 25.0 0.13 bid 42 Restrict exercise -
57 16.0 0.08 bid 10 Walking exercise -
* Treatment withdrawn because  of vomiting
C A S E m
3
4 
11
14
16
36
48
51
52
53
54
55 
58
Dosage
[mg/kg/day]
8.9
8.9 
8.8
10.0
10.0
10.0
8.3 
7.5
5.0
10.0
5.0
8.0
6.3
P h e n y lb u ta z o n e  T re a tm e n ts :  
Regime
bid
bid
bid
tid
bid
bid
bid
tid
bid
bid
sid
bid
sid
Duration
[days]
14
14
14
14
3*
14
42
14
14
14
18
60
14
Other disease/treatm ent 
C.D.R.M.
Cotrimoxazole - U.T.Inf.
Other advice 
Reduce weight
Reduce exercise 
Reduce weight
Diet control
Lead exercise 
Lead exercise 
Reduce weight 
Diet and rest 
R est
Reduce exercise Flea dermatitis:
Insecticidal Spray ev. 10d
Restrict to walking 
exercise. R educe weight.
Reduce exercise 
Reduce weight
* Treatment withdrawn because  of vomiting, inappetance and dullness. 
C.D.R.M. = Chronic Degenerative Radiculo-Myelopathy 
U.T.Inf. = Urinary tract infection
PLT a n d  P h e n y lb u ta z o n e  T re a tm e n ts :  
c a s e  NO. Treatment Dosage Regime CumtioQ
[mg/kg/day] [days]
Other advice
7 PLT Cinch. 22.9 bid 14 Reduce weight
Pred. 0.11 & light exercise
PBZ 11.4 bid 14 n n m m
10 PBZ 8.5 tid 14 Lead exercise
PLT Cinch. 22.7 bid 5 m m
Pred. 0.11
Cinch. 11.4 bid 5 m m
Pred. 0.06
Cinch. 5.7 sid 5 m m
Pred. 0.03
[No other d iseases or treatm ents in th ese  two dogs]
N
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o
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Initial PLT Dose Rates Tmg cinchophen/ka/dayl
R ecom m ended  
treatm ent range
Total of 36  d o g s  treated
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P L T  T r e a t m e n t :  E f f e c t  o n  C o n d i t i o n  S c o r e s
Case no. Lameness Weightbearing Joint Mobility Stiffness
Pre Post Biff Pre Post Biff E ra  Post Biff Pre Post Biff
1 [30d] 3 1 2 1 0 1 1 1 0 3 1 2
2 [6d] 4 4 0 1 1 0 0 0 0 4 4 0
5 [17d] 3 2 1 0 0 0 0 0 0 2 0 2
6 [17d] 2 0 2 0 0 0 1 0 1 2 0 2
7 [14d] 2 0 2 1 1 0 1 0 1 3 0 3
10[21 d] 4 0 4 0 0 0 2 2 0 3 1 2
12[37d] 3 1 2 1 0 1 2 1 1 3 0 3
18[15d] 1 0 1 0 0 0 1 1 0 3 1 2
19[21d] 1 1 0 0 0 0 1 1 0 3 3 0
20[7d] 1 1 0 0 0 0 0 0 0 1 1 0
21 [14d] 0 0 0 0 0 0 0 0 0 0 0 0
22[7d] 1 1 0 0 0 0 0 0 0 0 0 0
23[12d] 2 0 2 0 0 0 0 0 0 2 0 2
24[14d] 4 1 3 1 0 1 2 0 2 4 1 3
25[7d] 4 0 4 0 0 0 0 0 0 1 0 1
26[8d] 1 0 1 0 0 0 0 0 0 3 0 3
27[7d] 0 0 0 1 0 1 0 0 0 3 0 3
29 [7d] 4 1 3 0 0 0 0 0 0 4 1 3
30[28d] 3 1 2 1 0 1 1 1 0 3 1 2
31 [14d] 0 0 0 0 0 0 2 2 0 4 2 2
32[18d] 3 1 2 1 0 1 1 1 0 3 2 1
33[14d] 1 1 0 0 0 0 1 1 0 2 1 1
34[21 d] 1 0 1 0 0 0 1 1 0 1 0 1
37[12d] 0 0 0 1 0 1 1 1 0 1 0 1
38[12d] 3 0 3 1 0 1 1 0 1 0 0 0
41 [14d] 3 2 1 0 0 0 1 1 0 4 3 1
42[40d] 2 0 2 1 1 0 1 1 0 2 1 1
43[14d] 2 2 0 0 0 0 0 0 1 1 0
44[45d] 2 0 2 1 0 1 1 1 0 3 2 1
45[14d] 3 1 2 1 0 1 1 0 1 3 1 2
46[48d] 3 1 2 1 0 1 2 0 2 2 0
47[25d] 2 0 2 0 0 0 1 1 0 2 1 1
49[90d]
50[16d]
2 0 2 1 0 
Treatm ent discontinued due to vomiting
1 1 1 0 2 1 1
56[42d] 3 2 1 1 0 1 2 1 1 4 2 2
57[1 Od] 3 2 1 0 0 0 1 1 1 3 2 1
D18
PLT T re a tm e n t:  O vera ll Im p ro v e m e n t
C ase No. Time for TOTAL SCORE Imorovement Ratina
Imorovement Elfi Post Diff -A Q. 1 2
[days]
1 [30d] - 8 3 5 •
2 [6d] - 9 9 0
5 [17d] 2 5 2 3 •
6 [17d] 2-3 5 0 5
7 [14d] 2-3 7 1 6 •
10[21d] - 9 3 6 • .
12[37d] - 9 2 7 •
18[15d] 5 5 2 3 •
19[21d] - 5 5 0 • t
20[7d] - 2 2 0 •0
21 [14d] - 0 0 0
22[7d] - 1 1 0 •0
23[12d] 2 4 0 4
24[14d] 3 11 2 9 •
25[7d] 1 5 0 5
26[8d] 1 4 0 4 •
27[7d] - 4 0 4 •
29 [7d] 7 8 2 6 •
30[28d] short 8 3 5 • ,
31 [14d] 1 6 4 2 •
32[18d] 7 8 4 4 •
33[14d] 3 4 3 1 •
34[21 d] <2 3 1 2 •
37[12d] 2 3 1 2 •
38[12d] 1 5 0 5 •
41 [14d] - 8 6 2 •
42[10d] 3 6 4 2 •
43[14d] - 3 3 0 •
44[45d] - 7 3 4 •
45[14d] 7 8 2 6 •
46[48d] - 8 5 3 •
47[25d] 2 5 2 3 •
49[90d] 1 7 2 5 •
50[16d] Treatm ent withdrawn b ecause  of vomiting
56[42d] 4 10 5 5 •
57[10d] - 7 5 2 •
* C ase 2: PLT treatm ent had no effect. Euthanased due to deteriorating condition.
t  C ase 19: PLT treatm ent w as withdrawn after 8 days because of persistent vomiting.
0 C ases 20, 21 and 22 were switched from treatm ent with Predno-Leucotropin to PLT without the 
withdrawal of treatm ent. Clinical signs without treatm ent were therefore not a sse ssed .
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PLT T re a te d  D o a s : P re  T re a tm e n t  L a m e n e s s  S c o re s  
20 i  Total of 35 trea ted  dogs
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X A n
PI PI
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L am eness sc o re
PLT T reated  D o a s: P o s t  T reatm en t L a m e n e ss  S c o r e s
20  - i Total of 35 treated  dogs
15 -
10-
0 1 2  3 4
L am eness sco re
PLT T reated  D o a s: D ifferen ce  in Pre 
and P o s t  T reatm en t L a m e n e ss  S co re
20-1
Total of 31 dogs showing 
lam en ess  before treatm ent
10 -
o
oz
0 2 3 -41 1
D ifference In Pre and P o st PLT Treatment
Lam eness Score
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P L T  T r e a t e d  D o a s :  P r e  T r e a t m e n t  W e i g h t b e a r i n g  S c o r e s
40 -i
Total of 35 trea ted  dogs
30 -
20 -
10 -
20 1
W eightbearing sc o re
PLT Treated Doas: Post Treatment Weightbearing Scores
40 -i Total of 35 trea ted  dogs
30 -
20 -
10 -
20 1
W eightbearing sc o re
PLT Treated Doas: Difference in Pre 
and Post Treatment Weightbearing Scores
2 0 - t Total of 16 dogs with reduced 
pre trea tm en t w eigh tbearing
Difference in Pre and Post
PLT Treatm ent W eightbearing S core
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P L T  T r e a t e d  D o a s :  P r e  T r e a t m e n t  J o i n t  M o b i l i t y  S c o r e s
25 -i Total of 35 trea ted  dogs
20 -
15 -
Jo in t mobility sc o re
10 -
PLT Treated Doas: Post Treatment Joint Mobility Scores
Total of 35 trea ted  dogs
Join t mobility sc o re
PLT Treated Dogs:
Difference in Pre and Post Treatment Joint Mobility Score
2 0  -i
Total of 24 dogs with reduced 
pre trea tm en t joint mobility
Difference in Pre and P ost Treatm ent
Joint Mobility Score
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P L T  T r e a t e d  D o a s :  P r e  T r e a t m e n t  S t i f f n e s s  S c o r e s
20  -i
Total of 35 dogs treated
Maon* 10-
oz
42 30 1
S tiffn ess  sc o re
PLT T reated  D o a s :  P o s t  T rea tm en t S t i f fn e s s  S c o r e s
20-1
Total of 35 dogs treated
10 -
0 1 2  3 4
S tiffn ess  sc o re
PLT T reated D o g s;
D ifferen ce  in Pre an d  P o s t  T reatm en t S t if fn e s s  S c o r e
15 i
10 -
Total of 32 dogs with 
p re trea tm en t s tiffn ess
Difference in pre and p o st treatm ent
stiffn ess score
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P L T  T r e a t e d  D o a s :  P r e  T r e a t m e n t  T o t a l  C o n d i t i o n  S c o r e s
Total of 35 dogs treated
10 -
6 ■
0 1 2 3 4 5 6 7 8 9 1 0 1 1
Total condition sco re
PLT T reated  D o a s:  P o s t  T reatm ent Total C on d ition  S c o r e s
Total of 35 dogs treated
Total condition  score
ELL. T reated  D o a s: D ifferen ce  in Pre 
and P o s t  T rea tm en t T otal C on d ition  S c o r e
10 -i Total of 34 dogs with a pre treatm ent 
total condition score > zero
2
73
D ifference in Pre and P ost Treatment
Total Condition Score
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P h e n y l b u t a z o n e  T r e a t m e n t :  E f f e c t  o n  C o n d i t i o n  S o o r p g
Sase no. Lameness Weightbearing Joint Mobility
Elfl Post Diff Pre Post Biff E l£  Post Diff Pre Post Diff
3 [15d] 4 4 0 1 1 0 2 2 0 4 4 0
4 [14d] 1 0 1 1 0 1 2 1 1 3 0 3
7 [14d] 2 0 2 1 1 0 1 0 1 3 0 3
10[14d] 3 1 2 0 0 0 2 2 0 3 2 1
11 [18d] 0 0 0 1 0 1 1 0 1 2 0 2
14[1 Od] 3 0 3 1 0 1 2 1 1 3 1 2
16[3d] 1 2 -1 0 0 0 1 1 0 2 2 0
36[14d] 3 3 0 2 1 1 2 2 0 0 0 0
48[42d] 4 2 2 2 1 1 2 2 0 4 2 2
51 [14d] 2 1 1 1 0 1 2 1 1 3 1 2
52[14d] 3 1 2 1 0 1 1 0 1 2 1 1
53[14d] 2 1 1 1 0 1 0 0 0 2 1 1
54[18d] 0 0 0 0 0 0 1 1 0 2 1 1
55[28d] 2 1 1 0 0 0 1 1 0 3 1 2
58[14d] 3 1 2 1 0 1 1 0 1 3 1 2
Phenylbutazone Treatment: Overall Improvement
C ase No. lime for TOTAL SCORE imorovement Rating
imorovement
[days]
Pre Post Diff J. Q 1 2
3 [15d] - 11 11 0 .*
4  [14d] 7 7 1 6 •
7 [14d] - 7 1 6 •
10[14dj - 8 5 3 •
11 [18d] - 4 0 4
14[10d] 5 9 2 7 •
16[14d] - 4 5 -1 •t
36[14dj 2 7 6 1
48[42d] 10 12 7 5
51 [14d] 6 8 3 5 •
52[14d] 4 7 2 5 •
53[14d] 3 5 2 3 •
54[18d] 2 3 2 1 •
55[28d] 10 6 3 3 •
58[14d] 2 7 3 4 •
* C ase 3: Deteriorated during treatment. Later euthanased.
t  Case 16: Treatment withdrawn after 3 days because of vomiting, inappetanceland dullness.
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P h e n y l b u t a z o n e  T r e a t e d  D o a s :  P r e  T r e a t m e n t  L a m e n e s s  S c o r e s
8 Total of 15 dogs trea ted
6
4
2
0
430 21
L am eness sco re
P h e n y lb u ta z o n e  T reated  D o a s: P o s t  T reatm en t L a m e n e s s  S c o r e s
8n Total of 15 dogs trea ted
n
430 21
Lam eness score
P h e n y lb u ta z o n e  T reated  D o a s: D iffe r e n c e  in  
Pre and P o s t  T reatm ent L a m e n e ss  S c o r e
Total of 13 d o g s with 
p re trea tm en t lam en ess
«□>OTJ
Oz
3 41 0 1 2
Difference in Pre and P ost Treatm ent
Lameness Score
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P h e n y l b u t a z o n e  T r e a t e d  D o a s :
Pre T rea tm en t W e ig h tb e a r in g  S c o r e s
Total of 15 dogs treated
10 -
n
■o
•5 6 -
oz
20
W eightbearing  sc o re
P h e n y lb u ta z o n e  T rea ted  D o a s:
P o s t  T rea tm en t W e ig h tb e a r in g  S c o r e s
15 "i
Total of 15 dogs treated
1 0 -ma
o■o
o
oz
20 1
W eightbearing  sc o re
P h en y lb u ta zo n e  T reated  D o a s:  D ifferen ce  in 
Pre and P o s t  T reatm en t W eig h tb ea r in g  S c o r e
15 -i Total of 11 dogs with reduced 
w eigh tbearing  pre treatm ent
1 0 -
oz
201 1
Difference in Pre and P ost Treatm ent
W eightbearing Score
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P h e n y l b u t a z o n e  T r e a t e d  D o a s :
P r e  T r e a t m e n t  J o i n t  M o b i l i t y  S c o r e s
10 - i Total of 15 dogs treated
o
oz
0 21
Jo in t mobility sc o re
Phenylbutazone Treated Doas:
Post Treatment Joint Mobility Scores
10 t Total of 15 dogs treated
o
oz
20 1
Jo in t mobility sc o re
Phenylbutazone Treated Doas: Difference in 
Pre and Post Treatment Joint Mobility
10 n Total of 14 dogs with reduced 
Joint mobility pre trea tm en t
mao■o
o
oz
20 11
Difference in Pre and P ost Treatment
Joint Mobility Scores
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P h e n y l b u t a z o n e  T r e a t e d  D o a s :
P r e  T r e a t m e n t  S t i f f n e s s  S c o r e s
Total of 15 dogs treated
10 -
a
6 -
oz
3 40 21
S tiffn ess sc o re
P h en y lb u ta zo n e  T rea ted  D o a s:  
P o s t  T reatm en t S t i f f n e s s  S c o r e s
1 2 - i
15 do g s treatedTotal
1 0 -
6 -o
oz
4 -
3 40 21
S tiffn ess sc o re
P h en y lb u ta zo n e  T reated  D o g s:  D ifferen ce  in 
Pre and  P o s t  T reatm en t S t i f fn e s s  S c o r e
Total of 14 dogs with 
pro trea tm en t s tiffn ess
Difference in Pre and P ost Treatm ent
Stiffness S cores
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P h e n y l b u t a z o n e  T r e a t e d  D o a s :
P r e  T r e a t m e n t  T o t a l  C o n d i t i o n  S c o r e s
Total of 15 d ogs  treated
Total condition  sco re
P h e n y lb u ta z o n e  T rea ted  D o a s:
P o s t  T rea tm en t T otal C o n d itio n  S c o r e s
Total of 15 dogs treated
mato■a
o
oz
2 -
9 10 11 1276 82 3 4 50 1
Total cond ition  sco re
P h e n y lb u ta z o n e  T reated  D o a s: D ifferen ce  in 
Pre and  P o s t  T reatm en t T otal C ond ition  S co re
Bn
Total of 15 dogs
m
a toT>
Oz
2 -
jX
75 640 1 2 31
D ifference in Pre and P ost Treatment
Total Condition Score
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Previous Treatments and Effects;
PREVIOUS TREATMENT
Case N o. Preparation/Drue Dosaeeline/ke/davl Recommendation Duration EFFE'
2 Prednisolone 0.14 e.o.d . 0.25-0 .5 14 m onths 1
5 Piioxicam 0.57 0.3 e.o .d . 14 days 1
10 Voren Suspension  
[Dexam ethasone]
[2mg]
0.056 l-2m g/dog 1 dose s/c 2
20 Predno-Leucotropin Tabs. 
Cinchophen 200m g 20 2 0 - 3 0 Constant 1-2
21 Predno-Leuco tropin Tabs. 
Cinchophen 200m g 11.4 2 0 - 3 0 Constant 2
22 Predno-Leuco tropin Tabs. 
Cinchophen 200m g 17.1 2 0 - 3 0 -- 2
23 Phenylbutazone 
Opdcorten [Dexam ethasone]
12.0
0.01
2 - 2 0
0.05
Constant 2
2 4 Phenylbutazone 20 2 - 2 0 Constant 1
27 Phenylbutazone
Prednisolone
15
0.25
2 - 2 0  
0.25 - 0 3
Constant 1
30 Fluvet [Flum ethasone] 0.0016 [1 tab] 0 .5 - 4  tabs/dog ----- 2
31 Phenylbutazone 13 3 2 - 2 0 6 m onths 2
36 Predno-Leuco tropin Tabs. 
Cinchophen 200m g 26.7 2 0 - 3 0 __ 0
Aspirin 5 25 asrequ. 2
37 Aspirin 10 25 — 1
41 Predno-Leuco tropin Tabs. 
Cinchophen 200m g 
Prednisolone
20
0.10
2 0 - 3 0
0 . 1 - 0 . 1 5
4  m onths 1
Phenylbutazone
Prednisolone
15
0.19
2 - 2 0
0 . 2 5 - 5
2  w eeks 1
44 Phenylbutazone 12 2 - 2 0 4  weeks 2
46 Predno-Leuco tropin Tabs. 
Cinchophen 200 mg 20.0 2 0 - 3 0 30  days 2
48 Predno-Leuco tropin T  abs. 
Cinchophen 200 mg 11.1 2 0 - 3 0 18 m onths 2 - 3
49 Aspirin 12 m g/kg as req. 25 ev . 8 hours - 2
54 Predno-Leuco tropin Tabs. 
Cinchophen 200 mg 20 2 0 - 3 0 14 days 0
56 Phenylbutazone 18.8 2 - 2 0 14 days 0
57 Predno-Leuco tropin Tabs. 
Cichophen 200 m g 2 4 2 0 - 3 0 10 days 2
58 Phenylbutazone 6.3 2 - 2 0 14 days 2
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Previous Treatments and Their Effects
Total of 22 previous 
treatments in 20 dogsPBZ/Dexam eth.
PBZ/Predn.
F lum ethasone □  No effect
□  Some FX 
E3 Marked FX 
■  Sound
D exam eth ason e
Piroxicam
Aspirin
P rednisolone
P henylbutazone
i-Leucotropin
1 082 4 60
No. of treatments
Comparison Between PLT Tablet 
Treatment and Previous Treatment Efficacy
PBZ/Dexam eth
PBZ/Predn V
Total of 18 treatments in 17 dogs where 
comparison between previous and 
PLT Tablet Treatment was stated
Flum ethasone
Piroxicam
Aspirin
P henylbutazone
m rss/ss/w /r/jzsm
Predno-Leucotro y////A
■ PLT Worse
m PLT Same
■ PLT Better
2 3 4
No. of dogs treated
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PLT Treated Doas; Overall Improvement Rating
Total of 35 dogs treated
Sound
Marked Effect
No Effect
Worse
 1 1 1 1 1 1
0 10 2 0  30
No. of dogs
Phenylbutazone Treated Doas: Overall Improvement Rating
Total of 15 dogs treated
Sound
Marked Effect
S o m e  Effect
No Effect
W orse
1 02 6 840
No. of dogs
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Addendum
Note: PLT Tablets is the name used in the text for a new preparation containing
cinchophen and prednisolone. The old preparation containing hexamine in addition 
to these compounds is called Predno-Leucotropin Tablets in this thesis 
although veterinarians and the manufacturers often use the abbreviation "PLT" to 
describe the product.
